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PART I 
Background, 
research questions 
and study design 

1 
General introduction 
For descriptive epidemiology, ... approximate estimates are 
better than no estimates. There is a need for a greater infusion 
of demographic ethos into the epidemiological estimation 
process in order to better inform health policies and planning. 
c.J.L. Murray & A.D. Lopez 
Intl'oduction 
This PhD thesis is rootcd in a mnltidisciplinary project, ca lied Technology 
Assessment lvlethods (TAM). The (ambitious) aim of the TAM project was 
to develop a comprehcllsive method of evalnating medical tcchnology in 
the perspective of multiple risk factors, multiple diseascs and multiple 
causes of death (Bonneux & Bai'endregt, 1991). Thc project was an at-
tempt to bettel' llllderstand the dynamics of populatioll health status, in 
particnlar in relation to medical intervclltions, but it was "lso lllotivated by 
thc rapidly rising health care costs of the past decades, whieh fueled the 
feal' that ever expanding casts might become economically unsllstainahle in 
the future (van der Maas & Habbema, 1986). The TAM project would 
provide a better lUlderstanding of the consequcllces for beth casts and 
popt!lation hcalth status of a \Vide array of preventivc aud therapeutic 
health care interventions, and through that offer the tools for policy makers 
to huy the better investments in health with a sustaillahle health carc 
budget. 
Two factors arc commanly held responsible for the increase in health 
care costs: aging and health care technology. "Aging" is the relative in-
crease in the numbers of elderly people in the population, and sillce the 
elderly have more diseases and more serious diseases than young people 
they are more expensive for the health care system. Agillg is brought about 
by two causes. The first is the consequellce of the post war baby boom: the 
large birth COhOl'ts of these generations are presently showing up as large 
numbers of people in middle 'age, who will become large numbers of elderly 
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in thc first four decades of thc 2Pt century. Thc secOlld canse of aging is 
that an ever larger majority of ca eh successive binh cohon reaches aId age: 
mortality at all ages has been declining, also among the e1derly. 
The aging of the baby boom cau hardly be held responsible for incre.ses in 
health care casts so far (the e1dest members arc presently ouly iu their early 
fifties), but it \Vill he the major canse in the fouf decades to come. The 
sec011d kind of aging has been in operation at least since the second part of 
the 191h century, and shows up as a trcmclldons increase in life expectancy: 
bet",een 1850 and 1990 Iife expectancy increased from about 40 (both 
sexcs) to 74 (men) and 80 (women) Uvlackenbach, 1996; Wolleswinkel-van 
den Bosch, van PoppeI, Looman, & lvlackenbach, 1997). 
\X/hile there is considerablc de bate abont the causes of this increase, 
and the rale of mcclicine was evcn dOllbted (NIcKeowl1, 1976), it is no\V 
accepted that impl'oved mcdical technology, prcvclltive and curative, is at 
least in part responsible (J\'lackenbach, 1988). Many diseases can now be 
cured or prevented altogether, but one of the causes of lowered mortality in 
particlliar among the elderly is undollbtedly longel' survival with previously 
fatal degeuerative diseases (chapters 4 aud 6). Mauy diseases thus 
increasingly turn from fatal into chronic disease, hut the diseasc process is 
seldomly stopped: those afflicted may survive, but with a high risk of dis-
abilit)'. 
This thesis addresses thc qllestion of the health of an aging popnlatioll, in 
interactioll with increasingly available and effective health care technolo-
gies. lvlore and more health care technologies are available, improving aad 
extending life, but possibly also extending life with disabilit)'. What will be 
the health care needs of th is rapidl)' growing group of elderly? 
The scope of this question is very wide, and this thesis offers only 
panial answers. ivlnch of thc thesis is devoted to the problem how one 
shol1ld go about getting even these partial answers, because they requirc an 
interdisciplinary effort with methads from epidemiology, demography aud 
economics. 
This genera I introduction provides the background of the research 
question and delineates the approach. Several consecutive and distinct steps 
are lleeded, which wc wiII describe here in general terIl1s, the dctail being 
relegated to the iutroductions to Part II to VI. We opeu by explaiuing the 
backgrouud of the debate on future morbidity. We show then the 
paramount importance of a disease specific approach to this questioll alld 
the need for computer models to ensure consistency and track dynamics. 
W/e close with summal'izing the main questions that wiII be addressed. 
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The compression or expansion of morbidity 
Backgl'ound 
The qllestion of the fllture health of the population, and in particulal' of the 
clderly poplliation, is in the international context known as "the com-
pression versus expansion of mOl'bidit)' ". The debate originated with 
papers b)' Gruenbel'g alld Kramer, who pointed out that the present ad-
vances in medical techllolog)' allow us te save the frail and disabled Erom 
dying Erom complications, alld that therefore the prevalenee of frailty and 
disability in the popttlatioll is bound to ri se (Gruenberg, 1977; Kramer, 
1980). Thc "faitures of success" would lead to a "paudemic of mcntal dis-
ordcrs and associated chronic diseases and disabilities". 
Their argument is th at when the incidence of chronic 'disease and dis-
ability does not change, but survival improves, the stocks of frail patients 
\ViII increase. They conclude that research should shift emphasis to discovcr 
preventabie canses for the conditions that will experience expansion. 
The antithesis is compression, and was put forward by Fries (Fries, 
1980). The ma in propositiou of Fries is that the length of lifc is fixed. Frics 
suggests that there is an ideal rectangulal' sllf\rival caused by a qllitc nanow 
distribntion of sa called "natural death" al'Olllld age 85, and that thc 
Amel'Ïcans (and, presumably, also ot her western populations Iike the 
Dnrch) have covered most of the distance to that idea!. wlortality will not 
decrease anymore, becal1se the gene tic potentialof the human species is 
limitecl, anel we have reachcd the limits. The second proposition of Fries is 
that chronic disease can be postponed. He points to the decline of cere-
brovascnlal' disease mOl'tatit)', gencrall)' attributed to hypertensiol1 control, 
and the decline of tebacco cOl1sumption. If incidence (inflow) decreascs, 
and mortality (ontflow) remains constant, stocks of prevalent frail patients 
\Vill dec rea sc. 
The expansion Ol' compression theories, as stated above, are built on 
opposite propositions: expansion assumes a decreasing l110rtality but fixed 
incidence, cOlnpression aSSU111es fixed mortality but deereasing incidence. 
lvlanton points out that both sccnal'Îos in fact "posit that chronic disease 
1110rbidity alld at least certain components of mortality have no nccessary 
counection (wlanton, 1982). He arglles that fol' many chronic conditions 
improved survival \Vill come about by sIO\ving the rate of progressioll of 
the pl'Ïmary disease process. "lu this ( .. ) case, duration, and hencc life ex-
pectancy, is incl'eased by l'educing discase severity." From th is he went on 
to develop the concept of "clynamic equilibrium": an expansioll of chronic 
conditious, with a simultallcous decrease in their sevcl'Ïty. 
The obscl'ved tendency to discollnect morbidity and 1l10rtality has 
largely persisted in studies that followed. On the one hand there is a lively 
debate on the hnman Iifc span and fnture developments in life expectancy 
(Roush, 1996). Based on the enormous rise of life expcctancy in thc past 
some authors predict further increases all the way to 100 ycars or even 
higher. Others point out tbat sneb incl'eases in !ifc cxpectancy would re-
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quire nnprecedentcd declincs in mortality: to achieve a lifc expectancy of 
100 l'ears mortalitl' at all ages would have to decliue bl' 50% from the 
1985 level, aud to reach 120 a decline of 90% would be needed 
(Olshanskl', Carnes, & Cassel, 1990). In th is debate morbidity is largely 
ignol'cd, but it cas)' to sec that a compressiol1 of l110rbidity would be ver)' 
hard to aehieve in the case of rapidly declining ll1ortality: major non-fata I 
callses of disability, such as 1055 of visiol1 aud hearing nnd 10co111otor and 
congenital discase, would have to declinc rapidly as weil. 
On the othcr hand man)' studies have tried to find empirical evidcnce 
of expansion or compression, usually operationalized as 'disability', with 
some finding cvidcnce of expansioll, but others of compressiol1, and some 
nothing much of either (Mathers, Robiue, & Wilkins, 1994; Perenboom, 
Boshuizen, & vau de Water, 1993; Robine, 1994; Wilkins, Chen, & Ng, 
1994). These studies tend to take life expectancl' more or less for granted, 
even to the extent of looking at relative compressioll and expansion of 
morbidity, or at 'healthy life percentage' (van de Water, 1991). Several 
methodological papers have pointed out that there are numerous difficul-
ties with the 1110st emplo)'ed method, that is based on cross-sectional 
prevalence data (chapter 16) (Bebbington, 1992; Brouard & Robine, 1992; 
Rogers, Rogers, & Belangel' , 1990). Unfortunately, the longitudinal data 
that wonld resolve these problems are extremel)' scarce. 
Another problem concerns the generic l110rbidity meaSl1re like 
"disability" that is- used in most empirica I studies. Several authors have 
argned that compression and expansion depend on the kind of disease and 
the kind of change in its epidcmiologl', and that at least distinction should 
be made between fatal and non-fatal discases (Manton, 1982; Olshansky, 
Carnes, & Cassel, 1990). \'(lhen medica I progress successfully lowers 11101'-
tality from fatal diseases Iike cardiovascnlar disease, but faüs to postpone 
the age at onset of non-fata I diseases like ûsteûarthritis and vision and 
hearing impairments, the latter will of course expand. 
Indeed, it is striking to nûte that the original pl'OpOllents of the ex-
pansien and compression theses had different diseases in mind. Gruenberg 
and Kramer rest llluch of their argument on the increased survival of pa-
tients with Dewn's syndl'ome and other congenital mental disorders, while 
Fries based his declining incidence on s111oking- and h)'pertensioll-related 
diseases. The developmeuts have been verl' different indeed for these dis-
eases: patients with Down's syndrome presently live on to develop hcart 
failure and dementia, whilc the incidence of cardiovascular disease has, in 
alllikelihood, been declining (see chapters 4 and 6). 
Three basic questions 
The main research question of this thesis is the one that is central to the 
compression and expansion dcbate: 
\ViII there be compression or expansion of marbidity? 
General întroc\uction 7 
The observation that compressioa and expansion dep end on the kind of 
disease led us to the first of two additional questions that detennine the 
methodologie al basis of th is thesis. \'(lhen overall poplIlation health status is 
the resultant of diverse developments on the disease specific level, a better 
understanding of the changes in overall health might be gained by studying 
the disease specific developments, and then derive the consequences for 
overall health. So the first additional question is: 
What can a disease specific approach contribttte to the understanding 
of compression and expansion at the level of overall population health 
status? 
This qnestioll puts the basis of OUl" approach to the expallsion and com-
pression discussion in the realm of epidellliology, the stud)' of the OCCUl'-
rence of diseases. Changes in overalllllorbidity aad mortality are explained 
by disease ineidence and survival, prevalellce and lllortality and their 
changes over time. 
The second additiönal question follows from the observation that inciden-
ce, prevalence and 1l10rtalit)' are cansally linked, and that changes in clisease 
prevalence, and hence mOl'bidity prevalence, are a d)'namic phenomenon. 
Changes in morbidit)' prevalence are the result of changes in incidence, 
survival, audlor cure, but as a stock varia bie prevalence aIso depends on 
past values. 
The bathtllb provides a useful analogy: the eU1'1'ent level of the water 
(the stock) is detennined by how long and how wide the tap has been open, 
and if and when you pulled the drain. The same holds for disease 
prevalenee: it depends on past inflow (incidenee) and outflow (eure and 
mortality). The study of dynamic changes, namely compl'ession and ex-
pansion, asks for dynamic modeIs (Manton, 1982). 
In combination with the disease specific approach this leads to a need 
for dynamic epidemiologieal 1l1odels. The seeond additional question be-
comes: 
HoUJ can epidemiology and modelling techniques be integrated into 
public health models fit to ansUJer questions of compression and ex-
pansion on the disease specific level, and on the level of overall 
population health? 
These two additional qnestions determine the methods examining the 
compression and expansion question in this thesis, and dlUS a large part of 
its contents. In part 1I severaI dynamic disease specific models are presellted 
which arc used to anal)'ze past changes, alld, in some cases, to make 
projectiolls. Parts III and IV present methods to synthesize thc disease spe-
eific resuIts: part III describes how multi-disease modeIs can be constructed, 
and part IV how disease specific prevalellces can be integrated to a generic 
indicator of poptliation health status. Because of the centra I importance of 
the two additional questiolls we \ViII fjrst elaborate on them. 
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Changes in disease epidemiology 
'~Ilorbidity~ is a general term, referrillg te a manifcstation of iII health. lts 
main determinants are the prevalcllce of discases and the 'severity' for thc 
individual of having that disease. 
The WHO introduced the concept of !DH, "Impairment, Disability 
and Handicap", to describe the consequences of discases. All impairment is 
the damage to a systcm. For example, all elderly woman with hip arthrosis 
has all impaired hip. Howcver, this impairmcnt ma)' by a purely 
radiologieal fincling, causing 110 sympto111s. Disability is the loss of function 
as a cOllsequence of that impainnent. The woman may have puin, walk 
with difficultl' and need a stick. Handicap is the soeial consequence of that 
disability. If she can not mount the bus anymore, and eau not go shopping 
in town, the woman is handicapped in that respect. 
The distinctiol1 between disabilit}' and handicap is rather snbtle, and 
serves to remind polk)' makers that handicaps ma}' be created Ol' avoided 
b)' the environment: a Iow instep bus ll1ight avoid the mobility handicap of 
the cxample without changing the disability. Howevcr, the distinction be-
tween impairmcnt and disability is very important. The impairlllent with-
ont disability is not an inunediate health problem. Hip arthrosis as a ra-
diologica! finding without symptollls or fl1nction loss might callse morbid-
it)' in the future, but not now. The he.t1th conseqllcnce of interest is the 
disability a disease causes. , 
The fntme health of the Netherlands is largeil' determined bl' the 
evolution of degenerative diseases caused by both life style and senescence. 
There is no sharp distinction between both etiologies. Thel' are both de-
terlllined by 'age', whieh is gcnetic potentia!, and 'environmcnt', illcreasillg 
or decreasing the speed of senescencc by promoting or dillunishing 
stochastic damage (fazwinski, 1996). Alzheimel"s Dementia would be the 
prototype of a mostly senescent disease, with hardly auy cnvit'onmental 
deterll1inants documented (Bretclcr, Claus, van Duijn, Launer, & Hofman, 
1992; Edelberg & Wei, 1996), lnng cancel' a life st)'le disease, cansed pre-
dominantl)' b)' smoking Ol' occnpational exposme (Davila & Williams, 
1993). 
The combination of changes in life st)'le va1'Îables and in the natural 
history of specific diseases through medica! illterventiolls pro duces a variety 
of possible changes in discase epidemiology: 
~vlore effective control of environmental damage will decrease disease 
incidence. Decreasing incidence of degenerative discases succeeds more 
of ten thl'Ough 'delal'ing' than thl'Ongh 'abolishing' disease. An example is 
smoking: damage indnced b)' smoking pl'Obabll' both canses disorders 
aud advallces their onset towards younger ages (Bartecchi, .NlacKellzie, & 
Sch1'Îel', 1994). The decreasing pl'evalence of smoking, and the ensuing 
declinillg incidcnce of smoking related disorders have consequences for 
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disease prevalence thar ma)' be hard to assess, as better risk profiles also 
improve the prognosis of fatal diseases, and lower mortality. 
Effective secondary preVCl1tioll through stepped-llp case finding wiII both 
increase incidence aud improve progllosis of degenerative disorders. 
Stepped-llp case finding increases incidence becallse both incidence of the 
degenerative disease and mOl'tality from all othel' callses increase by age 
(chapter 8). Occult disease is uncovered which would have passed 
llnlloticed iE the patient had died between the moment of early diagnosis 
and clinical manifestation (Black & Welcll, 1993; Cole & Morrison, 
1980). Earlier, milder manifestations and consequences of the targeted 
disease will increasc, but partly avoid later, more SCVCl'e manifestations 
(de Koning, van Oortmarssen, van lneveld, & van del' lviaas, 1990). 
Again mortalit}, will decrease. An example is breast cancel' screening. 
Thc effective pl'evelltion ancVor postponement of recurrent discase aftel' a 
first c1inieal manifestation (sometimes ca lIed tel'tiary preventioll, a less 
well defined concept) decreases recurrences, and more severe disease 
states will be postponed. An example is platelet inhibitor and beta-
blocking treatmcnt of coronal'y heart discase. Survival improves, aud 
again patients live longer, and in milder disease states (chapter 4) 
Successful treatment of potentially fatal events will prevent death, but 
will not llecessarily cu re thc disease process. The sllrvivors of damaging 
disease atracks are at risk for funhcr chronie discase. An example is 
tlll'ombolysis in acute myocardial infal'ctioll, causing increases of conges~ 
tive heart failme and probably stroke patients (chapter 4) 
Revalidation and rehabilitation (anotber intel'vention ca lIed sometÎlnes 
tertiary pl'evelltion) may prevent long term disability. An examplc is rc~ 
habilitation aftel' acute stroke (Dennis & Langhorne, 1994). 
Treatment 01' palliatioll of CXiStillg symptoms may Împrove the well-be-
ing, witb or withont improving the progllosis. 
Any specifie disease ma}', depending on ctiology and natural history, be 
amenable to anc or more of thesc processes, resulting in changes in disease 
specific incidcnce, prevalence, mortalit)' aneVor scverity. Several of the 
processes are gencratcd by health care intervcntions, the application of 
",hieb depends, amollg other things, on technologieal innovation and pol-
iey decisions, and hence are difficult to prediet. 
Thc idiosyncrasy of these discase specifie dcvelopments makes statements 
about compressioll or expansion of morbidity not very helpfnl if they are 
l'estl'ieted to thc gcneric lllorbidity level. Thel'efol'c we have chosen to 
analyze epidemiologie changes on the disease specifie level, and only then 
synthesize resnlts to changes in overall morbidity and mortality. We wil! 
nse qnantitativc modelling of diseases as a tooI, and show the power of 
sneh models both in integrating data from various sources as in dcmon~ 
strating the effects of dynamie changes. 
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Models of disease 
Meta-synthesis of knowledge and figures 
Tile best wa)' to study expansioll or compression is to set up all ideal stud)', 
obtaining all the desil'cd figures about determinants, incidence, prevalcllce 
and l110rtality of diseases of interest with the best l11ethodology available. 
However, even if such all ideal stud)' wDuld he available (the Framingham 
heurt study about cardiovascular disease goes a long way), infcl'cnce to 
anothcl' popltlatioll is not straightforward, as man)' detcl'minallts ma)' 
differ in character and distributiOll. 
But comprehensive infol'mation on changes over time of a specific 
disease epidcmiology is scarce. Thcl'c are man)' papers abont incidence, 
prevalenee, survival, lllortality or risk factors, but ver)' rarely about pat-
terns in all of these simnltaneonsly. Theories abont incidence increases 
rarely tr)' to explain wh)' ll10rtality of the same disease and at the same 
time was decreasing, alld vice versa (Adami, Bergstrom, Sparen, & Baron, 
1993; Bonnel1x, van Oorrmarssen, & Barendregt, 1993; Broderick, Phillips, 
Whisnan!, O'Fallon, & Bergstralh, 1989)(chapters 6 and 8). Important 
determinants, sllch as hypertension, are said to be incl'easing without 
explaining wh)' au important 'target disease', such as stroke l11ortality, is 
decreasing sharply (Oei & Erkelens, 1995). Ol' papers about observed 
prevalenccs do not even begin to explain why other studies abollt the same 
prevalenccs in ver)' similar populations show completel)' different figures 
(Bonneux, vau de Mheen, Gunning-Schepers, & van der Maas, 1996; Van 
Leer, Seidel, & Kromhout, 1994; Van Leer, Verschuren, & Kromhout, 
1994). 
Quantitative disease models help making sense of the many sources of 
information abol1t disease occurreuce b)' combillillg knowledge from 
varions som·ces. Snch models describe quantitatively the simplificd disease 
histor)': incidence, survival and deatIl. Complications, snch as heart failnre 
aftel' an acute myocardial infarction, are discase stages with their o\\'n in-
cidence, survival and death embedded in the discase history. Depending on 
the research ql1estion, and consequently on thc disease history as specified, 
and the available data, time series of secondary event rates cau be gener-
atcd: reCllrrence, admissioll and illtervelltiou rates, or prevalcnce of varions 
discase states. 
The main use of the model is to force consistency on the various data 
and assumptions. It can be fitted to existing data, and the congruit)' of 
assmnptions check ed. This type of models might, as all analogue to the 
techniqlle of meta-analysis, be ca lIed meta-synthetic. They aim to explain 
observatiolls from the past from many different sonrces by combining all 
relevant findings in a comprehensive and qnantificd theory. Examples of 
meta-sYllthetic modelling are the disease lllodels in part Il. 
General introduction II 
Time and age 
Time and age are aften considered s)'nOI1)'mous: we grow older in step with 
the passage of time. \Xlhen a population is followed through time, however, 
we have to deal at all)' point in time with pcople of all agcs. Describing a 
population throngh time therefore requires separate age and time 
dimensÎons. 
The models used in this thesis alwa)'s have all age dimension: age is 
snch an important determinant of health that the models would lose much 
of their relevance without it. Changes in Încidence and survival at )'Ollnger 
ages affect prevalence and mortalit)' at older ages, alld snch changes in the 
age pattern are described in particulal' for cardiovascular disease. This im-
pact of changes at younger ages on the health status of the aid er popltlation 
might be ca lied "age d)'namÎcs". 
Not all models in the chapters to co me have a time dimensiol1: in 
man)' cases some variant of the period life table is used. Thc peri ad life 
tabie, while describing the "age dynamics", is a static model because it 
ignores d)'uamic effects of time, and explores anI)' stead)' states. Aperiod 
life table states qncstions like "What would be life expectancy if mortalit)' 
remained constant for at least a centur)' at the level of a certaÎll periad" , or, 
for a multi-state life tabie: "What would be the age speeifie prevalence if 
incidencc alld survival l'emained constant at a cel'tain leveP' . Bccanse the 
incidence and survival in practice do not sta)' constant, the steady statcs 
described b)' the life table wil! never occor in reality: the)' are ideal types. 
For many research qucstions, whcre dyllamie changes over time are 
not dh'ecd)' the issue, snch models have the attraction of greater simplicity. 
A go ad example of the power of a simp Ie statie model is to be found in 
chapter 23, where stationary popl1latiolls with alld without a disease are 
compared. As a disease is eliminated both as sonrce of costs alld as canse of 
death, the age speeifie population changes and the ensuing finaneial 
conseqnences of eliminating fatal and non-fatal diseases can be calculated. 
But the statie life table does not describe the pathway from the original 
steady state with the disease to the alter native steady state without it. 
A dynamÎc model can describe this passage of time. Ir call iIlustrate 
explicitly the changes of di se ase pl'evalence over time, driven by the vurious 
in- and ourflows. A dynamic model is more realistic, but pays fol' that 
l'CaliSlll with increased complexity. If this complexity ovel'steps a threshold, 
thc results beeOlnes hard to interpret and validatc. The reader caB compare 
chapter 4, The futHre rise of heart failure, and chapter 5, The 'new' aid 
epidemic of coronary heart disease. Bath handle the question of changing 
corona1'y heart disease histOl')', but chapter 4 nses a complex dYllumic 
simnlation model with both time and age dimellsions and chapter 5 a 
simplified statie 1l1ulti-state model with only an age dimension. 
Same research questions, however, require a dynamie model, becanse 
the passage of time detennines the answer. In chapter 16 we use the com-
plex dynamie heart disease model to show how eross-sectional prevalenees 
used in caleulations of health expectancy ma)' bias a trend analysis. And in 
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chapter 24 we explicitl)' compare static and d)'namic anal)'sis of the health 
care casts of smoking, and demons tra te that, while thc issues of time and 
agc seem straightforward enough, there rcmains ample scope for confusioll. 
Simulation of the unobsel'ved 
An important applicatioll of lllodels is to provide answcrs to "what ir' 
questions. These 'what if' questions eau be distinguished in two kinds: 
business as usual and business not as HsuaL Business as Hsual questiolls 
sünply extrapolate CUl'rent trends into rhe fntnre to assess what this future 
may look like. Given the populatioll structllre in the Netherlands, with the 
large post war birth cohorts, a population projection will preferabi)' be part 
of thc extrapolation, but other trends, likc in discase incidence alld survival, 
ma)' be cxtrapolated too. Such scenarios can be found in chapters 4 and 6, 
where disease mode Is are llsed to project future cardiovascular morbidity 
and mortality. 
Business not as usual questions involve interventions. Simlllation of 
the consequences of specific interventions using a lllodel are "best guesses" 
if na empirical data are available bccause either the intervention is rela-
tively new, or follow up or sample size of a study needs to be unreasonably 
large to yield statisticalI)' reliable results. In chapter 9, the question is asked 
"\,(!hat are the conseqnences for hip fractnres, if we call manipnlate bone 
mineral density?". Because frail bones are but one of the many nnderlying 
causes of hip fracrures, illcreasing bone mineral density can only have but a 
limited impact. Because menopause and decline of estragen levels start at 
around 50, and hip fractul'es occur predol11inantly af ter 80, a horl110ne 
l'eplacement therapy tdal in the general population would have to run for 
decades before an)' effect would become measllrable. 
Anothel' reaSOll to use simldation may be that thc intervention is in 
fact unrealistic: in chapter 23 whole disease categories are eradicated in a 
cause elimination !ife tabie, ancl in chapters 20 and 24 smoking is entil'ely 
abolished. Snch simulations arc thought experil11ents, used, for example, to 
assess the importance of discases and risk factors for population health 
status. 
Multi-disease models 
A consequence of our decision to analyze epidemiologie changes on the 
disease specifie level is that we somehow must 'add up' the disease specific 
results to arrive at a comprehensive picture of the changes in population 
health status. This synthesis of disease specific results has two aspects. One 
is " methodology that allows many disease specific modeIs to coexist and 
together describe the health of a poplliation. The secOlld aspect concel'l1s 
the development of a meaningful statÏstic to SUlllll1arize and measure th is 
multi-disease description of population health status. This second aspect 
will be intl'oduced in the llext sectioll, in this one we turn to the first. 
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Whcn multiple disease specific models are nsed to describc the health 
of a single population they will have ra interact. This interaction eau oeCl1l' 
in a number of wars. Fol' example, when the nnmbel' of people dying from 
one disease goes down, numbers of deaths from othel' cal1ses wilI, aftel' 
some time lag, rise. Another example are discases that shal'e a common risk 
factor, such as the group of smoking relatcd diseases. Changes in the risk 
faetol' expOSUl'e will in that case affect a gl'onp of diseases simultaueously, 
and changes in one disease will affect all other diseases that share the risk 
factol'. A funher compIication OCCl1rs when anc disease acts as a risk factor 
for another disease, for example coronary heart disease, whieh is a risk 
factor for congestive heart failure, and diabetes, a risk factor for several 
other diseases with cardiovascular disease among them. 
In fact, diseases may interact in very compIieated and idiosyncratie 
ways. The art of modelling is to describe the intel'actions that are known 
weil enough and al'e deemed important, given the research qllestion, and ra 
igllore the unimportant and obscure. Part IH descrihes the methodologieal 
and mathematical foundations of the disease modeIs and formulates a set 
of simplifying conditiollS that allow these modeIs to interact in a lllulti-
disease environment, taking into account subsritution and competition of 
causes of death, comor.hidity, and risk factors, while keeping a l'eign on 
model complexity. 
From disease specific prevalenee and mortality 
to generic morbidity and a measure of popula-
tion health status 
Oll the disease specific level expansion and compression of mOl'bidity can 
be regarded as relatively straightfOl'ward: it simply is a qucstioll of changes 
in prevalence of diseascs. The disease specific modeIs of part II therefore 
look at prevalence of disease, as a rcsult of changes in incîdence, survival, 
and demography. 
Things get more complicated when severit}' of discase is taken into 
account: fol' example, does less ischemie heart disease but more heart fail-
ure cOllstitute a compression of heart disease, all expansion, or pcrhaps 
neither? And what ahont comparisolls hetween entirely different discases, 
like ca neer and heart disease? And, to complicate matters even further, how 
does bcing alive (but ill) compare to bcing dead? 
These complications are the consequence of looking at population 
health status as the result of bath Illorrality and 111orbidity, and of 11101'-
bidity frommultiple diseases. When only mortality is used the measurement 
of population health status is relatively simpie. Mortality is unambiguous: 
eithel' you al'e alive, Ol' you are dead. Cause specific mortality is more 
umhiguolls, beeallse rhe nnderlying cause of death registration aSSllmes that 
thcre is but one underlying cause; particularly at older ages, dcath is aften 
the result of a faiJure of multiple systems. But .cccpting the 'one dead, one 
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cause' ruIc, lllortality from anc disease eall casHy be compal'cd to lllortality 
from allother. 
But if not jnst ll10rtality but morbidity toD is taken inro account, dis-
case needs to be compared bath to dea th and to othel' diseases. Fo!" exam-
ple, thrombolysis saves many acnte m}'ocardial patients fro111 death, but 
some will pa)' the price of disabilit)' from heart failme (chapter 4). To 
'value' the effect of throll1bol)'sis Oll morbidit)', the )'ears lived with heart 
failnre have to be compared to the )'ears lost if IlO throll1bol)'sis had been 
admillistered. Ta vahlc a successfn! anti-tobacco poliey, a \Vide range of 
diseases have to be made comparabie, from stroke ancl COl'onary heart dis-
case over a whole family of cancers to chranie lnng disease and even hip 
fractul'cs. 
Part IV is devotcd to this ql1cst for a comprehcllsive measnre of 
population health status that includes both lllortalit)' alld morbidity, and is 
fit to indicate quantitatively compression and expansion of morbidity. Wie 
arglle, with ~Illlrray (.~Ilurray, 1996), that time is the common denominatol' 
that aHows compadson between diseases and between l110rbidity and 
mortalit)'. Time lived (life expectanc)'), or not Iived ()'ears of life lost), and 
time lived with disabilit)', and thus not lived health)'. 
The comprchensive meaSllre of popllJation he"lth status that is still the 
most used is life expectallcy, whieh expresses average time livcd, but since 
this me as lire does not include l110rbidity it obviollsly cannot address the 
compression and expansion question. A grOltp of reseal'chers therefore 
prop ase Health)' Life Expectanc)' (01' Health Expectanc)' for short), which 
stands for a whole famil)' of indicators (Mathers, Robine, & Wilkins, 
1994). The predominant approach is to use the prevalence of genedc mor-
hidity, such as disahility, measurcd through a cross-sectional survey, and 
combine it with Cl1rrent l110rtaJity to obtain a Health Expectancy by ig-
noring the )'ears lived with morbidit)' b)' the life table cohort (Sullivan, 
1971). 
Secn from the pel'spective of our approach th is implementatioll of 
Health Expectancy raises two problems. The first is to obtain a generic 
1110rbidity, starting from disease specific prevalences: the relation betwcen 
the two is not at all ohvious. The secOild problem concerns the years lived 
with mor bi dit)': b)' ignoring these )'ears morbidit)' is implicitl)' being 
eqllated with 1110rtality, and th is leaves hardly ally room to deal with se-
vcdt)' of morbidity. As is being shown in chapter 17 this ma)' reslllt in 
counter-intnitive hehaviour of the indicator. 
Bath problems were addressed b)' the \Vork of Mmm)' and colleagues 
on the Disabilit)' Adjusted Life Years, Ol' DAL Y (Mnrra)', 1996). The 
DAL Y is based on a disease specific approach, and nses disease- and stage-
specific disabilit)' weights to map discases to disabilit)': time lived with 
discase is weighted for the severity of the discase, with wcights betweel1 0 
(equivalent to full health) and 1 (eqnivalent to death). 
Unfortunately, as wc cxplain in the intl'oduction to part IV, because 
the DAL Y includes changes in the population strncture, for example the 
large post World War II bab)' boom cohorts, it is not ver)' snited for an-
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swering questions of compression and expansion that ongillate !rom 
changes in epidemiologl'. Moreover, the DAL Y is geared for cost-effec-
tiveness studies, and includes discounting of future life years, and an age-
weighting schedule which may produce counter-intuitive results (see chap~ 
ter 18). 
In chapter 19 we therefore propose to combine elements of the Health 
Expectancl' and DAL Y indieators in the Disabilitl' Adjusted Life 
Expectanc)', or DALE. The DALE is a life expectancl', and therefore ab-
stracts from popttlation structUl'e, and inclndes a disease specific approach 
with disability weights developed for the DAL Y. This setup allows to assess 
the impact 011 pop111ation health statns of changes in disease epidemiolog)', 
inclnding changes in disease severit)'. 
Given the DALE approach, the ql1estion of compression or expansion 
of morbidity can be operationalized as 'Under whieh eonditions will the Iife 
expectancy Iived with disability, weighted for severity, increase or de-
crcase?'. This qllestion is identical to: 'Dnder which conditions will the 
differenee between Iife expectaney and disability adjusted life expectaney 
increase or decrease?' Popnlation )'ears Iived in a prevalent discase state are 
obtained from incidence-pl'cvalence-mortalit)' disease ll10dels nested in a 
life table approach. These years are weighted for severit)' of the specified 
disease state. Combined with a life expectancy they yield a DALE. Overall 
morbiditl' is now defined as the diffet'ence between life expectancy, and 
disability adjusted life expectanc)': these are the years lost by disability, 
weighted for severity. If th is difference increases, morbidity expands, if tbis 
difference decreases, mOl'bidit)' compl'esses. 
Compression, expansion, and health care costs 
In the debate on compression and expansion of ll10rbidity the relatioll with 
health care costs has never been far away. Indeed, one could argue that 
concerns about health care costs fuel mnch of the debate, with proponents 
of compression c1aiming that prevention will dccrease health care costs 
(Fries, et al., 1993), ",hiIe an expansion would, in all likelihood, cause a 
relendess rise in costs (chapter 23). 
This makes sense: diseases and disability are determinants of health 
care costs. To investigate the matter we can map, as with disability, health 
care costs generated by a specific disease to incidence-prevalence-mortality 
models, nested in a life table approach. The research qnestion of compres-
sion or expansion of l110rbidity is then rephrased as a question of compres-
sion Ol' expunsion of health care costs, detennined by age, sex and diagno-
sis. However, as we will urgue more explicitly in the general discussion 
(chapter 27), the readers of this thesis must be wnrned that these parallel 
research questions do not imply parallel answers. lndeed, the historieal 
demographie and epidemiologieal transition was typically accompanied by 
compression of 1l10rrality, and very likely by compression of disability, but 
expansion of health care costs (Barendregt, Nnsselder, & Bonnenx, 1997; 
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Murray & Lopez, 1997). Indeed, if we take the large burden of morbidity 
and mortality Erom matcl'nal causes in developing conntries as an example, 
the role of health care is obvious. AtlS\veriug th is large health care need wil! 
ask for expansion of health care services as cnnse considerable compression 
of tllorbidity and mortality. 
As with disability the effect on cOlupression and expansion of casts 
depcllds on the changes in disease specific epidemiolag)'. In part V two 
chapters are devoted to the impact of prevention on casts. In chapter 23, 
l1sing a cause elimillation life tabie, large categories of diseases are elimi-
nated as causes of costs and of death. The costs of added life years af ter a 
fatal disease is eliminated are of ten higher than the health care costs of the 
disease before climinatioll. Only eliminating nOll-fatal diseases may yield 
health care savings (ignoring the casts of the prevention program). Chapter 
24 looks at the prevention of smoking and the impact of smoking on health 
care casts. In this chapter we show that smokers are more expensive to 
health care when alive, that a non-smoking population generates higher 
casts, but that neverthe1ess, givcn suitable assnmptiollS, abolishmcllt of 
smoking would be financially beneficia!. 
The evolution of senescence 
This general introduction has so far outlined the approach to the question 
of cotnpression and expansion taken in this thesis: all analysis on the dis-
ease specific level, followed bl' a synthesis to population health status out-
come, bath in tCl'ms of health alld health care costs. FrOlll there we take 
ane more step: a reflection on the underlying causes of morbidity and 11101'-
taliry and the possible consequences for compression and expansion. 
Part VI is devoted to the ultimate cause of age-related morbidity and 
lllortality. Why is aging synonymous te an increasing probability of be-
coming disabled and dying? Why does frailty increase with age? Why do 
mortality rates increase with age? \'(Ih)', in other \Vords, does SCllcscence 
exist? 
Epidemlologists aud dCl11ographers, let <lIane economists, may be 
tempted to dismiss sueh questions as ontological, or even metaphysical. But 
the answers to the questions of senescent mortality and morbidity are to be 
found in the charaeteristics of senescence. IE life span is fixed, as Fries and 
many others claim, huw is it fixed and at what age? Fries argues for arOlllld 
age 85, but others (and bettel' demographers), using basically the same 
mortality data as Fries, find that there is no evidence at all of a 'ceiling' of 
life expectancy (Manton, 1982). If out' death is genetically 'progranuned', 
'deprogrammation' might be possible, doubling or quadrupling our life 
span. But if mortality decreases further, what \ViII be the consequences for 
senescent morbidity? Will mortality be postponed, but not morbidity, 
giving l'Îse to Kramers' pandemie (Kramer, 1980)? Or wiII we age 'success-
fully' ? 
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Epidemiology, all empirical science based 011 observations among 
hmnans, is hard!y suited to answer snch theoretica! specula ti ons, as our life 
span is long and our actual !ife expectancy is unprecedented in human 
history. Evolutionary biologists, however, do ask these questions about thc 
nature of senescence. Senescence is obscrvable in most complex animal and 
plant species kept in sheltered conditions. The first consequence is that it is 
high!y improbable that the rea sans of snch all universa I phenomenon 
should be haphazard or coincidental. The secOlld consequence is that 
questions about senescence may be tested 011 other species, with a 11111Ch 
shorter life spa u thau homo sapiens. 
The npshot of these modern evoilltionary theories of senescence is that 
aftel' the age of reproduction is reached, energy consuming maintenance 
systems are neglectcd, in favour of that reproductioll. Thc ensuillg degra-
dation is more or less equally timed by the same life history, the callses of 
senescellce being omnipresent in genes regulating these maintenance sys-
tems. Inferenees relevant for futul'c popnlation health are many: 
1. A population life expectancy beyond 85 year is hard I)' likely for the 
foreseeable future, as natural selection had 110 effect whatsoever 011 the 
fenotype be)'ond that age. 
2. Genetic manipulation of senescence is unlikely, at least for the foresee-
able futnre, as the nl1mhel's of genes and gene illteractions il1volved 
should be extremely high. 
3. Seuesceut morbidit)' aud mortalit)' are related processes: death and dis-
ease are both 'natura!'. 
4. But slO\viug dowu the decay of maintenauce might be possible. Those 
who wish to 'eompl'ess morbidity' are then weIl advised to focus epi-
demiologiea! research on nOll-fatal diseases, the major detel'lninants of 
1110rbidity inlow mortality countries. 
Summary and research questions 
The central matter of interest in this thesis is the fllture of population 
health status in the Netherlauds. This is operationalized as the l11ain re-
search question: "\1'ill there be compressioll or expansion of morbidity?". 
In order to answer this questioll we fonl1111ated two additional re-
search ql1estions: "'X'hat cau a disease specific approach contrihnte to the 
nndel'standing of cOll1pression and expansion at the level of overall pOpl1-
lation health statns?", and: "How cau epidellliology aud 1ll0deIliug tech-
uiques be integrated into public health modeIs fit to auswer questious of 
compression alld expansion on the disease specific level, alld on the level of 
overall poplliatiou health? 
Fl'Om the two basic questious follows the road takeu: part II preseuts a 
number of disease specifie models, nsed to describe and undel'stand disease 
epidemiolog)' aud the changes therein. Iu part III a methodology is 
developed to integrate disease specific 1110dels to a cOll1prehensive Public 
Health model. Part IV describes how to summarize disease specific preva-
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lcnces and monulir}' to an indicator of populatiol1 health status, pCl'lllittillg 
an answcr to thc maill research question in tcrms of health. 
COl1seqncllces for health care casts of preventive interventiol1s, of ten 
advocated as the wa)' to compression, are shown in part V. Part VI prescllts 
an entirel)' different outlook at the same problem of morbidit)' and 
lllortality, searching for an llitimate canse of agc related degcncrative dis-
case in evolutioll theor)'. It formulates expectations about fnture lllortality 
and (senescent) morbidit)' based on the disposable soma theor)'. And fi-
nally, in part VII, we discuss our filldings and try to provicle an allswer to 
tbc three resc.:uch questiol1s. 
The remainder of part I is fOl'llled h)' chapter 2, the dirty hands of the 
epidemi%gist. In th is chapter wc argue that the nse of models in epide-
miology is a scientific endeavour, part of epidemiology. Epidemiology has 
to do with 'din)" data, and has to make the best ol it. Epidemiolog)' tries to 
answer answerable questions abont health and disease, with the aim of 
improving the health of populations. ModeIs ma)' help, h)' c1arifying and 
interpreting data in a consistent context. 
Obvionsly, as soon as we venture out from the islands of solid facts, 
we lllay make mistakes. Bnt, as iVlurray aud Lopez suggest, epidemiology 
needs to take some lessons of 'demographers ethos' (Mul'ra)' & Lopez, 
1996). Even il the facts are ver)' scarce, demographers use ever)'thing that is 
available and still construct a 'most plan si bie' population and a 'most 
likel)" population forecast. The on I)' alternative left to public health epi-
demiologists is to refuse to dirt)' their hands, to leave the public health 
poliey makers on their own and to complain about the wrong decisions 
decades af ter they have been taken. 
Our readers should keep in mind that we bOl'l'owed heavily not only 
from the demographers' tooIs, but also from their ethos. 
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Abstract 
2 
The dirty hands of the 
epidemiologist 
The main object of epidemiolog)' is to pro vide answers to practical 
questions in public health and medicine: 'Does factor A elevate or 
lower the risk of disease B?', 'Is treatment A better than treatment B?'. 
Designed as a (natural) experiment in selected study populations, the 
tested hypothesis is not immediately applicable. Public health models 
therefore take (quantified) theories and apply these to a (simulated) 
populatiol1 with due observal1ce of other risk factors, other diseases 
al1d other causes of death. The questiol1s the)' are el1deavoril1g to an-
swer are:' Wlhat wil! happen if we decrease factor A in the populatiol1?', 
'What wil! happen if we il1troduce treatmel1t A in a populatiol1 with 
disease Cf'. 
-+-
A good epidemiologist has dirty hal1ds, but a clean mil1d. 
Geoffrey Rose 
EPidemiologieal research studies the health of people with the explicit aim of improvillg th is in the future. In epidemiology, the research question ean always be redueed to a earefully specified sub question 
from the sets of lHow can we treat future patients better?! Ol' 'How can we 
enable futtlre populalions to live langer and heallhier?'. The sub questions 
tend to be very practical: lIs it plausible that treatmcnt A is better than 
treatmellt B?' 'Is it plausible that factor A yields a higher or lower risk of 
disease B?,l 
Tested epidemiologieal hypotheses yield relative estimates and ean not 
be applied direetly for poliey purposes. For example, well-founded research 
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has delllonstrated that in a female population aged 50-69 screened with 
mamll1ography, breast cancer mortality is a qual'ter lowcr than in rhe con-
trol popnlatioll.:! This pl'ovidcs illfonnatiol1 about the measuremcllt of a 
single effect (cleath) in a stud)' poplliatioll. Policymakers, howcver, are in-
terested in the actua! population, in absolute effects (the number of added 
life yearsl and in eventnal undesirable side effects of the program. The an-
swcr \Vill thercfore be influcnced by the incidence of breast cancel' and 11101'-
taliry in that population, by classificatioll iurD stages in diagnosing the 1111-
screened population (the worse, the greater the effect), by the expected de-
gl'ce of participation, etc. They arc naturally also interested in the resources 
they wi1l11ced to reserve: people, and money. 
Opcrational l'csearch alld scenario mode1s take epidemiological theories 
<tud appl)' these to a 'realistic' - alheit simnlated - population; the research 
questions become 'What if we treat patients with therapy A?' and 'W/hat 
happens if we perform health intervention B (for examp!e breast caucer 
screening) in the (Dutch) population?'. 
This assumes the application of epidemiologieal knowledge in prac-
tice. Various Dutch epidemiologists, following in the footstepsof Mietin-
nen, reject such applications of epidemiologiea! theory in the practice of 
publie health. 3.< We are defending the proposition that app!ication consti-
tutes an integra! part of epidemiology, and that without practical appliea-
bility) epidemiologl' beCOll1eS an activitl' without meaning and hence with-
ont a furute. 
The scientific process 
In scientific thinking about l'cality) a distinction can be made between ini-
tia! conditions (exposure in epidemiology), the causa I relationship (the hy-
pothesis) and aresuit (the effect).s From two elements, the third follows. 
The search for the causal relationship is the 'building of the theory': an un-
derll'ing law is assumed based on relations between the initial conditions 
and the observed results. A typiea! statement would beo a causa I relation-
ship exists between smoking alld Inllg cancel'. In a 'prediction', the theorl' is 
applied: the result is predicted based on the initial conditions and the the-
ory. A typica! statement is the following: if smoking behavior changes, a 
change in the incidence of lung cancel' may be expected. In an 'explanation' 
the hypothesis is given and with an explanation of the result being soug!n 
on the basis of the initia I cOllditiollS. The statement in this case wonld be: 
the observed rise in lung cancel' mortalitl' in women mal' be attributed to 
the increase in smoking bl' women in the past. 'Testing' illvolves qnestion-
illg the theorl': if I have a new set of initial cOllditions and results, does ml' 
causal relationship still hold up? 
Nlakillg connections, inferring causality, influellcing snpposed causal 
processes and subsequently the inferred causality in the light of the induced 
changes are all one and the same research pro ce ss. A problem is posed, an 
answer is snbsequentll' sOllght. To return to the lung cancel' problem: at the 
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end of the forties, astrong rise in Illng cancel' mortalit}' was observed. The 
causal relation to the increase in smoking habits was satisfactorily demon-
strated. Anti-smoking campaigns were initiated dUl'ing the sL'Cties. Young 
men smoked less and the prediction that deaths from lung cancel' would 
decrease in these cohorts were confirmcd. Thus epidemiolog)' delivered a 
practical answer to a practical question, from which man)' men are now 
re.ping the benefits. 
Good research starts with a research question: \,(/hat is the probJem? 
\Vhat questioll am I seeking to answel'? This leads to the stud)' design in 
whieh the vadous hypotheses can be tested. Given the answer found, the 
problem can be approached. Application of a theory, whether as a predic-
tion or policy advice, is inseparable from the development thereof. Seeking 
answers to questions which do not present themselves seems to us to be a 
senseless activity for an epidemiologist. 
Another practical example is that of the l'Undomized controlled study 
of breast cancer screening. The problem is: I Breast cancel' mortality is the 
largest cause of death from cancer in women. eau this be l'educed? The 
research question is: IDoes mammography screening redl1ce breast cancel' 
mortality?', The policy questiol1 is: IShould screening be implemented or 
not?I, If it had been impossible fol' screening to be carried out because, for 
example, mammography had proven exorbitantly expensive, the bottom 
would have fallen out of the study: the problem can na langer be answered. 
These studies then become senseless experiments on over a quarter million 
wamen. 
Dangerous models or dangerous theories? 
Quantitative modeis, such as, for example, those nsed in evalnating breast 
cancel' scrcening6 , are nothing more than a systematized theory, eontaining 
well-tested hypotheses which are to be quantitatively specified and which 
derive from all kinds of medica I and epidemiologieal research. In view of 
the plethora of relations and their interrelatedness, nowadays they are en-
tered in a computer, as the)' can then be calculated far more rapidly. The 
eonsequenees of interventions, as calcnlated by the model are snbseqllently 
compared with the observed realit}', and any lleecssary adjnstments are 
made to the model. 
More complex hypotheses in the farm of mathematic.lmodels entail a 
funher specification of qualitative theses. I.e. the qualitative statement that 
'smoking causes lung cancer' is easily knocked down b)' the tl'llthful obser-
vation that the large majol'ity of smokers does not have lung ca neer, nor 
wiII ever develop this, This statement becomes more correct when quanti-
fied: 'H you smoke, )'ou have a ten times higher chance of dying of lung 
cancel' than if )'ou don't smoke.' Note the inferred causalit)', the hypotheti-
cal model (a simple risk funcrion) and the predietion. Expand this to in-
elude more and mQl'e stratified risk factors and more causes of death and 
carefully specified time spans between changes in risk factors and the cause 
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ol death, and the computer model PREVENT is obtained7 • PREVENT at-
tcmpts to s)'stcmatize epidemiologieal knowledge about risk factors, such 
that the results are lIsefn1 to policymakers. Ta this end, the program com-
bines the prcvalcllce l'atcs lllcasnred in the Nctherlands (hypertcllsion, 
smoking behavior, cholesterol levels, etc.) with the relative risks accarding 
to the medical literature for all relevant disorders, thc expected time lapse 
betwcen a change in risk aud effect, aud illterventiolls to be specified by thc 
user in these risk factors. The sale differcnce between thc statement 
'Smoking causes caneer' <tud PREVENT is OllC of refinemcllt: bath make 
predictions abont the illcidcllce of cancel' based 011 causally assumed, em-
pirically measured relations. But PREVENT does more: it provides infor-
matioll abont the time span in whieh these changes are expected. To me as-
ure the effects of a changed smoking behavior, at least 20 years are needed. 
The program offers information about other disorders caused by smoking: 
cardiovascular disease and chronic lnng disease. It demollstrates the over-
whelming effect on the aging ol the Dutch poptdation on absolute figmes, 
despite the expected age-specific decrease. The ultimate goal is to show 
policymakers what will probably happen if the smoking behavior of a 
popttlation is altered. With that, PREVENT allSlvers the original problem 
formulated in the relevant epidemiological research: '\Vhat can we do 
abont the rising lung cancel' mortality?', 
It is extremely unlikely that PREVENT's predictions are quantitatively 
all 'correct'. Like all hypotheses, they are partly based on tiny stepping 
stones ol knowledge and partlyon giant steps ol inlerences and extrapola-
tions across oceans ol ignorance (with thanks to Geoffrey Rose lol' the im-
agery (note)). Hence hypotheses and inherent predictions about the lutme 
must be interpreted with cantion. Of ten, an awareness of the fact that 
computer models are na more than series of specified, more or less hypo-
thetical relations is lacking. The olten-used statement that models offer 
simplified representations is c1umsily lormulated; we propase amending the 
statement to models are a representation of a limited number of opinions 
about reality. 
Yet this limited number of opiniolls is nevertheless more extensive 
than can be overseen by the human mind all at once. It is extremely diffi-
cult to estimate contradictory consequences. To give another example: 
bl'east cancel' screening has bath desired and undesired effects. On the 
credit side is the greater number of wamen who live langer and the smaller 
chance of severe terminal cancel' as a result of the rednction in breast can-
cel' mortality. In the debit column are the lunds ancl people to be deployed, 
as weIl as the extra induced morbidity due to the anxiety aroused, early 
diagnosis and lalse positive results. The expected effects cannot all be over-
seen at onee. The breast cancel' screening model of the Department of 
Public Health (MGZ) carefully disentangles the advantages lrom the disad-
valltages, the cal'dinal hypo thesis being that screening with mammography 
promotes early diagnosis and improves the prognosis. The model does not 
'Învcnt', it assnmes th is tested snpposition from carefnIly contl'olled studies. 
II, as a competent sdentist, anc should clisagree with this, then the model is 
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discarded. In other words: one rejects the underlyillg hypotheses. Just as 
evel')' other hypothesis is discarded with which one should disagree. As a 
result, onc then belongs to a scientific 111inority, which is fine: there call be 
no scientific discl1ssion without scientific minorities. But one does not evade 
rcsponsibility: the pdce of an error is just as high. Advocatcs of screening 
may expose whole popnlations to feal', anxiety and useless treatments, op-
ponents perhaps cause l1nnecessary suffering aud all early, preventabie 
death. The choice is a thankless one, but unavoidable. 
Epidemiologists cannot nor shonld make this choke; that is the task of 
those responsible for policymaking. But they mI/st respond to the question 
posed to them, to the problem submitted to their consideration. Policy 
which is not based on the best possible estimation of the consequences of 
the choice to be made is irresponsible. The fact that it is a C01111110n OCCUl'-
rellce is no excnse: mere frequency does not make something automatically 
right. 
Conclusion 
Like all hypotheses, modeIs can and will make mistakes. The history of 
medicÎne is studded with errors of this kind, some fUlmy, some downright 
appalling. Yet by building hypotheses, applying these and testing them 
against the forccasts generated, by adjusting them accordingly, (medical) 
scÎence cau take a tiny step forward. Strict proof of whethcl' Ol' not these 
are correct will never be obtailled: tIf you insist on strict proof (or strict 
disproof) in the empirical scicnces, you wiII never benefit from experience, 
and you will never learn Erom it how wrong you are ts • .iVledicine is an 
unbelievabll' slipperl' field, and the task of epidemiologl' is to scatter a few 
pebbles in an effort to reduce the number of people who break their necks. 
In this image, the modeIs should be seen as organized attempts to lal' a 
pa th from the pebbles scattered throughout, a pa th which can be trodden 
bl' doctors, policl'makers and patients. It is the nature of the epidemiolo-
gis t's joh which will cause him to get his hands dirty in canying out these 
activities. To quote that wise man, Geoffrey Rose, again: !IA good cpide-
miologist has dirtl' hands, bnt a clean mind." Epidemiologists work with 
incomplete, distorted, 'unclean' data which will l'ield up a part of their un-
derll'ing secrets onll' when placed in a clarifying context. 
A clinical physician is a pragmatist; based on his (insufficient) know-
ledge he attempts to address the needs of the individual patient as best he 
can. An epidemiologist is likewise a pragmatist. Based on his (equally iusuf-
ficient) knowledge he attempts to address public health care needs as best 
he can. Attempts to l'cdefine epidcmiology as a theoretical scÎcnce makes na 
allO\vance for the problem presented: how to reduce humau suffering 
caused bl' disease aud premature death. Separating the testiug of hypothe-
ses in empirical modeIs from appll'ing these hypotheses in simulation stud-
ies in no wal' advances the quest for the right auswers and should therefore 
he rejected as being cOllnterproductive. 
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Note 
Geoffrey Rose was the (charisma tic) head of the Epidemiology department 
at the London School of Hygiene and Tropical Medicine. The quotes were 
taken from his opening lecture of the M.Sc. in Epidemiology training 
(1987). 
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PART 11 
Disease models 

3 
Introduction 
111 the general illtroductioI1) we observed that compl'cssion or expansion of morbidity depends on the consequences of dynamie changes and the type of diseases subject to these changes. This led us to two questiolls: 
why is a disease specific approach to the <genedc' ql1estioll of compl'cssion 
or expallsion of l110rbidity l1seflll, and how ean Pllblic health models, 
integl'ating epidemiology and ll10deling techniques, contribute to a better 
Ullderstanding of these changes in mOl'bidity? 
Thc chapters of part II demonstrate some of the answers to these 
questions, and the new problems whieh arise. The explanatory varia bles 
are changes in iueidence aud mortality of a speeific (group of) disease(s), 
the results arc changes in prevalcllce of that disease. The examples show 
changes in the two major Canses of death (cal'diovascnlal' diseases and 
cancer) and one cause of disability (hip fractmes). The last chapter of part 
II (chapter 10) antieipates part IV, and shows how morbidity and 
mOl'tality of a specific disease can be integrated in a single generic indicator 
of health status. The subject is dementia, whieh is not only a Ieading cause 
of morbidity aud health care costs in the Netherlands (Polder, Meerding, 
Koopmanschap, Bonneux, & van del' Maas, 1997), but whieh is also 
assoeiated with considerable excess mOl'tality (aIso shown in chaptel' 10). 
Synthesizing knowledge 
The first step is to identify the changes in the main event rates, incidence 
and mortality. Time series of disease specific mortality cau be abstracted 
from vital statistics. Becallse we are interested in changes, the maiu 
assumptiou needed is not that the Dutch cause of death register is 
absolutely reliable (whieh we know it is not (Mackenbach, van Duyne, & 
Kelson, 1987)), but that variations in registering and co ding practiees are 
relatively constant over time. This assumption holds for younger ages. At 
older ages, where a single cause of death is hard to identify, changes in the 
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'underlying canse of death' arc morc casil)' biased by chnnging registratiol1 
aud codification practices of uncertaiu causes of death (Dali & Peto, 1981). 
Time series of disease incidellce are harder to come by. Fot' the most 
frequent causes· of death, acute myocardial infarctiolls aud stroke, na 
incidence registers exist, and we have to rely on health care demand 
dependent hospital registers. \\1hcn illcidcllce registers exist, as for ca neer, 
incidcllce figures arc likewise dependcllt on changing health care 
technology and increasing patient awareness (Dali & Peto, 1981). Ta be 
registered, any patient has to consnIt the health care system, a potential 
cancer diagnosis has to be suspected, and the diagnostic technology 
available at that time has to be able to confirm the diagnosis. However, 
keeping these drawbacks in mind, health care registers are aften the only 
sonrce of epidemiologieal information over longer periods of tünc and/or 
larget' populatiolls. Ignorillg sneh all important souree, because it is less 
than perfect, violates one of the central pl'Opositions of public health 
epidemiology: appraximate estimates are better than na estimates (Murray 
& Lopez, 1996). 
A true incidence, the fil'st manifestation of a disease, is rafely 
registered as snch. \Y,1e had to reconstt'llct changes in incidence 
retrospectively by nsing varÎol1s manifestatiolls of the disease and a model 
of the disease history. This technique, calIed 'backcalenlation', has been 
used befare to calculate unobserved HIV infections from the incidence of 
AIDS and assumptions of the incubation time between infection and 
disease (Rosenberg, Biggar, Goedert, & Gail, 1991). We used pre-
dominantly attack rates (the sum of fatal and non-fatal disease events), 
taken from vat'Îous health care registers, and calcnlated an incidence which 
fitted these events thl'Ough pl'Obabilities of recurrence and death taken from 
the literature. The obtained incidence rates arc hypothetical, but reflect the 
available time series and figures trom the epidemiologieal literature. As 
prevalence of a chl'onic degenerative disease is cletel'mined by incidence and 
death, the prevalence of patients with a history of a clinical manifestation 
of the studied disease can be caleulated by the same backcaleulating model. 
If time series of health care use are fitted to time series of canse specific 
1110rtality, the resulting prevalence expands ot' compresses, depending on 
the changing in- and outflow caused by the time dependellt event series. 
Examples of sueh backcalculating incidencelprevalence/mmtality models 
are in chapters 4, 5, 6 and 8. In chapter 4 to 6, prevalellce and l1lunbers of 
patients with hcart disease or stroke are the main outcomc of interest, 
while in chapter 8 a range of possible colmectal cancel' survival 
distribntiolls is backcalculated, consistent with admission and 1110rtality 
trends. 
If incidence of a specifie diseasc is available (01' can be 
'backcalculated'), and the relation between that incidence and potential risk 
factors is known, changes in incidence can be projected, bascd on changing 
risk factor distribntions. In this thesis, we present no risk factorlevent 
models based on historieal trends in risk factors. The major reason is lack 
of data: while there is mnch written about risk factor prevalences, the 
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available figmes about important risk factors such as cholesterol and 
hypertension are amazingly scarce and remarkably inconsistent (Bonnel1x, 
van de Mheen, Gunning-Schepers, & van der Maas, 1996; van de Mheen, 
Bonneux, & Gunning-Schepers, 1995). "Lack of data" is even true for 
smoking: to model the relationship betweell smoking and cancel' incidence, 
the lag time between exposure and disease incidence is potentially that long 
that at least half a century of detailed information about smoking behavior 
is needed (Kunst, Looman, & Mackenbach, 1993). However, we used an 
extremely simple 'prospective' model in cllapter 9, where a lifetable-like 
model is used to adjust age dependent hip fmctme rates for (age dependent) 
bone mineral density. This allows to calculate expected changes in hip 
fractnre rates, 'iE' bone 10ss at a certain (menopansal and postmenopausal) 
age is stopped Ol' slowed. 
Chapter 7, based on statistica I modeIs, is a mix of both 'projective' 
and 'backcalculating' concepts. It shows how the sharply declining 
coronary heart disease mortality rates (without concomitant changes in 
admission rates) precedes the trend rl1pture in stroke admission and 
nlortality rates: the expanding vasenlar risk, inferred from the decreasillg 
nlortality, increases the incidence of eompeting vascular diseases s11ch as 
stroke and heart failure. 
If there has been no or very little evidence of changes in incidence and 
lllortality, sneh as in dementia, ealculation of changes in prevalenee is not 
very relevant. However, if changes are expeeted, a single indicator of lost 
health, combining the life years lost to severe disease and to death is of 
great interest to health policy. Chapter 10, using dementia as an example, 
anticipates methods in part IV and describes a method for quantifying the 
burden of disease, integrating both prevalence and death in a single 
meaningful indicator. Pharmaceuticals which are able to slow the pro-
gt'ession of dementia without toa many unpleasant side effects are under 
development now, and are expeeted to appeal' on the drug lllarket soon, In 
future work, we will use the methods elaborated in clIapter 10 to gauge the 
effects on the burden of disease of dementia of such treatments. 
Tracking changes in disease epidemiology 
Part II has two aims. The first we discussed in the previous section: how 
disease mode1s ean illtegrate epidemiologieal knowledge of various SOllrees. 
In th is section we show how sneh epidemiologieal lllodels ean track the 
consequences of changes in event rates for the bnrden of morbidity of a 
specific disease. Chapters 4 to 7 describe the most important cardio-
vaseular diseases, namely eoronary heart disease, heart failure and stroke. 
Even within cardiovascular diseases, strongly related to the same type of 
vascular atherosclerotic processes, very different dynamics are to be ob-
served betweell the vadons diseases in the recent past. 
In coronary heart disease, incidence was postponed, probably because 
of improved hypertension control and decreased smoking prevalence. This 
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should lead to lawel' disease prevalcllce, but discase dnratioll was illcreased 
to~ (sec chapters 4 and 5); on balallce, prevalenee increasecl. Particularly 
when thrombolytic thel'apy revolutionized treatment of acute myocardial 
illfarction, man)' patiellts survived, but with all impail'cd heart function, 
alld heart failnre illcidcnce and prevalcllce increased. Thc effect was that 
both disease free life expectancy and that life expectancy with disease 
expanded. As mortality was lowcred at all disease stages, prevalcllce 
increase cumulated in the 1110St sevel'e clisease stages. In sum, rhe recent 
histor)' of coronary heart disease was a typical example of expallsioll of 
morbidity, bath in numbers and in severity. In stroke, incidence declillc 
was prominent, but survival improvements rather limited. Becallse of the 
older age of stroke patients, the illcreased survival was cut short by 
mortality from other causes, and the sum of remainillg morbidity was 
declillillg: the history of stroke betweell the sevellties and 1987 was a rather 
t)'pical exalllpie of compression of morbidity (see chapter 6). 
The 1110rbidity changes in these cardiovascular diseases that share 
many common characteristics and risk factOl'S were thus completely 
opposite, driven predominantly by differences in available health care 
techllology. Disease duration illcreased rapidly among patients suffering 
from heart disease, becallse of increasillgly effectÏ\'e therapies. Amollg 
strake patients, incidence was delayed more (partl)' becanse of successful 
hypertension control) and death was delayed less. At the oldest ages, 
prevalence of stroke survivors tended to increase becallse of increasing 
numbers of survivors, but this increase was more than balanced by the 
decreasillg llumbers of young stroke patients. 
Chapter 8, about colorectal caneer, shows how in solid cancers 
incidence of ten is increasing, fueled predominantly by increasing case 
detection, but lllortality is decreasing, hopeful1y as a consequence of that 
earlier detection. Here too there are opposite dynamics: numbers of new 
and oid patients increase, numbers of interventions increase and health care 
needs increase, but the burden of morbidity is the sum of the morbidity 
caused by diagnosis and (demanding) treatment and the very severe 
morbidity of terminal disease preceding cancer deatl" If eariy detection 
succeeds in delaying death, both numbers of patients aud disease duratioll 
are expauding, but the severe end-stage of cancer is compressing. 
In chapter 9 we cOllsider hip fractures, whose rates are increasing 
since decades (Boereboolll, De Groot, Raymakers, & Duursma, 1991). Hip 
fractures are among the most important sources of health care costs among 
elderiy wamen (Polder et al., 1997), and the bllfden of morbidity has to be 
considerabie as well. \Y,1e show that cOlllpression by increasing bone mineral 
density willnot be as straightforward as of ten thought. Hip fractures are a 
senescent disease with a multifactorial character. Pl'evention of the fast 
menopausal bone ma ss loss byestragen decrease precedes the age of high 
hip fracture rates with several decades and will have but moderate effects. 
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Conclusion 
In this part of our thesis we show the Împortance of considering specific 
diseases in the de bate of future morbidity. Within a large disease group 
with l'nany shared characteristics snch as cal'diovascular disease, there may 
be opposite morbidity trends for specific diseases. Even in a single disease 
the character of morbidity may change as the pl'evalence of val'Îous disease 
stages change: in colol'ectal cancel' (characteristic of most solid tUl110rs) the 
bUl'den of mild morbidity increases because of increasing incidence but the 
burden of severe morbidity preceding cancel' death tends to decrease. 
These results are obtailled by using epidemiologieal models, reprodncing 
observed event rates by a quantified disease history, the main parameters of 
the history taken hom the literature. 
But the integration to overall populatioll health requires more than 
single disease models. The occnrl'ence of various diseases ma}' depend on 
the same risks (old age and senescent deca)' is the most striking example, 
but also smoking causes a wide variety of diseases), and changes in 
population health are detennined by more than just one disease. Part IV 
and part V will explain how these disease specific results can be integrated 
to changes in overall poplIlation health status. 
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Estimating clinical morbidity 
due to ischemie heart disease 
and congestive heart failure. 
The future rise of heart failure. 
Abstract 
Objectives: Man)' deve/oped coemtries have seen dec/ining morla/it)' 
rates for heart disease, together with an a//eged dec/ine in incidence and 
a seeming/)' paradoxica/ increase in hea/th care demands. The paper 
presents a model for forecasting the p/ausib/e evo/ution of heart disease 
morbidit)'. 
Methods: The simu/ation model combines data from different sourees. 
ft generates acute coronaI')' event and mortality rates from published 
data on incidences, recurrences and /ethalities of different heart disease 
conditions and interventions. 
Forecasts are based on p/ausib/e scenarios for dec/ining incidence and 
increasing surviIJa/. 
Resu/ts: Morta/ity is postponed more than incidence. PreIJa/ence rates 
of morbidity wi// decrease among Ihe young and midd/e aged, but wi// 
increase among the e/derf)'. As the mi/der disease slates act as risk fac-
tors for the more seIJere, effects wi// cumu/ate in the most seIJere disease 
states, causing a disproportionate increase in seIJere morbidity in o/der 
people. 
Conc/usion: Increasing hea/th care needs in the face of dec/ining mor-
'Ia/ity rates are no contradiction, but reflect a trade off of mortality for 
morbidity. The aging of the popu/ation wi// accenllwle this morbidity 
increase. 
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Introduction 
Hemt disease, comprisill.g ischemie heurt discase and cOllgestive hean failllre, 
is not only the leading cause of death aud lost life expectancy in most 
W'esterll countries, but also anc of the most imporrant sourees of morbidity 
and health care casts. I Aftel' a period of increasing mortality dUl'ing the fifties 
<1nd sLxties, the same countries have witnessed ct dramutic decline of ischemie 
lleart disease 1l10rtality (age adjllsted), with the United States taking the lead.' 
Thongh thc dynamics are not completely understood, time trends in kllOWll 
risk factors for ischemie heart disease (hypertension, cholesterol, smoking) in 
\VcstCl'll COllutrÎes indicate ct deal' decline.3,4,5 Therefore it is reasonable to 
attribnte at least part of thi:-; clecrease in mortality to a decrease in illcidcllce. 
The observed sharp decline in 1l10rtality, together with the probable 
decline in ÏllCidence leads one to expect a concomitant decrease in health care 
utilization. In rea!ity, however, health care providers all over the Western 
world are facing inCl'eases in demand. Af ter its introdllction, the lltilization of 
perclltaneous translnminal coronary angioplasties has il1creased almost 
exponentiall)', while the growth in utilization of coronaly artery bypass gl'aft 
surgery has merely slowed.6 Viewed superficial1y, the observed increases in 
demand are incongt'llCnt with the snpposed decrease in need. 
But is need truly decreasing? Basic epidemiologie theory teaches us that 
if mortality slows down faster than incidence, prevalence will increase. 
Although the Framingham Heart Stud)' has shown a small decline in 
incidence, astrong increase in prevalence has been observed, indicative of a 
survival gains. 3 This improved prognosis has been partly cansed by improved 
risk factor distdbutions, but medica I therapy has also contributed.7,s 
Recently, beta-blocking agents, platelet aggregation inhibitors, coronary 
artery bypass gmfting surgery and Al1giotensinc Convertil1g Enzyme 
inhibitors have been applied in chronic therapy, and thrombolytic therapy in 
emergencies. All have proven to be effective in randomised controlled trials 
of high stalldards.9 ,JO,ll If trends in risk factors and survival remain 
favourable, the fnrther decl'ease in incidence and mortality of ischemic heart 
diseasc is likely to be accompanied by a continning increase in prevalence. In 
\\festern countrics, the increased prevalenee will be accentuated by the ageillg 
of the bab)' boom genel'ation, born aftel' World War 11. Tms cohort will 
reach middle age with its concomitant heart disease risks: the increase in age-
specifie prevalence wiII be accompanied by an increase in sheer size of the 
older age groups. 
To make a quantitative alla lysis of the dynall1ics of the heart disease 
epidemie, we dcveloped a simulation model for the most important mani-
festations of ischemie heart disease and congestive heart failllre. Available 
illformatioll from the medica I literature was combined with data obtained 
from mortalit)' and 1110rbidity registers. We explored the future of heart 
disease 1110rbidity in the Netherlands by different scenarios. 
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Methods 
Model stl'UctUl'e 
The deterministic state transltlon modelnsed divides the popltlation Ullder 
study (here the entire Dutch population) into homogeneous subpopulations, 
ca lied states, defined by age, sex and disease history. Each year, the 
popnlation Il ages !! by 1 year aud the states are updated. Transitions from 
one state to another are governed by probabilities, extracted from registries 
and literature. Transition probabilities are independent from the preceding 
states and depend only on the current state (Markov chain assumption). i2 
The structme of the model resembles the Coronary Heart Disease Policy 
Model of Weinstein c.s., but we have excluded cardiac arrest as a prevalent 
state and included congestive heart failure. l3 
The morbidity model consists of tbree mait, sectors: the first mond, 
model, the ischemie hemt disease model, aud the congestive heart failure 
model. Persons developing heart disease, the rate of which is dependent on 
age and sex, move into the first month model, whieh characterises the initial 
event and its inlll1ediate sequelae duriug the first 30 days following the onset 
of disease. Persons in WhOlll congestive heal't failure for111s the fil'st heart 
disease event move direcdy into the appropriate model. Survivors of the first 
30 days enter the ischemic heart disease model or the congestive heart failure 
model that describes the remaining II months of the first year, and all 
snbsequent years. Persons with ischemie heart disease ean move into the 
cOllgestive heart failure model, but not vice versa. Death Erom heatt disease 
is modeled through the specific transition probabilities of the model. In all 
prevalent states persons are subjected to an additional risk of death from all 
other causes, COl'l'ccted for heart discase, bascd on nationallife tables. H 
The first mond, model covers the month inllnediately aftel' the initial cardiac 
disease event (Figure I). This event may be angina pectoris, an acute 
coronary event (all acute myocardial infal'ction and/or cardiae arrest) Ol' 
congestive heart failure (congestive heart failure). Persons suffering a first 
acute coronary event may die before reaching a health care facility ("deaths 
before admission 11). Onee taken Înto care, thcy are subjected to a fnrthcr 
death risk C'deaths in hospital!!). If the persons snrvive the eoronary event, 
the pump funetion of the heart may be pennanently impaired. Patients with 
heart failure aftel' an acute myocardial infarction enter the congestive heart 
failure model, the others move into the ischemie heart disease model. Persons 
with a [h·st diagnosis of congestive heart failure or uncomplicated angina 
proeeed to the ischemie heart disease and congestive heart failnre model 
respectively. 
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Demography I1 
Age,Sex 
First CHF t-
event 
.--
First Monlh Il 
Model 
-./ ACE+ ~ eHF i-
JHD Stales in m 2-12 fCHFJnm2-:~~ after onsel of IHO 
"' after JHO even +/-ACE history 
CHF state 1st yr t /1_ 
after ACE+CHF evenl 
~ 
IHD events in m 2-12 
.I ACE + H- Non-falal ACE I r- after onsel JHD ï eHF ?ACE, ?CABG, ?PTCA ! 
l--- ... CHF state in s lI_ subsequ. years 
T ~ IHO stales Jn subsequ. yrs. 
+1- ACE hislory HCHF in subsequ.yrs I Non-falal ACE I 
+/- intervenlion hislory after IHO event 
1 1 H lHD events in subsequ.yrs. ACE+ 
?ACE, ?CABG, ?PTCA eHF 
Acute Ischemie heart disease deaths 
Late Isçhemlc heart dlsease or 
congestlve heart fallure deaths 
or procedural deaths . 
I1 Prevalent State I1 Even! in previous stale Oisease speeifie death 
(Dealh of other causes occurs Jn alJ prevalent states, al any time) 
Note: 
CHF is congeslive heart failure; ACE Is acute coronary event; IHD is ischemie heart disease; 
CABG is coronary artery bypass graft; PTCA Is percutaneous transluminal COfonary angloplasty. 
Figure 1 - Tile heart disease model 
On entry, the ischemie heart disease model distinguishes between angina 
pectoris alld acute coronary event states. Conditional on these states, 
patients face passible new events in the 2 ta 12 ll1anths aftel' their first 
incident, ratlging fr0111 an acute coronary event, a coronary artery bypass 
grafting, a percutaneous transluminal COl'onary angioplasty to all possible 
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combinations of these. Each combination of evcnts in a state has a 
prabability of sndden death from ischemÎc heart disease dependent on the 
cnrrent event, the current state (and therefore the ischemie heart disease 
history) and the patient's age and sex. The patients also risk heal't failure as a 
sequel of an acute corollary event (" acnte corona1"y evellt + congestive heal't 
failure" in the fignre) 01' as a consequence of chronÎc ischemic damagej these 
patients move into the congestive heart failure model. If none of the abovc 
occurs, patients wiII remain in the ischemÎc heart discase model. 
Aftel' dûs first year, patients remaining in the ischcmic heart disease 
model are reclassified into 4 ncw states, conditional on previous disease 
history. These states arc dcscribed b)' the pl'esencc or absence of all acnte 
coronar)' event or of all Întervention. These patients face the same cvents as 
the previous yeal'. At the end of cach subseqnent model year, persons lagc' 
one year and are reassigned to statcs that l'eflect their updated histor)'. 
Persons with heart failure aftel' an acute myocardial infarction face a 
high risk of dying during the first year." On surviving this first year, they 
move to the congestivc heart failure state describing the subsequent yeal'S, 
whel'e they will stay until their death; this state was called "chronie", to 
distinguish it from the first, critical year following snch a complicated in-
farctioll. In these "chronicI! years the model assumes that mortality rates are 
lower. All other patients developing heart failurc iml11ediately enter the 
chronie cOllgestÏve heart failure state. 
Although non-fatal acute coronary events are possiblc in the congestive 
lleart failnre state, snch events 110 langer effect any change in the assigned 
state. Patients in the congestive heal't failure state face an annual probability 
of dca th due to cardiovasculal' causes whieh may be classified as acute 
myocardial infarction (lCD 410-411), chranÎc ischemÎc heart disease (lCD 
412-414), congestive heart faiJure (lCD 428-429) or stroke (lCD 430-438). 
We have incol'porated stroke as another specific cause of death, because the 
Framingham Heart Study showed that, due to comman risk factors 
(hypel'tension and diabetes), congestive heart failure is associated with 
increascd rates of stroke and death of stroke. l6 
Ineidenee and reeUl'l'enee rates 
Reliablc and recent incidence data on heart disease are not available in the 
Netherlands, as in many other coulltl'Ïes. Illciclellce figures have been esti-
matcd by an iterative non lineal' procedure fro111 observed numhers of events 
(acute myocardial infarctiolls, ischemie heal't diseasc deaths, interventions) 
and externally estimated transition pl'obabilities. 17 In this section we give a 
brief account how they were derived. The transition pl'obability matrix for a 
typical age grollp (60 - 64 year) is fllrnished in table 1. The complete tran-
si ti on matrices with a more detailcd account of references arc available from 
the anthors on request. 
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Table 1 - TransitIon probabilities for the age group 60-64. 
first Incidence In the tatal populatIon 
acute coronary event 
angina pectoris 
congestive heart failure 
M 
0,80% 
0,47% 
0,20% 
yearly probabIlItIes of an acute coronary event in the dlseased populatIon 
• in Ihe population with a history of acute coronary event 
Befere na intefVenlion in 1 st y 
Befare percutaneous transluminal coronary angioplasty in 1st y 
Betore coronary artery bypass grafting in 1st y 
After congestive heart failure in 1st y after acute coronary event 
After na intervention in y > 1 
After any intervention in y > 1 
After congeslive heart failure in y > 1 
5,3% 
7,1% 
10,7% 
20,5% 
2,8% 
4,3% 
7,3% 
• in Ihe popufation with a hislory of uncomplicated angina peetoris 
Betore na intervention in 1st y 
Before percutaneeus transluminal coronary angieplasty in 1st y 
Berere coronary artery bypass grafting in 1st y 
After ne interventien in y > 1 
1,5% 
3,7% 
5,5% 
1,5% 
F 
0,26% 
0,30% 
0,09% 
5,3% 
7,1% 
10,7% 
19,4% 
2,8% 
4,3% 
6,2% 
0,6% 
3,7% 
5,5% 
0,7% 
After any interventien in y > 1 2,2% 2,2% 
probabilitles of congestlve heart fallure In the dlseased populatio" 
interventio" rates 
within 1 month after acute coronary event 
after 1 menth after acute coronary event 
After angina pectoris 
coronary artery bypass grafting 
in ist y after acute coronary event 
in y > 1 after acute coronary event 
in ist y after angina pecteris 
in y > 1 after angina pectoris 
8,5% 
2,5% 
1,0% 
11,3% 
2,3% 
15,9% 
3,2% 
11,1% 
2,5% 
0,5% 
5,9% 
1,2% 
8,8% 
0,6% 
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Table 1 - conthlUed 
M F 
percutaneOl/S transluminal coronary angioplasly 
mortality rates 
heart disease: 
in 1st y after acute coronary event 
in y > 1 after acute coranary event 
in 1st y after angina pectoris 
in y > 1 after angina pectoris 
Vlithin the 1st month after an acute coronary event 
first acute coronary event, before admission 
first acute coronary event, inside hospital 
recurrent acute coronary event, befare hospita! 
recurrent acute coronary event, inside hospita! 
recurrent acute coronary event after congestive heart failure, 
befare hospita! 
recurrent acute coronary event after congestive heart failure, 
inside hospital 
operative mortality after 1st coronary artery bypass grafting 
operative mortality after recurrent ooronary artery bypass 
grafting 
procedural mortality after percutaneous transluminal coronary 
angioplasty 
1st-12th m after acute coronary event Vlilh congeslive heart 
failure 
in y > 1 after congestîve heart failure 
All other cal/ses of death in all states 
2,6% 1,9% 
0,5% 0,4% 
3,9% 2,9% 
0,8% 0,8% 
17,4% 18,0% 
8,4% 11,0% 
24,0% 24,8% 
12,7% 16,5% 
47,1% 44,0% 
18,9% 22,0% 
1,4% 3,0% 
3,4% 3,4% 
0.7% 0.7% 
19,9% 17,9% 
13,0% 11,0% 
1,14% 0,64% 
acute coronary event: Acute Coronary Event (including acute myocardial infarction, unstable 
angina pectoris and cardiac arrest) 
angina pectoris: Uncomplicated Angina Pecloris 
congestive heart fai/ure: Congestive Hear! Failure 
coronary artery bypass grafting: Coronary Artery Bypass Grafting 
percutaneous transluminal coronary angiop!asty: Percutaneous Translumina! Coronary 
Angiography 
in y > 1: In the years subsequent 10 the first year after an event. 
44 Disease models 
T otal munbers of admissions for acute myocard ia I infarction (lCD 
4101::1), total numbers of hospital deaths, und total numbcl's of intervclltiol1S 
by age and sex are available from the Ilutionwide hospital register 19,:!O,21,22, 
Patients with symptomatic infarctions who arc not admÎtted to hospital (60/0, 
in the Netherlands limited to the oldest age groups) are added." A constant 
ratio for the probability of dying before hospital admission versus dying 
inside the hospital from all acnte coronary event is assumed,'W,21,24,25 
Reported probabilities of recurrent acnte coronary events vary widely, from 2 
0/0 to 13 % aud more per year, depending 011 age, case-mb, aud selection 
criteria,13,26,27,2S,29,30 \\Te have assnmed that ischemie heart disease patients 
without congestive heart failure have a first annual probability of a recurrent 
acute coronary event of 0.062. This is consistent with the estimate of Wein-
stein et al of 0.078, iu willch patients with congestive heart failure are 
încluded, 13,31 ReCUlTcnce rates arc strongly age dependent. Wie assumc the 
age distribution to be idelltical to the known age distribution of a fu'st acute 
coronary evellt in the reference population. 
First acute coronary events aftel' an history of angina pectoris were mod-
e1ed based on data derived from the Framingham study, showing that male 
patients with angina pectoris, who have sllffered no previons acute myo-
cardial infarction, have a relative risk of 0.54 compared to those with a 
previol1s acute myocardial infarction.32 Female patients with angina pectoris 
have a relative risk of 0.45 compared to male patients.3! 
Patients eligible for coronary artety bypass grafting surger)' run a risk 
for reCl1nent events that is twice that for patients who are not eligible,3!,33.35 
coronary artery bypass grafting rednces hazard rates by 20 %.".37 Lacking 
data on the effectiveness of percutaneous transluminal coronary angioplasty, 
we assl1lned the relative risk for recurrent acute C01'ona1'y event to be 1.5, 
with a rate reduction of 10 %. 
Intervention rates 
Interventton rates are knowll to vary widely from country to country and 
even frolJl hospital to hospital."·39 We have nsed age and sex specific nation-
wide output data and assumed constant proportional relations between states 
ta esttmatc the numbers of illtervcntions Ul each state. The risk of an 
intervention in ullcamplicatcd angina pectoris versus the risk of an 
intervention af ter suffering an acute coronary event is 1.4: 35 % of patients 
with a history of an acute corona1'y evellt are patentially eligible for an 
intervention compared to 50 % in ullcomplicated angina.-W,4! The risk of 
nndergoing an intervelltion the first year af ter all ischemie heart discase event 
versus the subsequent rears was taken to be 5.'" The annual probability of 
having a sllbseqnent illtervention af ter a first intervention is 1 % (coronar)' 
artety bypass graftillg) and 0,5 % (percntaneons trallslnminal coronary 
allgioplasty).43 For ever)' 10 successfnl percntaneous trallslnmillal c01'on<\1'y 
angioplasties, another 4 are considered to be not successfnl dne to 
restenosis. +I If both coronary artety bypass grafting and percntaneous 
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transluminal coronary angioplasty oecuned in the same year, percutalleous 
translumillal eoronary angioplasties are ignored. 
Heatt failure 
Heart failure due to ischemie heart disease is caused by acute events or by 
chrollic ischemie damage. 18 % of the ischemie heart disease patients snrvive 
an acute myocardial infarction with irreversible heart failnre as a sequel,33,3-I 
The distribution by age, sex and previous ischemic heart disease history is 
assumed to be the same as the distribution of in hospitalmortality by age, sex 
and previons ischemie heart disease rustory aftel' an acute myoeardial 
illfarctioll. 
The annual probabilities of developing congestive heart failure, given an 
ischemie heart disease history, are estimated from the Framingham Heart 
Study.17 We obtained the published anoual event rates of 1.5 % given an 
uncomplicated angina pectoris history and 3.0 % given a history of an acute 
coronary event and adjusted to aUow for the number of acute cases caused by 
an acute coronary event. The age distribution was cakulated by applying a 
relative risk of 3.0 (angina pectoris) and 5.0 (acnte myocardial infarction) to 
the age specific incidence data taken from Framingham. 17 
The incidence rates of congestive heart failure withont a history of 
ischemie heart disease are calcnlated by assuming that persolls in whom 
congestive heart failnre is the certified cause of death sll1'vived their Hrst 
diagnosis of congestive heart failure for 5 (males) to 7 years (females).II.I'.I'.17 
Heatt disease mortality 
The total age- and sex-specifie in-hospital mortality rates foUowing acnte 
coronary events and interventiol1s are known in the Netherlands.20,22 The 
relative risk of dying aftel' a subseqnent versus a first acute coronar)' event 
was taken to be 1.5. 13,23,45 Pllblications are available in which the figures on 
mortality due to a subsequent versus a first coronary artery bypass grafting 
operation are given.46 The relative risk of death dne to percutaneous 
translumillal coronar)' angioplasty versus coronary artery bypass grafting is 
O.5.47,4S Procedural l110rtality due to a subsequent or a fit'st pel'cutaneous 
tl'allsluminal coronary angioplasty is taken to be the same. 
Risk of death during the first year af ter acute myocardial infarction fol-
lowed by congestive heurt failure was assumed to be 25 0/0; the distribution 
by age was const1'llcted by exponential inter- and extrapolation of data taken 
from Ahnve et aL" The annual mortality risk of heart failure during the 
subsequent years is assumed to be constant, i.e. 10 % (females) and 13 % 
(males).15.17.33.45 Of aU deaths caused directly or indirectly by heart failure 25 
% (female) and 37 % (male) are attributable to rec,ming ischemic heart 
events, and another 25 % (males) and 35 % (females) to stroke (and hence to 
non-cal'diac disease). [7 The figures for non fatal acute coronal'y events in 
persons with heart failure are estimated by asstuning a case fatality of 60 %. 
Figure 2 - Observed and 
simulated events in 1985 
Admissions far acute myocardial 
infarctian are the rates of 
patients discharged with as 
primary diagnosis acute myo-
cardial infarction (lCD 410), 
deaths in hospital are the rates 
of patients with this same 
diagnosis dying in hospital.20 
Deaths from acute myocardial 
infarctian are the tota! rates of 
death from acute myocardial 
infarction (lCD 410),21 The solid 
lines with symbo1s show ob-
served numbers, the dotted line 
represents the simulation by the 
heart disease model. The simu-
lated points given for the group 
aged 85-89 apply solely to these 
S years, while the observed 
pOints are for the open ended 
category "85 +". 
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All persons in all states are subjected te the risk of dying of other 
diseases, adjusted to allow for the causes of death unde1' study aud based on 
Dutch life tables. 
Results 
Calculated estimates fol' 1985 
Figllre 2 shows the obsel'\'ed and simnlated evcnts of acnte myocardial 
infarction: total admissiol1s and deaths in and olltside the hospital by age and 
sex. The model closely reproduces the observed data. The gap between 
sil11ulated and observed rates in the older age groups represents reeognized 
acute l11yoeardial infal'ction, which are not admitted to a hospita!. 
Ca1culated prevalenees of heart disease by age and sex are shown in 
figllre 3. Heart disease is more eoncentrated in the oldest age groups in 
females, while the burden of morbidity in the male population is ah'eady high 
at middle age. The levelling oH and decrease by age in the prevalence of 
clinical ischemie heart disease in men shown in the figure is eaused by the 
steep rise in the incidence of eougestive heart failure and sudden cardiac 
death, redncing clinical ischem.Îc heart disease incidenee. Prevalence of all 
hemt disease reaches up to 25 % in the age groups of 70-74 (males) and 80-
84 (females). Women suffer relatively 1110re of ten thau men from angina 
peetOl"is and congestive heart failure, but less often Erom severe ischemie hemt 
disease. This has been confinned time and again inl11any sl1rveys.32,49,50 
Projections for 1985-2010 
Disease specific lllol'tality is the direct resllit of incidence and survival. If two 
of these elements are known, the thil'd eau be calculated. As the decline in 
ischemie IlCal't disease mortality, which has been observed since 1975, is 
indisputable, we postulated an ongoing decline of th is l110rtality into the neal' 
future. \'(Ie provide three plansible scenados, based on varying assnmptions 
of fnrther decreasing incidence rates and improviug prognoses (see table 2). 
The reference scenario, based on the Framingham Heart Study, supposes 
that one thi1'd of the l110rtality decline is explained by a decline in incidence 
(-1.0 %/)'ea1') and that two thirds is explained by an increase in su1'-
vivaI.3,4,8,9,26,Sl In an extreme "low incidence change scenario" we as-
sume that the incidence decrease is even less: - 0.5 % /yea1'. This is the mag-
nitude of change p1'edicted by a risk factor model, based on changes in risk 
factor prevalences in the Netherlands.5 In an extreme 11 high incidence change 
scenario", we assnme a high decrease in incidence (-1.7 % pel' year). 
Figure 3 - Cumulated prevalenees of 
heart disease by age and sex, the 
Netherlands, 1985 
Uneomplicated angina pectons is 
defined as angina pectoris only, without 
a history of an aeute myocardia! 
infarction. Ischemie heart disease 
without congestive heart fai/ure 
describes all patients with a history of 
ischemie heart disease but without 
congestive heart failure, All ischemie 
heart disease comprises all ischemie 
heart disease, incJuding patients who 
deveJoped congestive heart failure after 
ischemie heart disease, All Heart 
disease summarizes all th ree conditions, 
The difference between all heart disease 
and all ischemie heart disease shows 
the preva!ence of congestive heart 
fa'llure, 
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Flgure 4 - Expected change In absolute and relative prevalences of patlents with ischemie heart 
disease, the Netherlands, 2010, compared wlth 1986. 
The dashed lines show the expected index of change in prevalence rates between 1985 and 2010 
(prevalence in 2010 divided by prevalence in 1985), with 1985 = 100. The solid Hnes indicate the change in 
absolute numbers, showing the force of demography. The heavier Hnes indicate the reference scenario, the 
thinner the bath extreme scenarios. 
Table 2 - Annual changes postulated In the scenarios. The extreme scenarios flgure 
between brackets. The mortallty decline (observed between 1975-1990) is kept equal 
tor all scenarios. 
Men Women 
Inddence -1,1% {-1,7%; -0,6%J -0,9% [-1,4%; -0,5%J 
mortality before admission -1,2% [-0,9%; -1,4%] -0.7% [-0.5%: -0.8%1 
mortality after adm. within 1st month -2,1% [-1,6%; -2,5%] -1,3% {-1,O%; -1,6%J 
late mortality -1,8% {-1,4%; -2,1%J -1,8% [-1,4%; -2,1%] 
Recurrence -3,1% (-2,3%; -4,7%] -1,9% (-1,4%; -2,9%] 
ischemie heart disease mortality -2,4% t -2,0%t 
t It is assumed tha! the mortality decline remains equal in all scenarios. 
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Figure 5a - Expected relatlve change in prevalence rates of ischemie heart dlsease, the 
Nelherlands, 2010 compared with 1985. 
Tha solid Hnes indicate the relative changes in number of ischemie heart disease patients 
without heart failure, the dashed those with heart failure (age specific prevalences in 2010 
divided by the same prevalenees in 1985). The heavier tines indicate the reference scenario. 
the thinner the two extreme scenarios. The relativa change of al[ ischemie heart disease 
patienls is shown in figure 4. 
Wie have projeeted these trends over the peri ad 1985-2010 to juxtapose 
the effects of demographie with epidemiologie change. The results are 
sllll1ll1arized in figllres 4 and 5 and table 1. Figllre 4 shows how the de-
creasing incidence together with the increase in survival results in lower 
prevalence rates in the yOlIng and increasing prevalence rates in older age. In 
age grollp 35 to 39 the deerease is abont 25%, while in age group 85-89, 
prevalenee inereases by 20% (males) and 10% (females). 
On superimposing the popltlation pl'ojections on these figures, a 
completely different picture is obtained, which is shown in the same fignl'e. 
The movement of the post-war baby boom generation into middle age and 
the sharp increase in the nllmber of the very eldcrly is deady revealed. To· 
gether with the projected increase in prevalence rates, this resnlts in a steep 
dimb in the nllmber of heart disease patients in the highest age grollpS. 
Hence, while epidemiological changes in cardiovascnlar disease result in an 
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Flgure 6b - Expected absolute change In numbers of patients wlth ischemie heart disease, the 
Netherlands, 2010 eompared with 1985 
The solid lines indicate the absolute changes in number of ischemie heart disease patients without 
heart failure, the dashed those with heart failure (age specific numbers of patients in 2010 minus the 
same numbers in 1985). The heavier lines indicate the referenee scenario, the thinner the two extreme 
scenarios. 
increase of prevalence rates of 10 to 20% for age group 85-89, the absolute 
number of patients \Viii more than double. 
Figure 5 shows the changes in age specific prevalences for different types of 
heart disease; Sa shows the relative changes of the rates and Sb the absolute 
changes in lHl1nber. The change in age-specific rates for all ischemie heart 
disease combined is the same as in figm·e 4. 
\V'ithin thc category ischemic hemt disease, figure Sa shows a relative in-
crease of severe ischemic heart disease. Prevalences of milder stages of 
disease act as a risk factor for the more severe. IE survival increases in all 
disease stages, effects will cumulate in the most serions stages: as more 
patients stay alive with ischemie heal't disease, more will have the opportunity 
to develop cOllgestive heart failure. 
Figure 5 b shows the changes in absolute terms: the relative decrease of 
prevalence at youllger ages has hardly any impact due to the low llllmber of 
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patients with ischemie heart disease at an early age. However, the 
combination of ageing and increasing survival of heart disease leads to a 
flood of middle-aged men with ischemie heart disease followed by a slmver 
wave of eldedy persons with heart failure. 
Table 3 shows expected changes in age standardized rates, nsing the Euro-
pean Standard Popltlation as stalldard, and in absolute nnmhers, combining 
the rateS with the expected population dynamies in the Nethedands. The 
mortality decline (obserl'ed between 1975 and '90 and projected over the 
next 20 ycars) is 50 stl'ong, that this will be evident evcn when cxpressed in 
absolute llumbers. Although the assllmed incidence decline of first 
m}'ocardial infarctions, which accounts for Olle third of the mortality decline 
is to~ 5111all to counteract the ageing of the Dutch popnlatiol1, the atrack rate 
of allmyocardial infarctions together willnevertheless decrease snbstantially. 
This is the result of the combined decline in incidcllce and reCUfl'CnCC; the 
better survival, on the other hand, throl1gh which the number of patients at 
higher risk of recurrent Înfarctions is increased, is not strong enough to 
coullteract this decline. Because more patients will stay alive and at risk for 
interventions and reinterventiolls, and because of the ageing of the population 
the lleed for coronary artery bypass grafting alld percutaneous transluminal 
COl'Onary angioplasty will increase by 1 % per year [range: 0.4 - 1.6J. The age 
standardized prevalellce ratias for milder ischemie heart disease tend to 
decrease, but those for ischemic heart disease complicated with congestive 
hean failure illcrease strongly: in absolute numbers, a growth of lllore than 
70 % is to be expected. 
Discussion 
Simulation 1110delling provides quantitative insight in epidemiologieal and 
publie health dynamies and in potential future developments. The infor-
mation needed for these modeIs can never be supplied by a single data sOlll'ce. 
Combining data from different sources is therefore appropriate, while the use 
of state-transition models provided a simple and comprehensible means of 
doing sa. The methods used are relatively easy to understand. The 
parameters of the model are meaningful to physieians and the results 
interpretable by health care providers, who are the principalusers. 
Nevertheless, in order to interpret results correctly,the limitations of this 
kind of modeIling should be understood. A number of simplifyillg as-
snmptiolls are always necessary to keep the model, and more particularly the 
nt1ll1ber of parameters to be estimated, manageable. 
We included eertain disease manifestations, and excluded others. Unlike 
\X'einsteill c.s., we excluded cardiac arrest as a prevalent state, but inclnded 
congestive heart failure. Cardiac arrest is highly lethal, and na major error is 
introdnced by mixing the history of those surviving an acute myocardial 
il1farctioll with that of a few snrvivors of a cardiac arrest. On the other hand, 
the indusioll of cOllgestive heart failure takes into account au important 
Table 3 -Age standardized rates (per 100000, using the European Standard Population as directstandard) and absolute numbers of 
admissions, interventions, patients and deaths due to ischemie heart disease (ischemie heart disease) and congestive heart failure 
(congestive heartfailure) in the Netherlands in 1985 and the projected index of change (1985 = 100) in 2010. 
The expected rates and numbers can be calculated by multiplying the figures for 1985 by the index of2010 divided by 100. The upper and lower 
bounds present the results of scenarios assuming extremely high or low incidence changes, but leading to the same mortality changes as a result of 
extremely low or high survival changes (see text). 
MEN WOMEN 
1985 Index of change in 2010 1985 Index of change in 2010 
(1985 = 100) (1985 = 100) 
Rates Numbers Rat. Numbers Rates Numbers Rat. Numbers 
acute coronary event incidence 267 16,438 76 [65 - 87] 114 [97 -130J 109 9.507 80 [71 - 89J 115[105-126] 
First admissions 214 13,150 80 [67 - 93J 119[100-139J 81 6,863 83 [73 - 94] 118 [105 -131] 
Admissions for acute coronary event 352 21,687 67 [60 - 73] 100 [90 -108] 122 10,529 73 [66 - 78] 105 [96 -111] 
coronary artery bypass grafting 96 5,797 84 [72 - 90] 128 [110 -147] 18 1,302 84 [72 - 97] 115 [98 -132] 
History of angina pectoris 1726 106,968 91 [79-104J 136 [119 -156] 1088 94,635 89 [78 - 99] 123[110-136] 
History of acute coronary event 2087 129,149 90 [79 -102] 136 [118 -153J 547 45,195 94 [82-106J 130[114-146] 
congestive heart failure with history of 575 35,761 118 [104 -131J 170 [149 -189] 284 29,251 115 [103 -125J 169 [153 -183J 
ischemie heart disease 
congestive heart failure without history 697 41,323 94 [88 -126J 144 [133 -163J 1 509 50,729 84 [77 -104J 130 [120 -146J 
of ischemie heart disease 
Deaths coded acute myocardial 194 12,045 54[tJ 80[tJ 82 7,889 63 [tJ 96 [tl 
infarction 
Deaths coded ehronie ischemie heart 106 6,422 65 [tl 96 [tJ 60 6,036 59 [tJ 90 [tl 
disease or congestive heart failure 
tin the calculation of upper and lower bounds, the mortality decline is assumed to remain equal. 
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eause of ehronie and severe 1110rbidity. By 1110delling the dynamies of and the 
relations between these different types and levels of morbidity a mOl'e realistie 
estimate of fuwre health care needs should be achieved. 
We used registered admissions for acute myoeardial infarction (ICD18 
410), deaths from ischemie heart disease (lCD 410-414) and eongestive heart 
failure (lCD 428-429) and transition probabilities extl'acted from multiple 
sourees in order to estimate incidcllces. This compllcates the assessmcnt of 
validity, which is thc most important problcm of th is or all)' other model with 
sneh complcxity. Thc model output reflects 'state of the art' clinical evidcnce, 
closely simulating present hospitalisation, intervention aud 1110rtality rates 
(see figure 2). lts esdmated prevalenees of clinieal disease eoincide closely 
with empirical observations.49,50,52 
Onl' forecasts arc based 011 mortality projections. For health care planning 
pUl'poses projections of incidcllce based 011 past risk factor prevalenees arc 
less reliable. Firstly, prevalenees of all known risk factors for heart disease 
are not available; prevalenee numbers which are available of ten show highly 
inconsistent resnlts between different studies. For example, estimates of the 
prevalenee of hypertension in Dutclunen from 50-59 y old vary between 14.4 
and 67 %Y' Seeondly, not all risk factors are known or observabie: 
projections only based on knowll risk factors are bound to undcl'cstimate 
futnre trends. 
The assmnption that mortality will continue to declinc is nncertain, but 
not implausible. Ir snpposes a progl'cssive change in risk factor distributiollS, 
a more widespread l1se of effective health care interventions in the future and 
ongoing technologieal advaneesY·S.9 The level of isehemic heart disease 
mortality expeeted in 2010 is comparable to that of 1950 (making 
allowances for changes in codification). If the absence of effective therapies 
in 1950 is taken iura account, this is not au extreme l'csnlt. Thc reference 
scenario supposes a decrease of incidence, explailling auc third of the 
mortality decline, based on the Framingham study! Other assumptions 
about incidence decreases and survival increases within extreme ranges are 
shown in the altcl'native scenarios.3,4,S These influence thc absolute magnitude 
of the expected changes, but not the direction. 
Declinillg incidence l'ates meun that the onset of disease is postponed but not 
halted. The delay in occurrel1ce causes a rednctioll of ll10rbidity in the yOlIng, 
which, however, is cancelled out with age. .iVlortality is deferred to all even 
greater extent, owing to a combination of the decreasc in incidence and 
improved pl'Ognosis. This 1110rtality decrease will be traded off for a steep 
increase of more severe morbidity in the aId. 
Changes in demography will preveut a decrease of new cases of heart 
disease. 13 However, while age specific incidence rates show a decline, acnte 
myocardial infarctiol1 attack rates wiII drop more strongly, due to a com-
bined reduction of incidence and recurrence rates; the il1creasing prevalences 
are insllfficient to cancel these reductions. The reference scenario predicts 
that a decline in attack rates whieh will be sufficiently strong to offset 
The future rise of heart failure 55 
popltlation ageing; this development has been observed in the Netherlands 
since 1985,19,20,21 But although disease illcidence rates are declining, 
intel'vention l'ates \ViII remaill unchallged, even assuming that illtel'venrion 
rates per group of patients in a certain disease state remain constant, The 
reason is that more patients will survive and that, on average, survival is 
longer, resnltillg in more people in disease states eligible for invasive corollary 
revascularisation procedures. 
The overall picture emerging from the hemt disease scenarios is one of 
transition from an acute to a more chronic disease: event rates are declining 
strongly, but the postponed lllortality is traded oEf for inereased 1l10rbidity 
and severity of disease among the elderly. This ean be observed in hospital 
admissioll rates in the Netherlands, in data from the Health Interview Survey 
in the USA and from the National Health Survey of Japan. 19,53 All of these 
data show increasing prevalellces of ischemÎc heart disease. As a 
consequence, overall health care needs will continue to rise, regardless of 
declining mortality alld incidellce. 
These calculations, based on empirical observations, shed a new light on 
Fries' eompression of morbidity theory.54 The eOlllpression of morbidity 
theory hinges on the proposition that the incidenee of disease will be post-
poned more rapidly than lllortality. For heart disease, the evidenee suggests 
that the deeline of lethality expands the number of years spent with heart 
disease mOl'bidity, regardless of the incidenee postponement. Healthy life 
expectancy is extended as expected by Fries alld assumed by the scenarios, 
but contrary to his prediction total !ife expectancy is extended even further. 
Among the middle aged and elderly, acute heart disease lethality in the 
Netherlands is high, inereasing sharply with age. Obviously, here would 
appear to be a serious potential for reduetion. In 1985, for example, the 
model eaIculated that 41 % of the 70 year old men died within 4 weeks of 
their fit'st acute coronary event.10.14 In om' scenarios 32 % [range: 30% -
34%1 are predicted to die within the same period in the year 2010, which in 
our view remaills a conservative estimate. Because heart diseases is 
concentrated in the older age groups, even small differences in the rates of 
change in incidence alld mortality call have major consequences, particulady 
now that pushing back mortality has been shown to be eounterbalaneed by 
all incl'ease in the more severe stages of hemt disease. \Vith short term case 
fatality subsequent to an acute event as high as it is, lowering this wiII remain 
an important goal of health care intervention. Should this aim be successful, 
the resltlting increase in the nmnber of survivol's wiIl boost heart disease 
mOl'bidit)' and lengthen life expeetane)' with disease. Only if health care 
interventions aimed at the l'Cdllctioll of mOl'tality subseql1ent to the event 
should prove a waste of time and money would there be 110 expansion of 
morbidity expeeted. 
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The new oid epidemie of 
eoronary heart disease 
Abstract 
Objectives: Ta quantify the ehanging prevalence of coronar)' heart dis-
ease as a consequence of declining mortalit)' and increasing hospital 
admission rates in the Netherlands in 1980-93. 
Methods: A multi-state Iife table describes the Duteh population in 
three disease states (healthy, one or more acute coronary events). The 
Iife table uses parsimonious assumptions about disease history to fit 
observed mortalit)' and registration rates from the nationwide hospital 
register. The outcome is prevalence by age, sex, time and disease state. 
Ranges show the results of varying sensitive assumptions. 
Results: The prevalence in 1980-93 was 4.4% (range 4.0-4.9) and 
1.4% (range 1.3-1.6) for men and wamen of 25-84 y. Between 1980-
83 and 1990-93, the clinical incidence changed liltie, but age adjusted 
prevalence increased by 19% (range 10-29) and 59% (range 47-73) for 
men and wamen respectively. This increase was more pronounced 
among the elder/y. 
Conc/usion: In the Netherlands, the sharply decreasing mortality but 
near constant attack rates of coronary heart disease has eaused distinct 
increases of prevalenee. The number of cardiovascular frail elderly is 
expanding rapidl)'. 
Introduction 
COl'Onary heart disease is the leading cause of death in the Netherlands, as 
in the rest of the world.! As the population is aging, the casts for COl'Onary 
heart disease are increasing fastly. In 1988, COl'Onary heart disease caused 
2.7% of all alIocabie health care casts in the Netherlands, in 1994 this was 
3.1 %.2-4 This relative increase makes corol1ary heart disease ane of the 
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[aster growing causes of medical casts in the Netherlunds.4 Part of th is in-
crease secms to be canscd by increasing health care needs. In the Nether-
lands, mortality rates arc decreasing steepl}', but hospital admissiol1 rates 
arc increasing.5 As less patients die suddcllly out in the SU'cet or at home, 
more arc admitted to the hospita I. As morc patiellts sUl'vivc an acnte myo-
cardial illfarctioll, more arc at risk of a recurrent infarction 01' congestive 
heart failUl'e.' 
This paper estimates the changing prevalcllce of coronary heurt disease 
as a conseqllcllce of the changillg disease history. An illcidellCe-pl'cvalence-
Illortality model describes a silllplified coronary IlCart disease. In such a 
model, inflow (incidence) and outflow (mortality) deterllline pools of SUl'-
viving patients.7 \Ve used available time series of hospital admission rates 
and mortality from the period 1980-1993 as flows, and calculated the 
prevalence of patÎents with a histor}' of an admission for a myocal'dial in-
farction b}' age, sex and calendar period. The incidence-prevalellce-mor-
talit}' model is a reduced, stationar}' version of a dynamic simtdation model 
published before.' We show that the decreasing coronary heart disease 
mortality callses the increasing hospital admission rates and we quantify 
the res\dting illcrease of prevalence. 
Methods 
Data 
The model uses as input numbers of patients discharged with the diagnosis 
of acute coronary event (lCD 410-411), by age, sex, calendar period (1980-
93), and olltcome (fatal or non-fatal) and numbers of de.th from vita I sta-
tistics by age, sex, calendal' pel'iod and cause of death.5,s,9 Fatal outcomes 
of hospital admissions are counted as acnte coronary deaths in hospital. 
The hospita! register is nationwide. Nearl}' all recognized acute coronary 
events are hospitalized lO•lJ , but silent or not recognized m}'ocardial infarc-
tious can not be coullted. The causes of death considered are acute coro-
nary heart disease (lCD 410-411), chronie coronary heart disease (lCD 
412-414), other cardiovascular discase (lCD 390-409; 415-459) and all 
other causes of deatIl. By definitioll, all acute coronar}' deaths are the Sllll1 
of all acute in and ont hospital coronar}' deathsj atrack rates are the sum of 
fatal and non-fatal acute coronary events. Age and sex specific rates arc 
calculated by using the midyear population of the Netherlands as person-
}'ears. 
Model 
Figure 1 illustrates the concept. A life table population without heart dis-
ease ('healthy') is subjected to au incidence of acute coronary eveuts and 
two mortality hazards: a risk of dying from cardiovascular disease other 
than coronary heart disease and a risk of dying from all other causes of 
death. These (and all other) transition probabilities are age (5 year age 
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In superscript is the cause of death (all other causes nol mentioned). All transition 
probabilities are age and sex specific. The subscript ~time" refers 10 the period after the 
event (immediaIe, firsl year or subsequenl years), Ihe subscript 'healthy', 'inc', 'ree', 'ace' 
to the status (heallhy, first event. recurrent event, or one of bath). 
groups) and sex specific. At the moment of incidenee, patients may die be-
fore admission to the hospital, to be eounted as a coronary death, or they 
may die aftel' admission and arc conllted as a fatal ontcome. If they sur-
vive, they move to a seeond Iife table state, the population with a history of 
an acute coronary event. Here they are at risk of recurrent acute coronary 
events and tIuee mortaliry hazards: a risk of dying from late eoronary heart 
discase, an increased risk of dying from other cardiovascnlar diseases and a 
risk of dying from all other eauses of deatIl. Risks of recurrenee or ehmnic 
eomnary heart death are higher during the first year aftel' the event. If per-
sons suffer a recurrent acute coronary event, their risk of dying is higher, as 
eompared to an incident event. If they sUl'vive, they move to a third life 
table state, the population with a history of multiple infaretions. Here, 
they are subjeeted to the same risks of dying from other eardiovaseular and 
non-cardiovascnlur causes, but at increased risk of recurrent events alld 
death from acute alld chl'onic coronary heart disease. 
Assumptions and sensitivity analysis 
There are four dimellsions in the history of an acute coronary event. The 
first is disease history. A history of corollary disease predisposes to new 
coronary heart disease events and other atherosclcrotic disease. 11 The prog-
llosis of such a recurrent evellt is worse than the first evellt.13~15 The secolld 
is age: the progllosis is heavily age dependent, the older the worse,13,16 Thc 
thil'd is duration: prognosis, compared to a reference popnlation, improves 
over time, 12,15,17 The fourth is gender: wamen have (age adjusted) less coro-
nary heart disease than men, while the fatality rates may be bath higher Ol' 
Iowcr. 1I ,12,17,IS 
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Table 1 shows how these dimensions are qnantified. Data about the 
distribntioll between fint and recurrent acnte coronary event at hospita I 
are lacking in the Netherlands, and are reconstl'Ucted by using clinical and 
epidemiologieal literature. \\Te made three assllmptions to estimate recur-
rence and incidcnce rates. Fit'st, that the proportion of l'eClllTCnces was 
30% (range 25%-35%; upper and lower figures between brackets are al-
ternative assu111ptions used in scnsitivity allalysis),II,I9-13 second, that the 
risk of a reClll'rCllCe incl'cased lillead)' by age21 ,:!3-25, third that the risk of a 
recurrence was 2.5 (range 2-3.5) times higher the first year than the subse-
qnent years,12,22 This yields an average risk the first year aftel' the myocar-
dial infarction of 6.5% (4.9%-8.1 %) at age 40 and 11.2% (8.5%-14.0%) 
at age 70, the subsequent years of 2.6% per year (2.0%-3.2%) at age 40 
and 4.5%(3.4%-5.6%) at age 70 (see also table 1, recurrence rates). These 
figures arc comparable to estimates pl'cviollsly used in simulation modeIs in 
thc Netherlands and in the USA6,:!6,:!7, based on data of the Framingham 
Heart Stndy ,:!,:!5,and other studies, also from the Netherlands,:!S,:!9 
The prognosis af ter a recurrent event is worsej we assumed that the 
odds of death aftel' a recurrent event was 1.8 (range 1.5-2.2) times higher 
than af ter a first cvent, H,15,:!1,B,:!4,30,31 Survivors may die from chronic coro-
nary heart disease. We assumed that the risk of dring of late COl'OnJry 
heart disease is 5.0 times higher during the first year than during all subse-
quent years.1:!,:!5 This figul'e is relatively high not only becal1se the risk is 
increased the first year, but also because the risk of being coded 'late COl'O-
Table 1 - Assumptions used to fit the observed series, 
1. Asymptomatic events are not counted. 
2. All persons with a symptomatic acute caranary event die or are admitted. 10,11 
3. The vital statistics' registration codes reliab!y acute and chronic coronary heart 
disease as a cause of death.11 ,48 
4. Of al! discharges for an acute caronary event. 30% (range 25%~35%) are 
discharges for a recurrent event. 11,19-23 
5. The risk of a recurrence increases linearly by age. 21,23-25 
6. The risk of a recurrence is 2.5 times higher in the first year after the event Ihan in a 
subsequenl year. 12,22 
7. The odds of dying after a recurrent event are 1.8 (range 1.5-2.2) higher than after a 
first ovont. 14•15,21 ,23,24.30.31 
8. The risk of dying of late coronary heart disease, and being coded as such, is 5.0 
times higher in the first year Ihan in a subsequent year. 12,25 
9. The risk of dying from other cardiovascular disease Ihan coronary heart disease is 
2.2 (range 1.6~3.3) higher among patienls with a history of an admission for acute 
coronary heart event than a healthy population. 25,32 
10. There are no differences among men and women, except the obseJVed differences 
in the time series of admission, mortality and in-hospita! survival 
11. The annual risk of a recurrence decreased by 20% (range 0-40%) between 1980-
83 and 1990_93.15,27 
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nary death' decreases over time, The longel' the period between hospita I 
admission and death, the more likely a patient will be coded 'other heart 
death' (particularly congestive heart failure). This increased relative risk of 
dying from other cardiovascular diseases is assumed to be 2.2 (range 1.6-
3.3) higher than among individuals without CHD history.15·32 
With these assumptions and data, the model is fully specified. The 
incidellce of a first acute coronary event, the acute fatality befare and aftel' 
reaching the hospita I and the 'late' mortality (coded as chronic coronary 
heart disease mortality) can 1l0W be computed by fitting the calculated 
lllortality alld admission numbers on the observed mortality and admis-
sions. 
All calculated rates and ratios are age and sex specific. Most .ssnmp-
tions are based on male di se ase history. Same state that coronary heart 
disease among females occurs later, but has a worse prognosis (even aftel' 
correcting for oIder ages), other studies show the opposite.11,12,16,23 Lacking 
reliable gender specific information, we uscd identical assumptiolls for dis-
ease histol'Y in women, 
The period 1980-93 is estimated first, cOllsidered as Olle homogeneous time 
period. Then the changes in that period are calculated by estimating the 
periods 1980-83 and 1990-93 separately, using the same assumptions, bnt 
the attack and mortality rates of the relevant period only. As it is not ver)' 
plausible that the probability of recmrence remained constant in the 80s -
the use of beta-blocking agents and platelet inhibitors became widespread -
we assumed that recmrence rates declined by 20% (0%-40%) between the 
two periods. 15,17 
Results 
Table 2 and figures 2 and 3 present input and results. All rates and ratios 
are age adjusted to the Dutch popltlation of 1980-93. Admission rates in-
creased between 1980-83 and 1990-93 by 30% among women and 10% 
among men, but decreased slightly among younger men (-6%). Mortality 
rates declincd steeply, with an even more pronounced decline among 
yOltllger men. 
Attack rates, the sum of fatal and non-fatal acute coronary events, 
declined slightl)' among men (-3%), and increased among women (+7%). 
Amollg younger men, the declille of attack rates was more prollOllllced (-
12 0/0). Amollg oider perSOllS, bath men and women, attack rates increased 
by 3 and 6%. This implies that improved survival explains the increase of 
admission rates at older ages (see figure 2. Nearly all patients which sur-
vive such an acnte coronary event wil! be admittedIl: lower death rates 
mean marc admissions. 
Table 2 - Overview of input data, assumptions and results. 
The bold figures are observed, the itaJic figures are assumptlons, based on the Jiterature. lncidence and prevalence are results. Between brackets are 
assumptions and results from the sensitivity analysis. All estimates are age adjusted to the population of 1980-93. 
Mean rates and ratios for 1980-93 (per 1000 persons per year)t 
age admission death attack recurreneet incidence prevalence prevalenee of recurrence 
Men 25-59 2.87 0.66 3.29 83 (63; 104) 2.78 (2.63; 2.92) 17.7 (16.8; 18.6) 3.0 ( 3.5; 2.5) 
60-84 13.56 10.34 19.47 112 (85; 140) 15.13 (13.90; 16.66) 139.1 (122.9; 157.0) 39.5 (41.5; 35.5) 
..................... ~~.:~......... ... ~:z.~_...~-.!s._...s.:~.~.. .... .1.O'3..v~;.1.~.8L. .... _ ..... s.:~.9..( ... S.:.1.1., .... s.:~:4:!.....~~3..( .. ~?~; .. ~~:O') .... _ ..... 1.1:0 .. (.1.1:~ ; .. ~:T2.. 
Women 25-59 0.61 0.15 0.70 91 (64; 105) 0.57 ( 0.55; 0.61) 3.4 ( 3.2; 3.6) 0.6 ( 0.6; 0.4) 
60-84 5.95 5.06 8.77 125 (87; 144) 6.83 (6.60; 7.39) 41.9 ( 38.9; 48.6) 9.8 (10.1; 8.4) 
25-84 2.10 1.52 2.95 119 (84; 137) 2.32 (2.24; 2.50) 14.1 ( 13.2; 16.2) 3.1 (3.3; 2.7) 
Re/ative change between 1980-83 and 1990-93 (%) 
age admission death attack recurrenee lncidence prevalenee prevalence of recurrence 
Men 25-59 -6.0 -42.3 -12.0 -20(0;-40) -10.1 (-13.9;-6.2) O.O( -4.1; +4.5) -9.0 ( +4.4;-20.9) 
60-84 22.9 -25.6 3.0 -20 (0; -40) +5.9 (-1.5; +14.0) 28.7 (+16.7;+42.0) 27.2 (+35.2;+19.3) 
............................. ~~.:~:4: .................... 9.:~._ ....... :~.s.:s.._ ............ :~:.s. ....... :~.o..r..0L::4.O'! ......... _ ....... :.O.:~ .. (.: .. s.:~: ... ~~.:!) ............ 1.9.:~.<...::s.:?;.~~.9.:~) ..... _ ...... 1.~::4:.~::.2.!:.9., ... ::S.:.22. .. 
Women 25-59 
60-84 
25-84 
22.5 
32.1 
30.0 
-30.3 
-27.5 
-27.7 
13.3 
6.3 
7.4 
-20 (0; -40) 
-20 (0; -40) 
-20 (0; -40) 
+15.0 (+10.8;+19.4) 
+1.4 ( -3.1; +6.2) 
+3.7 ( -0.8; +8.4) 
t Recurrence rates shown are rates the first year after a coronary heart disease event 
34.2 (+28.7;+39.9) 
64.8 (+50.6;+80.2) 
59.1 (+46.6:+72.5) 
27.2 (+46.2;+10.3) 
90.0 (+104.0;+76.7) 
80.3 ( +95.3;+66.0) 
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The calculated incidence and l'ecnl'l'ence rates are based on the as-
sumption that 30% (25%-35%) of all admissions are recurrent, and the 
risk illcreases by age. The resulting recurrence rates among coronary heurt 
disease patients are consistent with previollsly used estimates and figul'es 
observed in the Netherlands.6,26,29 The seemingly higher reCUl'1"ence rates 
among women is because women are older. 
Clinical incidence changed probabi)' little between '80-83 and '90-93. 
Only among younger men, the decrease seems quite certaÎn. Among 
yonnger women, clinical incidence increases. 
The prevalence of patients ever admitted for an acnte coronary heart 
event is tmee times higher among men than among women .. ,_ lont of 7 
Dutch men and 1 out of 24 Dutch women between 60 aud 84 have been 
admitted for an acute coronary event. These prevalences have been il1-
creasing recently, predominantly among elderly, cansed by the the in-
creased snrvival bath of out of hospita I and in hospita I (see table lb aud 
figure 3). Over one decade, there are - age standardized - 19% more sur-
viving men and 59% more surviving women with acute coronary heart 
disease patients to care for (see figure 3); amoug persons aged 60 aud more, 
prevalence increased b)' 29% (men) and 65% (wamen) . Among women, 
the relative changes are more pl'OnOlUlCed , but we have to keep in mind 
that the absolute levels are far lower thau among men. The prevalence of 
l'eCUl'l'ence increases in the same order of magnitude, more among the eld-
erl)'. These wil! be at the highest risk to develop congestive heart failure. 
Sensitivity analysis 
The main assnmptions in this model concern prognosis of an acute C01'O-
nary event and the distriblltion of attack rates hetween incidellce and recul'-
rence. The model is litde sensitive to varying assumptions ahout prognosis, 
snch as the prohahility of dying of a first versus a recurrent event or the 
probabilit)' of d)'ing from other cardiovascular disease. Because the model 
fits observed admission and death rates, var)'ing assul11ptions about prog-
nosis wiII 'win some and lose some'. If the hazard ratio of death aftel' a 
recurrent versus all incident event is high, the hazard of death aftel' a first 
event is relatively low, hut more will he at risk of a recurrent event, which 
will have a worse pl'Ognosis. Over all, the duratiou of disease wil! llOt 
change much, and neitl,er wil! the calculated prevaleuce. 
The model is sensitive to assl1mptions abont proportions of recurrence. 
These wm l'edistribnte incidences and recnrrences: low l'ccnrrence means 
high illcidence, and cOllsequently a shol'ter disease dumtion to obtain the 
same death l'ates. The uncertainty abont incidence and recurrellce rates 
dominates the uncertainty of the calculated results. 
Validity 
Figure 3 shows observed prevalence in the Rotterdam Stud)' of more Ol' less 
the same period (1990-92).33 We did not use au)' figUl'es of the Rotterdam 
Figure 2 - Observed admis-
sion (acute coronary heart 
disease) and mortality (coro-
nary heart disease) by gen-
der, age and two periods. 
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Stud)' ra specify the model. The close agreement is noteworth)'; the some-
what lower pl'cvalence corresponds with the expectatiolls: observed pl'cva-
lence will lag behind expected figures as a conseqnence of d)'namic effects 
(sec discllssiol1}.34 Thc disappearing declinc of pl'cvalcl1cc at oldest ages is a 
characteristic cOllseqncllce of climinishing mortality pressnre: more persons 
with heart disease slll'vive untill cider ages. This depencls 011 changes in 
past flows, and the intC1'lllCdiary position of prevalenee in the Rotterdam 
stnd)' between the stationar)' estimates for 1980-83 and 1990-93 is there-
fare consistent. The assl1111ption of lillendty in the calculation of rccurrCllce 
rates might callse the lowel' prevalenee in the youngest age group: iE the 
reCUl'rellCe rates at yOl1llger ages are toD 10w\ incidence and consequently 
prevalence is overestimated. Among women the observed age gradient is 
stecper than cxpected, with lower prevalenee at younger ages. This might 
be due to somewhat lowel' coronary heart disease in Rotterdam than in the 
whole of the Netherlands", or to a less well specified fenlale coronar)' heart 
disease epidemiolog)'. 
Discussion 
The used model combines available administrative data about admission 
and dcath rates with parsimonious assllmptions in a stationary mnlti~state 
model to caleulate expected bealth care needs for patients with a bistor)' of 
a single or a recurrent acute c01'onary event. The results snggest expansion 
of heart disease morbidit)' in the recent past in the Netherlands. Expected 
incidence remains nearly constant, mortality declines rapidly. Prevalent 
patients fil! the gap between constant incidence and decreasing mortality, 
sl1rviving till ol der ages. These are at risk for further coronary and other 
cardiovasculal' disease, and boost health care needs. 
These results might be biased b)' the nature of the data Ol' the assumptions 
made to specif)' the model. We used administrative data, not designed for 
stud)'ing the epidemiolog)' of coronary heart discase. But there are no fi-
nallcial incentives to register a particl1lal' dia gnosis, and trends in 111yoCa1'-
dial infarction rates of such administrative hospital register data compare 
weil to trends in epidemiologie studies." To be registered as an acute 
corona1'y event depellds from the patiellts' awarelless and doctors' diagllos~ 
tic acuit)' and decision between competing choices. Illdeed, it is likel)' that 
increased awareness of womens' risks for coronary heart disease partly 
causes the increase of clinical incidence among women, pal'ticularly among 
yOl1ngel' women,37,38 Doctors (and patients) rarely expect coronary heart 
disease among youngel' wamen. This is certainly not ullique for the Neth-
erlands. In the Fl'amingltam Heart Stud)', the prevalence of unrecognized 
infarction is higher among wamen than among men,39 The NIONICA cen-
ters signal a definite c01'l'elation between Jawel' admission rates and higher 
case fatalities among women, suggesting tbat Ie ss severe cases are missed in 
those centers \vith low admission rates, 11 Among men, howevcr, awareness 
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has been high, and admission rates correspond well with epidemiologieal 
event rates. 11 
Is there ancillary evidellce that the truc incidence changed? Surveys of 
risk factors in the Netherlands show little change over th is period.40 There 
is little evidellce that the hypertension prevalence decreased recently, no 
more than that prevalence of treated hypertellsives increased in the most 
recent period,'H,42 Neithcr is there cvidence thélt cholesterol increased or 
decreased in the population iu that period.40 Smoking prevalence stopped 
decl'casing sincc the beginlling of the eighties:to lndeed, the post world-war 
female binh cohorts, who teok np smoking in large numbcrs in the sixtics 
and are now al'riving in middle age, might Cause part of the suspected in-
crease in coronary hcart disease among younger women . .J.3 Lung canccr 
l'ates are inereasing rapidly among Duteh women. H Denmark signaled the 
same rapid inereases of female lung cancel' and a relative increase of eoro-
nary heart diseasc among women. 45,.J.6 \""\'hilc part of thc increase in inci-
denee among women might be cal1sed by increasing detection of more be-
nign cases, part of it seems real, caused by the evolving smoking epidemie 
among women of the baby boom generation. 
The mortality register is reasonably valid for corona ry he art disease 
Erom a popnlation perspective." Nlally studies, both obsel'vational and 
theoretica I, have obsel'ved the coronary heart disease mortality in the de-
veloped worid, aud linked to improving tl'eatment.5,6,15,17,22,23,27,.J.7 OnIy 
changes in coding practice might have introdllced artefactllal changes ovcr 
time periods. While they can't be exluded, there is no evidence of such 
changes. 
\X1ith a constant incidence, and a decreasing mOl'tality prevalcnce has 
to expalld inevitably. Our life table calculations show impressive increases, 
partÎcularly among the elderly. These changes are calculated by stationar)' 
life tables, assuming a steady state. Prevalence is a 'stock' varia bie, built 
up by incidence and mortality flows from the past." The calculated preva-
lence assurnes that the in- and outflows remained constant in the past. In a 
dynamic population, the true prevalence will lag behind the calcnlated 
prevalence from a stead)' state model, as it takes time to build up preva-
lence. The true prevalence will be reached only if the present rates wonld 
remain nnchanged long enongh (and the condition of a steady state is fu11-
filIed). 
How do these resnlts compare with previons resnlts?' Qna!itatively, the 
results of the pl'evious paper remaill intact, but quantitatively the present 
l'esnlts, showing the prevalence increases in the recent past, are more pre-
cise, building on more data and fewel' assumptions in a simpier model. 
Because the ÏllCidence changes wel'e lowel' in the Netherlands and the 11101'-
ta!ity changes higher than previonsl)' expected, the prevalellce increase is 
higher thall previousl)' expected. Particularly the increase among women 
of the large post world war birth coho1'ts, consistent with alowel' mortality 
decline and high historical smoking nptake rates, is an ominous sign, which 
may indicate that the gendel' gap is closing, but from the wrong end. 
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\X'e conclude that in thc Nctherlands, the recent history of coronary hea!'t 
disease shows expal1sion of 1l1ol'bidity. Life expectancy free of coronar)' 
disease does not change, onIy the life expectancy with disease increases. 
Thc recent, steep mortality dedine dominates the discase epidemiology. 
\X'hile there is circnmstantial evidence of dec1ining incidence among 
yOllllger men, the same eviclcllce snggests illcreasillg illcidcllce among 
yonnger women. Thc illcreasillg prevalcllce is probably bought by snccess-
ful health care interventions. As many survivors \Vill lead satisfactory lives, 
thls is a great success of modern (heart) health care. However, the lack of a 
recent declinc in acute coronary Îllcidcllce, attribntable to nnchanging 
smoking prevalence in the eighties, and the recent incrcase of smoking 
anlOng yauth40, shaw that there is litde place far call1placency. The l11.rked 
declinc of mortality has resnlted in large pools of prevalcnt survivol's. As 
soon as the therapeutic progress wiII halt, even temporal'ily, we suspect that 
the coronary heart disease mortality wiII start increasing again, particularly 
al11allg the e1derly, as a result af 'pastpalled' de.th. 
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Stroke trends in an aging 
population 
Abstract 
Background and Pl/lpose: Trends in stroke incidmce and survival de-
termine changes in stroke morbidity and mortalit)'. This study exam-
ines the extent of the incidence deeline and survival improvemmt in the 
Netherlands from 1979-1989. In addition, it projects flIture changes in 
stroke morbidit)' over the period 1985-2005 when the coul1try's POPIi-
lation will be aging. 
Methods: A state-evmt transition model is IIsed, which combines Dlltch 
poplIIation projections and existing data on stroke epidemiolog)'. Based 
on the e1inical cOllrse of stroke, the model describes historicalnational 
age- and gender-specific hospital admission and mortalit)' rates for 
stroke. ft extrapolates observed trends and projects future changes in 
stroke morbidity rates. 
Results: There is evidence of a continuing incidence deeline. The most 
plausible ra te of change is an annual deeline of -1.9% (range: -1.7 to 
-2.1) for men and -2.4% (range: -2.3 to -2.8) for wamen. Projecting a 
constant mortalit)' deeline, the model shows a 35% decrease of the 
stroke incidence ra te over a period of twent)' )'ears. Prevalence rates for 
major stroke will deeline among the younger age groups but increase 
amollg the oldest due to increased survival in the latter. In abolute 
",unbers this results in an 18% decrease of acute stroke episodes and 
an 11 % inCl'ease of major stroke cases. 
Conclusions: The increase in survival cannot fully explain the observed 
morta/it)' dec/ine and, therefore, a concomitant incidence deeline has to 
be assumed.Aging of the population partially outweighs the effect of 
an incidence deeline on the total burden of stroke. Increase in cardio-
vascular survival leads to a further increase in major stroke prevalence 
among the oldest age groups. 
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Introduction 
The dyuamics of stroke morbidity and mortality arc of major interest for cli-
nicians as weil as for epidemiologists and bealtb policy makers. A cbanging 
stroke epidemiology results from cbanges in incidence and survival. The bal-
allee between these trends detcl'mines the numbcl's of short and long term 
stroke survivors within a population. Recclltly, the debate 011 the relative COll-
tribution of trends in illcidence and survival to stroke mortality declinc has 
illtensified, complicated by different stud)' methods and inconsistent results l -4, 
In the Netherlands as weil as in the USA, stroke mortality bas been de-
clining for all age groups since the early sixties 1.'-6. In the Netberlands, the 
age-adjusted decline from 1979-1989 has been a constant 3.1 % pel' year for 
men and 4.0% for women, while in tbe USA mortality decline bas been 5.7% 
and 5.20/0, respectively3,6, Au incidence decline has also been observed7.9, as-
cribed to bettel' hypertellsion control and a decline in smoking prevalence7,8,IO, 
Observed incidence trends are confoullded by the introcluction of computer-
ized tomography, improving the specificity of the diagnosis but also increas-
ing case fincling. Declines in sho1't- and long-term case fatality have been 
docmnented for the last decades7,9,11+13, explail1ed mainly by a better prognosis 
aftel' intra-cerebral hemorrhage, by increased hypertension controF,1O alld by 
a bettel" preventioll alld treatment of complications, especially of cal'diac dis-
ease. However, the ohsel'vecl 1110rtality decline has started long ago and can-
not be full)' accounted for by obsel'ved changes in risk factors. Most likely, 
botll incidence and case-fatality decline willremain largely unexplained'·ll. 
This stud)' determines the most plausible range of incidence and fatality 
decline that explains the il11pressive observed reduction in stroke mortality in 
the Netherlands by means of a state-event modelH. In addition the model is 
applied to project future changes in stroke incidence and prevalence using the 
calculated trend values. 
Material and methods 
Stroke mortality trends are detel'l11inecl by changes in stroke incidencc, sur-
vival, recovery, l'eCÜrrellce, and mortality from other diseases. Given this 
complexit)', a mathematical model is indispensableH • We developed a state-
event model that is based on clinical course of stroke (figure 1). Combining 
data from variolIs SOUl"CeS, the model describes the epidel11iology of stroke in 
the Netherlands. 
The basic principle of a state-event model is that patients move from one 
particular state to aóother af ter experiencing a particular evcnt. H,16 The like-
lihood to move from ane state to another, a transition probability, is inde-
pendent Erom the preceding states or events and depends only on the current 
state defined by disease stage, age and gendel' during the event. All probabili-
ties are age and gender specific. There are five year age groups ranging from 
25 years to 90 and over. The model combines a demographic component, 
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I Demography I 
age, sex 
~ 
I First TIA I 
~ 
TIA First stroke J 
t 
I All slroke, firsl monlh I 
I~recovery I 
I Minor slroke I J Major slroke ~ 
~ .,. 0;-
~ -"l Disabilily lt 
I Recurrent stroke I I Recurrent strok~ I 
Exces s cardlac death 1 Stroke dea th 
Prevalent State Event in previous state Disease specific death 
Note: Death trom other causes occurs in all prevalent states, at any time 
TIA is transient ischemie attack 
Figure 1 - Diagram presentIng the state-event model for stroke. 
First year states and states tor all subsequent years have been combined to facilitate the 
depiction of the model. 
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cOlltallllllg the most like1y national population projections16, and a stroke 
specific component, Risk of death from other causes is accounted for in all 
states. 
During computation the model annually generates first incident cases 
from the demographic component, These enter the respective states within 
the stroke specific component and follow the various flows with the model. 
Simultaneously, the model also annuaJly updates all existing prevalent states 
for recurrences and their consequences. 
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\,\'ithin the stroke disease component of the model two events can occur: 
a transient ischemie attack (TIA) or a stroke, both defined as in the Oxford 
COllllllunity Stroke Project (OCSP).17.18 W'e distinguished different states for 
the first year and for all subsequent years together. Because the flows in the 
model during the fjrst year and the subsequellt years are a11110st identical, 
these twO year states for each cOlldition are depicted together to dadfy the 
presentation. In bath TIA states the patient has an increased risk of stroke. 
Aftel' the first year, patients with a history of a TIA enter the "subsequent 
years" state and run a lower stroke risk. A separate first mOllth state aftel' a 
fit'st stroke allows for the acute phase with a high risk of disability and death. 
Aftel' a first stroke patients enter this state. Patients surviving the first 1110nth 
are left either with a minor Ol' major stroke as defined by a Rankin grade 0-2 
and 3_5 19 respeetively, and are divided up between the hvo separate states. 
Patients with a history of stroke run a risk of recurrencc. If th is oeclU'S, there 
is an cxcess risk of dying or having a major stroke. In the first year state for 
major stroke, some patients recover, defined by Rankin grade 0-2. The reeov-
ered patients enter the minor stroke state. The remaining fraction moves to 
the major stroke state for all subseqllent years. In bath major stroke states a 
patient suffers a delayed death due to a first and disabling stroke. 
One model assumption is that in the acute ph ase al most all deaths eall 
be contribnted to the first stroke and only a few to the other causes of death. 
In th is phase, the risk of reelU't'ence and the exeess risk of death from heart 
disease are not accollnted for due to an absence of recorded data. AIso, a sin-
gle state for all subseqnent years togethel' implies that the reenl'rence risk in 
subsequent years state is the same for all following years. This is supported by 
recent Dntch data.20• In addition, we do not distinguish strokes eaused by 
intraeel'cbral hemorrhage and those eaused b}, eerebral infarction. From a 
patient-based view, these are different. At the aggregated population level a 
distrinction is Ie ss useful as duombotic infaretions make up more the 80% of 
all thc stroke eascs. 17,!4 }'o'lol'cover, the survival aftel' a hemorrhagic strokes is 
reaching the level of survival aftel' an infarction as a re sult of improved prog-
nosis and incl'eased detection of smaller and less hannful bleedings.2! 
Thc origiJl of the erude data llsed to calcnlate the base-line input is snmma-
rized in table 1. We have calcnlated the age-specific tmnsition probabilities 
nsing the results of Dutch population-based studies, if available. If incom-
plete, they have been used to check selected compamble figures of other white 
populations as listed in the tabIe. Relative risks are used when eomparing 
risks for one patient eategol'y with allother. Ratios are nsed as transition 
probabilities without fmther caleulations. The choiee of measme depends on 
the way the data have been made available. 
The risk of a first TrA is caleulated using the incidence figmes from the 
OCSp l '. Age-specifie probabilities are calculated by exponential interpolation 
and are compamble to data from Dntch prÎmary care practiees (NUHI)" and 
also the Rochester study". The relative risks of stroke aftel' a first TrA 1'e-
ported by the OCSp30 have been interpolated alld are multiplied by the 
populatioll risks from the Tilburg Epidemiologieal Study of Stroke (TESS) 
Stroke trends in an aging popltlation 79 
Table 1 
Crude literature data used to calculate base-line transition probabilities within the 
stroke model and resulting transition probabilities for the group of patients aged 70-74 
years. 
Crude data Probability 
Measure Figure (70-74 y) Souree 
FirstTIA Rate 
Rate 
0.4211000 0.0037/0.0026 NUHI21 ; OCSp18 
First stroke 
Death from firs! stroke 
Major disabiHty after first stroke 
Recovery from major stroke 
Stroke after TIA/minor stroke 
tirst year <75 years 
tirst year> 75 years 
subsequent years 
Late death from major stroke 
Ratio 
Ratio 
Ratio 
RR 
Ratio 
MHR' 
Cardiae death after TIA or RR 
stroke MHR** 
Cardiac death after major stroke RR# 
1.6211000 
0.20 
0.39 
0.76 
13.2 
4.5 
5.0 
0.17/0.42 
1.261 
3.2 
0.665 
1.57 
0.01210.010 
0.21/0.21 
0.39 
0.22 
0.09/0.07 
0.05/0.04 
0.15/0.11 
TESS21 ; OCSp17 
TESS24; OCSP 17 
DGp25; OCSp17 
OGp25. New 
Zealand26 
NUHl23rOCSp30r 
Dutch TIA Trial20 
Duteh Registrv' 
N Carolina27.2S 
0.038/0.025 Dutch Tia Trial" 
N.Carolina27,28 
0.06/0.04 N.Carolina27.28 
TIA, transien! ischemie aUack; RR, relative risk; MHR, multivariate hazard ratio. 
* risk comparison: age (X+10)/X 
** risk comparison: women/men 
# risk comparison: major/minor stroke 
and the OCSP (scc below)l7,ll to caleulatc agc-spccific absolntc stroke risks 
aftel' a TlA, 
Probabilities of a first stroke are ealeulated by averaging the results of 
the ineidcnee studies by the OCSP and thc TESS that have produccd similar 
figures 17,ll, Because the TESS included fewer age groups, the results of both 
studies are combined to have reliable incidence figm'es for as many age 
groups as possible, Results are consistent with the NUHI data 14,21, Age-ad-
justed all stroke case-fatality rates from the TESS study have been corrected 
for l'eCUlTences by ass111l1Î.ng a double recurrence death hazard, The resulting 
case-fatality ratios of the OCSP and TESS are neady identical (19% and 
20%), Thc probability of residual major disability aftel' one month is as-
smned to be constant for age and gender.26 
The recurrence risk for minor stroke patients is assumed to be the same 
as the first stroke risk for TJA patients, The ratio of the risk of dying aftel' a 
recturence versus the risk aftel' a first ever stroke is 1.5.27 For the risk of a 
major stroke after a recurl'ence the same ratio is nsed. ReClurence risk in the 
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Figure 2 
Logarithmic graph showing age-specific admission rates and death rates in the Netherlands in 1985 
for all cerebrovascular accidents (lCD codes 430-438, except 435) according 10 the national 
registries6,28 and as calculated by Ihe state-event model for stroke. Model admission rates are based 
on the model events rates for aH strokes together multiplied by age-specific chanees of hospital 
admission found in a Outch study.28 
subsequent years state af ter a minor stroke is estimated half the first year 
risk/o with the same risk of dring and of major stroke, given the recurrence, 
as during the first rear.:>':> 
The probability of recovery from major stroke has been calculated by 
age grollp and is the same for bath sexes.11 In agreement with various stud. 
ies9 ,21,17,:29 reClll'rCllCe risk aud subsequent death aftel' major stroke has been 
estimated by dOllbling the hazard ratio of the same parameter as found by 
Howard et al'? for the minor stroke grallp. Late stroke mortality dllring sub-
sequent years is half the risk in the first year state. The reClllTenCe risk in the 
subsequent years state aftel' a disabling stroke is half the first year risks,lO as 
assumed fol' minor stroke. 
The excess age-specific risk of death from ischemie heart disease (lCD 
410-414) in the prevalent states has been calculated by ll1ultiplying the haz-
ard ratios for cardiac death'?·" with the age-specifie risk of death from 
ischen~c heart disease for the general Dutch pop111ation.6 
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Risk of death from other eauses is ealculated using the all eauses death 
rates from the national death registry correeted for the stroke related figures 
(rCD codes 430-438). 
The stroke disease component of the model in combination with the demo-
graphic component describes the stroke epidemiology for the Dutch popula-
tion in steady state. 50 far it has been presented with fixed transition prob-
abilities. The model estimates stroke prevalence for the baseline year (figure 
2) after assl1ming the same transition probabilities dnring the precedÎllg years. 
The model allows for age-speeific time trends for all the transition 
probabilities depicted iu figure 1. This allows for plausible projections over 
langer periods. The value of these trends are calculated by time series analysis 
of available figures from comparabie populations. A trend is defined as the 
a1111nal percent change) which means an exponential change. To ca1cnlate this 
kind of trend, first, a log-transformation is applied. The regression lille, 
through the log-transformed figures of each time interval is determined by a 
least squares fit. The regression coefficient, 01' stope, of this line, is the alluual 
percent change of the time series figures.5 
DurÎIlg compntation two sets of trends are used. One set consists of all 
"attack 11 parameters: the risks of a TIA, first stroke or recurrence. The other 
set includes all parameters regarding acute and late case-fatality of stroke 
accounting for the decreasing severity of stroke. This study focuses on the 
first stroke incidence and case-fatality trends. 
These trends in transition probabilities are not very weIl documented. 
The Rochester study' is the only study that produces age and gender speeific 
data on the secular changes bath in stroke ineidence and fatality. We applied 
the Rochester ineidence and ease-fatality trends to the respective attack and 
case-fatality sets of trends within the model. This can be done as the Dutch 
incidence figul'es for TIA and stroke as weIl as case-fataHty ratios over a sin-
gle two-year period agree with comparable Rochester data.21 .".24 We ignored 
the recent, most Iikely temporary, incidence increase for Rochester caused by 
increased case-finding because of the introduction of computed tomography.7 
Trends in the two remaining transition probahilities, the risk of major stroke 
aftel' stroke and the chance of recovery trom a major stroke are not kuown 
aud are assumed constant. The applicatioll of the Rochestel' incidence and 
Table 2 • Annual incidence and case·fatality trends applied in the stroke model and 
goodness~of-fit of the corresponding model mortality trends with the empirica I Dutch 
national mortality trend for 1979~1989. AIIl va lues indicate a good fit (P>O.6, df=10). 
Men Women 
Annual trend (%) Fit Annual trend (%) Fit 
............................................................... -.......... -.......... -........................................ _ ............ 
Scenario Incidence Case fatality x' Incidence Case fatality x' 
Upper -1.7 -1.7 1.02 -2.3 -1.7 1.08 
Rochester -1.9 -1.3 0.46 -2.4 -1.3 0.55 
Lower -2.1 -1.0 0.71 -2.8 -1.0 0.72 
Figure 3 
Plots of rwo-way sensitivity 
analysis of two variabJes: the 
stroke incidence trend and the 
case~fatality trend. The iso~ 
mortality lines shown are for 
Dutch men (3.1%) and women 
(4.0%) during the period 1979· 
1989. Rochester trends for men 
and women are plotted as weil 
as the most extreme values for 
bath trends found in the 
literature. The plausible range of 
incidence decline (the grey 
area) falls within the range of 
vaJues re~orted in the 
literature?10. ,33 
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survival trends appeal' te l'eprodllce almost identical sex-specific mortality 
trends as obsen'ed in the Netherlands from j 979 te 1989 (sec table 2).'-' 
This seems logical as both populations are mainly white and comparable in 
most other aspects. Other combinations of trend va lues for illcidence and 
case-fatality, however, can also account for the observed l110rtality de-
dine.S,12,16.31+33 The difficnlty is that trend values are reported 1l10stly 
separately from each other and without corresponding overall mortality 
trend. 
To solve this we llsed a two-way sensitivity analysis of incidencc and 
case-fatality trends to determine a plausible ranges of va lues (fig 3). In the 
analysis, for each value of one set of trends we calculated the cOlTesponding 
value of the ot her set that, in combination, leads to the same 1l10rtality dc-
dine. Under the condition of a fixed mortality decline, thc illcidence and 
case-fatality trends are invcl'sely proportional. \'?hen the incidence rates dc-
crease, the case fatality rates have to increase five times as rapidl)' to out-
weigh tbe decreasing mortality declinc. The main reaSOll for this is that the 
case-fatality aftel' a first stroke is 200/0. This inverse relation leads to the iso-
mortality lines in figul'e 3. The area above the Iines indudes those values of 
trends that lead to a larger mortality dedine. The area belo\\' indndes the 
val nes that lead to an lesser mortality decline. The range of reported values 
for case-fataHty trends is small.9,12 As a reslllt, it defines a much narrower 
Table 3 
Estimated standardized stroke rates (European population as direct standard) and 
absolute numbers ot stroke cases in the Netherlands tor 1985 and projected future 
changes tor the year 2005 of standardlzed stroke rates and absolute numbers ot 
stroke cases relative to 1985, assuming continuing Rochester-like trends and 
population projections by Dutch Central Bureau tor Statistics16, 
1985 2005 (% change) 
Rates Numbers Rates Numbers 
Men: 
First strokes 171 10600 ·35 -16 
All strokes 224 14000 -37 -19 
First major stroke 67 4210 -34 -14 
prevalence major strokes 275 17300 -15 +11 
Prevalenee minor strokes 700 43900 -12 +15 
Stroke deaths 68 4170 ·46 -30 
Wamen: 
First strokes 128 11200 -36 -9 
All strokes 159 15000 -38 -17 
First major stroke 46 4260 -35 -15 
Preva!ence major strokes 200 18400 -17 +8 
Prevalence minor strokes 466 41300 -13 +11 
Stroke deaths 51 5110 -45 -23 
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Graphs showîng the age-specific prevalence rates of major stroke for 1985 and 2010, after 
computation for a period of 20 years. Far the 2010 projection, the results of two runs are shown. 
During the tirst run, only the Rochester incidence trend (a decline) is applied 10 all "aHack" 
parameters. During the second run, the Rochester case-fata1îty trend (a150 a decline) on all stroke 
case-fatality parameters is added. 
range af values far a possible incidence decline than is reparted in the 
literature. 
Statistica 1 testing af the results af the camputatians is dane b)' campar-
ing madel results with the abserved natianal data, A x' gaadness-af-fit test is 
used (see appendix), 34 A value af P>O,S far this test indieates a gaad fit af the 
camputed results and the abserved data, The gaodness-af-fit af the madel 
age-specifie stroke martality rates and strake admissian rates (first and recur-
rent strokes tagether) is given as weil that af the trends in the madelmartality 
rates. 
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Results 
The stroke model produces nation-wide projections regarding the stroke epi-
demiology inclllding fitst stroke incidence, stroke reClurences as well as 
stroke mortality and prevalence. Figure 2 shows the model ontcome regard-
ing national stroke hospital rates, including bath fatal and non-fatal cases, 
and national stroke mortalit)' rates for the 1985 baseline )'ear. There is a 
good fit for the age groups up to 80 )'ears between model outeomes and the 
natioual data of the same )'ear': the X' for men is 8.10 and 6.37, respeeti"el)' 
and f01'\"omen is 6.21 and 8.15 (all P >0.5, db 11). These X' "alues support 
the "alidity of the model. The national admission rate" for the 85 year aid 
and over from the hospital registry is lower than the model admission rate, 
as the latter refers to the age group 85-89 ani)'. The lower model stroke 
deaths rates of the same age group are most probably due to an ovel'1'egistra-
tion of stroke deaths for this age group in general praetiee and/or a possible 
underregistration of ineidenee in the OCSP "nd TFSS. 
Table 3 lists the aggregated model results for 1985, and the relative 
change of output resl1lts for year 2005. Here trend va lues are nsed assuming a 
continuing Rochester-like scenario and therefore a continuing mortality de-
cline. All rates are deereasing and there are na major sex differenees. As all 
attack rates, including risk of recurrence, are assumed to decrease, all stroke 
rates decrease more than first stroke rates. Because of improved survival the 
drop in prevalenee rates is considerabi)' less. The projected decline in stroke 
death rate, is the same as during the past twenty year in the Netherlands.5•6 
This has been the basic assumption of this projection. 
The effect of the aging of the post-war baby boom is shown in the shifts 
in absolute nnmbers: less decline in all-stroke cases and all increase in preva-
lent cases. The langer life expectancy of Dntch women is refl~cted in a 
smaller decrease of first stroke cases and stroke deaths. In genera 1, the inci-
dence decline outweighs the expected increase in absolute lllunbers of acute 
stroke episodes with the aging of the post-war generation. Nevertheless, in-
creased survival increases the absolute lllunber of prevalent cases considera-
bly. 
Resltlting prevalenee rates for major stroke are given in figure 4 and 
agree with the population-based rates found in Finland and Rochester. 30 The 
same figure also demonstrates the trend dynamics by a step-wise inclusioll of 
the two "attack" and Hcase-fataHtyH sets of trends that are based on the time-
series anal)'sis of the Rochester data. A decreasing incidence of stroke results 
in a decreasing major stroke prevalenee alld also a decreasing minor stroke 
prevalence (data not showll). This decreasing effect all prevalence is neady 
halved by an increase in survival, especially of major stroke patients and, to a 
lesser extent, of minor stroke and TIA patiellts who live langer with the risk 
of suffering a debilitating stroke. The effect of survival impl'Ovement on 
stroke prevalence increases with age. This l'esults in au increase in stroke 
prevalence among the older age groups. 
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Thc two-way sensitivity analysis determincs the plausible range of values 
for the illcidence trend that explail1s Dutch stroke lllortality declinc, givcn thc 
reported survival improvcmcllt. Figure 4 shows that the values for thc iucÎ-
dencc trend range betwcen 1.7% and 2.1 % per year for men, aud between 
2.3% alld 2.80/0 pcr reut' for women. The figlll'C also demonstrates rhat, if 
ane supposes 110 illcidcllce declillc7 au unreported annual improvement of 
sm'vival of over 5% would be necessaty to effect the observed mortality de-
cline. On thc othcr hand, au incidence decline of morc than 3 % for men 
wDuld imply all llnreported absence of survival impl'OVemcllt or even a dere-
rioration. In Table 2, the resnlts of a goodness-of-fit test of the model mor-
taIiry trends aud the empirical trend are given for duce plansible scenario IS: 
one with the highest case-fatality improvement, one with the lowest case-fa-
ta!ity improvement and a Rochester-like scenario that tnrns ont to be in be-
tween these two case-fatality declines. Assnming no incidence decline and the 
highest knowll annoal case-fatality improvement resnlts in a mortaHty decline 
that doesnit fit to the national figures. 
Figllre 5 shows the prajected age-specifie absolute changes in prevalence 
rate during the 20-year periad. The decrease of age specific stroke mortality is 
largest for persons in their late 60s and 70s.' Case-fatality decline within 
these age groups has also been limited alsa,' sa for these persons a rather 
large incidence decline has to be assumed. Consequently, stroke morbidity 
among these groops is decreasing remarkably, for men at a younger age than 
for wamen. Later in life, the increase in survival results in a large increase in 
stroke prevalence, offsetting a relatively small incidence decline. In Figure 5, 
all opper and lawer limit of the age specifie pl'evalence changes is given. 
These limits are determined by the extreme va lues of the plausible ranges for 
incidence deeline and case-fatality decline as reported in Figure 3. A smaller 
incidence decline resolts in a smaller prevalence decline among the yonnger 
patients and a higher morbidity among the older groups. The restiiting 
pl'evalence changes in these alternatives scenariois, again assuming a constant 
mortality deeliue, however, are only slightly different. 
Discussion 
Downward trends in the accurrence of ischemie heart disease and stroke 
charactel'ize changes in health within the aging population: l'cduced disease-
specifie mortality l'csults in a relatively limited increasc in life expectancy but 
might cause a langer period of severe disability from the same disease." In the 
case of stroke, the major question is whether declining mortality rates are 
rcsldting in a paradoxically incrcasillg burden of disease, especially alllong 
the oldest. The answer depends on whether one supposes mortality and 
morbidity to be compressed against an alleged fixed biologica I upper limit to 
the life span, or whether one supposes a mortality decrease in the oldest age 
groups and a parallel expansion of morbidity. In the farmer scenario health 
care provision results in a decrcase of lllorbidity but in the lattel' it may weIl 
result in an incl'easc of chronic lllorbidity. 
Figure 5 
Graph showing the projected age-
speeifie absolute change in 
prevalence rate in the Netherlands 
over the period 1985-2010. The 
most plausible trends in ineidence 
and case-fataJity are assumed, 
resultlng in continuation of a 
Roehester-like scenario. Upper and 
!ower limits have been ca)eulated 
using the most extreme values of the 
range of plausible ineidenee and 
case-fatality trends found through 
sensitivity analysis. 
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Oul' <\nalysis is based 011 empirica! data from different som"ces. None of 
the large population-based studies, or clinical trials has been comprehcnsivc 
enollgh to be able to assess the extcnt of incidcllce declinc and survival im-
provement in relation ro stroke l110rtality declillc. The resnlts show a plausi-
bie range of a considerable incidence dccline for the Netherlands. As 111ortal-
ity decline in the USA has been much higher,' most likell' incidence decline 
has also been higher. For the Netherlands, conseql1cntly, Figure 5 confinns a 
most likely scenario for stroke with a compression of morbidity in the near 
futnre, but with an increase of major stroke prevalcllce among the very aid. 
At a younger agc dominant incidence decline results in a decrease in mOl'bid-
ity. For the oldest age gronps, however, the decrease in case fatality is larger 
than the calculated incidence decline and thcrefore the rcsnlting mortality 
decreasc is small i.e appl'oximately 1 % alll1nally.6 At these ages the l'esnlt is, 
indeed, a trade-off of strake mortalit)' fol' morbiditl'. The prajected changes 
in 1110rbidity are snpported by recent observations: age-adjnsted admissioll 
rates for stroke are decreasing in the Nethedands:!5 and definitely also in the 
USA among whites. 35 In both countries the average age of stroke patients is 
increasing .. ~_9,35 111 the Nctherlands, the average age of patients admitted to 
long-term care institntions, which is indicative for the prevalence of major 
stroke, is increasing as is the average disability score.:!9. This confirms the 
changes towards a higher major stroke prevalel1ce among higher age gronps 
as reported in Figure 5. SimiIarIl' the average sta)' of severcl)' disabled in 
llnrsing institntions is increasing and consequently Dntch mortality statistics 
are showing a parallel increase of late cerebravascular deaths (lCD code 438) 
among the 0ldest. 6 Thc incl'ease in institutionalization is not explained by 
sodal factors, as the intensive home care programme has been cxpanding the 
last five years to cope with wuiting lists of chronic paticllts with major 
strokc.6 
In addition to incidence and survival, stroke morbidity ratcs are de ter-
mined bl' the risk of residnal disabilitl' aftel' stroke and the chance of recov-
ery. In this respect, some groups are running larger risks af ter a stroke due to 
concomitant debilitating diseases such as atherosclerotic heart disease or 
other risk factors, snch as hypertellsion. It is haped that ongoing empirica I 
studies may be able to allswer qucstions regarding stroke trends in these pa-
tient grollps now that their survival is improving. 15 Also, empirical studies 
will have to answcr related questions 011 co-morbidity and disability from 
othel' diseases among the aged. 
An important question is: will stroke mortality continue to decline? Be-
canse most of the mortality decline is nnexplained, no one cau be snre of the 
answcr, nor does the stroke model answer this question. In its projectians it 
assumes the same continuing mortality dccline, as this decline has been very 
constant in the Netherlands. Our model demonstratcs the dYllamics of stroke 
morbiditl' change. Both in the Netherlands and the USA there are still bene-
fits to be gained from large-scale hypertension controland rednction of 
smoking.,,3,35,37,3s Better illtervention possibilities might further improve prog-
nosis. Population benefits froln recurrence pl'eVelltioll are limited, because of 
the relativell' high first stroke fatalit)' and relativel)' low recurrence risk. The 
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eHeets of inereasing eardiae disease prevention and treatment are already evi-
dent and will further illcrease survival. 
The influence of demographic changes differs between the Netherlands 
and the USA. Stroke prevalenee wil! increase less in the USA, because of the 
less extreme aging of the population. Stroke incidence and morbidity rates are 
higher for blacks. However, for tbis group mortalit)' dedine parallels the de-
dine for whites. 4 \X'ith a lllortality trend of the same magnitude, similar dy-
namics in stroke lllorbidity might be taking place. These issues can onIy be 
dealt with aftel' induding population-specific transition probabilities and 
demographic and epidemiologieal trends in the state-event model, whieh is 
possible. 
In conclllsion, this study supports evidence of a further decline in stroke 
incidenee. 3 It also supports the observation39 that a huther improvement of 
survival of the older age groups as a result of therapentie interventions may 
result in a langer period of severe disabilit)' befare dcad" Thc findings arc of 
importanee for setting health care priorities for the aged, especially in regard 
to the nursing needs of stroke patients during the acute, rehabilitative, and 
chronic phase of their illness. 
Appendix 
Testil1g tiJ. goodl1ess-of-fit 
Age-specific computed stroke figures are compared with the nationalregistry 
figures. This is done b)' using the standard farm uIa for the eh i-square test for 
largel' tables: Z' = I((O-E)'/E), d.f= (C-i)." Here 0 represents observed fig-
ure in bath groups of data and E the expccted fignre. E is based on the cal-
culation (R . N)rT where R is the sum of the computed and the registry fig-
ure for the age group involved, Nis the total of all age groups, and T the to-
tal for all age groups of the computed and registry figures together. C is the 
Illunber of age groups. The number of degrees of freedom is the product of 
the nnmber of age gl'onps minus 1 and the number of categories (i.e. com-
puted and observed) minus 1. 
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Regression analysis of recent 
changes in cardiovascular 
morbidity and mortality in the 
Netherlands 
Abstract 
Objectives: Ta test wether recent dec/ines in morta/ity (rom coronar)' 
heart disease were associated with increased morta/it)' (rom other car-
diovascu/ar diseases. 
Design: Poisson regression ana/)'sis o( nationa/ data on causes o( death 
and hospita/ discharges. 
Setting and subjects: The popu/ation o( the Nether/ands, 1969-93. 
Main outcome measures: Annua/ changes in mortalitj' (rom coronaI')' 
heart disease, stroke and other cardiovascu/ar diseases and annua/ 
changes in hospita/ discharge rates (or acute coronar)' events, stroke 
and congestive heart (ai/ures. 
Main results: Patterns o( cardiovascu/ar mortality changed abrupti)' in 
1987-93. Annual deeline in morta/it)' (rom coronaI')' heart disease in-
creased sharpl)' (or wamen and men, (rom -1.9% (95% con(idence in-
terva/: -2.2% to -1.6%) and -1.7% (-1.9% to -1.4%) respectivel)' in 
1979-86 to -3.1% (-3.5% to -2.6%) and -4.2% (-4.6% to -3.9%) in 
1987-93. The long standing dec/ine in morta/it)' (rom stroke levelled 
0((: (rom annual change o( -3.3% (-3.7% to -2.8%) and -3.2% (-3.7% 
to -2.8%) in 1979-86 to -0.1% (-0.7% to +0.4%) and -1.1% (-1.7% to 
-0.5%) in 1987-93. Morta/it)' (rom other causes o( cardiovascular 
death started to increase, (rom -2.0% (-2.4% to -1.6%) and -0.2% 
(-0.5% to +0.2%) in 1979-86 to +1.5% (+1.0% to +2.0%) and +1.9% 
(+1.5% to +2.3%) i/1 1987-93. Hospital discharge rates (or acute 
coronar)' heart disease, congestive heart (ailure and stroke increased 
93 
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during 1980-86. During 1987-93 discharge rates for stroke and coro-
nar)' heart disease stabilised, but rates for congestive heart failure in-
creased. 
Conc/usion: Improved management of coronar)' heart disease seems to 
have reduced mortalit)', but same of the gains are lost to deaths from 
stroke and other chronic vascular diseases. The increasing numbers of 
patients with coronar)' heart disease who survive wi/l increase demands 
011 health services for long term care. 
Introduction 
In the early· 1970'5 mortality from cardiovascular diseases started te declinc 
in many indnstl'ialised countries,l Despite cOllsiderable debate, 1110St observers 
would agree rhat rednctiolls in risk factors, particularly smoking and 
hypertellsion, was the more effective than improvements in trcatmcnts in 
achieving this decline in the 1970s and 1980s.'·7 In the mid 1980s, however, 
management of acute myocardial infal'ction was revolutiollised, particlllarly 
by thrombolytic therapy, causing steep decreases in mortality fro111 coronary 
heart disease.8-1O 
Coronary heurt disease is not the only cardiovascl1lar discase, however, 
and other cardiovascular diseases, snch as stroke and congestive heart failure, 
share many of the same risks.5 [J I:? Thc improving prognosis of coronary 
heart disease cansed by improved management shonld increase thc l1umbcl' of 
sllrviving patients at high vasenlar risk. \\fe present a time series analysis of 
Dutch natiol1wide statistics to illustrate the relatioll between mortality from 
C01'ona1'y heart disease and other cardiovascular diseases. 
Methods 
Souree of data 
For our mortality analysis, we used the registcl'ed nnmbel's of death by cause, 
age (from 25 til! 84 y), sex and calendar yeal' from Statistics Netherlands. i3 
We took account of only primary causes of death and considered three causes 
of cardiovascular related death: coronary heart disease, stroke and all other 
causes, including unknown causes of sudden death. '4 Table 1 shows the lCD 
codes (international classification of diseases) that we searched fol'. 
The secOild database we used was the hospital register. This provides 
nationwide coverage and is complete sincc 1980. The rcgister Îllclndes 
hospita I patient's diagnosis at discharge :is classified by the trearing physician 
and codified by local staff. For every discharge, the vital status of the patient 
is rcgistered. Patients dying during thc ambulance ride Ol' at entry in the 
emel'gency r00111 are not admitted, and are eOllsidcrcd fdcad out of hospitalf. 
Again, we considcrcd only primar)' diagnoses. 
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Statistical analysis 
\\le estimated trends over time by Poisson l'egl'ession alw.lysis. 15 \\fe nsed 
midyear pOPJtlations as pCl'son-years and we specified five yeat' age gronps 
(categorieal) 'and calendar yeM (colltinnous) as independent varia bles and 
mortality as dependent variabie. \V,Te anaJyzed the trends from vita I statistics 
over 1969-1978, 1979-1986 and 1986-1993 and trends from the hospita I 
register from 1980-1986 and 1986-1993. We choose 1987 as the cut-off 
point because of the apparent ruptnl'e in trend in that yeal'. 
Results 
figurc 1 and tabie 2 show changes in mortality from cardiovascniar diseases 
and in discharge rates from hospital for stroke, acnte coronar)' heart evcnts, 
and congcstive hemt failnre. 
For women, all cardiovascular related death rates declined from 1970 
tiIl 1986, suggestillg a change in C0111mon risk factors of 1110st cal'diovascnlar 
discases. Dnring 1987-1993, however, changes in cal'diovascnlal' mOl'tality 
levelled off, from -2.3 % per year in 1969-86 to -0.7 % per year in 1987-93. 
Mortality from coronaty heart disease decreased steeply, but other vascular 
related death rates started to increase in 1987. Mortality from stroke levelled 
off aftel' a long period of decline. 
For men, changes in cardiovascular related mortality during 1969-1978 
were limited to a decline in mortality from stroke. During 1979-1986, the 
rate of decline in cardiovascula1' l'elated morrality incl'eased, driven by 
declining death rates ftom C01'ona1')' heart and stroke; rates for othel' 
cardiovascular causes of death changed litde. In 1987-1993 mortality &'om 
coronary heart disease declined steeply, but dca th rates from stroke declined 
less steeply and death rates from other ca1'diovascnlar canscs seemed to 
incl'ease. 
Table 1 . lCD codes used In search tor changes in cardlovascular morbidlty and 
mortalily in the Netherlands durlng 1969-93. ICO-8 and ICO·9 (international 
classificatIon ot diseases, eighth and ninth revisions) used tor analysis ot death 
reglstered In Statistics Netherlands,13 and ICD·9·CM (international classltlcation ot 
disease, ninlh revislon, clinical modlflcatlon) used tor analysis ot diagnosis at 
discharge listed In hospital register. 
Disease 
cardiovascular disease 
coronary heart disease 
stroke 
acute coronary events 
congestive heart failure 
ICD8 
(1969-78) 
ICD9 
(1979-93) 
390-458.782.795-796 390-459.798-799 
410-414 
430-438 
410-414 
430-438 
ICD9-CM 
(1980-93) 
430-438 
410-411 
428-429 
Women 
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Age standardised (Outch population of 1980-93 as direct standard) annual mortalities and hospital discharge rates for cardiovascuJar diseases in the Netherlands. 
Tabl.2 
Age standardised rates (per 100 000 population) and annual percentage changes in mortality and hospital discharge rates for the population of the 
Netherlands during 1969~93. (Data on national mortality trom Statistics Netherlands 13 and data on hospital mortality and morbidity from hospital register) 
Period 1969-78 Period 1979-86 t Period 1987-93 
rates (SE) percentage change rates (SE) percentage change rates (SE) percentage change 
(95% Cl) (95% Cl) (95% CL) 
Women 
National mortalfty trom: 
Cardiovascular disease 443(1.1) -2.3 (-2.5 to -2.2) 349 (0.8) -2.3 (-2.5 to -2.1) 289 (0.7) -0.7 (-1.0 to -OA) 
stroke 125 (0.3) -3.3 (-3.6 to -3.0) 90 (0.2) -3.3 (-3.7 to -2.8) 74 (0.2) -0.1 (-0.7 to +OA) 
Coronary heart disease 180 (OA) -1.0 (-1.3 to -0.8) 148 (OA) -1.9 (-2.2to-1.6) 114 (0.3) -3.1 (-3.5 to -2.6) 
Other 138 (0.3) -3.2 (-3.5 to -2.9) 111 (0.3) -2.0 (-2A to -1.6) 101 (0.3) +1.5 (+1.0 to +2.0) 
MortaJity in hospita! trom: 
Cardiovascular disease 124 (0.3) -0.7 (-1.1 to -0.2) 109 (0.3) -1.6 (-2.0 to -1.1) 
Stroke 42(0.1) -1.5 (-2.3 to -0.7) 36 (0.1) +0.4 (-OA to +1.3) 
Coronary heart disease 38 (0.1) +0.2 (-0.6 to +1.0) 31 (0.1) -5.5 (--6.3 to -4.6) 
Other 44 (0.1) -0.7 (-1.5to +0.1) 42 (0.1) -OA (-1.2 to +0.3) 
Hospital discharge rate 
Stroke 213 (0.8) +0.7 (+0.3 to +1.0) 204 (0.7) -0.0 (-0.4 to +0.3) 
Acute coronary event 211 (0.8) +2.7 (+2.3 to +3.1) 235 (0.8) +1.1 (+0.8to+1.5) 
Congestive heart failure 141 (0.6) +2.5 (+2.0 to +2.9) 160 (0.6) +1.3 (+0.9 to +1.7) 
Table 2 - continued 
PeriOd 1969-78 Period 1979-86 t Period 1987-93 
rates (SE) percentage change rates (SE) percentage change rates (SE) percentage change 
(95% Cl) (95% Cl) (95% CL) 
Men 
National mortality trom: 
Cardiovascular disease 762 (2.4) -0.4 (-0.6 to -0.3) 687 (2.4) -1.5 (-1.7to-1.3) 583 (2.1) -17 (-1.9 to -1.4) 
Stroke 146 (0.5) -1.9 (-2.2 to -1.5) 117 (0.4) -3.2 (-3.7 to -2.8) 99 (0.4) -1.1 (-1.7to-0.5) 
Coronary heart disease 419 (1.3) -0.1 (-0.3 to +0.1) 369 (1.3) -1.7 (-1.9to-1.4) 287 (1.0) -4.2 (-4.6 to -3.9) 
Other 198 (0.6) 0.0 (-0.3 to +0.3) 201 (0.7( -0.2 (-0.5 to +0.2) 197 (0.7) +1.9 (+1.5 to +2.3) 
Morta/ity in hospital trom: 
Cardiovascular disease 238 (0.9) -0.7(-1.1 to-0.3) 214 (08) -1.9 (-2.3 to -1.5) 
Stroke 59 (0.2) -2.2 (-3.0 to -1.4) 53 (0.2) -0.6 (-104 to +0.2) 
Coronary heart disease 84 (0.3) -1.3 (-2.0 to -0.7) 65 (0.2) -5.8 (-6.5to-5.1) 
other 95 (0.4) +0.7(+0.1 to +1.4) 96 (004) 0.1 (-0.5 to +0.7) 
Hospital discharge rale 
Stroke 322 (1.1) +1.3 (+0.9 to +1.6) 302 (1.0) -0.0 (-0.4 to +0.3) 
Acute coronary event 621 (1.5) +104 (+1.1 to +1.6) 635 (1.4) -0.4 (-0.6 to -0.2) 
Congestiveheartfailure 229(0.1) +3.7 (+3.2 to +4.1) 281 (1.0) +1.1 (+0.8 to +1.5) 
t 1980-6 for the hospital register data 
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These npward changes are similar to, but less deal' than, those seen 
among wamen. 
The hospita I register showed an increase in discharge rates for acute 
coronary heart disease, congestive hemt failure and stroke in 1980-86. In 
1987-93, the discharge rates stabilised for stroke and coronary heart disease, 
though rates for coronary heart disease still increased among wamen. The age 
adjllsted case fatality ratio for an acute coronary event decreased from 13.6% 
(95% confidence inter va! 13.3% to 13.9%) for men and 18.4% (17.8% to 
19.0%) for wamen in 1980-81 to 7.9% (7.7% to 8.1 %) for men and 9.9% 
(9.5% to 10.2%) for wamen in 1992-93. The case fatality ratias for strokes 
remained constant at abont 17.7 % for bath sexes since 1987. For cOllgestive 
heart failure, both sexes showed an age dependent increase in discharges by 
calendar date. In more recent years, more patients were hospitalised at higher 
ages. 
Discussion 
Our stndy provides circnmstantial evidence that the sharp drop in mortality 
from coronaty heart disease between 1985 and 1993, the levelling off of 
mortality from stroke, and the incl'ease in monality from congestive hemt 
failnre are cansally linked by the same process: the increased survival of 
patients with coronary heart disease. Cardiovascular diseases share many of 
the same risk factors, and having one disease increases the risk for others: a 
history of ischemic heart disease increases the risk for other hemt diseases, 
nota bil' heart failure and dysrythmias, and these increase the risks for 
cardiogenic stroke. 16 As the prognosis fol' coronary heart disease improves the 
increasing numbers of snrviving patients wiII illcrease the pools of people at 
high risk of other heart diseases and stroke. These will resnlt in increasing 
dca th rates from stroke and other cardiovascnlar discases. 
Validity of study 
The changes we observed might have been cansed by changing diagnostic 
habits, policies for referral or mies of classification. The validity of the Dntch 
register of canses of death is reasonable. 17 Ally changes in coding between 
cardiovascular and non-cardiovasclllar canses of death are likely to have been 
small and nnable to bias seriollsly trenels over time. The possibility of 
miscIassification between different causes of cardiovascular related death is 
high, bnt the observed pattel'lls in bath the hospita I register and the mortality 
statistics were consistent (sec table 2). 
General Practice registers have shown that nearly all patients sllspected 
of having an acute myocardial infarction are hospitaIised in the 
Netherlands. IS Death rates bath ontside hospita! and in hospita I showed 
snbstantia! redllctions, which makes it lInlikely that deaths ontside hospital 
were exchangecl for deaths in hospita!. Moreover, the secnlar trend of 
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ïmpl'ovillg pl'ognosis has been documcllted before, in the Netherlands as 
elsewhere l and has beclllillked to improved managcmcnt.-18-10 19 
Part of the increased rates of discharge of patiems ,"drh stroke anel the 
decrease in case Earulit)' in the early 1980s was caused by the introdnction of 
computed tomography, which ascertained more benign lesiolls. 6 7 20 Since 
1987, the incidcl1ce of and l110rtality from stroke have rcmaillcd constant, 
suggesting a steady state in survival. Thc sharp decl'case in lllortality Erom 
C01'Ol1a1')' heurt disease and the concomitant levelling oH of mortality fro111 
stroke af ter a long period of decline has also been observed in the prospective, 
poplllatiol1 based Nlinnesota heurt survey. 7920 The age dependcllt increase in 
mortality from congestive heart failure rates bas also been documented 
before.21 -24 
Secular risk factor changes might explaiu the observed changes, but 
these have been modest (at best) in the period lUlder study in the Nether-
lands. 26 
Conclusion 
Improvements in tl'eating coronary heart disease seem ulldeniable, but some 
of thc gains made are lost again to deaths from stroke and congestive heart 
failnre. This has important consequences for public health, as increasing 
llumbers of surviving but disabled patiellts with chranie cardiovascnlar 
disease are boosting demand for health carc. 
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Diverging trends in colorectal 
cancer morbidity and mortality 
in the Netherlands 
Earlier diagnosis comes at a price 
Abstract 
In developed countries, time trends in incidence of colorectal cancer 
differ markedly from trends in mortality. This study sought to explain 
simultaneously changes in both colorectal cancer incidence and mortal-
ity. Data on first admissions, interventions and outcome from the na-
tional hospital registry over the period 1978-1989 and data on mortali-
ty from Statistics Netherlands over the same period were analysed b)' 
age-period models and subsequently entered in a Markov-chain model, 
simulating disease history from first admission to death. Over the pe-
riod 1978-1989 age adiusted numbers of first admissions and interven-
tiom increased with respectively 37 % and 32 %, whife mortalit)' de-
clined with 8 %. For every 100 patients admitted in 1987-89, 13 more 
will survive compared to 1978-80. Of these, 3 wil! be saved b)' im-
pro ving results of primary treatment but the other 10 wil! survive their 
diagnosis the subsequent 10 years. Although progress in treatment has 
been made, therapeutic improvement can account onl)' for the smaller 
part of the divergence between morbidity and mortalit)'. Increased di-
agnostic activity, raising incidence and lowering mortality simultane-
ousi)', is the most likel)' cause of the llI1explained divergence. 
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Introduction 
Cancel' registers in many developed cOl1ut1'Îes detect illcreasillg incidences 
of caneers l111related to smoking, aud commonly attribute these illcreases to 
changing envir01l111cutai hazards,l,l Howevcl', in the same countries, trends 
in cancel' mortality differ strikingly Erom trends in incidencc; as a rule mor-
tality has been going down while itlCidence has been going up.'" This di-
VCl'gcnce betwccll illcidence and lllortality ean be explaillcd by improved 
therapy and/or decreasillg lcthality, 1,2 Advallces have been made in specific 
thempies, sneh as the dramatic improvements of treatment in juvenile can-
eers aud thc more modest gains realized by adjuvallt chcmotherapy in ad-
vanced breast and colOl"ectnl cal1cer.5,6 Unspectacular but effective aspec-
ifk changcs, however, have contribnted pl'obably even more to lowercd 
Cancel' lethality, because they are applied to thc majorit)' of solid tnmours: 
better preparation of the sUl'gical patients, safer procedures aud anaesthc-
sia, improved control of illfectiol1s, more effective reanimation, etc. 
An alterllative hypothesis explaining this divergence is illcreased case 
detection. By lowering diagllostic thl'esholds lesions with less invasive po-
tential are added, increasing incidellce and improvillg prognosis at the same 
time.7 IE this is the case, it implies that part of the observcd morbidity in-
crease is iatrogenic and maybe preventabic. To shed light on the Iikeliness 
of either explanatioll we have looked at incidence, ll10rtality and survival 
from colorectal cancer in the Netherlands. 
ColOl'ectal cancel' is the secolld most frequent cancel' among men and 
women in the Netherlallds, showing an incidence increase l'e1ative to mor-
ta!ity (fignre 1). In the Netherlands, mass screening for colOl'cctal cancer is 
not recol11ll1ended. The Dutch polie)' makers feel that the unavoidablc in-
crease in morbidit)' aud costs, indllced b)' the man)' false positives (faecal 
occult blood testing) andlor b)' more demanding diagnostic procedures 
(sigmoido- 01' coloscopy) are not justified b)' the still nncertaill decrease in 
mortality,S,9 But individnal ph)'sicians ma)' feel otherwise, alld are free to 
act accordingly: long before mass screening for breast cancel' was intro-
dnced in the Netherlands, the regional cancel' registr)' showed incl'easing 
numbers of s111all tu1110urs, witnessing earlier diagnosis. 1O Contrar)' tG 
breast cancel' we do not possess accuratc data about colm'ectal cancer 
stages at prima!'y dia gnosis in the Netherlands. Such illformation would be 
much harder to interpret allyway, because staging in colorcctal callcer is 
morc depelldellt of modern diagnostic imaging. This may give rise to stage 
migration: previollsly missed invasion of deeper tissues ma}' be diagnosed 
b}' more modern diagnostic imaging, sneh as magnetic resonance imaging 
(wIRI), causillg an al'tefactual migration frommiIdcl' to more severe disease 
stages. 11 
This paper pl'esents the trends in first admissions for colorcetal cancel' as 
pril11ary diagnosis, major interventions durillg these first admissions to the 
hospital and Illortality over the period 1978-1989 in the Netherlands. 
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Figure 1 
. Fuillines and symbols show the age standardized rates (30-64 year) of first admissions, major interventions and deaths for the Netherlands. Dotted lines and 
open symbols show the cancer incidence and mortality from the South Eastern Netherlands (1978-1987) and the national cancer incidence (1989).14 The 
error bars show 95% confidence limits (see text). 
Table 1 
Age standardized incidence and mortality per 100 000 per year and their standard errors (in brackets), by sex, period and 
souree. The cancer register figures trom the period 1978-1987 are trom the Southeastern regio" only; those trom 1989 are 
the first available national data (see text). 
Men (30-64 y) 
1978-82 
1983-87 
1989 
Women (30-64 y) 
1978-82 
1983-87 
1989 
incidence 
34.9 (1.3)' 
42.0 (1.9)' 
37.3 (1.0) 
incidence 
34.7 (1.3)" 
35.8 (1.7)' 
31.8 (0.9) 
Cancer Register 
mortality 
17.9 (1.0)' 
19.2 (1.3)" 
15.1 (0.6) 
Cancer Register 
mortaJity 
17.6 (1.1)" 
15.2 (1.1)" 
13.2 (0.6) 
* From the Southeastern reg ion; all other data are nationaI. 
ratio 
1.95 (0.14)" 
2.19 (0.18)' 
2.47 (0.12) 
ratio 
1.98 (0.15)' 
2.35 (0.21)' 
2.41 (0.12) 
1 st admission 
28.2 (0.3) 
33.9 (0.4) 
35.9 (1.0) 
1st admission 
27.8 (0.3) 
30.2 (0.4) 
31.2 (0.8) 
Hospital register 
mortality 
14.9 (0.2) 
15.3 (0.3) 
15.1 (0.6) 
Hospital register 
mortality 
14.4 (0.2) 
14.2 (0.3) 
13.2 (0.9) 
ratio 
1.90 (0.03) 
2.21 (0.05) 
2.38 (0.12) 
ratio 
1.93 (0.03) 
2.14 (0.05) 
2.36 (0.17) 
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Thc change in pl'ognosis needed to explain the divergence between in-
cidence and mortality is quantified, and we conclude that it is unlikely that 
improved therapy can explain the improving prognosis. 
Patients and methods 
0Jumbers of deaths for colon and rectum cancel' (International Classifica-
tion of Diseases, 9th revision, nrs. 153 and 154) by calendar year (1978-
1989),5 year age group (30-64) and sex have been obtained from Statistics 
Netherlands.!2 Pel'son years at risk are approxil11ated by the midyear 
population of an age and sex gronp in a calender year. Summary estimates 
over age are calculated by l1sing direct standardisation l using the European 
Standard Population as weights; standat'd errors are calculated by 
LWa~a ( 2) //2 
a Na 
where 0 are the numbers, N the midyear population, w the weigilts and a 
the 5 year age groups between 30 and 64. 13 Colon and rectum cancel' are 
taken together in one grollp to avoid possible changes in codification. 3 
Nationwide data on colOl'ectal cancel' incidellce are available since 1989.!4 
The regional cancel' register in the Southeastern Netherlands (SE-N) pub-
lishes cancel' illcidences since 1975, but the poplliation covered is relatively 
small (I million) and in the period of interest (1978-1989) the colOl'ectal 
cancel" mortality in SE-N was significantly higher than in the rest of the 
Netherlands (see figure 1 and table 1 ).15.16 
Therefore, we used primarily national hospita I register data as a proxy 
for incidence. In additiol1 to administrative data the hospital register rec-
ords the diagnosis at discharge (prÏmary and secondary), the result at dis-
charge (a live or dead), all major interventions, and \Vether it is a first ad-
mission for the considered cancel' or not. \Y,Te cOllsidered first admissions 
with colOl'ectal cancel' as primary diagnosis (International classification of 
diseases, 9th revision, nrs. 153-154) and major intervelltions dnring first 
adlllission as partialol' total colectomy, reetnmamputatioll or entero-
stomy.I' ComparÏng the (national) incidence for 1989 with the first admis-
sions of the hospital register, we decided to limit the analysis till age 64. 
The hospital register became increasingly incomplete in the elder age 
gronps, bnt for the younger age gronps the incidence corresponded closeI)' 
with the first admissions (see figure 1 and table 1). It has been shown be-
fore that more than 97% of all patients nnder 65 with colorectal cancel' are 
treated in the Netherlands.!S Therefore, the nationwide hospitall'egistcl' of 
the Netherlands is an acceptable proxy of coloreetal cancel' incidence, if 
Iimited to the )'Ollng and middle aged patients (30-64 year). 
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Figure 2 - The Markov model of colorectal cancer. 
Incidence is determined by age and sex. Persons may die in hospital (CFR), or may be 
cured (c). If not, they face a time dependent probability of caneer death P(t) (see 
appendix). All patients run a risk of dying trom other causes and a higher risk of a second 
primary tumour. 
Period trends in intel'vention, first admissioll al1d mortality rates have been 
estimated by loglillcar regression allalysis,l9 Thc observed rutes are related 
to age-group, sex aud caleudar year as follows: 
Ea,$ = Na,se( aa" + /3a" "x) 
where E is the expected number (of deaths, first admissions or interven-
tions) aud N the midyear population, a denates 5 year age groups from 30 
to 64 year, s sex aud x is the caleudar year, IJ is the slope of the regres sion 
line of the logarithm of the rates of ever)' age and sex group versus calendar 
year, and l'epresents the trend of age alld sex specific rates over time. Sum-
mar)' estimates over age are calculated by specifying only sex as explaua-
tory IJ varia bIe, 
The disease history is modelled by a Markov type state transition model 
(see figUl'e 2), The model assmlles three groups of patients af ter definite 
diagnosis: a fraction which dies during first admission (fufther ca lied CFR, 
'case fata!it)' ratel), a fractioll which leaves hospital 'cured' and a fraction 
",hieh \Vill die of the disease at same later point in time, pl'ovided they do 
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not die hom other causes (funher ca lIed 'not cured'). The probability of 
dl'ing from colorectal cancer for the not cured is lognonnally distributed 
over time characterised by a geometrie mean (identical to the median sur-
vival time) and varÎal1ce (see appendix).20 Conseqnently the model accom-
modates changes in 4 components of prognosis: the probability of snrviving 
primary treatment, the probabilit)' of being cnred and - if not cured - the 
median survival time variance beforc d)'ing from colorectal cancel'. The 
case fatalit)' ra te (CFR), defined as the fmction that dies in hospital within 
2 months of primar)' diagnosis, is known from the hospital register. The 
fraction whieh is cnred approximates the fraction surviving 10 year af ter 
hospita I discharge (corrected for death from other causes): the risk of dying 
more than 10 l'ear aftel' diagnosis of colorectal cancel' equals the risk of 
death of the reference population.2! All patients, the cured and the not 
cnred, run twiee the risk of the reference popnlation for a second primary 
coIOl'ecta! cancer.12 All persons, healthy, cured and not cured, run a risk of 
d)'ing from all other causes, detennined bl' Dutch life tables corrected for 
colm'ectal cancel' death. 12 
The survival distribution is 'first estimated by an iterative nonlinear 
least squares regression, weighted fol' the nnmbers of death, based on sur-
vival figures from the Norwegian and SE-N cancer registry.23,14 Then, by 
nsing incidence and survival the model determines expected mortality: the 
model starts from observed Î11Cidence aud calculates expected numbers of 
death, given a stated survival and cure rate. Combinations of cure rates and 
survival periods williead to age specific estimatcs of mortality, which may 
or may not be different from observed estimates (see appendix). Numerons 
pairs of cu re rates aud survival periods have been tested. The variance be-
tween calclllated and observed nnmbers of deatlls is tested by assuming a 
Poisson distribution of the probability of death (see appendix)." If the cal-
culated numbers differ significantly from the observed (p<0.05), that spe-
cific pair of cu re ra te and survival period is rejected as unlikely. 
Results 
For both sexes, mtes of fkst admissions increase over the period 1978-
1989, while mortality remains sta bIe or dedines (see figme 1). The cancer 
incidence and mortalit)' of the South-Eastel'll NetherJands show the same 
trend, although the incidence 1110rtality ratios are somewhat higher (see 
table J). The cancer incidence of 1989 cor1'esponded dosely with the first 
admission rates of the hospita I register of the same )'ea1' (see figut'e I). 
Table 2 shows the annual changes b)' age and sex, estimated b)' the log-
linear age-period lllodels. Over th is l'elatively short periad, first admissioll 
rates increased with 39.9 % (M) and 20.4 % (W), rates of major interven-
tions aftel' primar)' diagnosis increased with 32.6 % (lvI) and 14.0 % (F), 
but mortalit)' nearl)' 1'emained sta bIe fo1' men (+ 2.2 %) and declined sub-
stantially among women (- 15.3 %). Hence, clinical incidence increased 
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with more than 35 % relative to mortality, and incidence of major iJlter-
ventions increased with 30 %. The standard errors (SE) in table 1 show 
that this increase of clinical incidcllce compared with mortality is highly 
significant. Nlajor interventioll rates during primury admission illcreased 5 
% less steeply than first admissioll rates: th is differcllce is statistically not 
significant, but probabJy indicates a shift fr01l1111ajor surgcl'y towards more 
11011 illvasive cololloscopic treatmcllt for early lesions. 
The case fatality rate in these age groups decliued quite strongly: from 
5.6 % (SE 0.5) for men aud 5.9 % (SE 0.5) for women in 1978-1980 to 
respectively 2.5 % (SE 0.3) and 2.4 % (SE 0.3). However, as shown in the 
same table 1, th is decline in lethality can only explain the smaller part of 
the observed difference between morbidity and 1110rtality trend: late 111or-
taHt}', exclnding deaths dnring first admission, increased with 9.2 % among 
men and decl'eased still among women (- 9.5 %). 
Tabl.2 
Annual change of admissions, major interventions and deaths by age and sex over 
the period 1978-1989j 'late deaths' reters to all patients dying after surviving primary 
diagnosis and treatment, and corrects for changes In operative lethallty. 
Menj annual change In % (standard errors between brackets.) 
1st admissions interventions all deaths late deaths 
............................... - ............................... _. .............................. ................................. 
30-34 0.0 (1.9) -2.2 (2.2) -5.5 (3.1) ·4.7 (3.2) 
35-39 0.2 (1.5) -0.4 (1.7) -3.1 (2.3) -2.4 (2.4) 
40-44 5.9 (1.5) 4.2 (1.2) 0.5 (1.7) 0.7 (1.8) 
45-49 3.1 (0.9) 2.4 (0.9) -0.8 (1.3) -0.4 (1.4) 
50·54 3.3 (0.7) 2.4 (0.7) 1.2(1.0) 1.9 (1.0) 
55-59 3.4 (0.6) 3.0 (0.6) 0.0 (0.8) -0.5(1.1) 
60-64 2.8 (0.5) 2.6 (0.5) 0.7 (0.6) 1.3 (0.7) 
..........................................................•... ....................................... _ ................................ . ................................ 
30·64 3.1 (0.3) 2.6 (0.3) 0.2 (0.4) 0.8 (0.4) 
Women; annual change in % (standard errors between brackets.) 
1 st admissions interventions aU deaths iate deaths 
.................................... ....................................... -................................. _ ................................ 
30-34 
35-39 
40-44 
45-49 
50·54 
55-59 
60-64 
30-64 
2.6 (2.1) 
-0.2 (1.6) 
0.1 (1.2) 
2.2 (0.9) 
2.0 (0.7) 
1.1 (0.6) 
2.2 (0.5) 
1.7 (0.3) 
3.2 (2.4) 
1.4 (4.2) 
-0.1 (1.2) 
1.0 (1.0) 
1.1(0.7) 
1.0 (0.6) 
1.6 (0.5) 
1.2 (0.3) 
-0.3 (3.7) -0.6 (3.8) 
·2.2 (2.5) -1.8 (2.6) 
-2.6 (1.8) -2.4 (1.8) 
-1.9(1.4) -0.9 (1.4) 
-1.3 (1.0) -0.5(1.1) 
-1.5 (0.8) -1.1 (0.8) 
-1.4 (0.7) -0.7 (0.7) 
-1.5 (0.4) -0.9 (0.4) 
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Table 3 shows relative survival rates which fit closely the observed il1ci-
dence alld mortality rates of two three year periods at the beginning alld at 
the end of the study period. Next to these simnlnted relative survival rates 
are the figures from Scandînavian and Dutch cancel' registries originally 
used for estimation of the survival distribution. The simll!ated (fitted) sur-
vival rates are slightly lower than the observed, This can be expected if the 
hospita! register misses a few very early lesions with good pl'ogllosis, cn}"-
able by non-invasive procedures (see discussioll). 
The relative survival expected for 1987-89 predicts that cure rates 
(equal to the 10 year relative survival ra te af ter hospita I discharge) have 
increased with 11.8 % points, given a constant medium survival time: from 
41.8 % (range: 38,8 - 44,5) in 1978-80 to 53,6 % (range: 51.2 - 55,1) in 
1987-89, In other words: for every 100 patients « 65 y) admitted in 1978-
80 6 died in hospital and 55 in the subsequent years; 9 years later less than 
3 died in hospital and 45 will die in the subsequent years, 13 extra patients 
survived a colorectal cancel' diagnosis, 3 thanks to lowered hospita I mo1'-
tality, 
Figul'e 3 shows areas of all pairs of cure rates and median survival time 
which fit the observed incidence and mortality within 95 % confidence 
Iimits (see appendix). As median survival increases, the corresponding cure 
ra te has to decrease to fit the g'iven mOl'tality. lndeed, two processes cau 
explain an}' change of mortality rates, given incidence: death from colorec-
tal cancel' can be cancelled (hence, pel'SOllS are clU'ed; arro\\' a in figure 3) 
01' postponed (hence, median survival is increased; arrow b in figul'e 3). 
Obvious!}', bath processes can also take place at the same time (arrow c in 
fignre 3), For example: the incidence and lllortality data of 1978-1980 can 
be explained by a median survival of 1.5 year aud a cure ra te of 0.44 or by 
a mediall survival of 3 year and a cure rate of 0.37. The illcidence and 
mortality figures of 1987-1989 can be explained by a median survival of 
Tabl.3 
PUblished relative survival rates from Scandinavian countries(23, 26, 34) and the 
Southeastern Netherlands (SE·N)(24) are compared with the simulated relative survival, 
which fits best observed first admission and mortality rates from the periods mentioned. 
Observed Simulated 
......................•.............. "" ...... "."."""."."." ... , ... " .... "., ".".", ..... ,,' .. 
" .. """.".".".".''''''''''''. 
Time after Finland Norway Sweden Sweden SE,N Netherlands 
diagnosis 1953-74 1972-75 1970-74 1975,79 1975-85 1978,80 1987,89 
2m 88,6 90,6 94,2 97,5 
1y 54,2 67,1 70,5 71,7 68,0 74,3 
3y 47,8 48,2 58,8 
5y 31,1 42,7 45 46,8 46,5 42,6 54,6 
10 Y 30,2 41,9 42,2 39,4 52,3 
112 Disease models 
~ 1978-80 til%,,11987-89 
0.30 '---:-':-:--~----'--~----'--~------' 
1.50 2.00 2.50 3.00 
median survival (in yrs.) 
Figure 3 - Two way sensltlvlty analysls. 
The two areas contain all pairs of cure rate and median survival of Ihe not cured which wif[ 
fit Ihe given incidence and mortality rates of 1978-80 and 1987-89 within 95% confidence 
limits. The arrows indicate three hypothetical explanations for Ihe difference between Ihe 
two periods: increase of numbers which are cured (a), increase of survival of the not cured 
(b), or a combination of bath (c). 
1.5 year and a cnre rate of 0.54 or a llledian survival of 3 year and a cure 
rate of 0.50. Figure 3 shows also that the model is llluch less sensitive to 
changes in assumptions about tI~e median survival time than cure rate: ta 
fit the same combinatiolls of incidcllce aud mortality, cure rates have ta 
decrease with an average of 4.2 % points (a relative decrease of 10 %) 
WhCll median survival increases with 1 rea .. (a relative ÎnCl'ease of morc 
thall 50 %). This is a cOllseqllence of the fact that more th all 80 % of 
th ase who eventllall)' \Viii die of colorectal cancer will do sa within 3 )'ears 
of their diagnosis. Conseqncntly, prolonged survival in the absence of cu re 
catl not explain mnch of the widening gap between incidence and mortal-
ity: cnre rates must have improved considerably. The most plausible ex-
planatioll for the increasing cure l'ates is increasing case detection. Earlier 
diagnosis probably improves effectivity of treatmellt9, and certainly in-
creases the numbers of morc benign lesiolls. 
Discussion 
The first qllestioll to be addressed concerns the validity of the data. We 
found incrcasing clinical incidence and decreasing mortality. For the con-
sidered age gronps colOl'ectal cancer mortality trends are generally valid.' 
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Artefaetual trends ma)' be eansed b)' higher diagnostie effieaey in more re-
cent periods: fewer fatal cancers are missed and more patients with wide-
spread cancer have the site of primary origin of their cancel' detennilled. 
But these changes in diagnostic practice \Viii increase l not lower disease 
specifie mortalitl" 
Incidence data are collected fro111 the hospita I register, which is not 
eonstrueted for epidemiologieal purposes. Bnt less than 3 % of yonng and 
middle aged patients with a primary dia gnosis of colorectal cancel' willnot 
be tl'eated, tlms hospitalisation rates for incident colorectal cancel' are 
nearly complete. IS If anything, patients with early lesions eurable by non-
invasive colonoscopic procedures tend do be treated more of ten in ont-
patient clinics, which will cal1se an artefactual trend of admission decrease 
instead of increase. Only sllbstantial changes in codification practices of 
bath admissions for colm'ectal cancel' and of major interventions 1l1ight 
have biased trend estimates; we can not exclude a priori such changes, but 
they seem nnlikely for sneh a short period aud for a disease sneh as eoloree-
tal caueer. And finalIl', the Dnteh hospita I register shows the same treuds 
as those observed in the regional cancel' register in 5011th Eastern Nether-
lauds (tabie 1 and fignre 1): similar aualyses will yield similar resnlts. Re-
giOllal differeuees do exist, bnt nevertheless are smalI: the Netherlands arc 
smalI, with a homogeneons populadon. 
Our analysis lllight be weakened by the cross-sectional nature of the inci-
dence and 1110rtality data, biasing our assesment of (longitudinal) changes 
in prognosis. Bnt the effects of thempy are period-, not eohort-depeudent 
and most deaths fro111 colorectal cancel' occur within 3 years aftel' primary 
diagnosis (tabie 3). The most recent mortality figures (1990-1992) suggest 
a sharpening decrease, particularly among men. 12 This would be inconsis-
tent with the hypo thesis that death is only postpoued, not cancelled: sueh 
postponecl deaths wonld cause a 'catch up' increase.of mortality. 
Increasing incidence and decreasing 1110rtality of colorectal cancel' call 
only be explained by a snbstantial improvement in prognosis. \Ve have 
quantified the expected increase in survival needed: cure rates, deEined as 
10 year survival aftel' hospita 1 discharge, has to increase with 12 % points 
between 1978-80 and 1987-89: from 42 % to 54 %. The simnlated sur-
vival distribntion for the beginning of the period (1978-1980) was similar 
to the ohserved Eigllres of cancel' l'egistries. The mortality soon aftel' pri-
mary diagnosis decreased indeed, as has been observed elsewhere.26,27 This 
ean be attribnted at least partIl' to inereases in therapeut ie effieaey: safer 
interventioll procedures and bettef post-operative care.27 However, as 
shown in table 2, th is change ean only explain the smaller part of the ob-
served divergence between morbidity alld lllortality. Recent adv3nces have 
been made in the adjnvant treatmellt of advanced colorectal cancel', but 
sneh treatments were rarely applied before 1990 in the Nethedands.s.6." 
\Y/e didn't Eind any other indication of advances in treatlllent whieh might 
have benefitted more than a small subgroup (sueh as patieuts with solitary 
hepatie metastases), exeept for the short term results of surgery. Couse-
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ql1Clltly, rhe statement that the divergence betweell illcîdence and mortality 
trends has been cansed by improved therapy, decreasing lethality, rcmains 
with ver}' little support. 
If we exclnde lcss likel)' alternative h)'potheses, snch as decreasing ma lig-
nancy of colm'cctal cancel' in hllmans, the most prohable explanatioll of the 
Împroving prognosis rcmains increased case detectioll. Earlier diagnosis 
deals with bath incidence aud lllortality simultaneonsly: 
l. Earlier diagnosis ma)' acconnt for decreasing lethalit)'. While this re-
mains a matter for dehate, there is llowat least some evidence that 
earlier diagllosis improves long term progllosis.9 
2. Eadier dia gnosis \ViII increase il1cidellce by shifting diagnosis towards 
all earlicr age. In screening theary this is called lead time.7,29 
Obviously, lead time alone would not canse all incidence increase: a 
tu mout' whieh is diaguosed at the earIier age (a - t) wiII not be 
diagnosed an)' more at age (a). But, in period (a - t) paticnts run a risk 
to die of other causes and colm"ectal cancel' incidence increases sha1'1'ly 
with age. The steeper the incidence increases with age, the more lead 
time will increase observed incidence rates, by moving dia gnosis to 
younger ages. For colorectal cancel', shifting the whole age s1'ecific 
incidence curve of 1978-80 with alle year towards a younger age 
causes an increase of the age standardized incidence with 12.5 %. 
But advancing diagnosis one year in the natural disease progression 
wiII cause a shift of incidencc by age which is always more than one year. 
This is caused bl' 'length time bias'; the slO\ver tumonrs grow, the likelier 
the)' are to be pieked np bl' earlier diagnosisY' How much incidence wiII 
)ncrease, given earlier diagnosis, depends again on the rclation of incidence 
with age and of the time distribntion of the 'silene pel'iod that tnmoul'S 
would have passed nnnoticed previonsl)', but are detected now. This dis-
tribution is nnkllown, but willl'eflect the variability of disease pl'ogl'ession. 
A high variabilitl' implies man)' slowi)' growing tumout's and a high poten-
tial to boost observed incidence. 5nch high variability seems likel)'; nnsus-
pected macroscopie colorectal cancel' during necropsy varies between 1 and 
1. 7 % in occidental countries, l'epl'esel1ting nearly 20 % of all incident co-
lorectal cancel's.30,31 \Vithout early dctection, many of those 'slow growcrs' 
wiII remain unnoticed because the person wil! have died bcfore, from other 
canses. 
\\fe conclnde that the incl'ease in incidence of colm"ectal cancel' and the 
concomitant decrease in lllortality cau not be caused by thel'apeutic Îlu-
provements onl)'. The most probable explanation of this divergence is in-
creased cancel' dctection. This has important epidemiologieal and health 
policy implications: 
Iucl'casing case-detection, that shifts cancel' dia gnosis to an earliel' age 
both of the patieut and the tU1110nl', incl'eases incidence (at least in age 
dependent cancers) and decreases mortality simultaneousi)', biasing both 
as indicator of nnderI)'ing cancer hazards. Time series of stage at pri-
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mary dia gnosis might confirm this; in the USA,'where incidcnce and mor-
tality diverge similarly, more early lesiolls are detected, while rates of dis-
tant disease remain stable.32 However, to evade stage migration bias, 
stages should be ascertained independent of modern imaging techniqlles. 
No recommended screening policy, Ol' even proof of benefit, was needed 
to increase case detection, and induce a parallel increase in major inter-
ventions. It is worrying that we don't know how much of the indllced 
lllorbidity increase is truly rewarded bya mortality decrease. 
Appendix 
The survival was 1l10delled by using a discrete approxill1ation of the 
lognormal distriblltion, with median survival JI, vadance ei and ti the i-th 
month aftel' diagnosis. The probability of stlrviving colorectal cancel' tiIl 
time ti P(S)" is then given by 
The subscript a refers to two age gl'OUpS (under 55 and 55-64); these age 
groups have been intl'Oduced becanse younger persons had alowel' CFR 
and a higher cure rate, resl11ting in a better survival. CFR is the fractioll of 
persons, first adll1itted for colorectal cancel', dying in hospital within 2 
lllonths, and c (for 'cmed') is the fraction of long term (10 y) survivors. 
Nlodels incorporating sex as determinant for survival were not significalltly 
hetter , and were ignored. c, pand (J are estimated from observed survival 
figmes, and then varied by the model (see further). 
The pl'esented cancel' model is a subsector of a comprehensive public 
health model, modelling several diseases, aud is implcmented as a continu-
ous time Nlal'kov chain, desCl'ibing discrete sub-populations, cycling in one 
year steps. The continuOlIs time specification allows multiple trallsitions in 
one time step.33 To th is aim, the parsimollious lognormal distribution, de-
fined by GVO parameters, is translated inte a seqllence of exponential wait-
ing time distribntions, described by four parameters, simulating the 
lognormal survival distribntion in the j\IIarkov model. 
The snbpopulation which sur\rives mortality related to primary diag-
nos is and therapy but which is not 'cm"ed', enters a first stage. They wil! 
leave that stage with transition probability pand median dmation -In 
(O.S)/P. Aftel' leaving this stage, parameter y distribl1tes snrvivors over two 
sllbpopnlations in two separate terminal stages, with transition probabili-
ties q and r leading to death from colorectal cancer. For the pl1rpose of this 
paper, these parameters have no direct practical meaning, except for simn-
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lating the 10gnormal survival distribntioll for a population of l111curable 
colOl'ecral cancer patients. 
The mean (and median) survival ol nncurable patients is changed by 
the model throngh P. The varia bles y, q and rare kept constant: changing 
these parameters has the same effect of prolonging the disease process. 
Random valnes between 0 and 1 are generated for the cu re rare c and for 
the transition probability P, and the calcnlated nnmbers of colmectal 
cancer deaths are then compared to the observed nnmbers by the scaled 
deviance (log Iikelihood ratio statistic). Let 0,., be the observed number 
and E,., the expected calcnlated by the model, with a relerring to all 5 year 
age-groups between 30 and 64 and $ to sex, then the scaled deviance ,çs is 
calculated bl' • 
If the calculated nnmbers differ significantll' (P<0.05), the pair of c and P 
values is rejected as unlikely. 
References 
1. Adami HO, Bergstrom R, Sparen P, Baron J. Increasing cancel' risks in yOllnger 
birth cohorts in Sweden. Lancet 1993;341:773-77. 
2. Davis D, Dillse G, Hoel D. Decreasing cardiovascular disease and increasing 
callCer amang whites in the United States from 1973 throllgh 1987. JA~,IA 
1994;271:431-37. 
3. Dol! R, Peta R. The causes of Cancer. Sources of bias in estimating trends in 
cancer lllortality, incidence and cUl'ability (appendix C). 1 Nat! Canc Inst 
1981;66: 1270-81. 
4. Rutqvist LE, Mattson B, Signomkla T. Cancer mortality trends in Sweden 
1960-1986. Acta Oncol 1989;28:771-75. 
5. Krook JE, tv1oertel CG, Gunderson LL, et al. Effective surgical adjuvant ther· 
al')' fol' high risk recta I carcinoma. N Engl J Med 1991;324:709-715. 
6. Slevin tvIL, Gray R. Adjuvant therapy for cancel' of the colon. BI' Med 1 
1991;302:1100-01. 
7. Black \\fC, \X'elch HG. Aclvances in diagnostic imaging and ovel'estimations of 
discasc prel'alence and the benefits of therap)'. N Engl J Med 1993;328: 
1237-43. 
8. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracl' of fecal occult blood 
screening for calorectal neaplasia. A prospective study using Hemoccult and 
HemoQuant tests. JAMA 1993;269:1262-7. 
9. lvlandel 1S, Bond ]H, Church TR, et al. Reducing lllortality fro111 colorectal 
cancel' bl' screening for fecal occult blood. N Engl J Med 1993;328: 1365-71. 
Trends in colorectal cancer 117 
10. Coebergh J\,(f\V, Crol1l111elin IvIA, Kluck Hlvl, vall Beek rvI, van der Horst F. 
Breast cancer in Southeaste1'l1 Netherlands: trends in illcidcllce and eal'iier di-
agnosis in an unscreened female population (in Duteh). Ned Tijdschr Geneeskd 
1990;134:760-65. 
11. Feinstein AR, Sosin DiVI, \Velis CK. The \'('ill Rogers phenomenon: Stage mi-
gration and new diagnostic techniques as a source of misleading statistics for 
survival in eaneer. N Engl J Med 1985;312:1604-8. 
12. Netherlands Central Bureau of Statistics. Death by causes of death, age and 
gender 1978-1989: Netherlands Central Bureau of Statistics, published annu-
all)'. 
13. Breslow I\TE, Day NE. Rates and rate standardizatioll. in: 11. The design and 
analysis of cohort studies. L)'on: International Agency for Research on Cancer, 
1987:48-79. 
14. Netherlands Cancer Registr"y. lncidence of cancer in the Netherlands 1989. 
First report.: Netherlands Cancel' Registr)', 1992. 
15. Eindhoven Cancer Registry. Cancer incidence and survival 1975-1987 in 
Southeastern Netherlands: Comprehel1sive Cancer Center South, 1991. 
16. Netherlands Central Bureau of Statistics. Atlas of callcer mortality in the Neth-
erlands 1979-1990: Netherlands Central Bureau of Statistics, 1992. 
17. Stichting Informatiecentrum voor de Gezondheidszorg. Classification of inter-
ventions (in Duteh): SIG, 1977. 
18. Coebergh JW\V. Epidemiologieal aspeets of ca neer in the elderl)' (in Duteh). 
The Practitioner 1990jl0:753-57. 
19. Clayton D, Schifflers E. tvlodels for temporal variation in cancel' rates. I: 
age-period and age-cohort modeIs. Stat Med 1987;6:449-67. 
20. Rutqvist LE. On the utility of the lognol'mal model for atlalysis of breast cal1-
eer survival in Sweden 1961-73. Er J CallCer 1985;52:875-83. 
21. Hakulinen T, Pukkala E, Hakama .M, Lehtonen iVI, Saxen E, Teppo L. Sur-
vival of cal1cel' patients in Finland in 1953-1974. Annals of clinical research 
1981;3 suppl 31:32-37. 
22. Harve)' EB. SccOild Cancel' Following Cancer of the Colon and Rectum in 
COllnecticut, 1935 R 82. Nat! Cancer Inst Jvlonogr 1985;68:99-112. 
23. Cancel' Registry of NOl'way. Survival of cancer patients. Cases diagnoscd in 
Nonva)' 1968-1975: Cancer Registr)' of Norwa)', 1980. 
24. Coebergh j\\l\X', Crommelin !vlA, vall der Heijden LH, Hop \'VC], 
Verhagen-Teulings l."lT. Survival of cancer patients in southeatern Netherlands 
in the period 1975-85 (in Dllteh). Ned Tijdschr Geneeskd 1991;135:935-943. 
25. Breslow NE, Day NE. Fitting modeIs for grouped data. in: 11. The design and 
analysis of cohort studies. Lyon: International AgcnC}' for Research on Cancer, 
1987:120-176. 
26. Enblad P, Adallli HO, Bergstrolll R, Glimelius B, Kruselllo U, Pahlman L. 1111-
pl'Oved survival of patiel1ts with cancers of the colon and rectum? ] Nat! Can-
eer Inst 1988;80:586-91. 
27. Gordon NLM, Dawson AA, Bellnet B, Innes G, Eremin a, ]ones PF. Outcome 
in colorectal adenocarcÎnoma: two seven-year studies of a population. Br iVled 
J 1993;307:707-10. 
118 Disease models 
28. \Vagener DJT, \V'ils AJN!. Progress in adjuvant treatment of colon nnd rectum 
eaneer (in Duteh). Ned Tijdsehr Geneeskd 1990;134:1689·1691. 
29. Cole PH, !vIorrison AS. Basic issues in population screening fOl' cancel'. J Natl 
Canc Inst 1980;64:1263·72. 
30. Berge T, EkeIulld G, !vlellner C, Pihl B, \"X'enckert A. Carcinoma of the colon 
aud rectum in a defined population. All epidemiologieal, clinical and postmor-
tem investigatioll of colorectal cancel' and coexisting benign polyps en lvlalmo, 
Sweden. Acta Chir Scand 1973;438 (suppl):1-86. 
31. Delendi lvI, Garcliman D, Riboli E, Saseo AJ. Latent colorectal cancel' fOUIld at 
necropsy. Lancet "1989;i:1331-2. 
32. Chow \'(!H, Devesa SS, BIot \"X'J. Colon cancel' incidence: recent trends in the 
Unired Stares. Cancel' Causes ConrroI1991;2:419-25. 
33. Chiang C. An introduction to stochastic processes. New York: \"'{file)', 1968. 
34. Füullsh Foundation for Canccr Research. Canccr in Finland 1954-2008. Hel-
sinki: CallCer Society ofFinland, 1989 (vol 42). 
Abstract 
9 
Senescence as cause of 
hip fractures 
Aim: Ta estimate theoretically the numbers of hip fractures among 
Dutch wamen caused by senescence in contrast to decreasing post-
menopausal bone loss, 
Design: A Markov chain model in a multi-state Iife tabie, 
Methad: Cross-sectional data of prevalenees of bom mineral density, 
measured in an epidemiological survey, are related to numbers of hos-
pital admissions for hip fractures among wamen of age ss and older, 
using a (published) relative risk for hip fracture of 2,6 (9S % confi-
denee Iimits 1,9-3,6) per decrease of 1 SD of bone mineral densit)', \\Ie 
vary the prevalenees of bone mineral density in the multi state Iife table 
and estimate expected changes in the number of fractures, 
Resu/ts: If bone loss ceases aftel' the age of ss, this would decrease the 
numbel' of fractures with 39,4% (9S % confidence Iimits 30,4%-
45,2%), If bone loss is delayed by 7,5 years, the number of hip frac-
tures would decrease by 14,8 % (10,0% - 19,9% aftel' 5 to 10 year 
dela)'), If complianee decreases by age, (3 % per )'ear), then the number 
of hip fractures would decrease b)' 5,6 % (3,4% - 11 % aftel' 1 %-5% 
decrease of complianee), 
Conc/usion: Bone loss is but ol1e of the man)' age related cal/ses of hip 
fractl/res, Populatiol1 based interventions tal'geting ani)' bone mineral 
del1sit)', while ignol'il1g comorbidity, have ani)' a Iimited potential for 
preventing hip fractures, 
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Introduction 
In thc Netherlands, as in man)' other C0l111t1'Îes of the west, the incidcnce of 
hip fractures in both men aud women over the age of 65 has increased, ex~ 
ceeding the number expected based on the aging of the population alone. I 
This is assumed to be assoeiated with the decreasing amount of ph)'sical 
activity in the popnlation, as a result of which bone density is lowcring.2 
But bone dellsity is not thc anely determinant of hip fractnres: over 90% of 
all hip fractures result from a fall.' Important determinants for the devel-
opmcllt of hip fractlll'CS arc, l1cxt to bone mincral density, sex, age, bone 
quality aud vurious factors which eall il1crease the rendency to fall, whieh 
wc have collectively assigned the term 'comorbidity' (figure la} . .J,5 
Thc illcidence of hip fractures over the age of 65 is t\Vice as high in 
women as in men.! Thc maximum bone density (the peak bOlle 111ass 
reached at age 20-30) is lower in women, and next to the age-dependent 
bone 10ss common for both sexes, an accelerated post-menopansal 
(cstrogen-dependent) loss ocellrs among women . .2 
The tendenc)' to fall increases in aId age due to comorbidit)' factms 
sueh as equilibrium disorders, deteriorating vision, decreased mobility and 
problems sneh as cardiovascl1lar discases and dementia. J-S Tbe chance of a 
fracture also incl'eases dne to diminishing protective reflexes. 6 A langer !ifc, 
particularI)' of persons with an elevated risk of faIling, ma)' explain part of 
the illcreasing nmnber of hip fractnres as causcd by cOl11ol'bidity. It was 
demonstrated eal'lier how decreasing mortality yields an incl'easing numbeJ' 
of chl'Onicall)' illY 
The object of this stud)' was to estimate, with the help of a simulation 
model, the number of hip fl'actures in Dutch wamen over the age of SS 
caused b)' decreasillg bone densit)'. We estimated subsequentI)' the llumber 
of hip fractures which conld be prevented by preventing or slowillg down 
the rate of bone loss. 
Methods 
Model 
Figure la displa)'s a simple conceptualmodel: the probabilit)' of a hip frac-
ture is determined b)' the risk of falling and degree of bone mineral density. 
The degree of bone mineral densit)' is determined b)' the level of peak bone 
mass and rate of bone 111ass 10ss. Bone ma ss loss is determined by age (this 
loss is accelerated in postmenopausal wamen) and comorbidit)'. The risk of 
a fall is also affected b)' these factors. Other determinants of peak bone 
ma ss and bone loss are discol1nted. Figure 1 b provides a highI)' simplified 
representatioll of the modelused: the risk of a hip fracture is detennined b)' 
age and b)' age-related decrease in bone density. The existence of disorders 
which affect bone quality more than bone quantit)' are ignored and in-
creases in bone mineral density are not allowed. 
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Flgure 1 - Conceptual (a) and simplifled (b) model for the development of a hip 
fracture 
Technically speaking, the model used was a Markov chain. A so-called 
discrete Markov chain divides a population into a discrete llllmber of ho-
lllogenous states; transition probabilities determine the chance of a popula-
tion changing from one state to another during a space of time (in onr 
model one year). Markov chains have na memory: the fut ure state is de-
tennined solely by the ClllTent state, not by ally past state. The presellt, 
highly simplistic model is unable, for example, to relate fut ure bone loss to 
the bOlle loss ill the past. For th is to be possible, the populatioll would have 
to be redivided into homogenous gl'OUpS, e.g. gl'OUpS of persalIs ill which 
the rate of bOlle loss is high, alld those in which this is slow. 
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Figure 2 .. Observed and simulated prevalences of bone rnineral density class byage 
(BMD class stated between the curves). The prevalence Is the area between two 
curves. 
The model lIsed described four classes of prevalence of bone density, 
ranging from c1ass 1 (highest), to c1ass 4 (Iowest), in the female population 
between 50 and 89 years of age, and related these to the risks of fmcture 
and mortalitl' in a Iife tabie. A cohort entered the model at the age of 50 
and subsequentIl' faced an annual transition probability of ll10ving from a 
higher to alowel' bone density class. The model optimized the transition 
probabilities till the prevalence of bone mineral densitl' found in the Rot-
terdam Stud)' was prodllced/ 
This was done by minimizing the maximal Iikelihood, ca!cnlated bl' 
the following eqllation: 
I(2 *(Oa *(111 ~:) -(Oa-EaJ) 
in which a stands for a particlliar 5-)'ear age group, 0 is the llumber of 
women observed in a defined bone mineral densit)' class (or the number of 
hip fractnl'es) dependillg on what we were calculating) and E for the num-
bel' expected bl' the model. The sum L was rendered as small as possible by 
using a nnmeric method of calcnlatioll throllgh an iterative changing of the 
transition pl'obabilities; the model cOllsequently corresponded maximally 
with the observed realitl'. 
Based all the prevalence rates of the different classes bl' age (figure 2), 
the relative risks for hip (ractnres according to bone mineral densit)' class) 
and the genera I age-specific fracture probability by age it then became pos-
sible to deterllline the age-specific fracture probability according to bOlle 
density class. The model taak into account the risk of dying from other 
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causes of death (calculated on the basis of the Duteh survival tabIe) and 
ft:om the consequences of a hip fracture. 10 
Data 
The bone density data were derived from the Rotterdam srudy.' The study 
population consisted of 7983 men and wamen of age 55 and up. Wie used 
only cross-sectional data of the 3375 wamen in whom the femoral neck 
bone density had been determined with the help of the dual energy X-ray 
(DEXA) methad.' The bone density distribution of this popl!lation was 
divided into 4 equal quartiles, cia ss 1 through class 4; the bone density of 
class 1 was> 0.90 glcm', of cia ss 2 < 0.90 z 0.81 glcm', of class 3 < 0.81 
and z 0.72 glcm' and in class 4 < 0.72 glcm'. The prevalence rates for each 
bone density class were then determined according to 5-yeal' age group (see 
figl11'e 2). 
Wie obtained the numbers of hip fracrures in 1993 in the Netherlands 
from the Dutch hospital register and calculated fracture rates by using the 
Dutch population in the middle of that year as person-years follow Up.11 
Wie adopted the relative risk of a hip fracrure according to bone den-
sity class Erom all article by Clll11l11ings et al.; in their poplliation, the risk of 
a hip fracture increased by a factor of 2.6% (95% confidence limits: 1.9-
3.6) per deerease by 1 standard deviation of bone density.I' This relative 
risk was converted ra bone density class specific risks based on the means 
of the 4 bone density classes and the standard deviation of the overall dis-
tribution of the Rotterdam study group (tabIe 1). The lower and upper 
limits of the 95% confidence level were used for the sensitivity analyses. 
Scenarios 
Variolls scenarios could now be calculated by vàrying the transition prob-
abilities between the fonr bone density classes; the age-specific relative fig-
nres were snbsequently converted iuta absolute figures for the Dutch fe-
male population of 1989. 
Table 1 - Relative hip fracture risk for different classes of bone mineral density 
(BMD) 
BMO class 
2 
3 
4 
mean 8MD 
(in glem') 
0.98 
0.85 
0.77 
0.65 
95% Cl = 95% confidence interval 
'1 SO= 0.13 9/em' 
t Calculated using published data. 12 
:t: 8MD class 1 is the reference class 
relative decrease relative risk for fraclure 
(in SDr (95% Cl t) 
0' l' 
1.1 2.7 (2.0 - 3.9) 
1.7 5.1 (3.0 - 8.8) 
2.6 11.8 (5.2 - 27.2) 
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Results 
Experiments were performed to test three lillCS of reasollillg: 
Halting of osteoporosis 
Thc first experiment is comparable to the elÎ1nination of a cause of death, a 
llluch-used technique in liEe tables,13 In an experiment of this kind, a spe-
dfic cause of dca th is elimillated aud thc theoretica I cohort wHl sllbse-
quently die from other causes of death based on (independent) substitute 
mortality risks; this techniql1c illustrates rhe huge significanee of substitute 
mortaHty. In ont' experiment, howcver, not a cause of dca th but a cause of 
discase (namel)' decreasing bone density) was elimillated aud the impor-
ta nee of the ot her age-related factors (in particular increasing comorbidity) 
was demonstrated. The decrease in bone density was artificially halted by 
reducing all transition probabilities between the bone density classes to 
zero: wamen consequcntly remaillcd in the same bone density class to 
which they had belonged at age 55 for tbe rest of their lives. The fraction of 
prevented fractures tlms depended on the bone density-dependent risk for 
fractul'cs, the sole parameter in the model not estimated on the basis of 
Dnteh data. For th is reason, this parameter was va ried in a sensitivity 
analysis. 
The resnlt demonstrated a reduetion in the nnmber of hip fractnres by 
39.4% (outer limits: 30.4 - 45.2) (tabie 2 and figure 3). The npper aud 
lower limits were based on the 95% confidence intervals for the relative 
risks in the study by Cnmmings et al." In other words: by completely halt-
ing all bone loss from age 55 up, 40% of all hip fractnres could be pre-
vented. 
Slowing the osteopol'otic process 
In the secolld experiment, the development of osteoporosis was not halted 
but slowed, from age 55 up. The model calcnlated the transition probabili-
ties in sneh a way that bone density prevalenees were achieved au average 
Table 2 ~ Estimated effect of the number of hip fractures in three scenarios 
accordlng to bone mineral density, versus the figures for 1993 
reference (1993) 
elimination bone loss 
slowdown (7.5 years) of bone loss 
decreased patient compljancet 
mean estimation 
9299 (100%) 
5640 (60.6%) 
7927 (85.2%) 
8779 (94.4%) 
'" 95% uncertainty limits calculated by sensitivity analysis 
lower and upper limits 
5093 (54.8%) - 6468 (69.6%)' 
7448 (80.1%) - 8369 (90.0%)' 
8448 (90.8%) - 8974 (96.5%)' 
t Assuming 80% of the women start at the age of 50 with a product which slows bone 
loss by 7.5 years and 3% discontinue therapy every year of life. 
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Figure 3 ~ Expected number of hip fractures if no further bone [oss were to occur: number 
of hip fractures in 5-year groups in Dutch wamen (observed as hospita! admissians in 
1993) and the number of hip fractures expected with the Markov model demanstrating the 
fit of the model. The dashed curves represent the expected number of hip fractures if na 
bone loss occurred after age 50. 
of 7.5 l'ears (5 to 10 l'ears in the extreme scenarios) later; this degree of 
delal' in bone loss is found in wamen taking estrogen." In other words: the 
experiment sIlOwed a 'treated' female population of 70 years of age (as-
suming a patient complianee of 100%) with a bone density corresponding 
to an 'untreated' population of 62.5 years of age (65 to 60 in the extreme 
scenarios). This )'ielded a reduction in number of hip fractures of 14.8% 
(10.0%-19.9%). The gain was limited bl' the inexorable aging process (see 
table 2 ànd figure 4). 
Deerease in patient eomplianee 
The third experiment took into account a mixed population with incoll1~ 
plete and changing patient cOl11pliance. An initial 80% of the wamen was 
assmned to be taking medication at the age of 50 which slowed bone loss 
by 7.5 years, as was the case in the previous experiment, but of which 3% 
quit per l'ear (1-5% in the extreme scenarios). This implied that bl' age 55, 
69% (62%-76%) of the wamen were still taking the medication, a 
percentage which fell to 44% (29%-65%) bl' age 70. Those who dis-
continued the treatment experienced an accelerated rate of bone los5 for 
three years until reaching the ba ne density the)' would have had without 
the protective drug. 15 ,16 In this scenario, the number of fracture5 decreased 
by 5.6% (4.3-11.0). The reason for this was that elderly persons exposed to 
the highest risks for fractures had stopped their treatment without deriving 
anl' more benefit from this (see table 2 and figure 5). 
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Figure 4 - Expected number of hip fractures if bone 1055 were to be slowed; numbers of 
hip fractures in 5-year groups in Dutch wamen (observed as hospita! admissions in 1993) 
and the number of hip fractures expected with the Markov model. The dashed curves 
represent Ihe expected number of hip fractures if bone 1055 were slowed by an average 7.5 
(sensitivity limits 5-10) years. 
Discussion 
The developmellt of hip fractures is largei)' associated with falling and with 
diminished bOlle strength.6,17 A hip fractlu"c is nearl}' alwuys the result of a 
fall, while the probabi!it)' of a fmeture is influcnccd inter a!ia b)' bone den-
sit)'. Falling is also caused b)' comorbidit)'3: calculations generated bl' the 
model we used suggested that at populatioll level, primary prevention from 
middle age on solell' aimed at bone densitl' will not be verl' effective. The 
mOl'biditl' which increases with age (frailty) continu es to remaill a eause of 
falls, and if the woman 's fall is an Ullhappy one, she will break her hip 110 
matter what hel' bOlle density is. Age is all important predictive factor in 
respect of hip fmetures, regardless of bone densitl"" 
A Duteh stlldy also demonstmted the low specificitl' and sensitivit)' of 
simple bOlle dellsity measurCll1cnts in the finger in relation to the develop-
ment of non-vel'tebral fraetul'es. [, Our stlldy confinned all this by inte-
gl'ating aggregated figures in a simple model: the fracture probabilities 
(obsel'ved in the Netherlands) increase fal' more (exponentially) with age 
than the reduction of bone loss (found in the ERGO study). 
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Figure 5 - Expected number of hip fractures with a decline in patient compliance in respect 
of osteoporosis inhibitors. Numbers of hip fractures in 5-year groups in Dutch women 
(observed as hospital admissions in 1993) and the number of hip fractures expected with 
Ihe Markov model. The curves represent the expected number of hip fractures if patient 
compliance decreased as follows: 80% of the wamen start to take a product at age 50 
which slows bone loss by 7.5 years and 3% (1 tiH5 in sensitivity analysis) discontinue their 
therapy each life year. 
Assumptions 
The results of theoretica I ma deis are detenllined by assllmptions. We as-
sumed that the number of hip fractures registered by the hospitals were an 
adequate representation of the epidemiological state in the Netherlands. In 
view of the gravity of the problem and the need for medical intervention 
this would uppear Iikely. \Ve hlfther assumed that the data on bone density 
from the ERGO file were representative for the Dutch population. Women 
in a nllfsing home were not included; the effect of the underestimated dete-
doration in bone density with age is compensated to a cel'tain extent by the 
overestimated chance of fracture for the genera I population. Moreover, 
only a small percent of the female population is a resident of a nursing 
home. Finally, we (still) have not been able to obtain a good estimation for 
the risk of fracture according to bone density for the Netherlands. The 
ranges used in the sensitivity analysis were therefore deliberately kept wide: 
the risk of fractures in bone density class 4 was 5-27 times as high as in 
cia ss 1. It is hardly Iikely that the true values in the Netherlands are outside 
th is range. 
Although the assumptions applied are consequently robust, caution 
must be exercised in iIiterpreting the results of such simple modeIs. The 
model itself is comparable to a survival table20, which gellerates a sYllthetic 
cohort based on cross-sectiollul probabilities. The results must be inter-
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preted like the life expectancy in survival tables, which would only be va lid 
if all other probabilities l'cmain constant in the future: changes in time are 
ignored. 
:Nloreover, onIy the two determillative predictive [actOl's of bone den-
sity and age existed in the highly simplified wodd of this theoretical model. 
A direct extrapolation to the rea I wodd would therefore be a far toa sim-
plistic represclltation. Fot' example, if estrogen replacement not onIy Î111-
proves bone density but also cardiovascular health, the effect of such re-
placement therapy \Vill he far more prollOllllced than simulated here. Ob-
servational studies have revealed that postmcnopausal women on honnone 
replaccmcnt therapy suffer 25-500/0 fewer hip fl'uctures, a mueh greater 
reduction than predicted by ou1' lllodeFl, Even if this may to same extcllt 
he disconnted, it rcmaillS reasonable to aSSllmc that this cardiovascnlar im-
provement will affect the fracture figures. 
The model, in this simplified farm, is not intended to show the effects of 
treatment of osteoporosis (for example in wamen cia ss 3 or 4) or to evalu-
ate the efficiency of screening. It is most certainly not intended for jlldg-
ments about clinical decisions for individual patients. The sole aim of th is 
study was to indicate the quantitative significance of comorbidity in the 
aging process which causes hip fractmes, for which th is simple model is 
ideally suited. It demonstrates l!Ow, if a single determinant of hip fractures 
is eliminated (bone density 1055), 'all other causes' rcmain which illcrease 
rapidly with age. The model demonstrates in quantitative terms that simply 
reducing the problem of hip fracwres to a problem of bone densities is not 
the right approach. 
References 
1. Boereboom FT, Groot RR de, Raymakers JA, Dlll1fSma SA. The incidence of 
hip fractures in the Netherlands. NethJ Med 1991; 38:51-8. 
2. Luw, !\tIR, \Vald N], 1vIeade nv. Strategies for prevention of osteoporosis anel 
hip fractures. BMJ 1991; 303:403-9. 
3. Grisso JA, KeIsey JL, Strom BL, Chiu GY, 1vIaislin G, O'Brien LA et al. Risk 
factors for f"lIs as a cause of hip fracture in WQmen. N Engl J !\'Ied 1991: 
324:1326-31. 
4. Ctunmings SR, Nevitt Me, Browner \"X'S, Stolle K, Fox KM, Ensrnd KR, et al. 
Risk factors for hip fractufe in white women. N Engl J Med 1995; 332: 767-
73. 
5. Cooper C, Barker DJ. Risk factors for hip fracture. N Eng! J Med 1995; 332 
814-5. 
6. Lauritzen jB, !v1cNair PA, Lune! B. Risk factors for hip fractures. A review. 
Dan med Bull 1993; 40: 479-85. 
Senescence as cause of hip fracwres 129 
7. Bonneux L, Barendregt 11, !vIeeter K, Bonsel G], .Maas P] van der. Estimating 
clinical morbidity due to ischemie hart disease and congestive heart failure: the 
future ri se of heart failure. Am J Publ Health 1994; 84:20-8. 
8. Niessen L\V, Barendregt 11, Bonneux L, Koudstaai PJ. Stroke trends in an 
ageing population. Stroke 1993; 24:931-9. 
9. Burger H, DaeIe PLA van, Hofman A, SchUtte HE, Birkenhäger Je, Pols HAP. 
\Verveldeformaties en botdichtheid bij ouderen; het ERGO-onderzoek. Ned 
Tijdschr Geneeskd 1995; 139: 2092-6. 
10. Boereboom FT, Raymakers JA, DUllrsma SA. lvlortality and causes of death 
aftel' hip fracrures in the Nctherlands. Nerh J fvied 1992j 41:4-10. 
11. SIG Zorginforlllatie. Bestanden van de Landelijke Î."Iedische Registratie over de 
Ziekenhuisopnames in 1993. Utrecht: SIG, 1994. 
12. Cummings SR, Black D!vI, Nevitt !vIC, Browner \Y,T, Cauley J, Ensrud K, et al. 
Bone densit}, at various sites for prediction of hip fractures. Lancet 1993; 
341:72-5. 
13. Namboodiri K, Suchindran C. Life table techniques and their appHcation. 01'-
Iando: Academie press, 1987:92-109. 
14. Felson DT, Zhang Y, Hamlan MT, Kiel DP, Wilson PW, Anderson JJ. The 
effect of postlllenopausal estrogen therapy on bOlle density in clderly women. 
N Eng! J med 1993: 329:1141-6. 
15. Christiansen C, Christiansen NIS, Transbol I. Bone mass in postlllenopausal 
wamen af ter withdrawal of oestrogen/gestagen replacement therapy. Lancet 
1981;i:459-61. 
16. Lindsay R, hart DNI, NIaclean A, Clark AC, Kraszewski A, Garwood J. Bone 
response to termination of oestrogen treatment. Lancet 1978;i:1325-7. 
17. Rubin CD. Southwestern internal medicine conference: prevention of hip frac-
tures in the elderly. Am J lvled Sci 1995;310:77-85. 
18. Melton 3d LJ, Kan SH, Frye )vlA, Wahner HW, O'FalIon WM, Rigs BL. Epi-
demiology of vertebrai fl'actures in wamen. Am J Epidemio! 1989; 129:1000-
11. 
19. Hemert Alv! van, Vandenbroucke JP, Birkenhäger JC, Valkenburg HA. predic-
tion of osteoporotic fractures in the general population by a fracture risk score. 
A 9-year follow-up among middle-aged women. Am J Epidemiol 1990; 132: 
123-35. 
20 . .NIanton KG, StaUard E. Chronic disease modelling. London: Griffins, 1988: 
207-10. 
21. Grady D, Rubin S!vI, Petitti DB, Fox CS, Black D, Ettinger B et al. Hormone 
therapy to pl'event disease and prolong life in postmenopausal women. Ann In-
tcrn Med 1992;117:1016-37. 

10 
The burden of morbidity and 
mortality from dementia 
Abstract 
The purpose of this study was to estimate severit)'-specific mortalit)' 
and to quantify the global health burden of dementia by assessing the 
time spent disabled with dementia and the life )'ears lost due to demen-
tia. We used mortalit)' data from the Rotterdam stud)', a population-
based prospective stud)' in the 55+ to calculate overall and severit)'-spe-
cific excess mortality for the demented. Lost life years were calculated 
by decomposing the (mixed) Dutch life table of 1990-92 in two popula-
tions, the demented and the healthy, using prevalence and excess (all 
cause) mortalit)'. Healthy life loss was calculated by a modified Sul/ivan 
technique, weighting for disease severity. Our results indicate that mor-
tality is increased in the demented, in all age, sex and severity groups. 
Mortality rate ratias are 2.1 (men) and 2.3 (wamen) with a range from 
1.7 to 3.4 (men) and 2.0 to 3.1 (wamen), depending on severity. 55-
year aid men lose 1.2 life years due to morbidity and mortality and 0.7 
!tIe years due to mortality resulting from dementia. Wamen lose 3.1 
and 1.9 life years respectivel)'. This population-based study provides 
evidence that mortalit)' is increased in the demented at all stages in-
c1uding minimal dementia. The quantified health impact on the general 
population is in the same order as that of lung cancer or stroke. 
Intl'oduction 
Dementia is gl'adually being l'eeognized amongst health poliey deeision 
makers as a major SOlll'Ce of disability in the gencl'al population. Stl'ategies 
aimÎng at prevclltion, early detection and tl'eatmcnt of the varions types of 
dementia with a primary focus on Alzheimer"' s disease are incl'casingly be-
131 
132 Disease models 
ing discussed and advocated (eg Mayeux, 1996; Whitehouse and Reiden-
bach, 1997). 
Dementia is a common health problcl11j its prevalenee rises exponen-
tially aftel' the age of 60. At least ten percent of the population beyond the 
age of 80 are affected in 'Vestenl C0l111tries (K<1tz111al1l1, 1976; J01'111, Korten 
and Hendersol1, 1987; Hofmann et al., 1991;). Dementia is associated with 
all illcrcase in dependent !ifc expectanc)' and therefore prescllts all impor-
tant burden for bath the individual and soeiet)' (Kal', 1991; Katzmann and 
Kawas, 1994). The socioeconomic consequcnces will presl1111ably becomc 
more critica I as life expectancy increases and the post war baby boom co-
hort reaches aid age. 
There is snfficient empirical evidcllce which docmnents decreased snr-
vival in the demented (Roth, 1955; Martin et al, 1987; Evans et al, 1991; 
Skoog et al, 1993). The relationship between disease severity and mortality 
has, however, not dearly been established (lvlayeux, 1996), probably be-
cause of lack of infol'll1ation on severity trom epidemiologieal studies or of 
suffieient sample sizes. The Rotterdam study, a large poptdation based lon-
gitudinal study of the 55+ (Hofman et al., 1991), permits estimation of age-
and stage-specific excess lllortality among the demented. 
lvleaningful indicators expressing the public health ill1 pact of a disease 
are the number of life years lost due to the discase and the l1umber of life 
)'ears spent, disabled, with the disease. One wal' of expressing the global 
burdell of a disease is to use a composite meaSllre of both. This type of 
health status index was first introduced by Sullivan (Sullivan, 1971). Ta 
allow for compadsons between lost life years due to death and due to dis-
ease-related changes in sevedty, the concept of disability-adjusted life years 
has been developed (Murra)' and Lopez, 1994). Discase stages are assigned 
weights between 0 and 1, where 0 denotes healthy and 1 the severest dis-
ability stage or death. The composite figure shows the loss of life due to 
excess mOl'tality and disabilit)'. 
Methods 
Study population 
The Rotterdam study is a cOll1ll1unity-based, prospective study among the 
population aged 55 years and over to estimate the prevalence, ineidence 
and detenninants of degenerative diseases in order to idelltify preventabIe 
causes of morbidity and mortalitl'. The stud)' population comprises the to-
tal cider population from a district of the eity of Rotterdam. It consists of 
3105 men and 4878 wamen (total 7983), aged 55 and older. They either 
lived at home or il1 one of six aid peoples' homes which provide a wide 
range of care cover1ng all stages of disabilit)'. In this population, 494 sub-
jects (6.2%) were identified with dementia. 
The approach to case-finding was a three-step procedure (Ott et al., 
1995). The MiniMental State Examination (MMSE; Folstein M., Folstein 
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S. and MeHugh, 1975) and Geriatrie Mental State Sehedule (GMS-A, 01'-
ganie level; Copeland, Dewey and Griffith-Janes, 1986) were used ta screen 
the study papulatian. 
Screcn-positive pcrsons undcrwcnt fllrthcr testing, bascd on the Calll-
bridge Examination far Mental Disorders of the Elderly (Rath et al., 1988). 
The third step consisted of ncuroimaging and clinical examinations by a 
neurologist and a nellropsychologist. This procedure was applicd to 94% 
of the stud)' participants. For the rcmaining 6% thc relevant mcdical in-
fOfmation was obtained from records of general practitioners and the re-
giOJlal instiUttc for outpatient mental health care. Diagnosis was established 
on the basis of all available test resnlts and ather information by an expert 
panel using DSM-lII-R criteria (Ameriean Psychiatrie Assaciatian, 1987). 
Subjects were classified as having minimal, mild, moderate, or severe dis-
ease. The c1assifieatian was based on the Clinieal Dementia Rating (CDR; 
Hughes et al., 1982) scale and, if a CDR score was not available, ou 
MMSE scores. MMSE ent-aff points of 30-24 (minimaI), 23-17 (mild), 16-
11 (moderate) andlO-O (severe) were selected on the basis of eal'l'elatian 
with CDR scores. 
Mortality 
The number of deaths over a mean fallaw-np peri ad of 2.34 years were 
available ta establish all cause martality risks. Mortality rates were caleu-
Iated using person-years, b)' five-year age groups and sex. Nlortality rate 
ratios were calculated for each age group and a combined estimate was 
abtained by the ivlantel-Haentzel method far stratified analyses. A Paissan 
regres sion model was fitted to assess the associatian between disease scver-
ity and mortality, using the non-dcmented study population as refel'ence 
group. The model had the general farm log (rate) = flO+fllsev+fl2age. Se-
verity was used as a categorieal varia bIe (5 stages, including healthy) and 
age as a continuol1s variahlc. Factoring of the age groups did not improve 
the model. 
Life years spent with dementia and life years lost due to dementia 
Life tables based on 1990-1992 vital statistie data from the Netherlands 
Central Bureau of Statistics were generated. We split the mixed life table 
popnlatian in twa homogeneons snbpapulatians, the healthy and the de-
mellted, using the age- and scx-specific pl'evalence rates ohsel'ved in thc 
study and the age, sex and severity-specific martality risks. The differenee 
between the life expeetancy of the tata I and the dementia-free population 
shows the effect of dementia on lite expectaney. 
Ta ealeulate a disability adjusted life expeetancy life years lived by the 
synthetie life table cohort (the Lx ealun1111 from a life tabie) are madified sa 
that HLx=Lx (I-PdxDdxl (Murray, 1994; Barendregt, Bannenx and van del' 
Maas, 1995). Where HL, is the nnmber of healthy years lived at age x, L, is 
the number of years lived at x fram the life tabIe, Pd< is the prevalenee of 
the variaus stages of dementia and Dd., is the disability weiglu assigned ta a 
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state of dementia. The following weights were used: 0.6 for mild, 0.81 for 
moderate and 0.92 for severe (Murra)' and Lopez, 1996). For minimal de-
mentia, not assigned in the Global BUl'den of Disease study, we used all 
intennediate weight of 0.3. In terms of health polie)', a weight of 0.6 im-
plies thar a polie)' maker wOllld not be able to choose between all interven-
tiou leugtheuiug the life of 1000 health)' individuals for one )'ear or an in-
tervention lengthening the life of 2500 mildI)' demented individu als for one 
)'ear (Mmray aud Lopez, 1994). 10 years gaiued among mildI)' dcmented 
patients is equivalent to 4 )'ear gained among healthy individuals. 
Results 
The demeuted population was mueh older than the non-demented. There 
\Vere more wamen than men in bath the demented and the non-demented 
study populatiáll. .lVIild and lllOdcl'ate were the 1110St prevalent disease 
stages (tabIe 1). 
Table 1 - Baseline characteristics of the study population 
Non-dernented Demented 
Tota! number 7489 494 
Sex 
Male 2986 (39.9%) 119 (24.1%) 
Female 4503 (60.1%) 375 (75.9%) 
Age group 
55 - 64 2706 (36.1%) 10 (2.0%) 
65 - 69 1408 (18.8%) 12 (2.4%) 
70 -74 1260 (16.8%) 27 (5.5%) 
75 -79 973 (13.0%) 60 (12.2%) 
80 - 84 622 (8.3%) 125 (25.3%) 
85 - 89 359 (4.8%) 155 (31.4%) 
90+ 161 (2.2%) 105 (21.3%) 
Mean age (range) 69.7 (55-106) 84.5 (58-101) 
Severity of dementia 
Minimal 68 (13.8%) 
Mild 204 (41.3%) 
Moderate 148 (30.0%) 
Severe 74 (15.0%) 
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Ovemll and sevel'ity-specific mOl'tality 
Mortality in the study population compared weil with corresponding 1990-
92 mortality data from the total population of the Netherlands (figure). 
Aftel' a mean follow-up period of 2.34 years (standard deviation 1.28; 
range 0.05, 6.08), 7.9 % of the total study poplIlation had died. In con-
trast, 43.4 % of the demented population had died. Aftel' adjusting for age, 
the overallmortality rate ratio of the male and female demented population 
was 2.1 (95% confidence interval 1.5 to 2.9) in men aud 2.3 (1.9 to 2.9) in 
wamen (tabIe 2). In both men and wamen this ratio tended to decrease 
with age. 
The mortality among the demented increased by disease sevel'ity. Pois-
SOIl regressioll allalysis confirmed this association (tabie 3). Remarkable is 
the increased lllortality risk of minimal dementia: 1.7 (950/0 confidence in-
terval 0.8 to 3.6) aud 2.0 (1.1 to 3.6) times higher in men and wamen than 
in the healthy population. This difference was statistically significant for 
wamen. Resnlts in men lack power because of the smaller sample. Nlorc 
sevel'e dementia was associated with higher excess mortality; severe demen-
tia increased the mortality risk by 3.4 (95% confidence interval 1.8 to 6.5) 
in men and 3.1 (2.1 to 4.4) in wamen. 
Table 2 
Mortality (deaths/1000/year) in the non-demented and demented populations, mortality rate raties (MRR) and 95% con-
fidence intervals 
Men Women 
Non-
demented Demented MRR 95% Cl 
Non-
demented Demented MRR 95% Cl 
Age group 
55-64 10.4 122.6 12.0 (0.3 - 74.0) 5.8 79.5 13.3 (0.3 - 84.0) 
65-69 25.5 0.0 0.0 (0.0 - 11.0) 5.4 212.2 40.0 (7.0 - 60.6) 
70-74 33.9 97.5 2.8 (0.3 - 10.9) 10.6 79.3 7.5 (1.4 - 25.6) 
75-79 61.4 181.0 2.9 (1.1 - 6.5) 31.0 192.5 6.2 (3.1 - 11.5) 
80-84 132.5 247.2 1.9 (0.9 - 3.4) 52.0 185.2 3.6 (2.3 - 56) 
85-89 183.1 296.3 1.6 (0.8 - 3.1) 121.3 264.9 2.2 (1.5 - 3.1) 
90+ 176.2 579.2 3.2 (1.3 - 8.7) 202.1 273.4 1.4 (0.9 - 2.0) 
Mantel-Haenszel combined 
2.1 (1.5 - 2.9) 2.3 (1.9 - 2.9) estimate 
Tabl.3 
Number (%) of deaths observed (by severity) and associated rate ratios (95% confidence intervals), adjusted tor age in 
demented men and wamen 
Severity 
Minimal 
Mild 
Moderate 
Severe 
Total 
Age (per year) 
Deaths 
observed (%) 
7 (30.4) 
18(39.1) 
18 (48.6) 
10 (76.9) 
53 (44.5) 
1) Based on Poisson regression 
Men Women 
Rate ratio 1) 95%CI p 
1.7 (0.8-3.6) 0.184 
1.7 (1.0-2.8) 0.035 
2.2 (1.3-3.7) 0.002 
3.4 (1.8-6.5) 0.000 
1.1 (1.1-1.1) 0.000 
Deaths 
obselVed (%) 
12(26.7) 
63 (39.9) 
50(45.1) 
39 (63.9) 
164 (43.7) 
Rate ratio 1) 95%CI p 
2.0 (1.1-3.6) 0.017 
2.4 (1.8-3.2) 0.000 
22 (1.6-3.1) 0.000 
3.1 (2.1-4.4) 0.000 
1.1 (1.1-1.1) 0.000 
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The burden of morbidity and Illortality from dementia 
Elimination of the excess mortality risks for dementia yielded 0.7 and 1.9 
years for men and wamen at age 55 (tabIe 4). In men the nllmher of lost 
!ifc yeal'S illcrcased with age, in wamen it remained constant. \Vomen lose 
1.2 "disahility-adjnsted" life years thl'Ongh morhidity, men 0.5life years in 
the male life tahle cohort. In total, 55 year aId men lose 1.2 years of ex-
pected disability-adjnsted life years, 5.3% of the life expectancy aftel' elimi-
nation of dementia and women lose 3.1 years, 10.7% of the l'emaining life 
expectancy, through dementia. However, the dementia-free life expectancy 
is still mnch longel' in wamen. 
Discussion 
\'('e have established the glohal bllrden of dementia for a district of Rotter-
dam and other popnlations comparable in terms of prevalence of dementia 
and mortality fignres. Decreased survival has been ShOWll by others for 
selected pop111ations sl1ch as nUl'sing home residellts or patiellts attellding 
outpatient geriatrie services or fol' small 01' otherwise l'estrieted population 
samples (Roth, 1955; Kay, 1962; Nielson, Homma and Biorn-Hel11'ickson, 
1977; Vitaliano et al., 1981; Bardey et al., 1985; Diesfeld, van Houte and 
Moerkens, 1986; Martin et al., 1987; Rodney et al., 1987; Knopman et al., 
1988; Walsh, \'('elch and Larson, 1990; Evans et al., 1991; Heeren, van 
Table 4 
Life expectancy (LE), dementla-free LE, disability-adjusted LE, LE after elimination 
of dementia, lost IIfe years and dlsabillty-adjusted lost life years in men and women 
at age 55, 65, 75 and 85 
Ufe Dementia· 
Disability· LE after 
Lost life 
Qisability· 
adjusted elimination adjusted lost 
expectancy free LE LE of dementia years life years 
Age Men 
...........................................•......................................... ........................ 
55 21.8 21.1 21.3 22.5 0.7 1.2 
65 14.2 13.3 13.6 14.9 0.7 1.3 
75 8.4 7.3 7.6 9.4 1.0 1.8 
85 4.6 3.2 3.6 6.0 1.4 2.4 
Wamen 
.......................................................•........................ ............................................. 
55 27.1 25.4 25.9 29.0 1.9 3.1 
65 18.6 16.8 17.4 20.5 1.9 3.1 
75 11.2 9.2 9.8 12.9 1.7 3.1 
85 5.7 3.8 4.3 6.7 1.0 2.4 
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Hemert alld Rooymans, 1992; Sulkava, Vaden and Erkinjuntti, 1992; 
Skoog et al., 1993) our analysis was population-based and allows more 
general conelllsions. The most striking fillding was significant excess mor~ 
tality in thc minimally demented, which is a va lid disease catcgory because 
of the cardul diagnostic procedure. 
This is in contrast with the fjnding of Evans (Evans et al, 1991) who 
nsed a cogllitive instead of agiobal measnre to assess severity. Onr results 
indicate that minimal and mild dementia are not negligible when estimating 
the burden of disease, as is sometimes suggested (Ritchie et al., 1994). 
The lllortality risk inc1'eased with severity in our analysis. These results 
are biologically plausible and they are in agreement with most of the few 
published observations addressing the association of excess mortality and 
discase severity (Nie!son et al., 1977; Vitaliano ct al., 1981; Bardey ct al., 
1985; Martin et al., 1987; Cooper, Bicke! and Schäufe!e, 1996; Heyman et 
aL, 1996). The magnitude of the associatioll in OU1' study was similar ro 
that reporred previonsly. Looking at age effects, excess ll10rrality was ex-
tremely high in the yOllugest in bath men and wamen. A similar observa~ 
tion was made in demented nursing home residents (Van Dijk et al., 1992). 
The relative risks in the lattel' population were higher than in our analysis, 
as might be expected, because they needed care; the age-re!ated gradient, 
howevel', was essentially the same. This is consistent with the concept thar 
dementia in the yOlIng has a more sevel'e course (Bareley et al., 1985; Dies~ 
feld, van Haute and Moerkens, 1986). 
We used changes in Iife expectancy and disability-adjusted Iife expec-
tancy as a comprehensive quantitative indicator of disease impact on 
health. The magnitude of the impact of dementia is compambIe with that 
of other major diseases as a canse of death, sl1ch as stroke or lung cancel' 
(Bonneux et al., 1997). 
This observation establishes dementia as one of the leading causes of 
death and disability and is consistent with all assnmption made by Katz~ 
mann in 1976 (Katzmann, 1976) that dementia may rank as the fonrth of 
fifth most cam man canse of death in the US. 
A limitatioll of our analysis is the omissioll of Ilursing home popula~ 
ti011S with the possible consequence of undel'estimating mortality and dis~ 
ability. Furthermore, wc did not differentiate between dementias with dif-
ferent aetiologies. This seemed justified, however, sillce there are only l11i~ 
nor differences in lllortality between the two major subgronps: Alzheimers' 
discase and va sc nl ar dementia (Van Dijk et al., 1991). We assumed that all 
excess 1110rtality in the demented results trom dementia. This may seem 
naive. In the e1derly, death is rarcly 1110nocausal, bnt the result of a com-
plex process involving several discases. Death from vascnlar dementia, in 
particular, is of ten caused by the underlying vascular disease. However, 
Alzheime{s disease is the predominant cause of dementia aud among these 
patients all excess mortality is most Iikely more attributable to dementia 
than anything e1se. 
Qnantification of the burden of disease, using a global comprehensive 
estimate, establishes dementia as one of the leading causes of mortality and 
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lllarbidity in the papltlatian of 55 and over. Martality fram dementia 
ranges in the same order as from lnng cancel' or stroke. These findings sug-
gest th at health policies shauld aim ta eliminate dementia as eause of death 
and disability. 
Appendix 
We ealculated martality far the demented and nan-demented by abserving 
that the tatal mortality rate (M) is the average of the rates far demented 
(M') and nan-demented (MO): 
M = P M' + (1 - p) M O (1) 
with p the prevalenee of dementia. Furthermore by definition Ît is true that: 
(2) 
with R the relative risk. By substituting (2) in (1) and rewriting we abtain: 
M 
MO=----- (3) 
pR + l-p 
far the risk of the nan-demented, and through (2) the risk for the de-
mented. 
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Introduction to part III 
Introduction 
In part II several disease models have been described and applied to analyze 
compression and expansion of morbidity Oll the disease specific level. This 
part and the next describe how the disease specific results can be ag-
gregated to a general description of population health status, with this part 
concentrating on the problcm how to model multiple diseases and causes of 
death simultaneously. Part IV deals with the question how the resulting 
mnlti-dimensional description of population health status can be mapped to 
a public health indicator. 
There are many criteria possible to distinguish between types of mod-
elling, but all important distinction at this point is the ane between micro-
and macro-silllulatiol1. ~1icl'o-sil11nlation is a technique whcl'c the unit of 
analysis and description is the individual, with macl'o-simnlation this unit is 
the population (or a part of it). This distinction is important because it 
detennines how population heterogeneity is handled. With micro-simula-
tion poptdation hetel'ogeneity is essentially not a modelling issue: the 
population is simply the sum of all individuals described, and each indi-
vidual ma)' have as man)' stochastically determined characterÎstics as is 
desirabIe (Habbema, de Vlas, Plaisier, & van Oortmarssen, 1996; van 
Oortmarssen, 1995). The hardest part is to extract the details without 
being ovel'whelmed by rhe generated infofmation. 
NIacro-simnlation, on the other hand, deals with whole groups of 
individnals at a time, alld therefore these grollps 11ll1st be hOl11ogeneous at 
tbe level of description. Büt in reality populations are heterogeneous: peo-
ple run different risks to contract various discases and to die ftom them 
depending on age, sex, risk factor exposure, alld gelletic disposition. Tbe 
standard way to dealwith this hetel'ogeneity is to sub-divide the populatioll 
into gl'OUpS that are sufficicntly homogeneous fol' the purpose of the 
research questioll. The al't of modelling is to decide when the subdivision 
has achieved a suffieient level of homogelleity, while keeping the llumbcr of 
gl'OUpS manageable. 
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Thc disease 1l1odels in the previons part all distinguished age aud sex, 
and in addition at least two (health)' and diseased), but usuall)' more health 
states (through distinction of more than one discase stage). This alread)' 
generates a large munbcl' of snb~divisions, but when multiple diseases are 
modelled simultaneousI)' the number of sub-divisiolls tends 1'0 explode 
becanse of disease interactions. Thc techniques descl'ibed in th is part are 
designed 1'0 allowan adequate description of multiple diseases and causes 
of death and their illteractÏolls, whilc avoiding all explosioll of the llumber 
of snbwpopulations, and are as sneh partic111ar to macl'o-simulatioll. In the 
General Discnssion we \ViII get back to this issue. 
There are five disease aud canses of death interactiollS that arc of 
impOl'tallce in a multiwdisease model, i.e. the relations between total 
monality aud disease specifîc mOl'tality, substitntion aud competition of 
causes of death, risk factors for diseases (which may be diseases them-
selves), mortality selection, and comorbidity. To model these interactions 
we distinguish two cases: homogeneity versus heterogeneity of disease risk. 
In both cases age and sex are standat'd dimensiolls of differentiation. 
Homogeneity of disease risk 
A stalldard assnmption in demography when dealing with multiple causes 
of death is independence: morralit)' risk of an)' one cause does not depend 
on the risk of any other cause. It call be shown that when the mortality 
risks are described b)' hazards (also called 'force of mortality', and 
mathematically the probabilil')' 1'0 die from a given cause during the time 
interval M, with M~O) and under the assumption of independence, total 
nlortality hazard is simpI)' the SlUn of tbe disease specific hazards (Manton 
& Stallard, 1988). When in addition it is assumed that the hazards are 
constant in a given age-intel'val thcy are eqllal to disease specific mortality 
rates (Manton & Stallard, 1988). 
Since disease specific morralit)' rates and total mortalil')' probablit)' are 
available from Statistics Netherlands it is possible nnder these assumptions 
to partition totalmortality (aftel' convers ion to arate) hetween a number of 
disease specific mortality rates and an 'all-other-causes' mortality rate 
simply by subtraction. 
The convenience of th is approach is that it describes mortalil')' on the 
level of risks. A change in an)' of the mortalil')' risk leaves the others, b)' 
virtne of the independence assl1l11ptioll, ullchanged. \Xlhen, fol' examplc, 
Olle canse of dca th is clinlinated, the other canscs are llllaffected. But 
numbers of deaths from the other canses will increase: alowel' mOl'tality 
risk in one age group will result in a higher number alive in the next. A 
higher number of persons alive, subject to the same mortalil')' risk results in 
a higher number of deaths from all the still existing causes of death. 
This mcchanism, called 'substitutiol1 of cal1ses of death', thus descrihes 
the interaction between causes of death on the level of numbers b)' 
assuming independence on the level of risks. In chapter 12 we expand tbe 
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mechanism to include disease incidence and prevalellce. A set of independ-
ence assumptions, again on the level of risks, is givcn, and pro of is provided 
that these are indeed sufficient cOllditions to describe substitntion of 
diseases and canses of death. In addition it is ShOWll that cOlllorbidity 
prevalence can be derived fro111 the prevalence of specific diseases by mul-
tiplication. This lattel' property allows to omit the explicit 1l10delling of 
c01l10rbid states, which hugely diminishes the 1l1unber of sub-populations to 
be distinguished. 
Heterogeneity of disease risk 
As already observed above, however, populations are not hOlllogeneous in 
disease risk. Some people run higher risks on one or several diseases, for 
example smokers run higher risks than non-slllokers on cardiovasclllar 
disease, a large number of callcers, chronÎc obstructive lung disease, and 
several more. Other well-known risk factors are hypertension and choles-
terol. Also diseases themselves can act as risk factors for other diseases, for 
example diabetes, which is a risk factor for cardiovascular disease, renal 
disease, alld others. 
Heterogcneity of disease risk resl1lts in mortality selection: becallse the 
exposed to a risk factor have a higher risk to contract a disease and to die 
from it, they are being selectively re1l10ved from the population. This 
mortality selection lowers the prevalence of the risk factor: when a popu-
lation consisting of a cohort of smokers and one of non-slllokers is fol-
lowed through time (none of the smok ers quits, and none of the non-
sl110kers takes up, and apart from the smoking the cohorts are compal'a-
bie), then the prevalence of smoking in the population \Viii decline with 
time, becallse the smokers have a higher risk of dying than the 110n-slllokers 
(Manton & Stallard, 1988). 
Changes in mortality selection cause a phen01l1enon called 
'competition of diseases and causes of dcath' . \X/hen, for example, a curc 
for lung cancer would be fouud, the then surviving smokers wonld keep 
their higher risks on cardiovaclliar and chronic obstructive lung disease. 
Because the grollp at high risk in the population incl'eases relative to the 
low risk group of non-s111okers, the average risk incl'cases: the incidence 
élnd mortality of cardiovascular and chronic obstructive lnng disease in the 
population will go up aftel' elimination of lung cancel' mOl'tality. Chapter 7 
in part II describes a likely case of competition of cardiovascular causes of 
death, which was presumably sparked off by the huge improvement in 
survival aftel' myocardial infarction that was achieved in the period 1985-
1990. 
Chapters 13 and 14 describe how multi-disease modeIs can handle 
heterogeneity of disease risks. In chapter 13 the incidence of non-insuline 
dep ende nt diabetes is estimated from prevalence and mortality. Since dia-
betes is a risk factor fol'. a number of diseases the mortality used has to 
include the risk from those canses as weil. Chapter 13 doubles as an ex-
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ample of the nsefnlness of illcidellce-prevalellce-mortality mode Is (0 pro-
vide all incidence estimate in cases as difficlllt as non-insuline dependent 
diabetes. 
This incidence is used in chapter 14 to model diabetes as a disease aud 
as risk factor fol' heart disease. Onee pel'SOI1S have developed diabetes they 
get assigned a higher risk on heart disease incidellce than the nOll-diabetics, 
hence higher prevalence ancl mortality. To allow for this poplliation 
heterogeneity (he poplllation is divided into non-diabetics aud diabetics. 
This sllb-division provicles for 'local independence': within each sub-
poplllation the inclependence conditions of chapter 12 hold, only fOl' the 
population as a whole they do not (Manton & Stallard, 1988). It is shown 
in chapter 14 that in sneh a heterogeneolls populatioll the pl'evalence of 
diabetes, and in particular the cOlllorbidity of diabetes and he art disease, 
\ViII l'ise if (he improvement in heart disease survival exteuds to diabetics as 
weIl. 
Risk factors in a homogeneous model 
Modelling risk factor hetel'Ogeneity through sub-division of the poplIlation 
iuto groups that are homogeueous in their risk factor exposure is feasible. 
\"X'hen the number of risk factors incl'eases, this solntion quickly becOlnes 
tiresome: the number of sUb-poplllatiolls needed is 2\ with n the number of 
risk factors. In man)' instances that follow (the life tables of chapters 19, 
20, and 24, as weIl as in the Prevent Plus model in the lattel' chapter) a 
simpIer approach is used: disease incidellce in a homogeneolls poptdation is 
a functioll of risk factor pl'evalence. Becanse of the homogeneolls pOpU-
lation mortality selection is not modelled. Tbe relative merits and dis ad-
vantages of this simpier approach, as comparcd to the heterogcncous 
lllodelling presented in this part, wiII be discllssed in chapter 27. 
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Coping with multiple 
morbidity in a life table 
One of the applications of the multi-state life table is il1 the field of 
Public Health, with states defil1ing various levels of health or functiol1al 
ability. Al10ther approach is to model Public Health by 100kil1g at the 
impact of il1dividual diseases, but, ul1fortunately, then two practical 
problems arise: there aremal1).diseases.al1d due to comorbidity people 
may be il1 several disease states simultaneously. Both problems tel1d to 
make the l1umber of states il1 the life table impractical/y large. 
111 this paper we introduce the proportiol1al multi-state life tabie. It 
is espedal/y desigl1ed to cope relatively easily with a large l1umber of 
diseases simultaneously, while al/owil1g for comorbidity. We provide 
proof of validit)' and al1 example implemel1tatiol1 for cardiovascular 
disease. 
Introduction 
The life table is a simple and mneh nsed instrnment for assessment of 
popnlation health statns. The standard life table prodnees life expeetaney at 
different ages, and the life expeetaney at birth is probably still the most 
employed indicator of Public Health. 
It is also a limited indicator, since it igl10res morbidity. This limitation 
becOlnes more severe when the bnrdell of disease shifts from aeutely fatal, 
lllOStly infections disease, to chronÎc degenerativc, lllOStly tlon-communica-
bIe disease. Af ter this so ealIed 'epidemiologie transition' (Oml'an 1971), 
that has taken place in the developed and is llndcl'way in an increasillg 
number of developing countries, the need for au indicator of popnlation 
health status that incllldes mOl'bidity beemnes acute. 
All important point of interest is the assessmcnt of the health impact 
of specific discases, both on morbidity and mortality, ond the effect of 
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changes in incidence aad survival, cansed by autonomous trends and pos si-
bie interventions. This cDuld help explain observed trends in population 
health status, make projections of future dcvelopmcnts, and perhaps cladfy 
the issue of compl'cssion versus expallsioll of morbidity, that is being de-
bated for quite same time now (Fries 1980; Olshansky, Rudberg et al. 
1991). 
Interest arises also from the need for optimal allocation of scarce re-
sonrces in the health care sector. For example, the 1993 World Develop-
ment Report from the World Bank made an estimate of the Global BI11'den 
of Disease by combining prevalenee al1d mortality data from a large 11um-
ber of diseases with a measnre of the seriousness of a disease (the DALY, 
Disability Adjusted Life Year), and with this indicator compared the cost-
effectiveness of varions proposed interventions (World Bank 1993; Mnrray 
and Lopez 1994). 
Ta estimate the total bnrden of morbidity one has to look at many 
diseases simultaneously, because, ulllike with lllol'tality, people may suffer 
from varions cOllditiOllS sillluitaneously (comorbidity), in particular at 
older ages. The total impact of diseases on population health status and 
disability does not simply add up: the relation between diseases, health 
status and disability is a complex one, and more sa with comorbidity 
(Verbrugge, Lepkowski et al. 1989). At high ages comorbidity becomes 
substantial, and it has implieations for intervention possibilities and effeets, 
and f';r the amount of disability caused. 
The methad of choke for the inclusion of morbidity is the multi-state 
life table (Schoen 1987). It is a weil established methad, backed by a con-
sidemble body of theory. In a multi-state life table the inclusion of multiple 
diseases while taking cOlllorbidity into account is straightfOl'ward: jnst add 
states defining the combined prevalence of diseases. This works fine for a 
limited number of diseases, but soon beeOll1eS unwieldy when that number 
inereases. For example, with only one state for eaeh disease the number of 
states to be defined is 2"_1, with n the number of diseases. 
\Ve present the pl'Oportionallllulti-state life table methad, that makes 
the inclusion of multiple diseases better manageable and allows for eomor-
bidity implicitly, without the need to define additional states. We impIe-
ment tlte methad for heart disease and stroke, and look at tlte effect of hy-
pothetical but not nnrealistic changes in incidenee and survival on disease 
prevalenee and eomol'bidity. Finally we diseuss limitations and extensiOllS 
of the methad. 
Method 
Desc1'Ïption 
Given the large number of diseases, of which many are rare, in practice one 
lViII have to limit the nUlllber of diseases in the life table to the ones deemed 
most important. This means tltat a life table witlt specific causes of death 
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will always have to include a category 'all other mortality'. This mortalit), 
rate from all other causes can be obtaincd by subtracting the sum of the 
inc1nded disease specific mortality rates from the total mOl'tality rate, as is 
done in cause elimination Iife tables. In the remaillder we will distingnish 
two disease specific mortality rates, and one 'all other causes' mortality 
rate. Of course there willlikewise be au 'all other causes' morbidity, for the 
present study, however, th is is ignored. 
The basic idea of the proportionalmulti-state life table method is very 
shuple: express age specific disease prevaIellce, instead of in numbers, in 
proportions of diseased among all alive at that age. Under certain inde-
pendence cOllditions the comorbidity rate of any number of diseases is then 
just the product of their l'espective rates. Sufficient independence assump-
tions for the case of two diseases and an 'all other mortality' cause of death 
are listed as Al-A3 in the next section, and they can be summarized as: 
the.incidence of each disease should be independent from all causes of 
death, except its own disease specific mortality (Al); 
disease incidences are independent (A2); 
all causes of death are independent (A3). 
The proportional multi-state life table is divided into sections: first a gen-
eral section, that is in fact a standard cause elimination life tabIe, and sec-
ondly, one section for each disease with an independent illness-death proc-
ess, that describes disease illcidellce, prevalence, and disease specific mor-
tality. Total mortality in the general section is calculated from an 'all other' 
mortality ra te and the disease specific mortality rates from the disease sec-
tions. Therefol'e changes in the disease sections that callse a change in its 
disease specific mortality feed into the total mortality, and thus these dis-
ease specific changes are reflected in the total mortality experience of thc 
life table cohort. 
Because the disease specific sections are independent and do calcula-
tions in rates they need not take iuto account the mortality from other 
causes of death: the general section computes for each age the number of 
deaths from all causes, and the age and disease specific prevalence in nllll1-
bers is just the prevaleuce rate of that disease times the nmnber of years 
lived in the age interval by the cohort. The same holds for the number of 
incidents and diseasc specific deaths. 
The age specific comorbidity rate from any nUll1ber of diseases is then 
the product of their respectÏ\'e prevalence rates, which just like the disease 
specific prevalence rates can be multiplied by the number of years lived in 
thc age interval in the genera I section of the life table to obtain comorbidity 
in ullmbers. 
Because each disease specific section does not need to be aware of to-
tal mortality or disease specific mortalities from other diseases each section 
is quite independent from all other disease sections and only linked to the 
general section by its disease specific U1ortality. 
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Proof 
Ta prove the methad described abave ta be equivalent ta a standard life 
mble we must show that pl'evalence, c0111orbidity, aud mortality thus cal-
culated are identical to results from a standard life tabIe. The fallawing 
three propositions state this more f01'mu11y (all three propositions concern 
age specific rates): 
1) The prevalenee in the disease section is equal to the prevalenee calcu-
lated in the presence of ot her diseases and causes of death. 
Jl} The camarbidity of the twa discases is the product of their respective 
prevalences. 
I1I)The disease specific l11artality in the disease sectian is equal ta the dis-
case specific 1110rtality calculated in the prescllce of other causes of 
death. 
Tbc general illdependence cOlldition for u-I number of diseases and 1 'all 
ether cal1ses of death' categor)' is: 
JJ~I 
pr{ Au'::; aJ ••• AI,,,_!:::; aJ ADj > ([J'" AD.1I > a} = pr{ An.1I > a}.I1 pr{ All'::; a, ADj > a} 
i=/ 
with: 
a: index for age 
AI,i" age at incidence of dÎsease i 
AD,;' age at death from disease i 
AD.,: age at death from all other causes 
(A) 
For specific numbers of diseases slightly weaker conditions ean be derived 
from (A) bl' integt'ation over incidences Ol' eauses of death, and without 
105s of generality we \ViII restl'ict Ol1fselves ta a sitnation with 2 diseases 
and an additianal 'all other causes' martalitl'. We will shaw that in this 
case the three independenee assnmptiol1S below are snfficiellt for proposi-
tion l-III to hold. 
lncidences and martalities are independent (except far the same disease): 
pr{ AIi:o:aIQ{ADj>a}}= pr{AIi:o:aIADi>a) Vi EZ 
Pr{ADj>aIAlj:o:a} VjEZ (Al) 
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Illcidences are mutnally independent: 
Causes of death are mutu.lly independent: 
with: 
Z: the set of dise.ses and S: the set of causes of death. 
Now let: 
Z={L,H). 
S={L,H,O) 
Nda): population prevalenee of disease L at age a. 
NH(a): population prevalenee of disease H at age a. 
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(A2) 
(A3) 
NHL(a): population prevalenee of comorbidity of diseases Hand L at age a. 
nH(a): prevalenee of disease H at age a in disease section. 
MH(a): population disease specific mortality of disease H at age a. 
mH(a): disease specific mortality of disease H at age a in disease section. 
Proposition 1 
The disease sectiou prevalenee aud the populatioll disease prevalenee eau 
be expressed respectively as: 
n/f(a) = Pr{ AlIf"; alADH > aj 
N U (a) = Pr{ AlIf"; al ADL > a, ADII > a, ADO > aj 
From equation (2) and Al it follows that: 
Proposition n 
(1) 
(2) 
(3) 
The population prevalenee of disease Land of the comorbidity of Hand L 
are: 
N da) = PI'{ All. ,,; al ADL > a, ADu > a, ADO > aj (4) 
N /fda) = Pr{ AlIf"; a, AlL"; al AD!. > a, AD/f > a, ADO > aj (5) 
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Br proposition I wc know that NH(a}=nH(a), and similarIl' for disease L. 
Proposition II now bec0111es: arc AI-A3 sufficient conditions for (6) to be 
true: 
Rewriting (5) gives: 
Pr( A III <; a, AfL <; a, ADH > a, ADL > a, Aoo > aj 
Pr( ADH > a, ADL > a, Aoo > aj 
(6) 
(7) 
The denominator of (7) can be partitioned bl' using (A3), to partition the 
nU111erator we use, in addition to (Al) and (A2), the property that incidence 
of a disease by definition has to occur before its mortality. This property 
allows us to write: 
Pr( AlL <; a, ADL > aj = Pr( AlL <; aj - Pr( ADL <; aj (8) 
Equation (7) then becomes: 
[
pr{ AlH ,; a. AlL'; (J, ADl! > aj - Pr{ AlH ,; a, ADL ,; a, Aoo > aj +] 
Pr{ ADH ,; a, ADL ,; a, liDO > aj - Pr{ ADH'; a, AlL'; a, Aoo > aj 
N lIL (a) -- (9) 
Pr{ A Dil > ajPr{ ADL > ajPr{ Aoo > aj 
Pr( Aoo > aj Pr( AlH <; a, ADH > ajPr{ AlL <; a, ADL > aj 
Pr( ADL > ajPr( ADH > ajPr( Aoo> aj 
Proposition III 
The population and disease section pl'Obabilities are respectively: 
MH{a) = Pr( ADH <; alADL > a, Aoo > aj 
/IIH (a) = Pr( AD/I <; aj 
Fl'Om A3 it follo\l's that: 
(10) 
(11) 
(12) 
( 13) 
(14 ) 
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An example 
A simple disease model 
We will illustrate the methad with two diseases and an 'all other causes' 
mortalit)'. Each disease is described b)' an illness-death process with anI)' 
one diseased state, consisting of jnst disease specific illcidence, prevalence 
and mortality, with age specific incidence and lllortality ratcs to be given. 
Recover)' is ignored. This disease model can be described b)' a continuous 
time Nlarkov process with threc states: ho' llon-diseased; Zo' diseascd; and do' 
dead. There are two transit ion hazards: y from healthy to diseased; and <p 
from diseased to dead. 
The equations below assume the transition hazards to be constant 
within age intervals, and to millimize the impact of this assumption the eqna-
tions use 1-year age intervals. \Y/e consider the age interval [a,a+l), \vith per-
sans distributed over the three health states, and define r, to be the probabil-
ity for a pCl'son in the healthy state h at exact age a to make two trallsitions 
within the age interval: from health)' to diseased and from diseased to dead. 
Let U be the time spent in that age interval in the health)' state, and V the 
time spent in the interval in the diseased state. Two transitions occur in the 1-
year interval when the Sllm of these times is smaller than 1: 
I'a= P{U+V~lj 
! 
f P{V ~ 1-u1U = IIjP{U = lijd 
o 
! 
fO-e-·,(l-"J}Yae-r'''dll (15) 
o 
jrpao- e-Y'} - Y ,,(1- e-e, ), y" * rp" = rp"-Y,, l-e-r, -Y e-Y' Y-In 
ti ' a - ra 
The state varia bles ha, Za, and da denote the proportioll of the population in 
the various states at age a. The states at a+ 1 are described b)': 
ha+! = ha e-Y' 
Za+! = h"O- e-r, - I'a} + Zae-·' 
da+! = h"l'a + za{l- e-·'} + da 
(16) 
(17) 
(18) 
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Prevalellce at exact age a is: 
Using eq. 16-19 we can express prevalenee at age a+1 as: 
Mortality probability at a is given by: 
and incidence density at a by: 
ia=i-e'Yo 
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(19) 
(20) 
(21) 
(22) 
\XTc eun now write prevalenee at a+ 1 as a function of prevalenee, incidence 
and mortality at a: 
na -lila + (1- na) ia 
na+l = i-111a (23) 
Life table setup 
In table 1 we show tbe set up of the general section of the life tabie. The 
first column contains the 'all other canses' lllortality rate, the second adds 
Table 1 
The general section of the proportlonal multl-state IIfe tabie. 
0° ö" q, I, 0 
0° 0 o~+ LOC i- e'ö, 100000 
d 
oï+ Lofl i_e'ö, {o-do 
d 
lP 'aU other causes' mortality rate 
0<1 disease specific mortality rate 
ti total mortality rate 
d, 
I.qo 
Other notation follows standard life table convention. 
L, 
0.5(/0 + {I} 
T, e, 
95 To LLa -10 a~O 
a=/ 
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to this the disease specific mortality rutes from the disease sections, and the 
third converts this to the total monality probability. From there on the 
general section is equal to a standard life tabie. 
Table 2 shows the setup of a disease section. The first two columns 
give the input, the incidence and mortality rates respectively, the latter one 
is used in the general section to detennine tata I mortality probability. The 
third and fOUlth column eonvert these to probabilities, and the fifth ealeu-
Iates the prevalence. 
Imp\ementation 
We have implemented th is methad, employing a spreadsheet, for heart dis-
ease (ischemic heart disease alld congestive heart failure combined) and 
stroke among Duteh males in 1988. Table 3 shows incidenee and mortality 
rates used in the calculations. Incidence of heart disease is based on various 
studies and u natiouwide hospita I register (Bounellx, Barendregt et al. 
1994), incidenee of stroke on a Duteh regional and several international 
studies (Nies sen, Barendregt et al. 1993), disease specific and total mortal-
ity rates are from the natioual bureau of statistics (Statistics Netherlunds 
1991; Statistics Netherlands Published annually). 
Calculations are done in a fuillife table (i.e. with 1-year age intervals) 
beeause of the erucial assumption, made to be able to subu'aet and SUll1 
mortality rates, that all hazard rates are constant during the age interval 
(Manton and Stallard 1988). Table 4 shows part of sueh a full life table 
wtth a general sectioll and a heart disease sectiou. In the latter nothillg is 
happening until, at age 23, the incidenee hazard r: beeOlnes greater than O. 
When the heart disease mortality ra te i5'!. is big enough it beeOlnes clear 
that the total mortality hazard Sa is the SUIll of 1l10rtality hazard from all 
other eauses (S~) ancl the disease speeifie rate. The disease prevalenee in 
numbers (N~) is obtained by multiplication of the prevalenee rate J1~ with 
Tabl.2 
A dlsease specifIc section of the proportlonal rnulti·state life table 
i, 
Yo 
" incidence rate 
8 disease specific mortatity rate 
i incidence probabitity 
m disease specific morta!ity probabiHty 
n disease preva!ence 
m, 
I -Ja -e 
n, 
o 
110-1110+(l-110)io 
1 -1110 
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the la column of the general section: bath 11~ and N~ are prevalenees at 
exact age a. Note that at these )'ounger ages the difference between hazards 
and pl'Obabilities does not show up in the l'Onnded fignres. Also note that 
by nsing cross-sectional data in a cohort model the estimated prevalenees 
will not fnll)' compI)' with observed prevalences in the presence of past 
trends. 
With this Iife table we first estimated the baseline age specific case fatalities 
(the disease specific mortality probability, given disease prevalence) from 
observed disease specific 1110rtality and estimated prevalenee, using simply: 
ma 
Pa=-
l1a 
(24) 
The resnlting base lillc val nes are rhen used to estimute the impact 011 dis-
case prevalenee aud on disease specific and total mortality of changes in 
incidence and case fatalities. 
Table 3 - Disease specific Incidence and mortality rates for heart dlsease and stroke, 
Netherlands,1989, males. 
Inddence is defined as incidence rate among the non-prevalent populalion, heart disease is 
ischemie heart disease and congeslive heart failure combined. 
Heart disease Stroke 
Ag. incidence mortality incidence mortality 
25-29 0.000115 0.000012 0.000071 0.000009 
30-34 0.000316 0.000048 0.000127 0.000021 
35·39 0.001190 0.000175 0.000225 0.000047 
40-44 0.003068 0.000462 0.000388 0.000100 
45-49 0.005730 0.000943 0.000670 0.000175 
50-54 0.009275 0.001710 0.001241 0.000389 
55-59 0.013079 0.003478 0.002319 0.000771 
60·64 0.016666 0.006122 0.003598 0.001431 
65-69 0.021097 0.010198 0.005607 0.002783 
70-74 0.028204 0.016316 0.008775 0.005379 
75-79 0.038341 0.024833 0.013772 0.009980 
80-84 0.051322 0.035256 0.021621 0.018235 
85-89 0.068518 0.046781 0.025794 0.025746 
90-94 0.098469 0.057755 0.029295 0.033099 
95+ 0.147829 0.065907 0.031636 0.036967 
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Cardiovascular disease in the Netherlallds (as in many other western COUll-
tries) has seen declining age specific mortality, for stroke at least since the 
early sixties, for heart disease since the early seventies. A closer look at the 
available evidence reveals that th is decline is most likely due to a combina-
tion of declining incidence and illcreasing survival (Niessen, Barendregt et 
al. 1993; Bonneux, Barendregt et al. 1994). We assess the impact of such 
combined trends by multiplying age specific incidence of both diseases with 
a factor of 0.9 (all ages), and multiply case fatalities (i.e. I-survival prob-
ability) likewise with 0.8, always comparing outcollles with the 1988 base 
year. These changes in illcidence and survival are compatible with the pre-
sU111ed changes in the past decade. 
Baseline results 
In table 5 the resulting disease prevalences for the 1988 base year are 
shown, both in rates and nllmbers. The prevalence rates are calculated l1S-
ing the average of 11~ alld J1~+I' the number are obtailled by multiplication 
of the average rate with the gelleral sections La column, alld are therefore 
higher than the prevalences in table 4. 
Impl'Oved survival 
First we increase survival with heart disease and stroke, while leaving all 
other parameters at their base valne. Figure 1 shows outcome expressed as 
indices (with 1988=100) of prevalences by age of he art disease and stroke 
and of the comorbidity of heart disease and stroke. Both prevalence rates 
show the same pattenl: illcreases for all age groups, but lUnch more so in 
older age groups. This pattern is Illuch more visible for stroke than for 
heart disease, because the base survival of stroke is worse and thel'efore an 
equal relative improvement has a larger impact. The comorbidity rate of 
heart disease and stroke, being the product of the two disease specific 
prevalence rates, shows the .same pattern even more strongly: for the high-
est age group it is 50% higher than the base line. 
The effect of improved disease specific survival on total mortality 
canSes a further strengthening of this pattern when we look at prevalence 
nUlllbers, because a largel' part of the initial birth cohort lives to high age. 
Comorbidity of heart disease and stroke is 65% higher for the oldest age 
group. 
Incidence decline 
Secondly we multiplied the age specific incidences with 0.9, again with all 
other parameters at their base value (figure 2). The age specific prevalences 
at the lowest ages stand at a corresponding 90% of the base rate, but these 
percentages edge up a bit with age. The lower prevalence rate in any age 
group results in a larger group at risk for incidence, which counter-acts the 
lower incidence rate. A silllilar result for cardiovascular mortality was ob-
served by Rose and Shipley (1990). The effect is stronger for heart disease 
Table 4. Proportional multi-state life table (partly) with a general section and a heart disease section. 
N~ is the product of Ia and n~ , all ether equatiens are in tables 1 and 2. 
General section Heart disease section 
age 5: 8, q, /, d. r~ 5: ·d la d ma d na N~ 
0 0.0078 0.0078 0.0078 100000 776 0.00000 0.00000 0.00000 0.00000 0.00000 0 
0.0011 0.0011 0.0011 99225 108 0.00000 0.00000 0.00000 0.00000 0.00000 0 
2 0.0005 0.0005 0.0005 99117 51 0.00000 0.00000 0.00000 0.00000 0.00000 0 
3 0.0004 0.0004 0.0004 99066 36 0.00000 0.00000 0.00000 0.00000 0.00000 0 
4 0.0003 0.0003 0.0003 99030 28 0.00000 0.00000 0.00000 0.00000 0.00000 0 
5 0.0003 0.0003 0.0003 99002 25 0.00000 0.00000 0.00000 0.00000 0.00000 0 
6 0.0003 0.0003 0.0003 98977 25 0.00000 0.00000 0.00000 0.00000 0.00000 0 
7 0.0002 0.0002 0.0002 98952 22 0.00000 0.00000 0.00000 0.00000 0.00000 0 
8 0.0002 0.0002 0.0002 98930 19 0.00000 0.00000 0.00000 0.00000 0.00000 0 
9 0.0002 0.0002 0.0002 98911 19 0.00000 0.00000 0.00000 0.00000 0.00000 0 
10 0.0002 0.0002 0.0002 98892 19 0.00000 0.00000 0.00000 0.00000 0.00000 0 
11 0.0002 0.0002 0.0002 98873 19 0.00000 0.00000 0.00000 0.00000 0.00000 0 
12 0.0002 0.0002 0.0002 98854 21 0.00000 0.00000 0.00000 0.00000 0.00000 0 
13 0.0002 0.0002 0.0002 98833 23 0.00000 0.00000 0.00000 0.00000 0.00000 0 
14 0.0003 0.0003 0.0003 98810 26 0.00000 0.00000 0.00000 0.00000 0.00000 0 
15 0.0004 0.0004 0.0004 98754 36 0.00000 0.00000 0.00000 0.00000 0.00000 0 
16 0.0005 0.0005 0.0005 98748 49 0.00000 0.00000 0.00000 0.00000 0.00000 0 
17 0.0006 0.0006 0.0006 98699 54 0.00000 0.00000 0.00000 0.00000 0.00000 0 
18 0.0006 0.0006 0.0006 98645 59 0.00000 0.00000 0.00000 0.00000 0.00000 0 
19 0.0007 0.0007 0.0007 98585 67 0.00000 0.00000 0.00000 0.00000 0.00000 0 
20 0.0007 0.0007 0.0007 98519 70 0.00000 0.00000 0.00000 0.00000 0.00000 0 
21 0.0007 0.0007 0.0007 98449 71 0.00000 0.00000 0.00000 0.00000 0.00000 0 
22 0.0007 0.0007 0.0007 98378 72 0.00000 0.00000 0.00000 0.00000 0.00000 0 
23 0.0007 0.0007 0.0007 98306 73 0.00002 0.00000 0.00002 0.00000 0.00000 0 
24 0.0007 0.0007 0.0007 98233 73 0.00005 0.00000 0.00005 0.00000 0.00002 2 
25 0.0007 0.0007 0.0007 98160 71 0.00007 0.00001 0.00007 0.00001 0.00006 6 
26 0.0007 0.0007 0.0007 98089 71 0.00009 0.00001 0.00009 0.00001 0.00012 12 
27 0.0007 0.0008 0.0008 98018 74 0.00012 0.00001 0.00012 0.00001 0.00021 20 
28 0.0007 0.0008 0.0008 97943 73 0.00016 0.00002 0.00016 0.00002 0.00031 30 
29 0.0007 0.0008 0.0008 97870 74 0.00020 0.00003 0.00020 0.00003 0.00045 44 
30 0.0007 0.0008 0.0008 97796 75 0.00024 0.00003 0.00024 0.00003 0.00061 60 
31 0.0008 0.0008 0.0008 97721 79 0.00028 0.00004 0.00028 0.00004 0.00082 80 
32 0.0008 0.0009 0.0009 97642 86 0.00032 0.00005 0.00032 0.00005 0.00105 103 
33 0.0009 0.0009 0.0009 97556 90 0.00049 0.00007 0.00049 0.00007 0.00132 129 
34 0.0009 0.0010 0.0010 97465 64 0.00067 0.00010 0.00067 0.00010 0.00174 169 
35 0.0009 0.0011 0.0011 97371 102 0.00084 0.00012 0.00084 0.00012 0.00230 224 
36 0.0010 0.0011 0.0011 97269 111 0.00102 0.00015 0.00101 0.00015 0.00302 293 
37 0.0011 0.0012 0.0012 97158 121 0.00119 0.00018 0.00119 0.00017 0.00388 377 
38 0.0011 0.0013 0.0013 97037 126 0.00157 0.00023 0.00156 0.00023 0.00489 475 
39 0.0011 0.0014 0.0014 96911 134 0.00194 0.00029 0.00194 0.00029 0.00622 602 
40 0.0012 0.0016 0.0016 96777 151 0.00232 0.00035 0.00231 0.00035 0.00786 760 
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beeause the base line prevalenee of heart disease is higher than the one of 
stroke. 
With bath diseases at 90% of their prevalenee rates for the young, the 
eomorbidity rate of course stands at 81 % for those ages, and is also edging 
up with age. Through the itnplied lower disease speeific mortalities this 
pattenl is more pronounced in prevalenee numbers: at the highest age dis-
ease prevalenees even exceed the base lille valne. 
Impl'oved survival and lowel' incidence combined 
The cOlnbined picture of improved survival and lawer incidence is in figure 
3. Lower incidence is reflected in 5 to 10% lawel' prevalenee rates at yonng 
Table 6 - Base IIne vafues tor the prevalence of heart dlsease, stroke, and thelr 
comorbldlty. 
prevalence rates prevalence numbers 
............................................................ , .......... ...................... - ...................... _ ...................... -
Age heart stroke comob heart stroke comob 
O· 4 0.0000 0.0000 0.0000 0 0 0 
5-9 0.0000 0.0000 0.0000 0 0 0 
10-14 0.0000 0.0000 0.0000 0 0 0 
15-19 0.0000 0.0000 0.0000 0 0 0 
20-24 0.0000 0.0000 0.0000 5 3 0 
25-29 0.0003 0.0002 0.0000 140 82 0 
30-34 0.0013 0.0006 0.0000 624 287 0 
35-39 0.0046 0.0013 0.0000 2241 633 3 
40-44 0.0137 0.0025 0.0000 6606 1195 17 
45-49 0.0318 0.0045 0.0001 15144 2118 70 
50-54 0.0612 0.0078 0.0005 28455 3648 229 
55-59 0.1003 0.0138 0_0014 44828 6159 629 
60-64 0.1441 0.0228 0.0033 60136 9533 1390 
65-69 0.1884 0.0349 0.0066 70041 12957 2459 
70-74 0.2327 0.0495 0.0115 71426 15201 3555 
75-79 0.2785 0.0660 0.0184 62772 14870 4156 
80-84 0.3274 0.0816 0.0267 45286 11291 3705 
85-89 0.3838 0.0888 0.0341 25242 5841 2241 
90-94 0.4640 0.0801 0.0372 10202 1762 814 
95+ 0.5403 0.0671 0.0363 2819 350 189 
Total 445968 85932 19458 
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Figure 1 - Prevalenees of heart dlsease and stroke (rates and numbers) by age after 
improved survival, index with baseline = 100. Legends: heart rates: prevalence rate of 
heart disease; eVA rates: prevalence rate of stroke; comorbidity rates: comorbidity 
prevalence rate of heart disease and stroke; heart numbers: prevalence numbers of heart 
disease; eVA numbers: prevalence numbers of stroke; comob numbers: comorbidity 
prevalence numbers of heart disease and stroke 
ages, and the increased survival causes up to about 150/0 higher prevalence 
rates at older ages. The now combined mortality effect pushes up disease 
prevalence nUlllbers at the highest ages above the illlproved survival-only 
case. And comorbidity, while being more than 15% lower for the young, 
shows a 20% (rates) and 55% (numbers) increase for the oldest age group. 
The l'esnlt are tilted index lines, with pivot points sOlllewhere between age 
65 and 70. 
Snmmed across ages the lower prevalenee at young and higher 
prevalenee at older ages on balance result in somewhat higher prevalenee 
numbers: 3 and 7% for heart disease and stroke respectively. Nnmber of 
years lived with disease as a percentage of total nnmber of years lived also 
increases, but a bit less: 2 and 5% respectively. 
Discussion 
Improved survival and decreased incidence have, as has been delllonstrated 
above, a similar effect on disease prevalenee: a relative shift of the bnrden 
of disease towards older ages. With improved survival all age gl'OUpS have 
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Figure 2 - Prevalenees of heart dJsease and stroke (rates and nUnlbers) by age after 
Incldence decllne, Index with baseline = 100. Legends: heart rates: prevalence rate of 
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prevalence rate of haart disease and stroke; heart numbers: prevalence numbers of heart 
disease; eVA number's: prevalence numbers of stroke; comorbidity numbers: comorbidity 
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higher pl'evalences, but the oldest mnch more so. Declining incidence low~ 
erS prevalence for most age groups, but older ages benefit less and the old-
est even have a higher prevalence. Combining bath changes turns the rela-
tive shift into an absolute one: yOllnger age groups experience less discase, 
older age groups more. In terms of disability this pattern \ViII be even more 
pronounced because of comorbidity: disability in mauy cases might be an 
almost exponential fllllction of the lHunber of co mor bid conditions 
(Verbrugge, Lepkowski et al. 1989). 
The decline in cardiovascular disease l110rtality is most likely due to a 
combinatioll of declining incidence and increasillg survival. Declining inci-
deuce may be uniqne to cardiovascular disease, cancel' incidence, for exal11-
ple, has been reported up, albeit based on inconclusive evidence (Adami, 
Bergstrom et al. 1993; Bonlleux, Van Oortmarsen et al. 1993; Bonneux, 
Barendregt et al. 1995). But increased survival probably extellds to many 
other chronic conditions: medical technology has seen more progress in 
management of chronic disease than in cure. Barring major breakthroughs 
this pattern is likely to continue. 
The question whether morbidity has been compressing or expanding 
must be seen against the epidemiological background of improved survival 
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for 1110st chronic diseases, with simultaneously decl'easing incidences for the 
large cardiovascular causes of 1110rbidity. Although it is diffieult to say 
what the overall effect of these changes has been, it is Iikely, in partieular 
when expressed in terms of disability, that there has indeed been an abso-
lute shift in the burden of disease from the yOUllg towards the old. 
If this pattern of a decreasing prevalellce at younger and an încreasing 
one at older ages \Viii iudeed turn out to be the prevailing development, it 
wonld seem that the debate on compressioll versus expansion of morbidity 
is being held in too simplistie terms. While morbidity is compressiug iu the 
seuse that there is less of it at younger age and it is being concentrated at 
higher ages, it is at the same time expandillg in the sense that there is more 
of it at older age and in total (both absolute and relative). Perhaps we 
should rethink our terminology. 
The shift in age distribution of disease described above has economie 
consequences as weil: it will inflate health care costs because of increased 
nnmbers of patients, who are older on average, have more comorbidity, 
and therefore are more expensive, 
Similar exercises have been done by Crimmins, Hayward et al. (1994). 
They use a standard multi-state life table with states of varying degrees of 
dependency, and look at the effects of changes in mortality and morbidity 
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rates. Their results seem compatible with ours, but unfortunately they do 
not report on changes in the age pattenlof dependcllcy, onI)' on expected 
dependent years and the proportion of totallife expectancy in a dependent 
state. 
The proportionalmulti-state life table method employed in th is paper 
provides a relatively simple method to incorporate several diseases in a life 
tabie, and keep track of comorbidity. To be sure, the standard multi-state 
life table method can bandie multiple diseases with comorbidity, but the 
resnlting life tabie S0011 becomcs awkward when the number of diseases 
increases. In particlllar, adding a disease to all existing standard mnlti~state 
life table requires a major update of the life tabie. 
With a proportional multi-state life tabie, in contrast, only the first 
two columns of the general section need to be updated, and the fom col-
umns of a ncw disease sectioll added. This aspect makes a step~wise expan-
sion of the life table to iJ1corporate all incl'easillg llllll1ber of diseases an 
attractive option. 
The price for this relative simplicity and flexibility is assumptions A 1-
A3 (or a similar set, depending on the number of diseases). They require the 
diseases to be independent, and the life table cohort to be homogeneous. 
\'\'hen other than independent diseases are desirabie these can only be 1l10d-
eled by defining additional states. For example, wh en diabetes and cardio-
vascular disease 'are modeled it is imperative to let diabetics have a higher 
risk 011 cardiovascular disease incidence, and perhaps also a worse survival. 
This can be achieved by doubling the number of states of the life tabie, one 
set for diabetics and one for non-diabetics. The independence conditions 
are th us relaxed to local independence. A similar setup can be done for risk 
factors like smoking and hypertension, but obviously there are practical 
limits to the number of dependent diseases and risk factors that can th uS be 
accommodated. 
Our implementation of the life table used I-year age intervaIs. As such 
this not a l'eqllirement, eq 15-23 eau casily be rewritten for widcr intervals, 
although in particular at higher ages wider intervals will bias results. 
NIinimizing this bias is a good reason for using l~year intervals, but an ad-
ditional reason is a wider application of the methodology that avoids a 
limitation the proportional multi-state life table shares with alllife tables: it 
eithel' describes a single cohort through time, or a poplJlation at a single 
point in time (Shryock and Siegel1976). 
Of ten in Public Health it is interesting to look at intervention effects 
on an elltire population through time. Prevent is a dynamic population 
model that links risk factor prevalences with disease specific and total mor-
tality, thus allowing estimates of decreased mortality af ter risk factor inter-
vention (Gunning-Schepers 1989; Gunning-Schepers, Barendregt et al. 
1989). This model has l!OW been extended to Prevent Plus that incorpo-
rates multiple morbidity, using dynamic vel'sions of the disease section of 
the proportional multi-state life tabie. Prevent Plus has a I-year time step, 
aud to avoid unwanted blending of disease prevalences between adjacent 
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age groups the age interval and time step of the dynamic disease models 
must be equal. 
The proportionalmulti-state life table method also forms the method-
ologieal basis of l\lJlvIPH, the Netherlands [ntegrated Model of Publie 
Health. l\lJMPH combines the dynamic population and risk factor ap-
proach of Prevent Plus with dependeut diseases (like diabetes aud cardio-
vascular disease) and multi-stage disease models (to allow for duration de-
pendence and differences in severity). This family of modeis, proportional 
ll1ulti-state life tabie, Prevent, Prevent Plus, aud NIMPH, with various lev-
els of complexity and data requirements, is used ta explare the research 
field of Public Health, with research question and available data determin-
ing which model is most appropriate. 
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Consistent estimates of 
NIDDM incidence, prevalenee 
and mortality 
Abstract 
Objective: Ta estimate NIDDM incidence in the Netherlands in the 
absence of a sufficiently large empirieal study. 
Research design and methods: An incidenee/prevalenee/mortality 
(IPM) model of NIDDM forms the basis. Prevalenee data were ob-
tained from a study whieh pooled existing prevalenee estimates. Diabe-
tes-related mortality was estimated using relative risks on all eause mor-
tality, the NIDDM prevalenee estimate, and Duteh all eause mortality. 
Diabetes-related mortality and NIDDM prevalenee allow to estimate 
incidenee using the IPM model. 
Results: Annual NIDDM incidenee estimates by age and sex, that are 
consistent with the prevalenee estimate and the diabetes-related mor-
talit)'. Estimates range (rom 8.1 per 10,000 (7.7 .. 8.8) for males aged 
40-44, and 7.0 (6.8 .. 8.0) for females, to 79.7 per 10,000 (69.5 .. 90.9) 
(or males aged 75-79, and 85.8 (80.6 .. 91.0) for females. This eompares 
weil with the few observations available. 
COllclusiolls: \Vhen empirieal estimates of incidenee are largei)' laekillg 
the methodolog)' described offers a useful alternative. The intemal con-
sisteney with the prevalenee alld mortalit)' estimates allows to use the 
set for the assessment of potential illtervelltion e(feets. 
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Introduction 
Describing the epidemiology of NIDDM is surprisingly difficult. All im-
portant reason fol' this is the difficulty to separate cases Ero111 non-cases. Uu-
like IDDM the anset of NIDDM is a gradual process, where at same point in 
time a clinically defilled threshald is reached and the patient becOlnes a case. 
Illitially the patient experienees few, iE any, symptoms, alld therefore a large 
part of all NIDDNI patients is nndiagnosed: same estimatcs arc as high as 
50% (1). 
In sneh a sitllation (difficult case definitiOll and a high pl'cvalence of oc-
cult disease) the abserved incidence and prevalence became highly dependellt 
on factors other than the truc occnrrence of disease. Factors inclnde patient 
and doctor awarCllCSS, level of case fillding, campaigns by patient orgalliza-
tions or goverumcnts, and changes in insurallce policies. This l'csl1lts in highly 
variabie estimates of illcidence and prevalenee. Studies of prevalence and iu-
cidence in the Netherlands show a variatioll in estimates by a factor of about 
3 (2-6). 
Laaking at disease specific martality, far most diseases the best recorded 
epidemiolagical aspect, is in the case of diabetes of not much help either. 
Diabetes is a risk factor for a numbcr of diseases, such as cardiovascular dis-
ease. When diabetes is an underlying cause far cardiavascular death it is sup-
posed ta be mentianed as such on the death certificate. This is not always the 
case since it is difficult far physicians ta establish the role of diabetes in the 
death process, especially at older ages when ca-morbidity is more frequent. 
Co ding of the death certificates also pralllates difficulties in interpretation. It 
is suspected that the cause of death registratiol1 ullderl'eports the number of 
deaths due to diabetes to a varying degl'ce over time, with large swings be-
tween snbseqnent lCD versiolls. The usefnlness of the cause of death registra-
tion for the study of diabetes epidemialagy is therefore limited, in particular 
far the elderly (7, 8). 
The ullcel'tainty about diabetes OCCU1'1'ence halllpers the assessment of 
the burden of discase, and of the potential gains in papulatian health status 
that cauld be made by a better control of risk factors far diabetes, and of dia-
betes itself. Asscssillg such gains l'equircs a consistent set of illcidence, preva-
lence, and mortality rates, which can be llsed as input in an epidemiologieal 
model. The impact of changes in incidence, for example by weight con trol, on 
diabetes prevalence and diabetes rel.ted mortality can be estimated with such 
a model. 
The purpose of the present paper is ta abtain a consistent set of diabetes 
incidence, prevalence and mortality. In a previons study we presellted au es-
timate of diabetes prevalence in the Netherlands, based on a pooled analysis 
of existing studies (2). By cambining the iucreased martality risk of diabetes 
with thc pDoled prevalenee estilllate in an incidence-prevalence-mortality 
model, au age and sex specific estimate of diabetes incidence is obtained. The 
estimates are compal'ed with the few observations available. 
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Data and methods 
Thc model 
lncidenee-prevalenee-mortality (IPM) ma deis of discase proeesses are useful 
tools in epidemiologieal research. Recent applieatiolls concern supporting 
estimation of illcidence, prevalence and survival in the face of nnreliable or 
incomplete data (9), an analysis of trends in colorectal cancel' incidence and 
1110rtality (l0), and an analysis of trends in stroke incidence alld slU'vival (Il). 
The main advalltage of IPNlmodels is that incidence, prevalence and mOl'tal-
ity figures are linked through the eatlSal ehain of a disease proeess, and this 
chain limits the possible combinations of incidence, prevalence alld mortality 
rates. Lin1Îts are imposed because auy prevalent case must have bec0111e inci-
dent at some younger age, and any person dead with a disease must have 
become incident previously and have been prévalent, however shortly. Jointly 
estin1ated incidence, prevalence and 1110rtality rates, nsing a callsaI111odel, are 
therefore intel'llally consistent (9). 
The 1110st convenient way to model a disease pl'ocess is to aSSl1l11e inde-
pendenee frol11 all other eauses of death. Under that assumption the mortality 
rate of the discase ean be obtained frol11 the disease specific mortality as re-
ported by the national statisties bureau, and an 'all other canses' ll10rtality 
rate ean easily be ealeulated (12). 
An indepeudeuce assumption, though convenient, is not appropriate in 
the case of diabetes mellitus: in addition to being eoded as a eause of death 
itself (ICD-9 250), diabetes also acts as a risk factor for a range of eauses of 
death, sllch as cardiovascular disease. 
The high mortality of diabetics from other discases results in an exeess 
totalnlOrtality: several studies have reported relative risks on all-cause mol'-
tality ranging from about 2-3 (men) and 3-4 (wamen) around age 40 to a 
little over 1 in ages around 80 (bath sexes) (13-17). This exeess mortality 
gives l'ise to l110rtality selection: because diabetics are selectively being re-
moved from the population, the prevalenee of diahetes is lower than it would 
have been if diabetics mn no excess ll10rtality risk. However, part of the dia-
betes exeess mortality is not expressed in rCD 250 mortality rates. Vnder 
these eireml1stanees a diabetes IPM model that assumes independenee of dia-
betes and all other mortality risk would, for a given incidenee and lCD 250 
111ortality, resnlt in too high prevalel1ce estimates. 
lnstead of using the lCD 250 mortality we therefore eonstl'Ueted a dia-
betes-related mortality (md), independent from. the eause-of-death statistics. 
This diabetes-related mortality equals all exeess mortality eaused by diabetes, 
however eoded in death statistics. Totalmortality for diabetics and non-dia-
betics is estimated from the average poptIlation total mortality, the relative 
risk onl11ortality for diabeties, and diabetes prevalence using: 
111 = pIIl + (1- p)lI/o (1) 
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and: 
m' = ma R (2) 
Substituting eq (2) in (1) we ean \Vrite the mortalit)' of the non-diabeties as: 
mO 111 
pR+ 1- p (3) 
The mortality due to diabetes from all causes in the popnlation m" then be-
comes: 
Where: 
p(R -1)111 
lil" = pl11°(R -1) = R 1 
p + -p 
m: average totalmortality rate; 
(4) 
ma: total mortality rate of non-diabetics, m': total mortality rate of diabetics, 
m": diabetes related mortality rate of popnlation; 
p: prevalence of diabetes; 
R: relative risk on total mortality, given exposure to diabetes. 
Age and sex indexes are suppressed. 
Given th is mortality rate in thc population alld the prevalenee of diabetes we 
eau llOW express incidence in the age interval a .. a+ 1 (ia) as a function of 
prevalence at a and a+l, and mortality at a: 
Equation 5 is based on the 
description of the disease proeess 
as a continllous time markov pro~ 
cess, and is derived elscwhere 
(18). A moving average is applied 
to the resulting age-specific inci-
dCllces to s11100th the discontinu-
ities that are cansed b)' the age 
gronp subdivision of the relative 
risks nsed (see table 1). 
(5) 
Table 1 . Relative risk (95% confldence 
Interval) on all causa mortality tor diabetics 
trom Ihe Veron. sludy (16). 
Ag. Men Women 
0-44 4.69 (1.71-10.2) 3.03 (0.03-16.86) 
45-54 2.33 (1.38-3.69) 3.43 (1.43-6.77) 
55-64 2.13 (1.76-2.56) 2.33 (1.63-3.22) 
65-74 1.50 (1.30-1.72) 2.27 (1.92-2.66) 
75+ 1.13 (1.00-1.28) 1.32 (1.20-1.44) 
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Figure 1 Prevalence of Diabetes by age and sex, pooled 
estimates of 16 studies (2). 
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The pooled estimate of prevalence was based on 15 studies, performed since 
1970, which estimated the clinical prevalence in the Netherlands (2). The 
studies largely fall into two groups: one based on registrations by genera I 
practitioners, and one based 011 sdf report in a surveys. For each group we 
Htted an exp~nential curve on age-specific prevalence using logistic regres-
sion. The fit based on the survey group of studies yielded a somewhat higher 
pooled prevalence than the one on the GP studies, due to one large GP study 
with rather low reported prevalence. The fitted curve of the survey studies 
forms the basis of the current analysis. Because of data limitations the pooled 
prevalence estimate is restricted to the .ge range of 30·80, .nd therefore the 
pl'evalence estimate concerns mainly l\.lJDDNI patients. Fignre 1 shows the 
prevalence l'ates by age of men and women respectively. Nlore details on the 
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pooled estimate have been published elsewhere (2), The relative risks for the 
ca!culations in this analysis are based on from the VerOlla stndy (tabIe 1) 
(16). This decision was based 011 all earlier study, in which we have compared 
several studies reportillg l'elative risks on all callse lllortality for diabetes (19). 
\Ve are aware of four studies in the Nethcl'lands that have reported illCÎ-
dence of diabetes mellitus (TabIe 2), these wil! be compared with our estima-
ti on of diabetes incidcllce. 
Results 
Figures 2 (men) and 3 (women) present an incidence estimate by age alld a 
lower and upper bOUlld, based on the estimates of relative risks <tud their 
95% confidence intervals &0111 the Verona study. Thc incidence estimates are 
ver}' sunilar for men and women, incl'casillg over the whole age range, and 
reaching a level of about 1 % pel' year at age 80 (see also table 3), The lower 
bound relative risks result in all illcidence estimate below the centra I estimate, 
the higher bOllnd in one above: with lowel' lllortality selection alowel' inci-
dence will be needed to reproduce the prevalence and vice versa, The differ-
ence benveen the lower and upper estimate is biggel' fol' men than for wamen. 
This is due to a relatively wider confidence interval of the relative risk (see 
also Table 1) and a higher absolute mOl'tality risk, 
In the figures 2 and 3 also the observations from four Dutch incidence 
studies (tabie 2) are presented, The data points are plotted in the middle of 
the (\Vide) age intervals, for the open ended highest age groups we used the 
average age of these gl'OUpS as cakulated with a life tabIe, The four incidence 
studies give rather similar results for yOllnger ages, but show all increasingly 
\Vide divergellce with age, with the ContillUOl1S Nlorbidity Registratioll 
(CMR)-Nijmegen estimate tending to be the highest, and the National Study 
the lowest. Comparillg our results with the four studies, our estimates seem to 
be 1110re Ol' less in the middle of the observations for all age gronps, except for 
the (nsnally open-ended) oldest where only the CMR observation is within 
the estimated !'ange, while the other studies report (sometimes 111uch) lower 
rates. 
Table 2 - Characteristics of the studies of Incldence of diabetes mellltus In the Nether-
lands 
Name of fhe study Period 
Sample 
Age Case-ascertainment size 
Sentinel stations (3) 1980-1983 162,626 0-65+ report gp 
Sentinel Stalions (4) 1990-1991 160,000 0-80+ report gp 
CMR'-Nijmegen (5) 1971-1993 12,000 0-75+ report gp 
Nalional Study (6) 1987-1988 335,000 0-75+ ·report gp in 3 months period 
* CMR: Continuous Morbidity Registration 
Report GP is a report by a genera! practitioner 
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Figure 2 - Incidence of NIODM in the Netherlands byage, Men, estimates based on 
IPM model, compared with age-specitic observations trom 4 empirical studies. 
2 
• 0: 
• CMR 82-93 
Sentinel90 
• National 87-88 
Sentinel80-83 
0.01 - -Higher bound RR 
--Central estimate 
- - - Lower bound RR 
0,005 
45-64 
• 
I 
1 
1 
1 ' 
1 : 
65-74 I: 
• I : 
I ' 
I:' 
I ' I: 
,: 
f' 
C -65+ 
/, , .65-79 
I, J,: j,,' .65-74 
;,: 
/ ' 45-54 h,' 55-64 • A' h , ' /:,,'''' 
25-44 ~ .~ 
o r,l!l-44 
30 
35-44 
40 50 60 
Ag. 
70 80 
• 75+ 
• 80+ 
'" 75+ 
Figure 3 - Incidence of NIDDM in the Netherlands by age, Women, 
estimates based on IPM model, compared with age-specific observations 
trom 4 empirical studies. 
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Discussion 
Ta estimate incidence aud prevalence of NlDDM sufficiently large empirical 
studies with adequate follow-up are preferred. Ta conduct such a study is 
difficult <tud expensive thollgh, and consequcntly most studies are tOD small 
to yield reliable estimates. This is truc in particnlar for incidence estimates, of 
which there are only a few, aud they are plagued hy small numbers when age 
specific rates are reqllil'cd. As aresnit the estimates vary widely. 
As all altel'native to direct ohservation, this paper describes all indirect 
methad to estimate the incidence of NlDDJ'vI. It is based on the prevalence 
estin,ate from a previous study, a pooled analysis of 15 empirical studies. 
Added to that is information about the excess mortality of diabetics as com-
pared to non-diabetics (16), and theoretical knowledge about the relation 
between incidcllce, pl'cvalence aud lllortality. 
Since na sex and age-specific estimates of relative risks for the Nether-
lands are available, excess mortality is estimated using relative risks on all 
cause ll10rtality {rmll the Verona study. This of course aSSlllllCS that these 
relative risks are applicable to the Netherlands. We feel that this assumption 
is justified, since, (although performed in different counties, in different peri-
ods and with different methods), most studies report rather similal' estimates 
of relative risks, taken into account the differences in age categories (13-17). 
Fot' a nnmhcr of reasons the Verona study was chosen: it is the most recent 
stud)', they reported age and sex specific relative risks, using the non-diabetic 
poplliation as the reference. 
With the relative risks from the VerOlla study, a diabetes-related mortal-
it)' rate is constructed. Because the diabetes-related mortalit)' rate includes all 
excess mortality for diabetics, it is independent from 'all other' mortality. 
Therefore it ean be used, unlike the specific mortality restricted to diabetes 
mellitus (lCD 250), in an incidenee-prevalence-mortality (IPlvl) model that 
assumes independence from the non-diabetes-related mortality. 
The diabetes-reIated mortality and the prevalenee rate are subsequently 
used as input for sueh an IPM model· to yield incidenee estimates. The esti-
mates comply weil with the available empirical incidence estimates from four 
Dutch incidence studies, but have upper and lower bounds that are consid-
embly more narrow than the observed range of values. Three of the four em-
pirical studies reported for the open ended (oldest) age groups a (much) lower 
incidence as compared with our estimates. This may be dne in part to the 
calculation of the average age for the oldest age groups with a life tabIe. Insti-
tutionalized people, who, 011 average, will be older than non-institutionalized, 
were not included in the empirica I studies, but are in the life tabIe. The cal-
culated average age wil! therefore tend to be higher than the actual one in the 
studies, causing the data points to be plotted toa far to the right. 
A second reason why these thl'ee studies report lowel' rates than the 
ClvIR-Nijmegen stud)' might be study design. ClvlR-Nijmegen is a small 
stud)', based on 4 general practices, with an active policy of completeness. 
The three other studies are much largel', and more dependent on the willing 
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participatioll of GPs. This will prodnce a propensity for toa low estimates, 
whieh, as always, wil! tend to be stronger for the oldest patients. 
An assumption implicit in using cross~sectional data is that there are na 
time trends in incidence and survival. \X1ith strong recent time trends in inci~ 
dence or survival currently observed cross~sectional prevalence wiII not be at 
their equilibrium values. For example, if incidence has recently Încreased, it 
will take several years for prevalence to reach the new higher equilibrium 
value. Since the incidence estimate is based on prevalence, it will reflect condi-
tions prevailing in the past, sa our estinlates may diverge from cnrrent iuci-
dence. 
The IPNI model used in this study ignores remission: au extra parameter 
would be required, with uneertain value. ane study evaluated the diabetic 
status of patients aftel' 8 years of follow-up, and reported a remission of 14% 
(20). However, there are reasans to suspect misclassificatioll at baseline to be 
responsible for at least same of these cases. \Vfe assumed remission to be 
mostIy temporary and too small to affect the incidenee estimates substantial-
ly. 
A weak point is the laek of an estimate for ages over 80. It would be 
desirabie to extend the age range of the analysis beyond th is age: NIDDM is 
a disease of the elderly, and on eurrent Illortality rates over half of the women 
and more than a third of the men sl1l'vive to at least that age. Sinee the esti-
mates wil! be used to assess the burden of disease and potentials for preven-
tion for NlDDM, we feel that sueh large parts of the population ought not to 
be excIuded. However, without areliabie prevalence estimate the procedl1l'e 
to estimate incidence breaks down. The message here is that bettel' data, in 
partieular on the oldest aId, are badly needed. 
The resttlting incidence estimates are internal consistent with the preva-
lence and 1l10rtality estimates, which is not necessarily a property of empirica I 
estimates, even when done in the same populatioll. For example, the hnge 
increases in prevalence (+400/0) sill1ultaneOlls with large decl'eases in inci-
denee (-20%), as reported 
for Manitoba between 
1986 and 1991, are diffi-
cult to explain (21,22). 
In a recent study 
Garancini et al estimated 
.NIDDM incidence from 
data on prevalence and 
diseasc duration using data 
from the Cremona study 
(23). In table 3 their results 
are eompared with the 
results of the present study. 
Their results are rather 
different: for ages between 
40 and 70 their estimates 
are mueh higher, and they 
Table 3: NIDDM ineidene_ estlmates per 10,000, 
trom the Cremona study (23) and present study. 
by age group and sex 
Cremona present study 
Age Men Women Men Women 
30-39 5 3 5 4 
40-49 15 15 10 9 
50-59 43 30 21 19 
60-69 70 78 42 41 
70-79 58 67 74 79 
80-89 31 50 93' 103' 
'At age 80 
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reach a peak of 70 (males) and 78 (females) per teu thousaud for the 60-69 
age gronp (our estimate is abont 40 per 10,000), and snbsequcntl)' slnmp 
down to abont 30 (males) and 50 (females) per 10,000 for the 80-89 group. 
This resnlt strikes us as rather implausible: the declining incidcllce sng-
gests a pool of snsceptibles that is being drained. Bnt NIDDM is a senesceut 
disease, glucose tolerance keeps declining with age for most peoplc, and not 
jnst for a linlited gronp (24, 25). While it is possible to uevertheless obtain 
sneh a peaked incidence curve of known diabetes, for example with a 
strollgly age depClldcllt illtensit)' of case finding, the nsefnlness as a descrip-
tion of diabetes epidemiology seems limited. 
The main resnlt Erom om' stud)' are estimates of 1\TJDDlvr incidence, that 
compare weil with the few empirical estimates available, and, importantly, 
are consistent with a correspolldillg set of prevalcllce alld excess 1l1ortality 
rates. This latter proper!)' allows to use the set as the basis for ftll'ther \Vork, 
that will concentrate on the assessment of the bnrden of disease of diabetes, 
and on the potentials for prevention. 
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Changing cardiovascular 
epidemiology and its impact on 
diabetes prevalence: 
a quantification 
Abstract 
Background: Several studies have reported increases in diabetes preva-
lence. Val'ious causes for such an increase may exist, but one might be 
the recel1t marked improvemel1t in heart disease survival. Sin ce diabetes 
is a risk factor for heart disease better heart disease survival wil/ tend to 
cause higher diabetes prevalel1ce. We quantitatively examine the impact 
of this effect. 
Methads: Life table techl1iques are used to estimate diabetes specific 
heart disease epidemiology. The changes in heart disease epidemiology 
betweel1 1980-83 al1d 1990-93 are used to estimate the impact 011 dia-
betes prevalel1ce of the dec/ine il1 mortality selection. Sel1sitivity of the 
result to alternative assumptiol1s 011 the excess risk for diabetics is de-
termined. 
Results: Diabetes prevalence shows an age related increase with a 
maximum of about 10% (numbers) and 2% (rates) for mel1 at high 
ages. The impact on diabetes prevalel1ce amol1g wamen is much 
smaller. The comorbidity of heart disease and diabetes shows age re-
lated il1creases that reach 50 to 70% at higher ages (bath sexes). 
Conclusion: The chal1ges il1 heart disease epidemiology are ul1likely to 
be a major cause of il1creasing diabetes prevalel1ce, but they are likely 
to cause a shable increase in the comorbidity of heart disease al1d dia-
betes. 
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Introduction 
Rccently studies fro111 various COlllltries have reported increases in diabetes 
prevalence.(1-31 \""{lhile the evidence is not alwars whally cOllvincing, the 
matter certainly deserves attelltioll, dnc to the considerabie impact of diabetes 
on public health. Diabetes mellitus is an important risk factor for a number of 
discases, among them cardiovasclllar disease (4), aud an increase of preva-
lence of diabetes may therefore adversely affect cardiovascular incidence, 
prevalenee, aud mOl'tality. 
Understanding the causes of the increase in diabetes prevalence is vital to 
the development of effective illtervclltiollS. Increased incidence is au obvious 
potential causc, and many countries have indeed seen increases in IDDlvI in-
cidence.(S, 6) For NIDDM the evidence is less clear (1, 2, 7), if only because 
incidence of :NIDDM is less well-defined. Indeed, on same estinlates about 
half of l\lJDDM patients goes about undiagnosed (8), and this circmnstance 
in itself might be responsible for the reported prevalence increase: with such a 
large pool of nndiagnosed paticnts a minor enhancement in case finding prac-
ticc will have a major impact on reported pl'evalence. 
Yet allother potential explanation for incl'eased diabetes prevalence is 
related to its role as a risk factor for cardiovascular disease. Because diabetics 
run a higher risk on cal'diovascular disease they are snbjected to cardiovas-
cular mortality selection: the increased risk of cardiovascular death tends to 
lowel' diabetes prevalence, sillce diabetics are selectively being removed from 
the population. For small causes of death the effect on diabetes prevalence 
will hardly be discernable, but since cardiovascnlar disease is such a large one 
it wili. 
The existence of mortality select ion opens a potcntial for increases in 
diabetes prevalence: wheu the mortality selection eases, diabetes prevalence 
will go np. Since the early 1970's mortality from cardiovascular disease has 
been going down tremendonsly in the Netherlands, as in many other coun-
tries. Between 1970 and 1990 age-standardized mortality from ischemie heart 
disease and stroke halved, and this decline can be attributed to a combination 
of lower incidence and improved survivaI.(9-11) 
In this artiele we estimate the effect of changes in heart disease epidemi-
ology on diabetes prevalellce. Wie nse data on heart disease incidence and 
survival and their trends, and life table techniques to combine them with dia-
betes incidence and pl'evalence. \\Te calclliate the increase in diabetes preva-
lencc and in the comorbidity of diabetes and heart discase as a consequence 
of the trends in heart disease incidence and survival. 
Methods 
Ta model the diabetes and hemt disease processes we use an extension of the 
standard life tabIe, the multi-state life tabIe, that distinguishes not just be-
tween 'alive' and 'dead', but allows for additional states like 'alive, healthy', 
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'alive, with heart disease', ete (12) . The model inclndes two disease processes: 
heart disease and diabetes, which are modelled as continuolls time markov 
proeesses.(13) Ta allow for the heterogeneity of a population eonsisting of 
diabetics and non-diabeties the population is divided over two life tables: one 
fol' diabetics and one for non-diabetics. 
Eaeh life table distinguishes a non-heart disease state, and a heart disease 
state. In eaeh state the life table cohort is subjeeted to 'all other mortality' 
probabilities. In the heart disease state an additional disease specific mortality 
probability is in force, which we assume to be higher for diabetics. People not 
in the heart disease state run a risk on incidenee probabilities for heart dis-
ease, which in the diabetics life table are also higher. Therefore diabetics have 
a higher incidenee of heart disease and worse survival than non-diabetics. 
Diabetes incidenee is used to link the two life tables: the life table cohort 
of 100,000 starts in the non-diabeties life table \Vith the lower heart disease 
risks, at each age incident diabetes cases are calculated nsing the incidence 
rates. These cases are transferred to the diabetics life tabie, where they are 
subjeeted to the higher heart disease incidenee rates. 
lncidenee and survival of heart disease is predominantly based on a na-
tionwide hospital register, various other studies are used in addition.(ll) 
Diabetes prevalenee is based on a pooled analysis of 15 Duteh studies.(14) 
Exeess mOl'tality for diabetics was calculated using relative risks on total mor-
tality from the Vermla study.(l5) Diabetes incidenee was baekealculated 
trom the excess mortality and prevalenee, using the same continuOlls time 
markov proeess teehnique.(16) 
We estinlate diabetes specific heart disease epidemiology based on the 
average incidenee, prevalenee, and survival for the 1980-'93 period.(l1) We 
assumed a rate ratio for heart disease mortality for diabetics of 3 at age 30, 
declining linearIl' to 1 at age 95.(4,17) In addition we assumed a relative 10-
year Illortality risk of about 1.4 for diabetic heart disease patients, based on 
several studies reporting mortaUty risk.(18-20) Together these assumptions 
farm the referenee case, which allows to backcalculate diabetic specific heart 
diseasc incidence. To gauge sensitivity we calculated alternatives with the 
excess risks put to zero, and with double excess risks. 
Ta estimate the influenee of changes in heart disease on diabetes epide-
miology the ealculations were repeated with identical diabetes incidenee and 
exeess risk, but with heart disease epidemiology averaged over the 1980-83 
and 1990-93 periods.(ll) 
Results 
Figures 1 and 2 show diabetes specific prevalenee of heart disease for the ref-
erenee estimate 1980-1993 for men and wamen respeetively. The differenees 
between men and women in heart discase epidemiology arc dear: men have 
mueh higher prevalenees (note that the Y-axes have different seales), and fe-
male prevalenee is shifted more to higher ages. Heart disease prevalenee for 
diabetics is higher, exeept at the highest ages: ÎtlCidenee of heart disease at 
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Figure 1 ~ Diabetes specific prevalence of heart disease, males, 
for the reference 1980-93 period, and for the 1980-83 and 1990-93 
periods. 
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Figure 2 - Diabetes specific prevalenee of heart disease, 
females, for the reference 1930-93 period, and for the 1930-83 
and 1990-93 periods. 
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those agcs is still higher for diabetics, but survival with heart disease declines 
with age and does so faster for diabetics because of the relative risk on mo1'-
tality risk. 
The higher heart disease mortality risk of diabetics causes lllortality se-
lection: figure 3 shows the effect on diabetes prevalence of changes in the 
relative risks. Putting the relatÎ\/e risks to 1 cal1ses diabetes prevalence to in-
crease, doublillg the excess risks causes it to decline. Two things can be ob-
served: the effect increase with age, but it is genera lil' small (resnits for 
women are not shown, but even smaller). 
The age effect is because mortality selection is stl'Onger where mortality 
is higher, sa in the yonnger age gronps effects are smaller than in the higher. 
A higher relative risk 011 heart disease illcreases the mortality selection, and 
therefore lowers diabetes prevalence rates at higher ages. The estimate with a 
relative risk of 1 givcs prevalence in the absence of mortality selection, and 
the diffcrence between this estimate and the best estimate is the potential in-
crease of diabetes prevalenee when mortality selection diminishes. 
Figures 1 and 2 also show heart discase prevalence based on the periods 
1980-83 and 1990-93. The differenee between the periods is a considerabie 
increase in p1'evalence for the higher age gl'OUpS, mostly cansed by improved 
survival. In addition there was a sma11 decrease in incidence for the yOllllger 
groups among men, but the rcverse seems to have happened among women. 
(11) 
Figures 4 and 5 show the effect 011 diabetes pl'evalence and the comor-
bidit)' of diabetes and heart disease, expressed as indices with 1980-83=100. 
The effect on diabetes prevalence rate is again small: it l'eaches a maximum of 
about 2% for men at high ages, for wamen it is even less. NIore pronounced 
is the increase of diabetes prevalenee in lHullbers: improved survival with 
heal't disease causes all age dependent rise, which reaches over 10% at age 80 
(men, with wamen again the effect is considerably less). 
The most strikillg rcsult in fignres 4 and 5 is the increase in the C0111or-
bidity of heart disease and diabetes: in bath rates and numbers an age-de-
pendent incre.se that reaches a maxin1l1m of 50 to 70% for the eldest. A no-
table diffrcnce between men and wamen is that the latter also see a consider-
able increase fol' ages undel' 65, while for the farmer the increase in that age 
group is ll1ueh more limited. This is caused by the difference in l10art disease 
epidemiology changes between the sexes in the age gl'OUp: a decline in inci-
dellce for the men, but all illcreasc fol' the women. 
Discussion 
Althongh the evidence is not llnequivocal there are severalreasons to suspect 
that diabetes prevalellce is increasing. Onc reason is increased incidence, ob-
sel'ved for type 1. Fot' type IJ a possible inct'ease in ÏllCidence might be caused 
bl' changes in risk factors, Iike obesity and ph)'sical activity.(I) The situation 
is complicated by the presllmed large pool of lIndiagnosed type IJ diabetics, 
186 
$ 
il. 
Mtf/ti~disease models 
0.2000 
0.1800 
--Reference 
0.1600 
- - - No excess heart disease mortality risk 
- -Increased excess heart disease mortality 
0.1400 risk 
0.1200 
0.1000 :/ 
:/ 
, 1 
0.0800 
:~ 
0.0600 
0.0400 
0.0200 
0.0000 +----1--+-+-+-----1--+-+--1---+--+----1 
~ • ~ • M M 00 MmM 00 85 
Ag. 
Figure 3 - Diabetes prevalence under varlous heart dlsease mortality 
risks, males. 
thar makes stepped-up case findillg result in a large increase in clinical preva-
lCl1ce, even in the absence of auy real epidemiologie change. 
Ta this already confusillg picture yet another explanatioll for increased 
diabetes prevalence is added: dill1inished cardiovascular morta!ity selection. 
Wc have shown that if the changes in heart disease epidemiology as observed 
in the last decade, mostly an ill1provell1ent of survival, apply equally to dia-
betics this results in an increase in diabetes prevalence in the !ife table popula-
tion, bath in rates ancl in llumbers. 
Thc fact that not just prevalenee lllunbers increase, but prevalcllce rates 
as weU, shows that it concerns more than snbstitl1tion of disease. Larger 
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Figure 5 ~ Prevalence of diabetes and of comorbidity of heart 
disease and diabetes. Males by age, indices of 1990·93 
estimates with 1980..g3 =100. 
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numbcl's of people alive, as is the case in the higher age gronps aftel' the heurt 
disease trends, means larger numbers of dia be tics, even when the diabetes 
pl'CValCllce rare is nnchallged. But sillce diabetics have higher henrt disease 
risks than non-diabetics, the)' are more stl'ongly affected by the lower 11101'-
tality, mortality selection cases, and thc prevalenee l1umbers of diabetics in 
the higher age grollps increase [aster than non-diabetics. Hence the higher 
diabetes prevalenee rates in the population. 
The increase has a distinct age pattern: none for thc younger age gl'OUpS, 
and growing with age. This age pattern is inherent to diminished heart dis-
case l110rtality selection: it only operates in the age groups where heart discase 
mortality is snbstantial. 
A similar but enhanced age pattel'n can be seen in the comorbidity of 
diabetes and heort disease: for the men the comorbidity prevalenee in the 
younger age groups is even lower (due to lower heart disease illcidence) with 
substantial increases in the highest age groups. The cOlllorbidity increase is 
almost completely due to the illcrease in heart diseasc prevalence rates, the 
diabetes rate increase only adds marginally. 
Onr calculations show that the impact of improved heart disease sur-
vival on diabetes prevalenee is generally rathel' small. A notabie increase in 
the number of elderly diabetic men can be observed, but sinee the lltlll1ber of 
non-diabetic men of the same age also increases the diabetes prevalcllce rate 
hardly moves. For wo men, due to the 1l111ch slnaller importance of heart dis-
case, the impact is even less. This result is l'ather robnst: doubling the excess 
risk of diabetics or removing it altogether hardly makes a differenee (see fig-
ure 3). 
J\lloreovel', there are two reaSOllS why the impact may have been overes-
timated. The first is that the introdllction of new medical intcl'ventions are 
probably in large part responsible for improved heart disease survival. With 
new interventions comorbidity initially, and perhaps permanently, acts as a 
eontraindieation. Presumably, for example, thrombolysis was applied to dia-
betie heart patients more reluctantly than to the general population.(21) This 
affects our ass111l1ption that the improvement in survival observed fol' the 
general population equally applies to the diabetic population, with the result 
that measUl'ed effects will tend to be smaller. 
The sccond reason for overestimation lies in the nature of life table cal-
culations. Life table analysis produces an estimate that fnUy reflects the im-
pact of the changed incidence and survival, in reality it takes time for this 
impact to develop. The increase in he art disease prevalenee between 1980-83 
and 1990-93 will, dne to these dynamie effects, have been smaller, and eon-
sequently the same goes for the impact on diabetes prevalence. 
On the other hand two reasons to snspect underestimation exists. The 
heart disease epidemÎc seems te have peaked in the early seventies, so the de-
cline in mortality has been going on for a longer time.(22) And not jnst hemt 
disease mortality has been declining: stroke, another disease diabetes is a risk 
factor for, has also seen declining mortality and presumably incielenee for a 
long time.(IO) 
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In all}' case the comol'bidity incl'ease that our calculatiolls produce seems 
to be big enough to have been observed empiriealil" The lvlinnesota Hcart 
Survey reported increased diabetes prevalence among cal'diovasclliar pa-
ticllts.(20,23) 
On balance we conclude that the changes in heart disease epidemiol-
ogy are llnlikely to be a major canse of increasing diabetes prevalellce, but 
that they are likely to canse a sizable illcrease in the comorbidity of heart 
disease and diabetes. 
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Introduction to part IV 
Introduction 
Compression and expansion of morbidity are explicitly concerned with the 
combination of the two fundamental aspects of population health status: 
l110rbidity and mortality. \Vhether either compressioll or cxpallsion occnrs 
depends on the balance betweell incidence of l11orbidity, cure and survival, 
and the resulting balance is a particular ontcome of mortality and of 
prevalence of morbidity, weighted for severity. 
Mortality is (and has since long been) measured routinely in many 
coulltries, including the Netherlands. Mortality by age and cause of death 
is being published by Statistics Netherlands anuually. While the cause of 
death registration is not without its problems, in pal'ticnlar for the elderly, 
mortality data are generally cOllsidered robust, aud arc available. 
Widely used indicators based on mortality are, in addition to (disease 
specific) numbers of deaths, derived measmes such as standardhed mortal-
ity (iu several variants), years of life lost (ditta) aud its couuterpart poten-
tial years of life gained, and, perhaps the best known, life expectancy. 
Morbidity data, ou the other hand, are generally either not available 
or elsc not robust. Best recorded arc data cOllcerning health Care ntilizatioll 
(like costs and hospita I days), but these indicators are notoriousl)' affected 
by changes in medica I technology, prices, and attitudes towards health, and 
arc therefore not considered good indicators of morbidity for most discases. 
As part II has made c1ear, natiol1wide data on disease specific incidence and 
pl'cvalence are not available for evcn sneh a large disease as eardiovaseular 
discase. Other important diseases where 11101'bidity data are scaree arc dia-
betes and respiratory disease. And data on generalmorbidity, like disability 
and self-rated health, rely on surveys and face numerous problems of va-
lidity. The Dutch national health survey, fol' example, has a non-response 
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rate of about 40-45%, and excludes the institutionalized popnlation (Van 
den Bos, van der Velden, van Sonsbeek, Nl1sseldcl', & Lenior, 1994). 
Given the available data, reseal'chcl's have tellded to rel)' on mortality 
based indicators of population health status, with Iife expectancl' at birth 
being a first choice. Life expectancl' at birth is generalIl' interpreted as the 
number of years a ncwborn eau expect to live, aud is all excellent way to 
sUllunarize mortality data, but as all indicator of popttlatioll health status it 
is one-sided because it ignores 1l10rbiditl" This would be no problem if 
l11ol'tality aud ll10rbidity always moved in the same direction: in that case 
mortalitl' is a good proxy for morbidity. But as has been shown in part II 
this is not always truc: heart disease lllortality has declined while simulta-
l1consly the prevalcllce of heurt disease increased, <tud the trends in 
colorectal cancel' incidence and mortality are divcl'ging. 
Mortalitl' can be a good proxy for morbiditl' when a fixed and known 
proportion of incident (or prevalent) cases dies, But some diseases cause 
relatively little or no mortalitl' but protracted periods of morbidity 
(locomotor alld respiratory diseases, for instance), while yet others, in par-
ticuIar cardiovascular disease, combine elements of chronic and acute dis-
ease: chronic disease intet'spersed with acnte periods that may have a fatal 
outcome, 
But while 1l10rtality based indicators give a biased view of population 
health status, so do morbidity based ones. The changes in heart disease epi-
demiology again provide a good example: the increase in prevalence of 
heart failure indicates a worsening of population health status, a judgment 
few people wonld agt'ee with, given the simultaneons decline in acute heart 
disease lllortality, 
The realization that population health status should be measured by 
looking at both mortality and morbiditl' has prompted researchers to con-
stmct indicators that combine the two. Given the plethora of indicators for 
mortality and especially for morbidity there are many ways to do this. Sev-
eral indicators that combine both have actually been implemented. Such a 
combined indicator is a natural calldidate for measllring compression and 
expansion of morbidity. In the remainder of this chapter we williook into 
the way mortality and mot'bidity may be combined in one indicator, list 
some implementation options, look at two implementations in same detail, 
alld defille a way to measnre compl'ession and expansion of mOl'bidity llS-
ing elements of both implementatiol1s, 
Time as a common denominator 
Since morbidity and mortalitl' are obviously different things ri common 
denominator is needed in order to combine them in one indicator, The 
conllllon denominator is found bl' looking at the wal' successful mortalitl' 
based population health status indicators, like Iife expectancy and years of 
life lost, are derived from mortality data. 
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Mortality is by itself not a very interesting indicator: since all peaple die 
the fact as snch car1'ies no infonnation abont popnlation health status. The 
cl'llcial point is the age at which mortality occu1's, but age-specific mortality 
is au unwieldy indicator because it cOllsists of a large array of nmnbel's. To 
derive an indicator the age-specific martality is canverted ta the average 
years of life lived (life expectancy) or number of life years lost. Thus the 
event of death is canverted ta time: time lived or lost (Murray, 1996). 
The literal interpretatian of these indicators raises problel11s. Life expec-
tancy, as it is commonly nnderstood, is calcnlated nsing period data, and 
therefore life expectaucy at bil,th is not the llumbe1' of yea1's a newborl1 may 
expect to live. \""{'hen the dedine in mortality continlles, as it presllmably 
will, the newbornl11ay expect to live langer, as has been the case dUrillg the 
20" century (Murray, 1994). 
Anather problem is the interpretatian of years of life lost. When we cal-
culate years of life lost in a papulatian by multiplying age specific nUl11bers 
of deaths with the life expectancy at that age, we are implying that every 
member of the poplliation can expect to live at least the average nllmber of 
years, which is a contradiction in terlllS. 
We therefare prefel' not aliteral interpretatian, but ane based on the 
abservatian that Iife expectancy and years of Iife lost are l11uch more sens i-
tive ta l11artality at yaunger ages than at alder (Shryack & Siegel, 1976). In 
other words, deaths at yonnger ages are being conside1'ed more severe, and 
therefore bath can be interpreted as mortality indicators that weight far age 
at death. Under the age-weighted interpretatian the applicatian of periad 
mal'tality data poses na prablems, and we do not il11plicitly perfarm can-
tradictory calculatians with years of Iife lost. 
Sa Iife expectancy and years of Iife lost are age-weighted martality indi-
cators with time as the unit of measuremellt. Given this, it is possible to 
combine morbidity and mortality in one indicator when we express 11101'-
bidity also in units of time, that are equivalent to the units used for the 
mortality indicators. 
The simplest and probably most frequently applied way to do this is by 
considerillg time lived with morbidity equal to time not lived due to 11101'-
tality. Most calculations of the sa ca lied health expectancy indicator use 
th is procedure: health expectancy is calculated accarding ta standard life 
expectancy methad, with the difference that years lived with marbidity do 
not count tawards the tata I years of life lived by the life table cohort (a 
formal expression for this calculatiou can be fouud in the appendix to 
c1 .. pter 16). 
Other, more complex methads cansider time lived with marbidity only 
partly equal ta time lost due ta martality. The size of this part can be de-
termined by trade-off methads like the time trade-of( and person trade-off. 
In the farmer methad subjects are presented a fixed peri ad lived in a de-
fined less than full health state, and are asked ta decide which part of the 
periad they wauld be willing ta give up when the remainder is then lived in 
full health (Torrance, 1987). The person trade-off methad uses a samewhat 
different perspective, but is basically the same (Murray, 1996). 
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As the less than full health state beCOll1CS more severe, most subjects are 
willing to give up a larger part of the pedod lived, and therefore the re-
sulting fractions that divide the fixed pedod between full health and death, 
have the dual illterpl'etation of sevel'ity weights for the health state unde!' 
consideration. These methods are used in Qualit)' of Life (QALY) research 
and to determine disabilit)' weigIns for the Disabilit)' Adjusted Life Years 
(DALYs). 
ThllS a continuUlll of poplliation health status indicators emerges, with 
011 rhe ane extreme life expectancy, where yeal'S lived with morbidity are 
considered equivalent to )'ears in full health, on the other health expec-
tancy, which considcl's years lived with ll10rbidity equivalent to years lost 
due to death, and in between indicators like the DALY, where )'ears with 
morbidit)' are considered par ti)' equal to years in full health, and for the 
remainder considered lost, with the allotment depcnding on the severity of 
the disease. 
Implementation options 
In addition to the different ways morbidity is tre"ted there are a number of 
other implementation options for a population health status indicator. The 
actual choices made in a particular case should depend on the intended a p-
plication of the indicator. Applications include monitoring population 
health status (cul'l'cnt level and changes over time), understallding observed 
changes, estimating the benefits of potential interventions, and resource 
planning and optimal resource allocation. Depending on the application 
important chokes arc: 
Life table versus real populatiolt. The most important determinant of 
health care needs is the size and age structure of the population. Applica-
tions involving resource planning and allocation should therefore nse a 
real population (which is meant to include projections of the future 
population). \\1hen comparing populations 01' studying trends in under-
Iying population health status a life table poptdation offers the advantage 
of abstractitlg from popnlation size and age stl'ucture. 
Static versus dy"amic populatiol1. ''\'hen time is an issue in the applica-
tion, for example when not just the si ze of au effect matters, but its tim-
ing as weIl, a dynamic population is uccessary. In general time will be 
more an issue in applications iuvolving resource planning. In man}' othel' 
cases simp Ier statie method wiJl serve. 
Prevaleltce versIIs iltcideltce/duratiolt. With a prevalence approach the 
amount of mOl'bidity in the POPUlatiOl1 is estimated dil'ectly, with an inci-
dence/duration approach estimates of incidence and duratiol1 are used to 
calculate the amount of morbidity. In the absence of past trends both 
methods will yield the same result, but othenvise the prevalence method 
describes the actual situation, including the legac)' trom the past, while 
the incidencefduration approach ignores the past and caletdates what the 
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present wonld look like if current incidence and dnration wonld have 
been in force in the past (Crimmins, Saito, & Hayward, 1993). The ad-
vantage of the incidence/dl1ration approach is the causal link from inci-
dence to mOl'bidity prevalence alld mortality, which allows estimation of 
intervention effects. In particular in combinatioll with dYllamic methods 
this is a very powerful, but also complex and data hungry methad. Tbe 
prevalence approach is lllllCh silllpler, and better snited for estimation of 
CUlTent pop111ation health status and Care needs. 
De(iltitiolt of morbidity. In principle any morbidity measme can be em-
ployed: generie measures like disability, self-rated bealth, or bealth care 
lltilizationj or one 01' more specific diseases 01' conditiollS. Of ten, and in 
particlliar for generic morbidity llleaSl1res, a threshold value has to be 
chosen. These choices are illevitably rather arbitrary, and have a large 
impact on indicator Ol1tcomc (:tvlnrray & Lopez, 1997). 
\Veights for severity of lIIorbidity. The previous section explained tbat in 
order to combine mortality and morbiditl' time lived with morbiditl' is 
made equivalent to time lost due to mortalitl" This can be done bl' simpil' 
equating the two (giving up all the time lived with morbidity, whieh has 
tbe dual interpretation of a O-weight), but more complex weighting 
schedules are also possible with, according to severitl', different weigbts 
for different heàlth states, diseases, or bath. 
ather weights. In addition to morbidity weigilts other weights have been 
emplol'ed to Illodify time lost due to 1l10rbiditl' and mortality. The origi-
nal DAL Y, as developed by Murray and colleagues aud applied in the 
Global Burden of Disease project, uses an age-weighting schedule that in-
tents to stress the time lost between the ages of about 10 and 55, while 
dowuplaying losses outside that range (Murray, 1994). In adynamie 
analysis (i.e. one that includes calendar time) losses and benefits are aften 
weighted for time preferenee (discounted), causing these losses aud bene-
fits to be less important as they occur fnrthcl' away in time (Drnnullond, 
Stoddart, & Tarranee, 1990). In economie analysis time lost is aften 
weighted for income (the human capita/ methad) (Koopmanschap & 
Rutten, 1993). Many more weightiug schedules are thinkable, but few 
are desirabie and sound, and even all three schedules mentioned here 
have their critics. 
Actual implementations 
Health Expectancy 
From varions permutatiolls of the optious in the previous section a large 
llumbcr of indicators ean be constrllcted, but two implementations domi-
nate the field: hea/th expectancy aud DAL Y. Fortuuately they are also good 
examples, becallse on a rating scale from simple to complex they occnpy 
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positions far ápart, with hea/th expectancy being a simple indicator and 
DAL Y a complex. 
Hea/th expectancy stands for a family of indicators which may differ 
in details, but the vast majority share the following characteristics (Robine 
& Ritchie, 1991). A health expectancy always uses a Iife table population, 
is statie, and in most cases employs the prevalence approach (dubbed 
HSl1 l1ivan-method"), a generic ll1ol'bidity measurc, and most calcnlate the 
indicator by excluding time Iived with morbidity (effectively giving a 0-
weight to that time). The prevalence method allows the use of cross-sec-
tional data, for example from a health survey, and the calclliation is 
straightforward (see appendix to chapter 16). 
Different definitions of what constitutes morbidity have been used, but 
a popular genel'Ïc measnre is "disability", resnIting in the Disability Free 
Life Expectancy (DFLE). But disease specific morbidity can also be used, as 
in the calcl1lation of a dementia-free Iife expectancy (Ritchie, 1994). 
The simplicity of this indicator is very attractive, and makes it par-
ticlllarly sllited fol' inexpcllsive alld quick estimates of current population 
health status. For many countl'ies estimates of, in pal'ticular, the DFLE have 
been made, but l1Ufortlluately comparisons between country estimates arc 
being hampered by differences in the definition of disability, threshold val-
ues, and survey methods (Boshuizen & Van de Water, 1994). 
The usefulness of the health expectancy indicator, in its most used im-
plementation with cross-sectional prevalences and a 0-1 weighting sched-
uIe, for answcring the question of compression versus expansion of mol'-
bidity is also limited. The ability to make comparisons over time is ham-
pered by the use of the prevalence method. In the prevalence method a 
stock varia bIe (prevalence) is combined with a flow varia bIe (mortality). 
Stock varia bles adjust only slowly to changes in the flow varia bles that 
gOVCl'I1 their vuluc, aud in chapter 16 it is shoWJl, using the heart disease 
model described in chapter 4, that this characteristic of stock varia bles 
leads to spurious trends in a health expectancy indicator based on the 
prevalence approach. 
Problems with the health expectancy indicator also originate from the 
routinely used O-weight for time lived with morbidity. This, firstly, makes 
the indicator very illsensitive to changes in severity of disabiIity: only when 
the changes cause people to cross the threshold value of disability will such 
changes show up in the indicator. And, secondly, as we show in chapter 17, 
all irnprovement of survival with morbidity resnlts as a consequence of this 
O-weight in an unchanged health expectancy at birth, and even in a declin-
ing ane at higher ages, rather than showing au increase. This connterintlli-
tive resnlt follows because the total number of healthy years Iived by the 
Iife table cohort remains unchanged, while at higher ages the cohort will 
have more snrvivors, thus less healthy years on average. \Xlhen researchers 
are aware of th is problem they can avoid the declining health expectancy at 
higher age (chapter 17), but as long as the survival improvement is not ac-
companied by an improvement in health status such that at least part of the 
years Iived with morbidity previonsly will become healthy years, the health 
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expectancy indicator with a 0 morbidity weigilt will not show an incl'ease 
aftel' survival improvement. This seems a rather awkward characteristic for 
a population health status indicator to be used for the study of cOll1pression 
and expansion of morbidity. 
DALYs 
The concept of Disability Adjusted Life Years (DALY) was developed with 
the optimal allocation of scarce resources in mind (World Bank, 1993). It 
uses a real population structnre, incidence/duration methods for the de-
scription of a large number of conditions, and morbidity weiglus by 
condition and severity. The DAL Y gives the number of life years lost by the 
population due to mortality and morbidity, with the latter caleulated by 
multiplying time lived with a specific disease by its weight for disability 
severity. 
Several other attributes distinguish the DAL Y. One is that futme years 
of life lost are being discounted (by 3%) to weigh for time preference (sec 
part V for more on discounting). A second is the use of a standard life table 
(model west, level 26) for the cabilation of years lost due to mortality. 
This table has a life expectancy that is higher than observed in any nation 
to date, and therefore the number of life years lost is systematically over-
estimated, not much for western countries and Japan, but quite a lot for 
snb-Saharan countries. ' 
Murray argues that the use of the same life table worldwide prevents a 
death at a given age in a high lllortality country to be less important than 
one in a low mortality country, and that equity requires that they should be 
valued the same (Murray, 1994). This makes sense, as long as the resulting 
estimate is not interpreted as actual years of life lost. Above we suggested 
an alternative interpretation of years of life lost as an age-weighting 
schedule for mortality, with death at a younger age being worse. This al-
ternative avoids the illterpretation problem. 
In addition to the age-weights for mortality by way of the years of life 
lost the DALY uses age-weights for bath morbidity and mortality, that in-
tent to count the years lost in the age range of about la to 55 as the more 
important, while playing down losses outside that range (Murray, 1994). In 
chapter 18 it is shown for the case of mortality that due to combined ef-
fects of the two age-weighting schedules not the range between about 10 
and 55 years of age is emphasized, but rather that between 0 and 27. 
Measuring compression and expansion: 
Disability Adjusted Life Expectancy 
Health expectancy (in the DFLE or similar variants) and DAL Y constitute 
just two instances of the set of possible poplilation health status indicators 
that combine l110rbidity and mortality. For our purpose of measuring com-
pression alld expansion we cali construct a suitable indicator alld define 
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compression and expansioll in its terms. This indicator is implementcd as 
fol!ows: 
Life tablc pOPlllatiol1. The indicator is to be nsed for eOl11parison over 
time, and therefore should abstract from changes in population size aud 
strl1ctnre. 
Disease spccific alld gelleric l11orbidity. Wie wallt to Iillk disease specific 
changes to population health status outcomc, and therefore a disease spe-
dfk approach is nccessary. But simnltaneously we need generic l11orhid-
ity: unless a ver)' large number of diseases is modeled the morbidity de-
seribed by the diseases \Viii be ollly part of total 1110rbidity. The solntioll 
is to describe the remaining lllorbidity as generic morbidity. 
ItICidel1ce/dllratioll alld prevalelICc approach. Onr objeetive is 1110stly to 
understand and explain observed, and estimate potential compression 
and expansioll from changes in disease incidence and survival, and th ere-
fore we need the causal model provided by thc Încidence/duration ap-
proach. But the remaining, generic morbidity we as su me to be constant, 
alld for that part of 1110l'bidit)' the prevalenee approach wil! suffiee. 
YVeights for II/orbidity severity. The indicatol' uses morbidity weiglHS b)' 
disease and, when changes within diseases are the subject, by severity of 
disease state, to avoid the problems that the O-weight fOl' mOl'bidit)' 
callses. 
In ehapter 19 we introduce the Disability Adjusted Life Fxpeetaney 
(DALF), an indicator that combines aspeets of both health expeetane)' and 
DAL Y. It is like a health expeetaney in that it uses a life table and an esti-
mate of the generic 1110rbidity measure disability. From the DAL Y it gets 
discase specific incidellee/duration modeIs and disability weigIlts for mol'-
bidity. 
\Vith the DALE we call now define compression and expansion of 
1110rbidity. \Y,Ie define compl'ession to Dccur wh en the life expectancy with 
disabilit)' (LED, the diffel'enee bet ",een life expeetaney and DALF) de-
creases, and expansion when it increases. Undcl' th is definition an incl'case 
in life expeetalle)' leads to expansion of mOl'bidity as the DALE inel'eases 
less (or l'emains the same or declines). Note that under this definition com-
pression is not necessarily a good thing (and neithcl' expansion a bad anc): 
eompression ean oeeur with declining life expeetaney and DALE, as long as 
the life expeetalley declines fastel'. 
Of teil in addition to the above definition, also ca lied absolute eom-
pl'ession and expansioll, the concept of relative compression and expansion 
is nsed (Robine & Mathel's, 1993). We say that relative expansion oeeurs 
wh en the ratio of LED alld life expeetaney (LEDILE) inel'eases, and relative 
compressioll when it declines. Note that llllder this definition relative com-
pressioll can occnr simnltaneously with absolute expansion, and absolute 
compression with relative expansion. This is in contrast with the definition 
by Robine and Nlathers, which is all effort to make these categories ll111tn-
al!y exclusive, but which produces difficult to classify cases when the life 
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expectancl' deelines (Robine & Mathers, 1993). In genera I it is best to re-
port bath life expectancl' and DALE and their changes, and not just the 
LED, to give a fuIl representation of the changes in population health 
status. 
The DALE, like the DALY, links the epidemiological concepts of dis-
ease incidence and survival to the population health status outcame, and 
ean therefore be used ta show that recent trends in eardiovascular disease 
eaused an inerease in life expeetaney and expansian of 1110rbidity, while the 
abolishment of smoking would res111t in incrcasing life expeetaney with 
cOlnpression of morbidity. Put differentll': the DALE is a population health 
status indicator fit ta allalyze the eOllsequcllees of epidemiologieal trends 
anel meelic<tl interventions in tertns of the eompression and expallsion of 
lllorhidity. 
But chapter 19 also lists two methodologie al problems with the 
DALE, bath originating from the use of a bottom-up, disease specific ap-
proach. The first problem is the existence of comorbidity. Comorbiditl' 
causcs problcms in twa ways: it breaks the ane-to-one carrespandence be-
tween prevalence of disease and prevalence of disability, and in addition it 
is unelear what disabilitl' weights should be applied to the comorbid condi-
tions. In chaptcr 20 we cxplore the nnccrtainty and scnsitivity surl'ounding 
the calculation of l'ears lived with disabilitl' bl' the DALE life table cohort. 
We conelude that in man)' cases the exact value of the disability weight will 
have anly a minor impact on the indicator, and that it might even be jnsti-
fied in aggregate analyses to iguore comorbiditl' altogether. 
The second methodologieal problem with the DALE as introduced here 
is thc estimation of the Hall causes" disability. wIul'ray uses a Hbrute force H 
approach for the DAL Y and the DALE to describe total disability by in-
eluding a very large number of diseases aud conditions (Murray, 1994; 
Murra)' & Lopez, 1997). OUl' DALE computation explicitly describes the 
disabilit)' caused by a limited number of diseases anI)', and obtains the sup-
posedly constant remainder by subtraction from an Hall-causesH estilllate. 
The latter is derived from a Disability Free Life Expectancl' in a rather 
rough procedure, aud while the result looks plausible enough, the proce-
dure is cert<tinly open for illlprovement. 
In most cases the DALE can be implemented as a statie life table 
measnre, but there is no reason why a dynamÎc version would be impossi-
bIe. In chapter 24 adynamie life table population met had is used (among 
others), which could easill' be applied for adynamie DALE toa. Also a rea 1 
instead of life table population could be used, whieh would make the indi-
cator verl' much, if not quite, the same as a DAL Y approach. 
The genera} conclusion here is that there exists a range of possible il11-
plementations for indieators that combine morbidity and mortality. DFLE, 
DAL Y and DALE are but d11'ee in stances of a large set of pos si bIe imple-
lllentations. The main point is to ehoose 01' construct the implelllcntation 
that, givcn thc application at hand, is most appropriate. 
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Health expectancy, 
an indicator for change? 
Abstract 
Study objective Health expectancy is an increasingly used indicator of 
population health status. It collapses both mortality and morbidity into 
a single indicator, and is therefore preferred to the totallife expectancy 
for populations with low mortality but high morbidity rates. Three 
methods of calculation exist: the Sullivan, double decrement, and multi-
state methods. This report aims to describe their relative advantages 
and limitations when used to monitor changes in population health 
status over time. 
Design The differences between the three methods are explained. Using 
a dynamic model of heart disease, the effect of the introduction of 
thrombolytic treatment on the survival of patients with acute myocar-
dial infarction is calculated. The resulting changes in health expectancy 
are calculated according to the Sul/ivan and multi-state methods. 
Main results As opposed to the double decrement and the multi-state 
method, the Sul/ivan method produces spurious trends in health expec-
tancy in response to the change in survival. 
Conclusions Estimates of health expectancy in a dynamic situation can 
be very misleading when based on the Sul/ivan method, with its attrac-
tively moderate data requirements. The multi-state method, which re-
quires longitudinal studies of population health status, is of ten in dis-
pensabie. 
Introduction 
In an artiele published in the Journalof Epidemiology and Community 
Health of December 1992 Margaret Bone evaluated the international efforts 
to measure the health expectancy as an index of a population 's state of 
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health, and its application as an indicator of changes in population hcalth.(1) 
For several years now all international nct\vork of researchers has been 
working to deal' up methodologieal issues, to standardize methods, to eu-
courage the collcction of appropriate data, and to ga in acceptance for the 
indicator in health policy.(2) 
Thc health expectancy (or healthy life expectancy) is derived from both 
mortality and morbidity, and indicates which part of the totallife expcctallcl' 
is spent in good health. Time trends in health expectancy help to detennine 
whether wc arc improvillg the llations health, or that we are jnst being more 
successful in prevellting severely ill people from dl'ing. This property makcs 
health expectancl' an important index in the ongoing debate, sparked oH by 
Fries, on thc compression or expansioll of morbidity.(3) 
There is 110 doubt that the snccess of the health expecrancy indicator is 
largely due to its intnitive appeal. It seems a straightforward extension of the 
notion of life expectancy, and is gencrally interpretcd as the average nUlnber 
of years a newbol'll will live without (serious) discase. It also has attractive 
flexibilitl', depending on the definition of "healthy": there havc been disease 
free, disability free, and quality adjusted life expectancy indicators.(2) As with 
life expectancl' itself, however, there is more to the health expectancy indica-
tor than meers the eye. 
For one thing, there are three different methods of calculating the health 
expectancy: the Sullivan, double decrement, and multi-state methods.(4) Fach 
has different data requirements, and produces different results. Most of the 
studies cited above employ Snllivan's method, named aftel' the researcher that 
pioneered its use.(5) The popularity of this method has a good reason: it is 
the least demanding in terms of data reqllirements. There is aprice, however: 
the Sullivan methad gives reliable results anly in a static environment. 
This artide considers the conditions under which simple health expec-
tancy indicators based on Sllilivan's methad can be l1sed, and those which 
I'equire the more demanding multi~state methad. The introductÎon of throm~ 
boll'tic treatment in hospitals and its effect on the health expectanc)' is used 
bl' wa)' of illustration. 
Methods 
The health expectancy indicator is known in various guises, which differ in 
their definition of health and how it is measured, but otherwise they are very 
similar. \XTe will cantine ourselves to the disease free life expectancy defini-
tion, more particnlarly ta life expectancy free from heart disease, but the ar~ 
gument can be generalized to apply to the whole range of health expectancy 
indicators. 
The health expectancy indicator is dearly an offspring of the standard 
life expectancy indicator, and employs the same method: a life tabie. In a 
standard life table a bit,th cohort of usually 100,000 people is subjected to 
mortality probabilities in relation to age. For each age, the total number of 
years the shrinking cohort has yet to live is calculated, and dividing th is total 
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by the number of people still alive gives the life expectancy for that particular 
age. The AppendL" (AI contaius a more formal description of th is cakulation. 
Tbree ways of detel'mining the health expectancy 
Three variations of th is procedure ma)' be used to calculate the health expec-
tancy: 
1. Sullivan's method nses disease prevalence data in relatioll to age to snb-
tract the numbcr of years the cohort still has to live with disease from the 
total number of years. The health expectancy is then calculated by dividing 
this number of healthy years by the uumber of people alive. As a rule the 
disease pl'evalellce data are fro111 a cross sectional survey; 
2. The double decremettt methad uses disease incidence data: the birth cohort 
is subjected to bath mortality and incidence pl'Obabilities, the farmer C01'-
rected for disease specifie mortality. From the cohort of people who are 
neither dead nor ill the life expectancy is cakulated according to the stan-
dard procedure; 
3. The multi-state methad also uses incidence probabilities to calculate dis-
ease prevalencc, but in addition allows for one Ol' more disease states ill-
cluding, when applicable, a "cured" state where the cohort may be subject 
to recurrent disease. It depeuds on the definition of "healthl''' whieh of 
these states wil! count towards the health expeçtanc)', but once this is de-
cided the cakulation proceeds in the standard way. In Appendix B an 
equation is given for health expectancy according to the Sullivan methad 
and the lllulti-state method with only one disease state, and na eure or re-
elUTent disease. 
It is evident that the multi-state methad is by far the most demanding in 
terms of data requirements. In fact only longitudinal studies lVith a long fol-
Iow up period and a sufficient number of rOllllds eall provide the nceessary 
detail. Sti1l, it is very attractive because it call cnpture the natura I course of a 
disease, and eall ellcompass patients who are eured or have intermittent dis-
ease free periods. 
The prevalence data used in Sullivan 's methad reflect implicitIl' this 
natura} course too, but in a very compJex way. Prevalenee is a stock varia bIe: 
current prevalence of spinal injuries among 40 year aid (farmer) cal' drivers 
covers an accumulated 22 years of cal' accidents that happened to drivers of 
as many different ages. As is ShOW11 in Appendix C currellt cross sectional 
prevalence is a funetioll of a long series of past illcidenee and ll10rtality rates 
(and cure rates, when applicabie). 
lncidenee and 1110rtality are flow varia bles: ClUTent acute mortality from 
spinnI injuries amollg 40 year aIds reflects th is years' cal' accidents to drivcrs 
of th at age only. While the multi-state methad uses only flow varia bles, the 
Sullivan methad e1l1ploys the flow varia bie "mortality" to calculate total 
Ilumber of years lived, and the stock varia bie "prevalence" for the diseased 
number of years. The inconsistent mix of stock and flow variables may lead 
to odd results. 
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The double decrement life tabIe, like the multi-state, uses only flow vari-
ables, is thel'cfore consistent, and has mach less demanding data reqnire-
ments. The drawback is that it, in effect, treats disease incidence the same as 
mortality. 
COlllpal'ing Sullivan and Illulti-state Illethods 
Ta illustrate out' argument we shall COlnpare results fro111 the Snllivan method 
with those from the l11ulti-state method. In order to ensure comparabilîty 
with the Snllivan methad we use the same incidence data and combine these 
with survival data to caleulate a prevalence. In both cases, the possibility of 
cure is ignol'cd - that is, all patients who have had a myocardial infarction 
will contribute ra the prevalenee of heart disease for the rest of their lives. 
Tbc model 
We use adynamie population model for ischaemic heart disease to compare 
the two methods. Ir is a state-transitioll model, that owes mnch to the Coro-
nar)' Heart Disease Policy Model of Weinstein et al.(6) Aftel' patients enter 
the disease model with a first manifestation of heart disease - angina pectoris, 
an acnte corollat'}' event, or heart failure - they are subject to risks of 
(possibly repeated) events snch as au operation or another acute co1'onary 
event. Dependillg on their state when an event occurs, they may be 1'efel'red to 
a new state, the}' may die, or they may l'emain where they are. 
Input inclndes the incidence of myocardial infal'ctious in relation to age, 
based on the nationwide Dutch hospital register.(7) Survival aftel' admission 
to hospital with lllyocardial infarction is based on the same register and, for 
the long term, on the results of the Fralllingham Study. Combined with an 
"all other causes" mortality we were able to reproduce vety weil the observed 
tllortality frolllll1yocardial infarction in the Netherlands.(8) 
The model is dYllamic in the sellse that prevalellce in each state depellds 
on the prevalenee in the pl'evious time pel'iod, and on illflow and ontflow 
varia bles. These inflow and ontflow varia bles can be lllanipulated to simttlate 
changes in incidence and survival over time. Output options include disease 
free life expectancies according to the Sullivan lllethod (using the d)'namically 
calculated prevalence) and the multi-state method (using a s)'nthetie preva-
lence based only on current incidence and survival). 
Effect of thrombolysis 
Fo!' our calenlations we use the hypothetieal example of the simult.neotts 
introduction of thrombolytie treatment in all Dntch hospita Is. The asstunp-
tion is that all hospitals introduced thrombolysis in 1991, .nd that none nsed 
it before that. \Y/e assumed a conservative, 25% reduction in acute, in-hospi-
tal deaths from m)'ocardi.1 infarction af ter thrombolysis, .nd c.leul.ted long 
term effects on (healthy) life expectancy keeping incidence and all other sur-
vival parameters constant.(9) 
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Figure ~ Total and dlsease free life expectancy after adoption of thrombolytic 
treatment in men, Multi-state method versus Sullivan's method. 
Results 
What ean we expeet from this intervention? Sinee thrombolysis has an effect 
on acute deaths only we expeet the totallife expeetaney to inerease suddenly 
between 1990 to 1991. Sinee the incidenee of myoeardial infaretion is kept 
constant, and beeause all people are eonsidered "heart patients" after a myo-
eardial infarct, the life expeetaney free from heart disease should remain tUl-
ehanged. 
From equations (3) and (5) we ean see how a change in disease specific 
mortality will, through the concomitant change in total mortality, instanta.' 
neously affect the total Illunber of years lived by the synthetic cohort, but will 
only gradually be reflected in population prevalenee. This results in an abrupt 
change in the Sullivan health expeetaney (up when mortality goes down, and 
vice versa), followed by a slow approach to the correct value. The synthetic 
prevalence of the multi-state method (eq. 7) is, however, like the total number 
of years lived, adjllsted instantly. 
In the figure we present the results f,om a 25 year simulation with the 
model. Total Hfe expectaney inereases suddenly, but tapers off somewhat 
afterwards as the now surviving patients drift iuto chronic heart disease aud 
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its high lllortality. The disease free Iife expeetaney aeeording to the ll1ulti-
state method remains unchanged, as expected. The health expectallcy ac-
cordillg to the Sullivall method, however, shows a quite different patterll: it 
rises initially almast as mueh as total life expectancy, then starts falling and 
reaches the llllliti-state line asymptotically aftel' "bout 40 years. 
Here the Sullivall method shows the disaclvantage of mixing stocks and 
flows. Thc constant illcidcllCC in combination with the lmvcr lllortality will, 
in the end, necessarily produce a higher prevalellce. Bnt the prevalenee at auy 
age is a fUllction of incidences and lllortalities at all lawel' ages. Aftel' a 
change in incidence or mortality, the prevalcllce in a population will have 
reached its new equilibrium valne only when all coho1'ts datillg from before 
the change arc extinct. 
While the prevalenee, and eonsequently the number of years lived with 
disease aeeol'ding to the Sullivan method, is still eatehing up, the lower mor-
tality has already raised the total number of years Iived by the Iife table co-
hort. Sinee the health expeetaney is ealeulated using the difference of total 
and diseased years Iived, the fast adjusting totallife expeetaney initially pulls 
up the slowly adjusting Sullivan health expeetaney. 
The Sullivan indicator shows an inerease followed bya deerease when it 
ought to remain unehanged. Only when the prevalences have settled down to 
the new equilibrium does the Sullivan disease free Iife expeetaney indicator 
produce no spnrious trends. In Appendix D we derive how many years it 
takes for the Sullivan health expeetaney to reaeh this equilibrium: this is de-
termined by the diffel'enee between the highest age in the Iife table eonsidered 
(typically something Iike 95 or sol, and the lowest age at which the disease 
lUlder consideratiol1 becOllles important (for chronic diseascs typically some-
where bet\veen 20 and 60). 50 it tUl'ns out that incidence, mortality (and cure, 
if included) must have been constant for aperiod from 35 to 75 years, de-
pending on the disease. 
Discussion 
The results show that the health expeetaney aeeording to Sullivan's method 
can produce mislcading results when dynal11ic effects are prcsent. It is truc 
that our example is geared to show tlils: a disease free Iife expeetaney indica-
tor of a disease that affects people rather eady inlife, yet has a relatively good 
survival, wilt be much more "off track" than, for instance, an indicator of Iife 
expectancy without terminal disease. 
We ean see from equations (4) and (5) in the appendix whieh disease 
characteristics wil! reduce the deviatioll from the correct vaJuc. The less cur-
rent prevalellce is influenced by past pl'cvalence, the sooncr the Sullivan 
he al th expeetaney will have approaehed the right value. This oeeurs, for ex-
ample, when mortality is high or itlCidence illCl'CaSes sharply with age. 
ClU'l'ent heart disease prevalence is dependent on past pl'cvalence, éllld 
heart disease is therefore a good example to provide the c1arification the issue 
apparently still needs. Bone attriblltes the eall for the use of longitudinal data 
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to the need to take into account explicitly reversals in disability.(l) That is all 
important point, but, as shown above, not the whole story. Robine and 
Ritchie are aware of the problem of interpreting a time series of health expec-
tandes according to Sullivan 's method, but they contribute this to the combi-
nation of period data (cunent mortality probabilities) with cohort data, 
which they say currently observed disability prevalence is.(lO) But observed 
disability (or disease) prevalenee is jnst as much period data as observed mor-
tality probabilities: bath are influenced by the historl' of the cohorts that 
make up the current population, prevalence only more so. Therefol'e their 
suggested remedy, to derive disability free life expectancy from period data 
only, willnot work. The problem originates from combining stock and flow, 
not period and cohort data. 
In a more recent article Robine et al. point ont th at health expectandes 
based on a combination of stock and flow variables pose problems when 
making between country comparisons.(ll) That is undoubtedly true, as the 
health expectancy is meant to estimate the impact of current health risks, not 
sa much the legacy of the past. Although the authors discuss the development 
of health expectancy over time, however, no mention is made that similar 
stock and flow pl'oblems occur when estimatillg trends. 
Ir could be argued that the example of the sudden introduction of 
thrombolytic treatment is a theoretica I and disl'l1ptive event, while things do 
not normally show such drama tic dynamics. But while its introduction in 
clinical pracrice admittedly will not have happened ovel'llight, an English 
study shows that thrombolysis taak about three years to go from practically 
zero to a new treatment plateau -long perhaps from a clinical point of view, 
but short compared with the kind of time lags assoeiated with the Sullivan 
methad (see appendix D).(12) 
In addition, although total mortality develops rather smoothly over 
time, disease specific mortalities show diverse and mnch more dyllamic pat-
terns.( 13) Fa!' example, male mortality from ischaemic heart disease in the 
Netherlands, standardized for population stmctme and indexed for 
1950=100, reached a high of 301 in 1972, and had fallen to 191 in 1990 
(with same allO\vance for codification changes over the period).(14) P1'e-
sumably the underl)'ing morbidity from ischaemic heart disease willnot have 
sta)'ed unchanged either. Given the vely long time lags involved, such 
changes wil! smel)' bias Sullivan health expectancy trend estimates. 
Most health expectancy estimates published sa fal' are disability free life 
expectancies, or same comparable health measure that is the compound result 
of a large uumber of diseases.(2) Interpreting a time series of Sullivan health 
expectancies based on snch a compound health measure becOlnes a daunting 
task indeed. The health expectancy thus measured is at any point in time a 
function of a large number of disease specific prevalences, each beilIg at same 
unknown point on the wa)' to a new (and probabI)' shifting) equilibrium. Ta 
disentangle this jumble and distinguish true change from delayed adjustments 
seems impossible. 
Recent studies report that health expectancy is increasing less than total 
life expectanc)', or not even increasing at all.(15, 16) But the decline in mol'-
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taliry rates in middle and old age started somewhere in the late 60s or eady 
70s, and given the response of the Sullivan health expectancy trend estimates 
to mortaliry declines - an initial overestimate of health expectancy followed 
by a long term decline towards the correct valne - these estimates will still 
display a downward trend as areaction to previous declilles in mortality, In 
combination with CUlTent mortality declilles the observed trend in Sullivall 
health expectancies may go either way, but provides 110 useful illformation. 
The observed stagnation of health expectancy, that has accompanied recent 
increases in total life expectancy may, therefore, very weil be an artefact of 
the Sullivan method. 
The double decrement method provides no via bIe alternativc. Although 
it is methodologically sound, it is far toa cl'ude for monitoring population 
health status by equating disease incideuce with death. This means that it is 
insellsitive to changes in disease prevalenee or severity that origillate from 
llew or better treatment that patients may benefit from or even be cured hy. 
This leaves the ll111Iti~state method. lt is consistent becallse it calculates 
disease prevalellce nsillg onl)' current flow varia bles, which ewnillates the 
pl'oblem of an inherÏted stock of patients that plagues Sullivan's method. It is 
potentially subtle enongh to track the changes in health status af ter, for in-
stance, the illtroduction of thrombolysis, that will not just prevent a number 
of deaths, but will also limit the damage to the heart for a number of patients 
who would have lived anyway. To use the multi-state method to its full po-
tential, however, detailed longitudinal data are needed, also on the disease 
specific level. The kind of model we have employed in this study also gives a 
better Ullderstanding of the dynamics of population health status, and it has 
similar data requirements. Ouly when we can monitor poptdation health 
status and explain the direction it is moving in, can we undel'stand what we 
are monitoring alld make informed suggestions abont improvement. 
Sullivan's method was intended to give an estimate of the health expec-
tancy, using readily available Ol' easily obtained data. In a population with an 
increasing total life expectancy it will be biased upward, but this may be a 
disadvantage weil worth putting up with. The method should not be pushed 
beyond th is goal, however, because what is a small bias in health expectancy 
will confound a trend analysis of a time series of health expectancies since the 
direction and size of the bias are time dependent. 50 the question "Is health 
expectancy is a valnable indicator for changes in population health" deserves 
a conditional "Yes" ~ the condition being longitudinal studies, that cau pro-
vide the input fol' multi-state life tables aud dynamic models. 
The short cut Sullivan 's method pl'Ovides, as compared to the multi-state 
method, is a dead end when it comes to the analysis of changes in health ex-
pectancy over time. 
Appendix 
A: Life expectancy 
Life expectancy is calculated by submitting a so caIled "synthe.tic" birth co-
hort of 100,000 people to age specific mortality probabilities. The birth co-
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hort is called "synthetic" becallse, alld this is important to note, the mortality 
probabilities used are the current probabilities. A real birth cohort has been 
submitted throughout life to mortality probabilities in the past that were, as a 
rule, higher than the current ones, and a cohort of newly borns will face fu-
ture probabilities that we expect to be lower yet. Because of these changes in 
mortality, the current life expectancy at age 0 willnot be equal to the average 
number of years to be lived by a cohort of newbo1'1ls. 
If we denote the synthetie cohort with I" with a the age index and am= the 
highest age considered, and the mortality probabilities with q" then the life 
expectancy e, is given by the totalnumber of years to be lived by the cohort 
at age a divided by the number alive at that age. Formatly: 
arm.-.;-J 
L 0.5(la + la+/) + I"=,ea=, 
e
a 
= ~a~ _________ _ 
la 
1 
Usiug 1",=i,{l-qJ we cau rewrite (1) to: 
arm~-l 
L la(1-0. 5Q a)+I"=,ea=, 
e
a 
= ..-'a'-_________ _ 
la 
2 
Life expectaucy is a statie estimator: because 1",=/il-qJ for all a auy change 
iu the current mortality q, is iustantly reflected in the total uumber of years 
lived to its full effect. In fact, the life expectaucy estimator aSSUlnes that the 
mortality probabilities have been unchanged for at least am= years. 
B: Health expectancy 
Health expectancy is calculated by not letting years deEined as unhealthy 
count towards the totalnumber of years to be lived. When P, is the age spe-
ciEic prevalence of unhealthiness (expressed as a proportion) then the health 
expectancy h, can be caleulated by: 
anm-l L 1,,(1-0.5q aHl- P a)+ la=,e"jl- Pa=) 
ha=~a,--------------------------------
la 
3 
Equation (3) can be used for bath the Sullivan and the multi-state methad, 
the differellce is where the prevalenee Pa comes from. 
C: Empirical versus synthetic prevalmce 
The Sullivan methad uses empirical prevalence' data obtained tllfough a sur-
vey or same similar method, while the multi-state method lIses the prevalenee 
ealeulated in the life table itself from the current incidenee and mOl·tality 
probabilities. The cross seetional prevalenee for a very simple disease proeess 
with incidence Ia and mortality Ma alld 110 cure is given by: 
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P' = (p'-I + I'-I)(i- M'-I) a a·1 a·J a·1 4 
AppI)'ing (4) recursiveI)' to itself, aud assUlning that prevaleuce at birth eqt,"Is 
zero, we call l'ewrite (4) as fo11ows: 
a·/ a·J p> LJ Ij-a+} IJ (1- M~-a+k)) 5 
J=f} k= j 
The prevalence as given b)' (5) is used b)' the Sullivau method, for the muIti-
state methocl the following equatious appI)': 
6 
a·J a·J 
p~ = LJ Ij IJ(1- MU) 7 
j=(} k=j 
This multi-state disease prevaleuce one !l1ight call, as au analogue to the Iife 
table cohort, a <lsynthetic prevalence". This synthetic pl'evalence is, ulllike a 
cross-sectional prevalence, not a stock varia bIe, because, being a fUllction of 
CUlTent incidence and mortality only, it does not depend on past values. 
D: Time lags 
From (5) and (7) it cau be deduced UIlder which conditions the Sullivan and 
multi-state discase prevalences at age a and time t will be equal: 
I'j"+} = ij 'cf j E[O .. a-iJ 
Mj-a+} = Mj 'cf j E [0 .. a -ij 
To put it differeutl)': past age specific iucidence ancl mortalit)' must have beeu 
eqaal to the CUl'rent incidence and mOl'tality for, depending on age, up to a 
yeal's. \\1hen ami" stands for the lowest age at which illcidence occurs dus re-
quil'ement relaxes to a-amin yeul's. Because the calculation of the health expec-
tancy alwa)'s uses the prevalence of the highest age am., (see eq. 3) th is implies 
th at the Sullivan health expectanc)' equals the mul ti-state health expectaucy 
whell age specific incidence and mortality have been constant for up to 
am ... v-flmin years. The same applies for cure probabilities, if included. 
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Changes in incidence and 
survival of cardiovascular 
disease and their impact on 
disease prevalence and 
health expectancy 
Abstract 
Background. Martality and incidence rates far heart disease and stroke 
are declining . All ather things being equal this abviausly wil/ increase 
life expectancy, but what happens ta disease prevalence depends on the 
balance between incidence and survival: it ma)' increase, decrease, or 
remain unchanged. The health expectanc)', in turn, depends on the bal-
ance between life expectancy and disease prevalence. 
Method. A multi-state Iife table is used ta calcttlate the impaet of vari-
aus combinations of changes in incidence and survival of heart disease 
and stroke on disease prevalenee, life expeetancy, and life expectancy 
without disease. 
Results 
• A better survival is not reflected in the health expectancy. Health ex-
pectancy at birth wil/ remain unchanged, and at higher ages it wil/ 
decline. This is a caunter-intuitive result, that cauld (and shauldj be 
remedied b)' giving Iife years with disease a weight greater than O. 
• Bath lawer incidence and better survival have the effect of relativel)' 
shifting the burden of disease fram )'ounger ages ta alder ages. Health 
expectancy at birth does not refleet such distributianal shifts. 
• The most likel)' future changes (judging fram the recent pastj in bath 
heart disease and stroke are a lawer incidence and a better survival, 
but the latter outrunning the first. Results are decreased prevalenees 
215 
116 l\tleasliring compression fll1d expansion of morbidity 
at )'ounger ages, together with increased prevalences at older ages 
ones, and especiall)' increased comorbidit)'. This rightl)' shows up as 
an increased health expectancy, but in as far as prevalence is a good 
indicator it also imp lies a greater need for care. 
Conclusions 
• Health expectanc)' would be a better indicator for public health if 
diseased (or disabled) Iife-years were weighted instead of ignored. 
This can be done, as the World Bank 1993 report has shown. An-
other way is using quality adjusted Iife years . 
• Polic)' makers wi/l be interested in the age distribution of effects from 
interventions. Unfortunately health expectancy at birth is rather in-
sensitive to such distributional changes, and while solutions are con-
ceivable the)' have the drawback of diminished intuitiveness. 
When health expectancy is used in a policy making environment it 
should be made clear that a higher health expectanc)' could very weil 
imply higher demand for care. 
Introduction 
Health expeetaney (Ol' health)' Iife expeetaney) is preferred to Iife expeetaney 
as an indicator for pop,dation health status beeause it is based not just on 
mortalit)', but also includes morbidity. As soon as a country has moved 
through the epidemiologie transition, that is when the burden of illlless has 
shifted from mostly infeetious, aeutely fatal disease towards mostIl' non-
cOll1municable, chronic disease, it beCOlnes highly desirabie to adopt an esti-
mator of public health that puts less emphasis all (ehild) mortality and more 
on (all .ge) morbidit)' than Iife expeetancy does. 
The \Vork of REVES on the health expect.ncy indicator - clearing up 
mcthodological issues, standardizing methods, encouraging data collection, 
and gaining acceptanee for the indicator in health policy - has met with con-
siderable suceess.(l) For example, in the Netherlands arecentl)' published 
comprehcnsivc over view of the health status of the Dutch population used 
health expectaney as the central sun1lna,!, indicator.(2) 
The success of the health expectancy indicator is in large part due, no 
doubt, to its intnitive appeal. Ir seen1S a straightforward extension of the no-
tion of life expectancy, and tends to be interpreted as the number of years 
someone can expect to live without (serious) disease, followed by a number 
of unhealthy years lllltil death. This intuitive appeal makes health expectaney 
an attractive instrument to comlllUnicate results from research to policy mak~ 
ers and the general publie. 
The ability to COlllll1Unicate results to people outside the small circle of 
directly illvolved researchers is an important asset. In th is paper we investi-
gate the behavior of health expectancy in reaction to a few hypothetical, but 
in view of the recent past not unlikely developments in the epidemiology of 
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cardiovascular disease.(3, 4) We look at the results of declinillg incidellce and 
incl'easing survival in tel'ms of changes in disease prevalence and health ex-
pectancy, and judge the information health expectancy provides on bath in-
tnitiveness and usefulness. 
Methods 
\\fe set up a multi-state life table with two diseases, heart disease (consisting 
of ischemic heart disease aud heal't failure), and stroke. States are: neither 
heart disease nor stroke, heart disease, stroke, comorbidity of heart disease 
and stroke, and the three absorbing states death from heart disease, stroke 
aud 'all other causes'. Inflow in the disease states depends on incidence prob-
abilities by age, outflow on survival probabilities, also by age, cure is ignol'ed. 
In all but the absorbing states people are subject to 'aU other causes' mortality 
probabiHties, that are independent from disease-specific survivals. Co-mor-
bidity is caleulated assuming disease independence. 
We use a subset of the input data collected for the stroke and heart dis-
ease models that are part of NIMPH: the Netherlands Integrated Model of 
Public Health. They consist of total mortality probability and disease-specific 
mortality rates from the Central Bureau of Statistics (5, 6). The incidellce 
pl'Obabilities are based on nation-wide hospital register data and regional 
studies.(3, 4) From incidence and disease specific and total mortality we cal-
culate age- and disease-specific survival probabilities.(7) 
We vary incidence of bath diseases by multiplying age-specific pl'Obabili-
ties with a factor of 0.9 (all ages), and multiply pl'Obabilities to die from a 
specific disease, given prevalence (i.e. I-survival probability) likewise with 
0.8, always comparÏng outcome with the 1988 base year. We look at age-
specific point prevalence aud disease-free life expectancy. 
Results 
Increased survival 
Fil'st we increase survival with heart disease, while leaving all other parame-
ters at their base valne. Figure 1 shows ontcome expressed as indices (with 
1988=100) of prevalences of heart disease and heart disease-free life expec-
tancy by age. Heart disease prevalence rate increases for all age groups af ter 
illcreased survival, but much more so in oider age gronps: a relative shift of 
the burden of disease towards older ages. In numbers this shift is still stronger 
because a largel' part of the initial birth cohort lives to high age. 
The health expectancy at birth (and up to about 40) remains constant, 
as one w0111d like to see from a disease-free life expectancy with disease inci-
dence and mortality from all other causes constant. But for older ages it in-
creasingly declines. This is of course as it should be: the number of years lived 
without disease in each age interval remains constant, but the older age 
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Figure 1 - Health Expectancy and heart dlsease prevalence, index 1988=100, by age, 
wlth constant incldence and increased survival. IHO: heart disease. 
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Figure 2 - Health Expectallcy and heart disease prevalence, Index 1988=100, byage, 
with decreasing incidence and constant survival. IHO: heart dlsease. 
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Figure 3 - Health Expectancy and heart disease prevalence, Index 1988=100, byage, 
wlth decreasing incidence and increased survival. IHO: heart dlsease. 
grollps become larger due to the declined mortality. Becanse the increase is 
soleiy in the diseased state the average number of years Iived without disease 
declines. Computationally sound as this may be, it is also highly counter-in-
tnitive that health expectancy at age 65 01' sa declines when survival with 
heart disease increases. 
Decl'eased incidence 
Secondly we multiplied age-specific incidence with 0.9, again with all other 
parameters at their base value (Figme 2). The age-specific health expectancy 
resulting from this behaves like one would expect: higher for all ages, but 
more so for the elderly where incidence rates are higher. More interesting is 
age-specific prevalellce: while at the lowest ages the prevalence rate stands at 
a correspollding 90% of the base rate, this percentage edges up a bit with 
age. The lower prevalellce rate in any age group results in a largel' gl'OUp at 
risk fOl' incidellce, which counteracts the lower incidence pl'Obability. 
As with the increased survival, this again results in a relative shift of the 
burden of disease towards older age gl'Olips. Throllgh the implied lower dis-
ease-specific lllortality, this shift is more pronOllllced in prevalence llllmbers: 
at the highest age this prevalence even exceeds the base value. 
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Inereased survival and deereased ineidenee eombined 
The eombined picture of better survival and lower ÏtlCidenee is in Figure 3. 
Lowcr incidcnce is l'eflected in 5 to 10% lower pl'evalences (llumbers) at 
young agcs, and thc illCl'eascd survival causes up to 250/0 higher pl'cvalences 
at older ages. The result is a tilted index line, with a pivot point somewhcl'e 
between age 65 and 70. 
Age-specific health expectancy is surprisingly unaffeeted by this: it stays 
within 3.5% of the baseline value, rising lllltil 65 and declining aftel" The 
countcl'acting influellces from increased survival and decl'eased incidence 
more or less cancel each other out. 
Co-morbidity 
For stroke prevalence a similar patterll applies as for heart disease: lowel' in-
cidence and better survival resnlts in a tilted index line with incl'eased preva-
lenee at higher ages. The age-specifie eo-morbidty of heart disease and strake, 
that lUlder the assumptian af independence af the diseases is simpil' the prod-
uct of the two prevalences (expressed aS prapartions), shaws the same tilted 
index line, but then in exaggerated farm. At higher ages the co-marbidity is 
about 50% higher than the base line value. 
Discussion 
Health weights 
Health expectaney is one of several efforts to measure the health status of a 
population by collapsing information on mortality and morbidity iuto one 
figure. Other ways include quality-adjusted !ife-years (QAL Ys), utility-based 
life-years, disability-adjusted Iife-years (DALYs). All these indicators have one 
point in eOlllillon: a life-year spend with disease is valued differently from one 
in good healtll. The main differences between health expeetancy and the 
other indicators are that firstly, far health expectaney the diseased Iife-years 
as a rule get a weight of 0, while the others nse something betweell 0 and 1, 
and secondly, that health expectaney nses the weights to calculate a healthy 
Iife expeetancy, and the others as a rule do not. 
Another concern abaut these methads is th at there is very Iittle contact 
between them. Far example, the Warld Bank reports tatal disability-adjnsted 
life-years last, an outcome that is very difficult ta interpret and makes cam-
parisolls between conntl'ies impossible, as thcy adnut, while all 11ecessary in-
gredients far a disability-adjusted life expectaney were available.(8) With 
some nota bie exceptions researchers seem happy to pUl'Sue theil' OW11 ways 
and tend to stress the differences between the methads rather than learn from 
athers and apply what is nseful.(9) 
The abave-reparted effect of increased survival an health expeetaney 
iIIustrates the disadvantage of this tnnnel visian. When life-years lived with 
disease are weighted 0 any increase in survival will have the l'csnlt shown 
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Figure 4 - Health Expectancy (unhealthy years welghted) and h'eart dlsease 
prevalence, Index 1988=100, by age, wlth constant Illcldence and Increased survival. 
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above: an unehanged health expeetaney at birth, but a deereasing one at 
higher ages. This means that medical interventiolls in ehronie diseases, by 
definition not able to eure the patients, but Iife extending andlor quality en-
hancing, are, as measured by the health expeetaney, at best worthless, or even 
detrimental. For a health status indicator meant to address the problems of 
measnring health in populations with a high prevalenee of ehronie disease 
th is seems a rather peeuliar eharaeteristic. 
There are two ways around the problem. One is to use 111ulti-state Iife 
table teehniques to look at the age-speeific health expeetaney of the healthy 
population at that age. This will at least avoid the deerease of the health ex-
peetaney at higher ages, although it \Viii still ren der any inerease in survival 
worthless. Aud of course it requires better data thau the Sullivan methad. 
Allother way is to use weights. When diseased life-years are weighted 
more than 0 all inerease in survival wiII show up as a higher health expee-
taney at bu,th, <l gain that iIlcreases up to some age, then starts to diminish 
and eventually may beeome a deereased health expeetaney for the highest age 
group (see Figure 4). This outeome mueh better refleets the populatiou health 
status aftel' an increased survival: it is an impl'ovement (unless the gailled life-
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years are sa awful they deserve a weight of zero) \Vith the disadvantage that it 
eauses higher disease prevalenee, especially at high ages. 
\Xlhich set of weights is nsed seems at this point rather immaterial: al-
most anytrung is better than the 0-1 seheme routinely employed in health 
expeetaney ealcnlations. At the previous REVES meeting an example of a 
quality adjusted life expeetaney was presented, and the World Bank's DALYs 
\Viii probably be used to calculate disability adjusted life expeetaneies.(lO, 11) 
Sueh eross-fertilization is bOlllld to produce a better health expeetanel' indica-
tor. 
Age distl'ibution 
Health expeetanel' is determined in large part b)' morbidity and mortalit)' 
from ehronie diseases, so changes in the epidemiology of chronic diseases 
should ideaIll' have an impact on health expeetane)'. Cal'diovaseular disease 
in the Netherlands (as in mally other western countries) has seen declining 
age-speeifie mortality, for stroke at least sinee the fjfties, for heart disease 
sinee the early seventies. A closer look at the available evidenee reveals that 
this decline is most likell' due to a eOlllbination of declining ineidenee and 
inereasing survival.(3, 4) 
Declining incidenee may be unique to cardiovascular disease, catlcer 
incidenee, for example, has been reported up (albeit based on ineonclusive 
evidenee).(12, 13) But inereased survival probably extends to many other 
chronie eonditions: medica 1 technology has seen more pl'ogress in the man-
agement of ehronie disease then in the eure. Barring major breakthroughs this 
pattern is likcly to continue. 
The effect _ of decreased incidenee and inereased survival on disease 
prevalenee has been demonstrated above: a relative shift of the bnrden of 
disease to\Vards older ages. It has also been delllonstrated that the health ex-
pectancy indicator is rather unresponsive to sneh shifts in disease distribntion. 
There are two points we would like to make here: 
If th is pattent of a decl'easing prevalenee at younger and an inel'easing one 
at older ages lViII indeed turn out to be the prevailing development, it 
wonld seem that the debate on compressioll versus expansion of morbidity 
is being held in toa simplistic tenns. While morbidity is compressing in the 
sellse that there is less of it at youngel' age, it is at the same time expanding 
in the sense that there is 1110re of it at older age. Perhaps IVe should redunk 
our terminology. 
Seeondly, the unresponsiveness of the health expeetanel' indicator to sueh 
developlllents is worrying. Most likely there is a IVal' to amend health ex-
peetanel' to refleet an age distribution shift (like reporting two health ex-
peetaneies: one at bit· th until age 75, and one at age 75), but the drawback 
is diminished intllitiveness. \X'e have seen the same in the compression-ex-
pansion debate: the nÎCeties of l'elative eompression and absolute expansion 
are pl'obably lost to all but the inner eh'cle of debaters. There mal' be na 
easy solution here. 
Changes in incidence and survival of cardiovascular disease 223 
Health expeetaney and poliey making 
Health policy has become a major issue in many conntries, 1110Stly because of 
evel" increasing health care costs. The health expectallcy' indicator is likely to 
become more important for policy making, because it gives a more balanced 
view of popnlation health status thalllife expectancy, without getting lost in 
a myriad of details. This increased use is no doubt in large part due to the 
\Vork of REVES, but, as wc have tried to show here and elsewhere, there is no 
reason for complacency yet.(H) 
Use of the health expectallcy indicator for policy making is not without 
danger of course. Like any summar}' indicator it glosses over a lot of detail, 
some of it of central interest to the poliey makel'. For example, if the age dis-
tribntion shift of disease deseribed above will indeed materialize health Care 
costs will increase becanse of increased numbers of patients, who are older on 
average, and have more comorbidity. It may come aS a nasty surprise to the 
policy maker that a virtually ullchallged health expectallcy will be accompa-
llied by illcreasing costs. 
It shol1ld be the responsibility of REVES now that health expectancy has 
become respectable to further improve on the indicator and to guard against 
inappropriate and uninformed nse. 
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DALYs: 
the age-weights on balance 
Abstract 
In studies for the 1993 World Development Report: Investing in Health 
Murray et al. developed the Disability Adjusted Life Year (DALY). 
This article examines one particular aspect of the DALY methodology: 
the weighting of Iife years by age. For the quantitative implementation 
of this notion Murray proposed a general equation to weight life years 
by age, which specifies that years Iived between the ages of 9 and 54 
have a weight greater than unit)', and years outside that range less than 
unit)'. The age-weighted Iife )'ears are used to calculate "expected years 
of Iife lost" (EYLL). Comparison of age-weighted and un-weighted 
age-specific life expectancies shows that the age range which becomes 
more important due to weighting is not 9-54 )'ears, but 0-27 years. This 
happens because the EYLL is an age-weighting system in itself, empha-
sizing the )'oung. The result of piling one age-weighting systems on top 
of the other gives an even stronger emphasis on the young than the 
EYLL generates by itself. Although this is unlikely to upset the results 
from the Global Burden of Disease study, we do not think it desirabie. 
And it is certainly different from what we were led to expect. 
Introduction 
In 1994, Murray et al. published a series of 8 articles in the Bul/etin of the 
World Health Organization (1-8) on the global burden of disease and on 
hea!th expenditures and intervention packages, which describe the basic 
studies ca ried out for the World Development Report 1993: Investing in 
Health (9). These artieles, now also available in baak format (10), give an 
overview of the methodology used to assess the global cost-effectiveness of 
specific health expenditure packages. The sheer sizc of the undertaking com-
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mands respect. This respect increases considerably when examination of the 
Bulletin papers and background material (11), reveals the care with which 
th is study has been carried out. 
The study deve/oped and applied several i11tlOvative concepts, one of 
which - the Disability Adjusted Life Year (DALY) - has attracted much at-
tention and generated controversy. However, use of a non-disease-specific 
concept like a DAL Y is inevitable when you want to compare the burden of 
morbidity (and its sequelae) of different diseases. The controvel'sy concen-
trates on two particular aspects of the DAL Y methodology, one of which we 
williook into - the weighting of Iife yeal'S by age; the othel' sensitive aspect is 
discounting of future life years (12). 
Wie must stress that we do not consider age-weightillg as snch to be in-
apprapriate or wrong; on the contrary, we think it may certainly make sense, 
depending on the pnrpose and cireu1l1stances. Howevel', precisely because it is 
controversial it is of great importance to apply it meticnlously. One weak 
point in the methodology as reported by Murray is that the age-weighting 
eventually produces a different result from what might be expected from the 
age weight function. Ta iIIusttate this we will fh'st briefly describe the DALY 
methodology, and then apply it using a life-table. 
The DALY methodology 
The methodology assesses the impact on public health, on bath morbidity 
and mortality, of various packages of health care that might be provided. 
J\IIost health care meaSllres are disease-specific illterventiolls, eithel' preventive 
or therapcntic, and this makes it imperativc to examinc the effects of inter-
ventions on a disease-specific level. To compal'e the impact of the interven-
tioil between diseases or health care packages it is llecessary to have a non-
disease-specific cammon denominatol'. 
The established comman denominator used to be mortality or mOl'taIity 
based me.sures like life expectancy and potential years of life lost (PYLL). 
Including morbidity in the public health impact means adopting a non-dis-
ease-specific measure to express the burden of diseases and their seque/ae. To 
express the combination of mortality alld 1l10rbidity in a single measure it has 
become a (disputed) standard to value one year lived in good health by 1, and 
a year lived with less than good health by a value between 0 and 1, depend-
ing on the severity of the health problem. The years not lived (lost to prema-
ture mortality) are assigned a value of o. 
Given the disease- and age-specific mortalities the "expected years of life 
lost" (EYLL) due to mortality call be estimated by ll1ultiplyhlg the Ilumber of 
disease-specific deaths for each age by the life expectallcy at that age (the sa 
ca lied "Iocallife expectallcy"), .nd thell summillg over all deaths. Years lost 
due'to morbidity can be estimated by multiplying the years lived with disease 
by the value between 0 alld 1, summing the thus-weighted years lived, .nd 
subtraeting this nntnber from the total unweighted number of years lived. 
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The sum of the years lost due to mortality and morbidity then gives the tata I 
bmden of this particular disease. 
The DAL Y methodology follows this basic scheme, while adding the 
following features of its own. 
The objective of measuring the tata I bmden of disease from all (important) 
diseases combined. This requires making consistent estimates of the inci-
dence, pl'evalence, and mortality of a great number of diseases, a number 
large enough to represent the major part of the population's health. Using 
an incidence, prevalence, and mortality model the researchers fm"ced their 
estimates to be internally consistent, and while undonbtedly some estimates 
may be inaccurate (13), this is a major achievement. 
The use of one standard life-table worldwide, and not different regional 
life-tables. Murray argues convincingly that this is necessary te compare 
"like with like", and not to value a death at a given age more in a high life 
expectancy country than in a low one (1). 
The use of disability weights. Six classes of disability severity were distin-
guished; using expert panels it was decided how many people with a certain 
disease would as a consequence be disabled, and how these were distrib-
uted over the six classes. Needless to say, this procedure has same weaknes-
ses, but in that respect the DALY is na exception among procedures to ob-
tain disability weights, 01' eqnivalents such as QALYs (quality-adjusted life 
years) and milities (14,15). 
The use of age-weights. Murray cites bath economic and socialrole argu-
ments to justify valuing lost years of life due to mortality and morbidity dif-
ferently by age. Intuitively most people will agree that a death of a newborn 
or a 90-year-old, while being tragic, is less sa than that of a 15-year aid. 
The qllantitative implementation of this notion is, on the other hand, a 
matter of much controversy. 
Murray propases the following general formuia to weight life years by age: 
C -fJx xe 
where C and pare cOllstallts, x is age, and e is the exponentiaL For 
C=0.16243 and 1\=0.04 (the values used in the study) the age-weight curve 
is as depicted in Figure 1. 
The disconnting of fntnre years. Although in economics it goes without 
saying that fl1ture CO$ts and benefits shonld be disconnted, it is not a gener-
alIl' accepted concept in the health sector that futme years of life should be 
treated similarly. 
In the end Murray presents a tather daunting general formuia that ca!Culates 
DALYs lost, combining the lost years due to mortality and morbidity, the 
age-weights and the discounting (1). Because the lost DALYs are ca!Culated 
using this general formuia, the effects of each step made to get the end resült 
remain obscure. This is illnstrated below by taking a closer look at the age-
weighting and its effects. 
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Figure 1 - The age-weight function Cxe-f3x where x is the age, e the exponential, 
C=O.16243 and p=O.04. 
Which ag es count for more? 
The age-weight function with the parameters as lllentioned above specifies 
. that years lived between the ages of 9 and 54 have a weight greater then 
unitl', and the years outside that range wiII have a weight less than unity, 
with a weight of 0 at exact age 0 (newborns). H, for simplicity's sake, we ig-
nare DALYs lost due to morbidity (ie the disabilitl' weights) and consider 
only mortalitl', the next step is to use the age-weighted life years to caleubte 
age-specific life expectancies that are needed to detennine the EYLL. We car-
ried this out using the 1986-90 life-table for Dutch wamen (16), and Figure 2 
shows the resulting age-weighted and unweighted age-specific life expectan-
des. 
The first thing to note is that the impact of age-weighting is Illuch less 
than Figure 1 would suggest: the weighted and unweighted curves are fairll' 
close. In partic111ul', the rather dramatic zero weight for newborns translates 
into all Duly minor downturn of the weighted curve. This is becallse the 
EYLL of a newborn reflects aIl the future life years the baby could expect to 
live, all of whieh are weighted more than zero. 
Secondly, and importandy, the age range whieh becomes accentuated 
due to weighting (the range where the weighted curve is above the unweight-
ed one) has shifted from between 9 and 54 to between 0 and 27 years. This 
shift towards youllger age becOlnes intuitive when ane considers, for exa.m-
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FIgure 2 - Age-speciflc IIfe expectancies tor Dutch womenj 1986-90. Unweigl,tedvalues 
the years IIved by 1 tor all agesj weighting is done using the curve of Figure 1, 
ulJweighted discOlIIJted and wèighted discoulJted use a discount rate ot 3%. 
ple, a woman of 40, with a life expectancy of 41 years. According to Figure 
1, 14 of those expected years will receive a weight greater than unity, and the 
remaining 27 a weight less than unity, yielding an average weight of less than 
unity. Only when, going towards younger ages, the lllunber of expected life 
years with a weight greater than 1 becomes large enough to counterbalance 
the lllunber with a weight of less than 1 (for this life-table, at age 27, when 
Iife expectancy is about 54), the weighted curve wil! get above the unweight-
cd one. \X'hile the calculation is correct, this resnlt may come as something of 
a surprise. 
Figure 2 also shows age-specific life expectancies with future years dis-
cOlUlted, bath with aud without age-weighting. It is apparent that the impact 
of discountiug, even at such a slight rate of 3 %, is much largel' than age-
weighting. The curve labeled "weighted discounted" is the familiar "DALYs 
lost due to death" curve (1). The discollnting of future years partIy redresses 
the shi& towards younger ages: the discounted age-weighted curve is above 
the discollnted unweighted curve in the range from 0-38 years. This is be-
cause the discounting mostly affects the life years lived at a higher age, years 
which are now more easily counterbalanced by the more-than-unity weighted 
years of middle age. 
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Discussion 
W/e have ShOW11 that the age-weight fUllctioll emphasizes deaths in the age 
range 0-27, instead of the range 9-54 years as suggested by Murray. The 
same will happen for disability when the disability weigilts are applied to the 
years lived: disability between 0 and 27 years will be emphasized, and outside 
that range played down. Adding diseounting displaees the emphasized age 
range to 0-38, but, strictly speakil1g, this is of na consequellce becullse dis-
counting is concel'ued with time preference, and not with age. Since .wIurray,'s 
arguments for age-weighting are 011 the onc hand economie (pl'oductivc yeul'S 
eount more), and on the other social (with middle-aged years more important 
than the extremes), we preSllll1e that the shift towards ehildhood and early 
adult years is unintended. 
It has apparently been overlooked that expressing a death (or disability) 
as "expeeted years of Iife lost" implies age-weighting as weil: younger deaths 
are emphasized. Thus, in the ealctdation of the DAL Y, one age-weighting 
system emphasizing the young is piled on top of another, whieh emphasizes 
the middle-aged. The result is an even stronger emphasis on the young, and 
de-emphasis 011 the old, than the EYLL generates itself. Whether this is ad-
vantageous or not, is debatable (we think not), but it is eertainly different 
from what we were led to expect. 
will Dur finding upset the results from the Global Burden of Disease 
swdy? That is very unlikely, given the rather small impact of the age-weight 
function on the age-specifie life expeetancies (sec Fignre 2). It might even be 
sensible to abandon the age-weighting function altogether, beeause of the 
disprop0l'tiollally large attention it has received, relative to its impact. IE it is 
retained, 011 the other hand, some rethinkillg seems appropriate. \X'ith the 
age-weight fllnction as it is now, Alice's reaction to the Jabbenvocky poem 
comes to mind: "Somehow it seems to fiH my head with ideas - ollly I don't 
exaetly know what they are!" (17). 
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Health Expectancy: from a 
population health indicator to 
a tooI for policy making 
Abstract 
This article presents a methodologic framework for a Disability Adjust-
ed Life Expectancy (DALE), an extended and enhanced variety of the 
common Health Expectancy indicator. The DALE is based on a causal 
link running from risk factors through diseases and disability to mor-
tality. This causal link al/ows the DALE to be used for evaluation of 
potential interventions and analysis of observed trends. The DALE 
methodology consists of a combination of a multi-state life table with 
explicitly model/ed disease processes and of disease specific disability 
weights. The article presents two illustrations: the impact on the DALE 
of trends in cardiovascular disease epidemiology, and the benefits of 
nonsmoking. Two problems of the DALE are discussed: estimating 'al/ 
other causes' disability and the presenee of comorbidity. 
Introduction 
Health poliey is coneerlled with rnaintaining and, where possible, impl'ovillg 
public health, given limited resources. The responsibility of health poliey 
makers is to choose among patendal illterventions. These chokes are lleces-
sary because the l1l1l11bcl' of potential illtel'Velltiol1s is virtnally unlimited, 
while resources are scarce. The dilemma was perhaps exposed most starkly 
by the Oregon experienee, where a list of publicly finaneed medical interven-
tions lUlder a budget constraint was compiled, albeit that poliey makers there 
in faet evaded the dilemma by passing it on to the public (Sipes-Metzler, 
1994). 
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Pan of hcalth poliey is on a generic lcvel, Iike providing sufficient hospi-
tal capacit)' aud braad acecss to medical services. Thc large majority of deci-
sions, though, are made on the level of diseases and risk factors. For example, 
should we provide screening for breast cancel' to wamen l11lder 50 )'ears of 
age? Is the widespread adoption of cholesterol synthesis inhibitors to be ree-
ommended, or should we instead concentrate on sllpplying folie acid to 
wamen with the desit·e to get pregnant? 
The diversity of the choices and outcomes makes it difficult to reach a 
decision, unless Ol1tcomes are mapped to some commOI1 denominator. Dis-
ability-free life expectancy provides sueh a com111011 denomillator, but its 
propertjes make it rather llllfit for popnlations with a high level of cbronie 
disease. Improvement of survival for the chronically ill, a major ontcome of 
much of modern medicine, is evaluated b)' the disability-free life expectanc)' 
estimator as being wortWess, or even detrimental (Barelldregt & Bonneux, 
1994). This seems hardly to be in correspondence with the appraisal of both 
medical professionals and the genera I publico 
In this paper a methodologic framework for a Disability Adjusted Life 
Expectancy (DALE) is presented. The DALE is based on a causa I chain that 
l"llllS from risk factors to disease incidence, from disease incidenee to disease 
prevalenee, from disease prevalence to disability prevalence, aud to disease 
specific and total mortality. This way the impact on Life Expectancy (LE) and 
DALE of varions prcventive and cl1rative interventions, and of trends in the 
epidemiology of specific diseases can be estimated. 
A multi-state, multi-disease life tabie for men is used to describe disease 
specific incidence, prevalence and lllortality from five diseases: cardiovascl1lar 
diseases, lung cancer, and Chronic Obstructive Pl1lmonary Disease (COPD). 
The disease specific disability weigIlts from the Global Bl11'den of Disease 
project (\'\Iorld Bank and \'{'!-lO (Murl'ay & Lopez, 1994b)) are applied to 
calct!late disability prevalence and a DALE. The inlpact on the DALE of 
trends in heart disease is sho\\'n, and the cnnent partly-smoking populatioll is 
compared with one that hypothetically is smoke-free. Two major problems 
with the approach are discllssed: the estimation of disability from all other 
causes, and the problem of comorbidity. 
Methods 
The ljfe table 
A multi-state life table with five diseases was set np: Ischemie Heart Disease 
(IHD), Congestive Hemt Failnre(CHF), Cerebrovasclllar Accident (CVA, or 
stroke), lung ca neer, and Chronic Obstructive Pulmonary Disease, inclnding 
ell1physell1a (COPD). Each disease is described by a continuous-time ll1arkov 
process, and consists of a single prevalent state. There are six absorbing 
'states: death from each specific disease, and from 'all other causes' 
(Barendregt, van Oortmarssen, van Hout, van den Bosch, & Bonlleux, in 
press). 
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Transition into the disease states depends on incidence probabilities by 
age, CHF in addition receives input from lHD. Disease specific 1110rtality de-
pends on survival probabilities, also b)' age, eure is ignored. In all but the ab-
sorbing states people are subject to incidence probabilities for all diseases 
(except when the)' are alread)' prevalent of that partict!lar disease), and to the 
'all other causes' mortality probabilities, that are independent from disease 
specific survivals. \X'ith the exceptioll of CHF, which prevalence and mortal-
ity dep end in part on IHD, diseases are assullled to be independent. 
The disease processes are instances of incidence-prevalence-mortality 
1110dels, that, by forlllalizing relatiol1ships bet\\~een these variables, enforce 
internal consistency of the data and allow to infer unobserved data ([vInrra)' 
& Lopez, 1994a). Age and disease specific survival probabilities eould th us be 
estilllated from incidence and disease specific and total mortalit)'. The tralls-
mission rate from IHD to CHF was estimated by making the liEe tabie preva-
lenee of IHD equal to observed prevalenee. 
Discase and Illol'tality data 
Input data are a subset of the data collected for the stroke and heart disease 
mode Is that arc part of NINlPH: the Netherlands Integrated }>'iodel of Public 
Health. The)' consist of total mortalit)' probabilit)' and disease specific mor-
talit)' rates from Statistics Netherlands (Statistics Netherlands, 1991; Statistics 
Netherlands, Published annually). The incidenee probabilities are based on a 
nation-wide hospital register data and regional studies (Bonnel1x, Barendl"egt, 
Nleeter, Bonsel, & van der lviaas, 1994; Niessen, Barendregt, Bonneux, & 
Koudstaal, 1993). 
Data on COPD ÏllCidence and prevalence are from the Contiul1ol1s 
Morbidity Registration (OvlR), a regional registràtion in four general prae-
tices (van \'{Teel, van den Bosch, van den Hoogen, & Smits, 1987). Since vir-
Table 1 - Proportlons dis ab led and distribution over severity classes tor 6 dlseases, 
and weights tor each severity class. From the Global Burden ot DJsease project. 
Severity class 
...................... .....................•.......................... . ........................... 
11 111 IV V VI 
Average 
weight 0.096 0.22 0.4 0.6 0.81 0.92 
prop dis 
IHD 0.725 0.686 0.14 0.14 0.034 0 0 0.126 
eHF 0 0.7 0.2 0.1 0 0 0.294 
eVA 0.35 0.3 0.15 0.1 0.05 0.05 0.306 
lung ca pre·terminal 0 0 0 0 0 0.096 
terminal 0 0 0 0.4 0.3 0.3 0.759 
eOPD 0 0 0.5 0.3 0.2 0 0.542 
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tually all Dutch have a GP these data are considered to he representative. 
Because of small llumbers (about 12,000 patients) data from JO years were 
averagcd. 
Disability weights 
Table 1 shows the disease specific disability weights from the Global Burden 
of Disease project for the five diseases. Each disease has a proportion disabled 
(in our case mostly equal to 1), and this proportion is distribnted over six 
severity classes, with c1ass I being the mildest and VI the worst. The weights 
cover a wide range: in the mildest class a persall is about 10% disabled, in the 
scverest over 900/0. This means that a person in one of the mildest classes 
would probably not nonnally be cbssified as 'disabled' when the health state 
is a dichotolllons varia bIe. 
Since the disease Illodels in the multi-state life tabie have just onc stage 
each, the average loss for each disease per unit time due to disahility was nsed 
insread of the various severity classes. The average was calculated from the 
proportion disahled, the distribution over the severity classes, and the weight 
of each c1ass (column 'average' in Table "1 J. Ll1ng cancel' has twO different 
weights, one for the terminal stage alld one for thc pre-terminal. In our cal-
culations the terminal stage was assllmed to last 3 months. 
An 'all causes' DALE 
An 'all causes' DALE was estimated by taking as a proxy for disability distri-
bution over age the distribution over age of casts of disease per person year. 
In a previous study, the 1988 Dutch health care casts have been allocated to 
age, sex, health care sector and discase category, hased on comprehensive 
dara on morbidity, mortality and direct costs. For each health care sector to-
tal costs were assigned to age, sex and primary diagnosis using utilizatiol1 of 
services, the Ilumher of patienrs or the expenditures per group of patients. 
1'vlost data were extracted from nationa} registers with nearly complete cover-
age. Health insurance covers 99.8 % of the Dutch population and accessibil-
it)' of health care is very high. Of all casts 25.2 % could not be allocated to a 
prÎmary diagnosis, eithcr because of missing infol'mation or becanse costs 
were Ilon-personal (administration, general public health services, etc). The 
data used in this stl1dy concern only the allocated hcalth care costs. A morc 
complete description of health care data-bases and methods used is given 
e1sewhere (Koopmanschap, et al., 1994). 
From these costs by agc and the popnlation structure 1988 all age spe-
cific cast per person was calculated. This age gradient was used ra allocate 
disability by age to a Iife table cohort such that the DALE from the Iife table 
at age 15 was equal ra the Disabilit)'-Fl'ee Life Expectancy (DFLE) in the 
Netherlands as estimated on basis of 1989-90 data from the Statistics Neth-
erlands (van den Bos, van der Velden, vall Sonsbeek, Nusselder, & Lenior, 
1994). Equating the DALE to the DFLE is wal'l'anted because the average 
disability weigilts of the DALE can be interpreted as the proportion of the 
discased considered unhealth)' by the DFLE (see discussion). 
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Cardiovascular trends and 
1l0llsll1oking 
This life table is used to look at the 
impact of trends in IHD and CHF 
incidcllce and survival on LE and 
DALE, and at the difference between 
the CUlTent partll'-sI11okillg popula-
tion and one that is smoke-free. In 
both cases it is assumed that an 'alt 
other causes' burden of disability can 
be created bl' simpil' subtractillg for 
each age the disabled years caused 
bl' the five diseases from the 'all 
callses' totui. In other words, eo-
morbidity is ignored. 
237 
Table 2 - Prevalenee of smoking (%) by 
age; and Relative Risks (RR) of 
smoking on incldence for 6 dlseases. 
Ag. 
group 
0-14 
15-19 
20-34 
35-49 
50-64 
65+ 
Prevalence of 
smoking (%) 
o 
20 
39 
42 
39 
34 
Olsease RR 
IHD 3 
Lung ca 10 
eVA 2 
eHF 
eOPD 25 
For the heart diseasc trends a combination of declining incidenee and 
inereasing survival that has been observed in the previolls decades was used 
(Barendregt & Bonnenx, 1994; Bonnel1x, Barendregt, Nleeter, Bonsel, & van 
der Maas, 1994). lncidence of bath discases is va ried bl' multipll'ing age spe-
cifie probabilities with a factor of 0.9 (all ages), and multiply probabilities to 
die from a specific disease, given prevalence (i.e. I-survival probability) like-
wise with 0.8, always eomparing outeome with the 1988 base yeal'. These 
Jl111ltiplication factors reflect cmllulative changes observed over a ten-year 
periad. 
Secondll', a hypothetical smoke-free population was created bl' using the 
smoking prevalences and relative risks in Table 2 to estimate 110nsllloking 
incidenees. Smoking is a direct risk factor for llID, eVA, Lung caneer, and 
COPD, and an indirect one (through !HD) for CHF. The Iife table was recal-
culated with the nonsI11oking incidences while keeping all e1se equa!. 
Results 
Table 3 shows the result from the 'all causes' DALE estimation procedure. 
The LE's show some slight differences, because total mortality probabilities 
are based on not exactly eorresponding time periods. The DALE is ealibrated 
to equal the Disability-Free Life Expeetaney at age 15, whieh gives a DALE at 
bü·th of 64.7 years. For most ages the DFLE and DALE are quite similar, and 
the Disabled Life Expeetaneies (DLE) are also ou a par. 
An estimate of the disease specific bllrden of disability, expressed as 
number of dis. bied person years of the life table cohort, is provided in Table 
4. The base line estimate shows that !HD, CHF, and CV A impose roughll' 
eomparable bul'dens of disability, lung eancer much less due to its lowel' inci-
denee aud high lethality, aud COPD far more. The five diseases together are 
l"espousible for abont 30% of the total bnrdell of disabilitl'. 
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Thc rop panel also shows the impact of the simultaneOlls decrease in 
IHD and CHF incidence and improvement of survival. The burden of dis-
.bilit)' for CV A, Lung cancer, COPD, and 'all other causes' all go slightly up, 
due to thc decrease in total mortality. lHD is down marginally, while CHF is 
clearIl' up. This is explained bl' the fact that CHF, on top of its improved sur-
vival, also acts as end-stage heart discase, which many IHD patients get if 
their survival of acute coronary events is long enough (Bonncux, Barenclregt, 
Meeter, Bonsel, & van der Maas, 1994), On balance total disability increases 
by 2 percent. 
figl11'e 1 shows age-specific DALEs (expressed as an index \Vi th the base 
linc value equal to 100) for decreased incidence, improved survival, and the 
combination, again for llID and CHF. Decreased illcidence results in a higher 
DALE throughout the age range (like a DFLE), improved sl11'vival results in 
an increase at youllger ages, and a decrease at older (unlike a DFLE, which 
shows no effect at bit·th and a decrease at older ages), and the combination of 
Table 3: Age specific Llfe Expectancy (LE), DJsabllity Free Lite Expectancy (DFLE), 
Disabîllty Adjusted Lite Expectancy (DALE), and Disabied Life Expectancy (DlE): 
outcome of tlle 'all causes' DALE estlmation. StatNeth: Statistics Netherlandsj 
est/mate: this paper. 
LE OFLE OALE OLE 
...................... ~ ............ . .................... _ ...................... ................. . ....................• 
Age SlalNelh estimate StatNeth estimate StatNeth estimate 
0 73.3 73.5 64.7 8.9 
15 59.3 59.4 51.3 51.3 8.0 8.1 
30 44.8 44.9 37.0 37.7 7.8 7.2 
45 30.5 30.7 23.3 24.5 7.2 6.1 
65 14.2 14.3 9.6 9.5 4.6 4.7 
75 8.5 8.5 4.6 4.5 3.9 4.0 
85 4.7 4.7 1.4 1.6 3.3 3.1 
Table 4: Disease speelfic, 'all other causes', and total burden of dlsability in person 
years of the lite table cohort, base line estimate with two variants, Indices base 
line=100. 
IHO CHF CVA lung ca COPO All olher Total 
Base line 43086 41576 22871 4014 150449 613053 875051 
IHO & CHF trends 42066 43977 23605 4150 154722 622611 891132 
index 98 106 103 103 103 102 102 
........................................ _ ............... _ ................. _ ................ - ........................................................................... 
smoke-free 28310 46069 19892 1160 18496 668278 782206 
index 66 111 87 29 12 109 89 
Healrh Expeeraney and polie)' making 
103 
102 
101 
x 
0 100 
~ 
EO 
99 
98 
97 
~~~~ ............. . .. . . . . . . . -...... 
--incidence 
. • survival 
--both 
o 10 20 30 40 50 60 
Age 
239 
70 80 90 
FIgure 1 - Disability Adjusted Life Expectancies (DALE) by age after separate and 
comblned decline in incldence and Improvement of survival for heart dlsease. Index 
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by age after a simultaneous decllne In Incidence and improvement of survival for 
heart disease. Index with base IIne equal to 100. 
240 
160 
150 
140 
~ 130 
~ 
.: 
120 
110 
. . . -. 
o 
.Measuring compression &1nd expa/lsion of morbidity 
--Ufe expectancy 
•• ·DALE 
. ' . 
-.. -
.-.' . 
10 20 30 
.. 
.. 
40 50 60 70 80 90 
Ag, 
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the two shows an increase for most ages, with anll1aximnm aronnd 65, and a 
slight deerease at the oldest age (mueh like a DFLE) (Barendregt & Bonneux, 
1994). 
Figure 2 shows an index line (again with base line value equal to 100) 
for the LE and DALE atter the heart disease trends. Clearly the trends in 
heart disease result in a higher LE and DALE, but the inerease in the DALE is 
a bit less, due to the improved survival. The recent trends in heart disease 
therefore seem to have caused an expansion of disability. 
The lower panel of Table 4 also gives the results for the hypothetieal 
smoke-free population. Disability eaused by COPD vil'tually disappears, lung 
cancer is much less, IHD is abont a lower, and CVA 10%, but CHF is 10% 
higher and 'all other causes' 9%. On balanee disability is 11 % less if smoking 
would not exist, largely due to the deerease in COPD disability. Figure 3 
shows the resulting index lines for the LE and DALE. A smoke-free popula-
tion would c1early not just have a higher LE, but would gain even more in 
disability adjllsted years: a- potential compressioll of disability exists if we 
wonld succeed in funher redllcing smoking. 
Discussion 
Health expectaney indicators eome in many varieties, but all have at least one 
aspect in common: they combine information on health states (however de-
fined) with mortality rates into a single indicator. Mostly health state preva-
lences are llsed (Sl1llivan method), in some cases transition probabilities 
(multi-state life table methad), and usually the unhealthy state is assigned a 
weigIlt of 0, althongh also ranges between 0 and 1 are sometimes used 
(Mathers, Robine, & Wilkins, 1994; Wilkins & Adams, 1983). 
Tbe DALE methodology presented in this paper differs on two ma in 
points from the more cnstomary indicators of health expectancy. The first 
point is the inclusion of a complete, if simplified, process leading from risk 
factor exposure and diseasc incidence te disability and mortality (see fignre 
4). The seeond is the use of a mueh more elaborate and disease specific dis-
ability weighing sehedule than the 0-1 weights of most health expeetaney 
ealeularions, whieh produce estimates of disability-free life expeetaney 
(DFLE). 
Estimates of DFLE sa far have mostly been of a deseriptive nature. Re-
searchel's have mostly limited themselves to estimating total mortality and 
disability prevalenee (the blaek boxes in figme 4), and ealeulated a DFLE 
from the two. There are two main applications for sneh estimates: anc to 
compare between COllntries (to see which COllntl'Ïes are doing better aud, 
perhaps, learn from that), and secondly to compare estimates within a coun-
try on different points in time (ta estimate trends). Although neitber applica-
tion is without its problems, these are relevant uses (Barendl'egt, Bonneux, & 
Van der lvIaas, 1994; BoshIlizen & Van de Water, 1994). 
Taking a thus measured DFLE beyond the use as a population health 
indicator is not possible, however. Neither total mortality nor disability 
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prevalencc allows one to infer what the rcasons are for its particular level and 
the changes thereill. A declillc in life expectancy, as cllnently observed in sev-
eral lvliddle and Eastern European countries, cannot be explailled (much less 
acted upon) unless it is broken down to its contributing causes of death 
(injuries and cal'diovascnlar discase seem important contriblltors) (Feachem, 
1994; World Bank, 1993). 
Much the same goes for disability. Disability is caused by diseases. Only 
when the observed level of disability can be attributed to specific diseases 
does it become possible to determine what policy wiII be most appropriate for 
improvement. Potential interventionist health policies are unlikely to be on a 
gel1eric disability level: thar is toD llllspecific. Health polic}' concentratcs on 
pre\'enting diseascs, cUrÎ.llg them, and providing care and extendillg survival 
when neitller works (affectillg the white boxes in figl1re 4). [vIuch of preven-
tion, almost all cure, and a major part of survival extending care is disease 
specific. \,\lhen researchers are satisfied to estimate DFLE using just total 1110r-
tality and disability prevalence (the black boxes in figl1re 4) they severely limit 
the possibilities for policy making. 
The sec01ld point distinguishing the DALE methodology from the CI1S-
tomary indicators of health expectancy, the use of disease specific disability 
weights, follo\\'s from the first. The disease specific approach requit'es a map-
ping from disease specific prevalenees to disability prevalence. Assigning 
weights to non-fatal health ontcomes is as such no ncw feature, witness for 
example the Quality Adjusted Life Years or QALY (Drunllnond, Stoddart, & 
Torrance, 1987). The particular mapping employed in this paper was devel-
oped for the joint WHO and World Bank Global Burden of Disease project, 
that was the basis of the 1993 World Developmellt Report Investing in 
Hen/th (World Bank, 1993). The disease specific disability weigilts were de-
veloped in an elabOl'ate and iterative process, involving a large numbel' of 
international disease experts, repeated Îl1ternal consistency checks, and inde-
pendent reviews (i'vIurray & Lopez, 1994a). More than 100 conditions were 
t1ms evalnated. 
On the basis of these disability weights, Murray and colleagues then 
went on to develop the DALY (Disability Adjusted Life Years), to be used in 
cost-effectiveness studies. Citing economie considerations all age-weighting 
schedule and a discount rate were applied (Murray, 1994). For theit· specific 
purpose, a cast-effectiveness srudy, these are legitimate (if debatable) add-ons 
(Barendregt, Bonneux, & Van del' Maas, 1996), but the build-in economic 
features render the DAL Y mIfit for thc calculation of a DFLE Ol' DALE 
(Ginneken, 1994). 
But the raw disability weights, on the other hand, provide an opportu-
nity to get around some severe Iimitations of the customary health expectancy 
estimator. They permit the use of a bottom-up, disease specific approach, 
which renders the estimator mnch more powerful. The weights also permit 
one to avoid the problem of the standard health expectancy, which evaluates 
all improvemellt in survival with disabilit)' as wonhless (at birth) or even det-
rimental (at higher ages) (Barendregt & Bonneux, 1994). The weights are 
available fol' a large llumber of conditiolls, including injuries. Currently work 
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is being earried out on refillemellt and fllrther validation of the disability 
weigIns (1I'1urray, 1996). 
One might argne that the elabOl<ate weighting system, with for each dis-
ease a proportion disabled, Rlld a distriblltion over 6 severity classes with 
specific weights (see Table 1), hampers the interpretation of the results, and 
therefore makes the DALE less intllitive than the DFLE. But this system seel11S 
primarily designed to allow the experts making the evalnations to account for 
disease heterogeneity. The more elaborate system eventnally collapses to just 
oue weigIlt per disease (the columnlabeled 'average' in Table 1) as loug as na 
changes in diseasc epidemiology oceur. 
This single weigilt can be illterpreted as the average disability weigilt for 
all people with that particttlar diseasc, or as the proportiall of people with the 
disease that is disabled (for those who do uot wish to part with the 0-1 
\veighting schedule). This equivalenee between an average weight and a divi-
sion in two proportions with weights 0 and 1 is analogons to the time trade-
off methad popular in Quality of Life research (Torrance, 1987). In the latter 
interpretation the DALE simpIl' becomes an aggregation of disease specific 
disability-free Iife expectaucies. 
This equivalence in principle also permits one to intel'pret an estimate of 
an 'all causes' DFLE as au 'all causes' DALE. The problem with this interpre-
tation is that the defillitions of what constitutes 'disability' are arrived at 
along vastIl' different wal's: one through expert opiniou ou severity of dis-
eases, the other through a population survey on the presence of disabilitl'. 
Although we expect bath methads to produce largely correspouding results, 
this is an untested (but testable) hypothesis. 
An cstimate of an 'all causes' DALE is a prerequisite to obtainillg an 'aH 
other causes' DALE, aud calUlOt be arrived at bl' simpil' adding up single dis-
case estimates for two reaSOllS. One l'cason is the hnge numbel' of diseases, fol' 
each of which estimates of incidence, prevalence, and lllortality would have 
to be made (aud checked for internal consistencl'), the other is that disabilities 
caused bl' single diseases do uot simpI)' add up due to comorbidity. 
In the present study the comorbidity problem aud the non-additivity 
that follows from it is ignored, and an 'all other causes' DALE is estimated by 
subtracting the disabilitl' contributions of the five diseases from the 'all 
causes l disability. The existence of comorbidity implies th at there are fewel' 
people with an)' disease than the sum over all disease prevalences. Since Olle 
eau have aspecific disability ouly ouce, this would imply that there is also less 
disability, but for the fact that comorbiditl' iu most cases seems to make dis-
ability more severe (Verbrugge, Lepkowski, & Imanaka, 1989). Sa all bal-
anee the bias 011 our 'all other causes' DALE estimate could go either way. 
This problem with the DALE methodologl' is as yet llusolved, although the 
work of Nusselder et al. (1994) suggests a possible SOllltiou. 
Auother problem with the DALE methodology is data: data reqllÎ1'e-
ments far exceed those of a DFLE, in particlllar a Sllllivau-type DFLE. \'\Ihile 
disease specific mortality rates will aften be available, this is eertainly not truc 
for discase specific incidence and prevalenee rates. Lack of epidemiologie data 
wiII in many cases thwart estimation of a DALE. 
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Despite the loose ends and higher data reqlliremellts the DALE method-
olog)' is weil worth pl11'suing. Earlier attempts to estimate the Îllflllcnce of 
specific diseases 011 health expectancy relied on combined canse eliminatioll 
alld Sullivall methods (.iVIathers, 1992; NllSSeldcl', van der Velden, Lenio!", 
van Sansbeek, & van den Bos, 1994). While th is certainll' prodllced illllmi-
!lating results, cal1se eliminatioll l'cmains a erude and unrealistic method. 
Criml11ins et al. (1994) lIsed a 11111lti-state life table techniqlle to look at the 
effect of changing mottalit)' and morbidit)' on health status and life expec-
tanc}'. Unfonunately they operatiollalized l110rbidity in terms of functional 
ability\ lcaving the readers wondering in ",hat wa)' the impnted changes in 
1110rbidit)' and mortalit)' might be brollgllt about. Stoto and DlIrch (1991) 
tried to estimate the impact of the US Health)' People 2000 targets on life 
expectanc)' and health)' life expectanc)'. Becanse of the lack of a method-
ologie framewol'k Iinking risk factors aud pl'cventive (aud, ene shollid add, 
curative) services to health status measnres and mortality they simply used 
causally nmelated changes in mortality and disability in a Snllivan life tabie. 
Their resl1lts arc therefore less than convincing. 
The DALE methodologl' represents such a framework that links risk 
factors, prevention and therapy to disabilitl' and lllortality. The cnrrent 
model is ver)' simpie, but could be extended b)' allO\ving more risk factors, 
levels of exposure, and lllulti-stage disease models. For example, when im-
provements in disease survival occur through decreased 1110rtalitl' in aente 
phases, patients tend to amass in the severest disease stage because all pre-
eeding stages act as risk factors for the severest stage (Bollneux, Barendregt, 
j\lleeter, Bonsel, & van der lvlaas, 1994; Niessen, Barelldregt, Bonneux, & 
Koudstaal, 1993). Snch a change in disease epidemiolog)' migllt have an im-
portant effect all associated disability. But of course the drawback of mlliti-
stage disease models is that data requirements multiply. 
The DALE is more powerfnl than the ellstomary health expectalley indi-
cator because it explains disabilitl' and mortalit)' through the epidemiologl' of 
their underlying canses, instead of just describing them as snch. Because the 
DALE encompasses the complete process from risk factors to diseases, to dis-
abilitl' and mortalitl', it provides polie)' makers with a much enhanced array 
of potential controls to manipulate. 
For the same l'enson it mal' help rcsearchers to bettel' lUlderstand the 
changes in population health status. OUl' exercises with heart disense trends 
and a smoke-free population are a case in point. Increased survival with 
ehronie disease is not restricted to heart disease: improved care for aeutely iIl 
patients tends to keep patients alive langer across a large array of chronie 
cOllditions. Just like with heart disease improved survival \Viii tend to amass 
patients in the end-stage of the disease, with the severest disability. Unless 
medicine finds wal's to stop the ehronie diseases Erom progressing, or health 
promoters can convince people to give up smoking, an expansion of disability 
seems inevitable. 
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Disability Adjusted Life 
Expectancy and comorbidity: 
exploring uncertainty and 
. . . 
senSItIVIty 
Abstract 
The Disabi/it)' Adiusted Life Expectanc)' (DALE) consists of a combi-
nation of a multi-state /ife table with expliciti)' modeled disease proc-
esses, together with disease specific disabilit)' weights. The expliciti)' 
modeled disease processes cause comorbidit)' to be a problem, in two 
different wa)'s. One is that due to comorbidit)' disabilities caused by 
single diseases do not simp I)' add up. And second, it seems that in most 
cases comorbidit)' makes disabilit)' more severe. 
\lfe present an al1alysis to explore qual1titatively the impact of un-
eertail1t)' about the severit)' of disabi/ity il1 the ease of eomorbidit)', al1d 
of the sel1sitivity of the estimate of il1tervel1tiol1 effects and the aggre-
gate level of disabi/ity il1 the populatiol1 for varia us assumptiol1s 011 
comorbidit)' prevalel1ce. \lfe use a multi-state /ife table with 5 diseases 
al1d 'all other causes' disabilit)', al1d do al1 il1terventiol1 011 smokil1g 
prevalel1ce. 
\lfe list the elements of the estimate that are Imcertail1, al1d look at 
the sensitivity of the outcome to variatioltS il1 the values of these Imcer-
tail1 elemel1ts. \lfe show that the disability weight il1 the case of comor-
bidity is but ol1e of a ral1ge of ul1certail1 elements, al1d that the sensitiv-
ity of the estimated years /ived with disability to variations il1 the 
comorbidit)' weight is relatively smalI. \lfe col1c/ude that for the estima-
tiOI1 of the DALE al1d of the impact of interventions on it other uncer-
tain varia bles than the disability weight of comorbidity deserve priorit)' 
for research. The use of a simple rule to assign a disability weight for 
comorbidity (/ike the highest weight of the constituel1t diseases), or 
even ignoring comorbidity altogether hardi)' affects DALE estimates. 
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Intl'oduction 
The Disability Adjusted Life Expectancy (DALE) is an extended and en-
hanced variet)' of the Health Expectancy indicator. The underlying concept is 
the establishment of a causallink running Erom risk factors through discases 
and disability to mortality. This causal link allows the DALE to be used for 
cvaluatiol1 of potential illterventions and analysis of observed trends. Tbc 
DALE methodolog)' consists of a combination of a multi-state Iife table with 
explicitl)' modelled disease processes, together with disease specifie disability 
weigilts (Barendregt, BOllllCUX, & van dcr j\'Iaas, in press). 
A major problem of the DALE methodology is the presence of COl11or-
bidity, in two different wa)'s. One is that due to comorbidit)' disabilities 
caused b)' single diseases do not simply add up. The existence of comorbidity 
implics that there arc fewer peopJe with an}' disease than the SHm over all 
disease prevalcnces. Since ane eall have a specific disability onIy allee, th is 
implies that in the aggregate there is less disability than the sum over all single 
discase disability. On the athel' hand, aud this is the secolld problem, it secms 
that in most cases comorbidity makes disabiJity more severe (Vel'brugge, 
Lepkowski, & Imanaka, 1989). Estimates of total disabilitl' that ignore 
comol'bidit)' will therefore be too high due to the first problem, and too low 
due to thc second problcm, and how the balance is of these countervailing 
tcndencies is not obviol1s. 
In this paper wc present all analysis to explore quantitatively thc impact 
of comorbidity on the estimated number of ycars Iived with disability. \,fe list 
the elelllents of the estimatc thar are llllcertain, and look at the sensitivity of 
the outcome to variations in the vallles of these llncertain elemcnts. \\fe con w 
eInde on the relativc importance of the disability wcigllts in case of comor-
bidity, as cOlllparcd to the contributions from the other sources. 
Methods 
DALE methodology 
Wle use the same multi-state life table as in onr earlier DALE calcnlations, 
with the exception that now cOll1ol'bidit)' is modelled explicitl)' 
(Barendregt, Bonneux, & van der .Nlaas, in press). Thc table consists of flve 
diseases: Ischemie Heart Disease (IHD), Congestive Heart Failul'e (CHF), 
Cerebrovascular Accident (CVA, or stroke), Lung Cancer, and Chl'Onie 
Obstructive Pulmonar)' Disease, including emph)'sema (COI'D). Each dis-
ease is described by a continuous-tillle markov process, aad consists of a 
single, age specific prevalent state (Barendregt, van Oortmarssen, van 
Hout, van den Bosch, & Bonneux, in press). There are six absorbing statcs: 
death from each specific disease, and from <all other causes'. 
Transitioll into the disease states depends on incidence prohahilities by 
age, CHF in addition receives input from IHD. Disease specifie mortality de-
pends on survival pl'obabilities, also bl' age, cure is ignored. In all but the ab-
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sorbing statcs people are subjeçt to inddençe probabilities for all diseases 
(exçept when they are already prevalent of that partkular discase), and to the 
'all other causes' mortality probabilities, thar are independent from disease 
specific survivals. \Vith the exeeption of CHF, whieh preva1cnce and mortal-
ity depend in part on IHD, diseases are assumed to be independent. 
Input data are a subset of the data wlleçted for the stroke and heart 
disease models that are part of i'.llMPH: the Netherlands Integrated Model of 
Publiç Health. They wnsist of totalmortality probability and disease spedfk 
mortality rates from Statistks Netherlands (Statistks Netherlands, 1991; Sta-
tistks Netherlands, Published annually). The inddençe probabilities of çar-
diovascular diseases are based on a nation-wide hospita! register data and 
regional studies (Bonneux, Barendregt, NIceter, Bonsel, & van der Nlaas, 
1994; Niessen, Barendregt, Bonneux, & Koudstaal, 1993). 
Lung Cancer incidence is from a regional study (Eindhoven Cancer 
Registry). Data on COPD inddençe and prevalençe are from the ContrnuOlls 
;v[orbidity Registration (CMR), a regional registration in four general praç-
tiees (van \X/eel, vall den Bosch, van den Hoogen, & Smits, 1987). Sinee vir-
tually all Dutçh have a GP these data are wnsidered to be representative. 
Beçause of small 11lunbers (about 12,000 patieuts) data from 10 years were 
averaged. 
Table I shows the disease spedfk disability weigIns from the Global 
Burden of Disease projeçt for the five diseases (Murray & Lopez, 1994). Eaçh 
disease has a proportion disabled (in om çase mostIl' equal to 1), and this 
proportion is distribnted over six severity classes, with class I being the mild-
est and VI the worst. The weights cover a wide range: in the mildest class a 
person is abont 10% disabled, in the severest over 90%. This l11eans that a 
person in one of the mildest dasses would probabI)' not normall)' be dassified 
as 'disabled' when the health state is a diehotomous varia bIe. 
Table 1 - Proportlons dlsabled and distribution over severity classes for 6 dlseases, 
and weights for each severity class. From the Global Burden of Disease project. 
Severity class 
.............. - .................... .. _ ............. _ ..... .......................................... 
11 
'" 
IV V VI Average 
weight 0.096 0.22 0.4 0.6 0.81 0.92 
prop dis 
IHD 0.725 0.686 0.14 0.14 0.034 0 0 0.125466 
CHF 0 0.7 0.2 0.1 0 0 0.294 
CVA 0.35 0.3 0.15 0.1 0.05 0.05 0.3061 
lung ca pre-terminal 0 0 0 0 0 0.096 
terminal 0 0 0 0.4 0.3 0.3 0.759 
COPD 0 0 0.5 0.3 0.2 0 0.542 
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Since the discase models in rhe multi-state life table have jnst ane stage 
cach, the avcrage toss for each discase per uuit time due to disability was llsed 
instead of the vadous severity classes. The average was calclllated trom the 
proportioll disabled, thc distribution over the severity classes, <tud the weight 
of each class (columll 'average' in Tablc 1). LUllg cancel' has two different 
weights, anc for the terminal stage and Olie for the pre-terminal. In our cal-
clllations the terminal stage was assumcd to last 3 111ol1ths. 
An important aspect of the DALE methodology is the estimatioll of an 
'alJ causes' DALE. Because the five diseases only describe a limited part of the 
total number of l'ears lived with disability bl' the cohort we need an estimate 
of the disabilitl' caused bl' 'alJ other causes'. This disability from 'all other 
causes' is estimated by snhtracting the disability modeled from all 'all causes' 
disabilitl" The 'all causes' disability is estimated nsing the Disabilitl'-Free Life 
Expectancl' (DFLE) in the Netherlands at age 15 as based on 1989-90 data 
from Statistics Netherlands (van den Bos, van der Velden, van Sonsbeek, 
Nnsselder, & Lenior, 1994). Ta distribute the assoeiated disability over age 
we assumed that health care casts are a good pro")' for disability, and that 
disability therefore shows the same distributioll over age as total health care 
costs pcr person yeal'. wlore details are in (Barendregt, BOllnCl1X, & van der 
.w1an5, in press). 
COlllorbidity 
In Dur earl ier DALE exercises we ignored cOll1orbidity: for each disease mod-
eled we calculated years lived with disability, alld the snm over the diseases 
was sllbtracted fro111 the 'all canses' disability to obtaill all 'all other callses' 
es ti mate (all dOlle age specifically). Taking explicitly acconnt of cOlllorbidity 
complicates the calculations considerably: the nnmber of combinations, given 
5 diseases, is 2'_1=31. Mally of these will have vanishing small prevalences, 
though, in particnlar the comol'bidities of three or more diseases. Ta simplify 
matters we therefore look at thc combined prevalcllces of all}' two diseases 
only. Heart disease is modeled as Ischemie Hemt Disease and Heal't Failure, 
and we assnme that people with bath are in fact Heart Failure patients. By 
means of these simplifications the llumbel' cOlllol'bid cOllditions l'educes to 9) 
in addition to the 5 single disease conditions. 
The prevalcnce of the comorbid conditions is calculated b)' assumillg 
independellce, and the disability weight is assul11ed equal to the highest 
weight (worst conditioll) of the constituent diseases. Both assumptions are 
subject to the uncertainty and sellsitivity analysis (see below). 
Uncel'tainties 
The calcl1latiol1 of a DALE with explicit attention to the impact of COJllor-
bidity iIlvolves several e1ements, all surt'ounded by at least some uncel'tainty. 
These elements are: 
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The estimate of the )'ears livcd with disability from 'all canscs'. Uncertainty 
is cansed by the procedure to derive this from the Dlltch estimate of DFLE, 
and by the estimation of the latter itself. 
Disease prevalcnces. The estimates of discase prevalences are based on a 
variety of som·ces, made internally consistent b)' nsing an incidence-preva-
lcncc-mortality model (Barendregt, BOllneux, & van der 1-daas, in pressj 
Mnrray, 1994). In the life table the prevalences are the resnlt of incidence 
and survival rates, we will vary only the former to examine the influence of 
different prevalence estimates (the eHects of varying survival rates are very 
similar for our current pnrposes). 
Comorbidity prevalence. W'hen diseases share a risk factor, they will most 
Iikely be c1nstered instead of being independently distribnted over the 
popnlation. Clustering will increase the munber of patients with comorbid-
ity. 
Disability weights. The disability weights from the GBD-project were ar-
rived at by expert opinion, and are without dOllbt subject to uncertainty. 
Disability weights for comorbidity. The baseline assllmption is that the 
wciglH in case of comorbidity is equal to the highest weight of the constitu-
ent discases, but it may ver)' weIl be lower or, more likely, higher. 
These arc the ullcertaill varia bIcs in case of the DALE cstimate. \'('hen 
looking at the impact of an interventiol1 on the DALE there is all additional 
uncertainty: 
Thc impact of the intervention on disease epidemiology. 
All uncertain variables are varied around the baseline value with +20%, 
+10%, -10%, and -20%. The intermedia te values allow to check for non-
Jinearities. In all cases we compare 
the ontcomes of disease specific 
disability, comorbidity disability, 'all 
other causes' disability, and 'all 
causes' disability with the baseline 
va lues. 
Ta look at the impact of an 
interventiou we created a hypo-
thetical smoke-free population by 
l1sing thc smoking prevalenees and 
relative risks in Table 2 to estimate 
nOlls111okillg illcidences (Ba reil dregt, 
van Oortmarssen, vau Hout, van 
den Bosch, & Bonneux, in press). 
Smoking is a direct risk factor for 
IHD, CVA, Lung cancel', and 
COPD, and an indirect one (thl'Ough 
IHD) for CHF, For each of the 
uncertainty variants the life table 
Table 2 - Prevalenee of smoking (%) by 
age; and Relative Risks (RR) of 
smoking on incidence for 5 dlseases. 
Age 
group 
Prevalence of 
smoking (%)r Disease RRt 
0-14 o IHD 
15-19 20 lung ca 
20-34 39 CVA 
35-49 42 CHF 
50-64 39 COPD 
65+ 34 
r Source: (Foundation of Public Health 
and Smoking) 
t Source: (van de Mheen & Gunning-
Schepers, 1996) 
3 
10 
2 
25 
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was recalcnlated with the nonsmoking incidences while keeping all else eqnal. 
Ta make the outcomes of the interventions comparable they arc cxpressed 
relative to these different DALE baseline cstimates of the uncel'tainty variant. 
Results 
All results are for the male papIllation only, Table 3 shows in the upper panel 
years lived with disability by the life table cohort for the five diseases, 'all 
other canses', and 'all causes" both while ignoring comorbidity and with 
comorbidity 1110deled, Disability attributed to specific single diseases is of 
course lower when comorbidity is 1110deled: depending on the disease by 15 
to 44%. Comorbidity under the baseline assmuptions accounts for almost 
20% of the disability caused by the five diseases, Total disability caused by 
the five discascs is 80/0 lower when comorbidity is taken into accoullt, making 
the 'all other causes' estimate 3% higher. 
Figure 1 shows differences (expressed as percentages) in years lived with 
disability as a consequence of 20% higher va lues for the uncertain vadables, 
Baseline results are represented by the Y~axis, and positive values designating 
more disability, and vice versa. 
Results are virtually symmetrieal for higher and lower values, A 20% 
higher estimate of the tata 1 years lived with disability has na influence on 
disease specific and comorbidity disability, but it increases the 'aH other 
canses' disability with 28%. Increased disease incidence (and hence pl'cva-
lence and l11ortality) tends to lower disability attributable to the other single 
diseases, becallse it tends to increase comorbidity. Two exceptions exist: 
higher IHD incidence increases the disability burden of eHF because IHD 
acts as a risk factor for CHF. And incl'eased lung cancel' incidence lowers 
Table 3 ~ Dlsease specific, all other, and total burden of dlsability In person years of 
the lite table cohort, base line estimates (up per panel) and Impact of smoking inter~ 
ventIon (Iower panel) for models with and without comorbldity. 
Baseline IHO CHF CVA 
lung 
COPO Comorb All other Total ca 
na comorb 43,000 42,000 23,000 4,000 150,000 0 624,000 886,000 
comorb 37,000 32,000 14,000 2,000 110,000 48,000 644,000 886,000 
% -15 -23 -39 -44 -27 3 0 
.............. - .................. ............ - .................................. - ................ _ ................ - . 
Intervention 
no comorb 28,000 46,000 20,000 1,200 18,000 0 682,000 796,000 
% -34 11 -13 -71 -88 9 -10 
comorb 27,000 43,000 15,800 870 14,600 8,000 707,000 817,000 
% -26 35 13 -61 -87 -83 10 -8 
........................... - ............... - ............................... - .................................. _ ....................... ............ - ..... 
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r"m",hi,-litu weights 
Disability weights 
11 Total 
Wl All other 
lJIl Comorbid 
ITl COPD 
GOPD 111 Lung ca 
incidence ITl CVA 
rrn CHF 
Lung ca 
~IHD 
GVA incidence 
GHF incidence 
IHD in~i"o,,~o 
20.0 
Total YLD 
-10.0 0.0 10.0 20.0 30.0 
Percentage change 
Figure 1 - Sensitivity (% difference with baseline, including comorbldlty) of years lived 
with disabllity estimates for 20% higher values of uncertain varia bles. Posltive values 
deslgnate more disablllty, and vice versa. 
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c01110rbidit)' disabilit)' because of its high lethalit)'. Increased disease incidence 
also increases total disability attrihntable to the five discases, consequently 
rhe disability Ero111 'all other causes' becOlnes Iower, in partienlar with IHD 
and COPD. 
Comol'biclity prevalcnce has a rather strong Îllflucnce on the disability 
attribntable to single diseases, bnt not 111nch on total disability cansed by the 
five diseases: 'all other' causes disability rcmaÎ11s vil'tually ullchallged. Thc 
disabilit)' weigilts have a lllarked influence on disability caused by the tive 
diseases, aud thercfol'c also 011 rhe 'all other causes' estimate. The weight for 
comorbidity, on the othel' hand, illflucllces only the amount of disability Erom 
comol'bidity, ulld has onl)' little inflncnce on the 'all other canses' disahility. 
Table 3 also shows (lmver panel) the difference explicit lllodeling of 
comorbidity makes when all interventioll is made. \"X/hen cOlllorbidity is ig-
nored the abolishment of smoking lowers disabilit)' of all discases in the life 
tabie, with the exceptiol1 of CI-IF. Disability Erom 'all other canses' illcreases 
9% because of longel' Iife expectanc)', and total disability declines by 10%. 
i\IIodeling comorbidity changes this, primarily becanse the intervention re-
duces comorbid disability by over 80%. Part of this reduction in comorbid 
disabilit)' becomes single disease disabilit)'. The reductions in single disease 
disabilit)' aftel' smoking abolishment are therefore smaller (COPO, lung can-
cer, IHD), change inta an i1lCrease (CVA), or the existing increase becomes 
largel' (CHF). 'AII other cause' disability increases a bit more, and total dis-
abilit)' a bit less. 
In figure 2 the sensitivity of the intervention ontcome to 200/0 higher 
values of the Ullcertain varia bles is presented: the resnlts are again virtually 
symmetrical, therefore thc l'csnlts fol' 200/0 lawer values are not shown. For 
each variant we first recalcnlatcd new baseline valnes of discase specific and 
'all other' disabilit)', and next looked at the post-intervention disabilit)'. The 
l'clative impacts of the intervelltions arc compared with the one of table 3, 
and the diffel'ence is again expressed as a percentage, with the baseline rela-
tivc impact repl'esented by the Y -axis, and positive values designating more 
l'emaining disability and Iess impact, and vice versa. 
Results go in the expected direction. Higher total disability before the 
intel'vention makes it less effective, becallse 'all othel" disability is higher, and 
\Vill substitnte more of the disability avoided by the intel'ventioll. 
Illdividnal disease incidence changes all show the same pattern (with the 
notabie exception of CHF disabilit)' aftel' IHO incidence change): higher 
original incidence causes the intervention to be relatively Ie ss effectÏ\'e for 
other diseases. This outcome is due ta several eHects. One is that the ot her 
diseases get a lower baseline disabilit)', because totalmortalit)' in the baseline 
is higher, and a largel' part of the disability is assigned to comorbidity. The 
second effect is that with a largel' baseline comorbidit)' disabilit)' more of this 
disability will become single disease disability due to the intervention. And 
the third effect is that the intel'Velltion avoids more mortality, and therefore 
more disease sllbstitntioll wiII occur, with conseqllently higher discase specific 
disabilit)'. On balance intervention impact, as measured by total disabilit)', is 
slightl)' largel'. 
-30.0 
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11 Total 
.~ All other 
Amount of 
Comorbidity [IJ] Comorbid 
El .:.:. COPD 
111 Lung ca 
El CVA 
Lung ca incidence IrnCHF 
~IHD 
CVA incidence 
CHF iin ,rirlpnr'p 
IHD incicjen,ce 
Total 
-20.0 -10.0 0.0 10.0 20.0 30.0 
Percentage change 
Figure 2 - Sensitivity of the relative impact of the smoking inlerventlon (% dlfference 
wlth the relative impact in table 3) for 20% higher values of uncertain variables. Posilive 
values designate less impact, and vice versa. 
256 Measuring compreSSiOI1 and expansiOl1 of morbidity 
All Încreased amount of comorbidity makes the illtervention on balance 
slightly less effective because 'all other' disability is higher: with higher 
comorbidity prevalence less of total disability is attributed to the explicitly 
modeled disease. Increased disability weigIltS gives a rather more effective 
intervention, because more disability is explained by the smoking-related dis-
cases. Higher comorbidity weights causes the pre- aud conseqnclltly post-in-
tervention comorbidity disability to be higher, but otherwise has only a small 
impact. And Hnally, a higher intervention impact causes the disease specific 
and comorbidity disability to be llluch lower, but because of the increased life 
expectancy the total number of years lived with disability by the life table 
cohort is slightly higher. 
Discussion 
In the DALE methodology, as presented in a previous paper, two major 
problems exist: the estimation of disability from all causes, and the exis-
tcnee of comorbidity. (Barcndregt, Bonnenx, & van der ~/raas, in press) 
These problems are related: an 'all causes' disability cannot be arrived at by 
simply adding the disability caused by individual diseases because of 
comorbidity. The same goes for obtaining an estimate of 'all other' disabil-
ity by subtracting disease specific disability from an 'all causes' disability. 
In the previons paper we ignored the pl'oblem, in the present ane we 
try to get au impression of thc magnitude of the error this introduced, rela-
tive to rhe errors due to the other elements in the estÏmation. Ta this end 
we modeled comorbidity explicitly in the multi-state life tabie, compiled a 
list of all the elements in the estimation procedure that are surrounded by 
ullccl'tainty, alld performed a sensitivity analysis of the ontcomes to varia-
tions in these elements. All ontcomes are expressed in 'yeal's lived with dis-
ability', which form the basis of the DALF calculation. 
First we compared the estimates of years lived with disabilit)' with and 
without explicit comorbidity (tabIe 3). Disease specific years lived with dis-
ability are cOllsiderably lowel' when cOlllorbidity is taken into account, but 
the largest part of these disability years are assigned to comorbidity. On 
balance disability explained by the diseases including comOl'bidity is 7.5% 
lower, causing the 'all other' disability estimate to be 3% higber. This 
lower explained disability and higher 'all other causes' disability in turn 
make the smoking intervention less effective: total disabilit)' years decline 
by 8% instead of 10% af ter smoking abolishment. 
The list of uncertain elements in the DALE estimation procedure in-
cludes the 'all causes' disabilit)' estimate, disease epidemiolog)', clustering 
of diseases that determines the prevalence of comorbidity, the disability 
weiglus from the Global Burden of Disease project, the disability weiglus in 
case of comorbidity, and, when evaluating the smoking intervention, the 
impact of smoking abolishment on disease epidemiology. 
The results of the sensitivity analysis in figures 1 and 2 show that the 
disability weiglus used for comorbidity have an impact on the amount of 
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disabilit)' due to comorbidit)', and through that on the amount of disabilitl' 
explained b)' the diseases, and 'all other' disabilitl'. The estimation of )'ears 
lived with disability (fignre 1) is most sensitive to respectivel)' the estimate 
of tata I disabled years, of the disability weights, the amonnt of comorbid-
ity, and the epidemiology of the individu al diseases. The inflnence of differ-
ent comorbidity weights is relatively small. 
For the intervention impact (fignre 2) the re sult is similar, with the 
qualification that the effect of different comorbiditl' weights on total dis-
ability af ter the intervention is, although still smalI, relatively larger. Be-
cause higher disability weights for comorbidity make the total amount of 
disabilit)' explained by the diseases modeled higher, the outcome on total 
disability nmonnts to an increased effeetiveness of the intervention. 
The overall eonclnsion is that the comol'bidity weigllts are jnst one of 
a range of uncertain elements in the DALE estimation, and onc with a rela-
tively small effect on the outcome toa. This despite the fact that the dis-
eases modeled are mostly high prevalence diseases (the exceptioll is lung 
caneer), with consequently a large amount of eomorbidity. But even with 
these high prevalence diseases the amount of total disabilit)' explained is 
only about 27%, leaving a large amount of 'all other causes' disability. 
When the part of total disability explained rises, through the ma deling of 
more diseases, the impact of the comorbidity weigIlts \Vill presumably be-
co me largel', because cOlllorbidity prevalence will be higher. 
Nevertheless, given the current lllllnber of diseases lllodeled, compar-
ing the present results with the earlier estimates (tabIe 3) suggests that in 
this case ignoring comorbidity altogether \Viii not have a large impact on 
. the estimate of total disability caused b)' the diseases, or on the disabilitl' 
avoided throllgh an intervcntion. 
Ignoring c01l1orbidity is an attractive option, because it avoids C0111-
plex modeling. Obviously it is not a feasible option ",hen comorbiditl' itself 
or the disability it eauses is the subject of study, but when the focus is on 
disability caused bl' diseases and on total disabilit)' it seems an appealing 
choice. In case comorbiditl' is included explicitly, without being the study 
snbject itself, simple assumptions on comorbidity disability weights wiII 
serve, because the impact 011 DALE estimates will be minor. 
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Update and summary 
ThiS part has looked at popttlation health indicators in general, and at three instances (Health Expectancy, DALY and DALE) in partieular. The research field is vivid, and work and debate on the matters ad-
dressed in the artic1es reproduced here continues. In this chapter we give all 
update of the Iutest results and snmmarÎze DUf COllcll1sions. 
Health Expectancy 
In chapter 16 we explain that measming trends in health expectancy with 
au indicator based 011 a prevalenee mcasnre of lllorhidity enconllters a 
problell1 because of the cOll1bination of stock and flow variables. The seri-
onsness, if not thc existcl1ce, of this problem is dispnted. Some authol's 
argllc that the prevalenee based indicator o111y faiIs in extreme circulll-
stances, and rhat UIlder cil'cnmstances typical of 1101'l11al populations the 
prevalenee based indicator is acceptable fol' trend monitoring (van de 
Water, Boshuizen, Perenboom, Mathers, & Robine, 1995). We hold that 
the example of the change in survival aftel' myocardial infarction through 
the adoption of thrombolitic therapy constituted one of these extreme cir-
CUll1stances, aud that other large changes in illcidence aud survival are 
known to have occllrred recently (Barendregt, BOll11el1X, & van der Nlaas, 
1995). 
Mathers and Robine showed that a prevalence based health expee-
taney indicator was able to largely followan incidence/duration indicator 
even aftel' trends in the incidence of disability (Mathers & Robine, 1997). 
However, the simulatioll that supported th is claim artificially removed the 
aspect which cansed most trol1ble in the simulation we present in chapter 
16: the effect that a change in slU"vival (flow varia bie) ill1ll1ediately changes 
the estimate of life expectancy, but only slowly morbidity prevalence (stock 
varia bie) (Barendregt, Bonnellx, & van der Maas, 1997). 
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In addition we argllc that in the compression <tnd expansioll disCllSSÎOll 
the varia bIe of interest is not health expeetaney as sueh, but the differenee 
betweenlife expeetauey aud healthy life expeetanel'. Siuee th is differeuee is 
mueh smaller thau health expeetauey but affeeted by the same absolute 
bias, the relative bias becOlnes considerable. Observed changes over time in 
life expeetauel' with morbidity are usually smalI, and eould therefore be 
affeeted to a large extent bl' this bias (Bareudregt, Bonneux, & van del' 
Maas, 1997; Mathers, 1994). 
Summarizillg DUf findings on health expectallcy as a Population health 
status indicator we can say that Ît is attractive because of its l111complicated 
methodology <tud data reqnirements, that estimates of CUlTent Populatioll 
health status \ViII be aeeeptable, but that methodologieal pl'Oblems exist 
when it is used to evaluate changes over time or within discase processes 
(which is whar compressioll aud expansiol1 of morbidity is about). Solu-
tions for these problems eau be found (for example using an incidence/ 
duration approach, or adopting more elab01'ate morbidity weights), but 
carry the cast of increased complexity and data reql1irements. 
DALYs 
111 ehapter 18 we have shown that the age weightillg sehedule of the DALY, 
contrar)' to appearances, emphasizes years lost due to mortalit)' between 
the ages of 0 and 27. Chapter 18 also claims that the same is true for years 
lost dne to disabilitl" In a response Mmray and Lopez point out this de-
pends on the dmation of the disability: for ehronic disabilitl' the empha-
sized age range would indeed be 0 to 27, but as the disability duration de-
clines this range changes to the 10 to 55 range. They give the example of a 
disability with a 5~year duration, that stresscs ages between 7 and 52 
(~"lnrray & Lopez, 1996). 
\'(Ie make two observations here. Thc first is that this makes the age-
weighting sehedille for the l'ears lost due to disability a rather complex 
fl111ction of the dUl'ation of disability, which, givcll different durations of 
disability, results in a different sehedule for eaeh condition. The aggregate 
age weighting in the DAL Y thus beeomes an amalgam of a large number of 
different age-weight sehedules, with, beeause it is domiuated bl' the years lost 
due to mortality, the highest weigIlt probably at very young age. This 
amounts to a l'egl'ettable 10ss of transparellcy for the rather intuitivc original 
idea that life years lost at verl' young or aId ages are not as severe as at ado-
leseenee and middle age. 
The seeond observation is that the shift towards younger ages of the 
emphasized age range is the eonsequenee of fjrst applying the age-weighting 
sehedule, and next d,e years of life lost ealculation. This order of calculation 
mal' make sense when years of life lost are indeed interpreted as l'ears not 
lived. But when years of life lost is interpreted as an age-weighting sehedule 
itself it does not deseribe a number of years that should have been lived at 
specific ages, but simply a weight to be applied to a death at a eertain age. 
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Figure - Age speelfle life expectancies for Duteh women (1986-1990), without the 
additional age weight sehedule, and with the addltional sehedule applied after the 
years of IIfe lost ealculation (denoted with "R.D.", or reverse order). Both discounted 
(3%) and undlscounted variants are showl1. 
Combining the two age-wcighting schedlIles would then mean multipl)'ing 
the nvo weigIlts for that age, or, which amounts to the same, first calcl1late 
years of life lost, and then appl)' the age-weighting schedule. The resulting 
curve is in the figure (compare the figures in chapter 18), which seems to 
reflect much better the original idea of the age weights. 
A similar approach could be used for disability: appll' ani)' the age-
weigilt of the age at incidence to future not age-weighted life years lived with 
disabilitl" While this would solve the problelll of a multitude of different age-
weighting schedules, it requires a different interpretation of the age-weights 
than was used in the origiIlal DAL Y. At present Murray and Lopez do not 
seem inclined to make an)' changes (Mmm)', 1996; Murra)' & Lopez, 1996). 
Summarizing we conclude that the DAL Y is a complex population 
health status indicator, even more complex than ,vmIld seem at first glance. 
It is geared to be an indicator for optimal allocation of resources, witness 
its use of a reat populatioll and discounting. This use also llecessitates a 
disease specific approach, and the establishment of a chain of causation 
running from disease incidence to prevalellce, disability prevalence, and 
mortalitl" 
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DALE 
A major problem with the Disability Adjusted Life Expectancy (DALE), as 
presented in this part, remains the estimatiou of 'all other disability'. The 
DALE descl'Îbes ouly a few diseases and their disability explicitly, and uses 
a generic 'all other disability'. Ta estimate this 'all other disabilit)" au esti-
mate of 'total disability' is nccded. In the absence of an estimate based on 
the disabilit)' weights from the Global Burden of Disease project, au alter-
native lllcthod was presented in chapters 19 and 20. An estim<tte of 'total 
disabilit)" was obtaiued h)' setting the DALE equal to the Disabilit)' Free 
Life Expectauc)' (DFLE), based on the Health Surve)'. 
In a recent article iVlurray aud Lopez prcsellted DALE estimates for 
each of the eight world regions they distinguish, using the full set of condi-
tions studied iu the Glohal Burden of Disease stud)' (Murra)' & Lopez, 
1997). The male life expectaucy in the Estahlished Market Economies 
(EME) is 73.4, virtually the same as the oue we ohtaiued in chapter 19. The 
DALE for the EME, on the other hand, was estimated at 67.4, while our 
DFLE-hased DALE is set at 64.7. 
In order to see whether a higher DALE would change the results of 
chapter 19, we recalculated the effect of smoking abolition with the higher 
DALE estimate. It turns out that the abolition of smoking iu that case 
would have a stronger beneficia I effect. When total disability is lower, 
while the disability of smoking related diseases remains the same, 'all other' 
disahility will be lowel'. With a lower 'all other' disability the substitution 
effect of the iucreased life expectaucy will be lower, and the compression 
becomes stronger. \Vhile this outcome is reassllrÎng, it also stresses that for 
this kind of assessment a direct estimate of the Dutch DALE is highly desir-
abIe. 
In summar)' we conclude that the DALE, although not without prob-
lems that still await solutions, is an attractive indicator of poplliation 
health status, that has a!ready found wider application. The attractiveness 
is based on several characteristics. The DALE, as a health expectancy, al-
lows camparisons over time and place. It is simpier than the DAL Y because 
it does not llse the age-weighting schedule <tud discounting, but it retains 
the esseutial propertl' of liuking specific diseases to overall population 
health status. We expect to see more applications of the DALE iu the fu-
ture. 
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PART V 
Population health status, 
prevention, 
and health care costs 
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Introduction to Part V 
Introduction 
CompressiOll and expansioll of l11ol'bidity concern in the first place the fu-
tnre health of popnlations, bnt in the debate the thonght abont the associ-
ared casts of health care has never been far uway. In the expansion scenario 
the pandemie of chronic discase is expected to cansc au explosion of health 
carc casts, while on the other hand compl'CSSiOll, in particular the compres-
sion to be achieved by successfnl prevention, is expected to offer patential 
s"vings (Fries, et al., 1993). In th is part we take a look at the issne of com-
pressioll, expansion, and health Care casts, without in <lIl)' way pl'ctendillg 
to be comprehensive. l11deed, we primariiy want to show that relations be-
twecil population health status and costs of care are not as straightforward 
as they may seem, and that this is a topic of research in need of further at~ 
tention. 
Chapters 23 and 24 bath look at the prevention of disease and its im-
pact on health care costs, Prevention of disease offers an interesting case: 
there is little doubt that expansion of morbidity through increased survival 
with chronic disease will canse au iucrease in health care costs. But with 
prevention it may go either way: on the one hand successfn1 prevelltioll will 
lower morbidity, and hence tend to lower health care costs, but simnltaue-
ously it may extend leng th of life, and th us increase casts. The net effect 
depends on the balance between these opposing tendencies (and of course 
on the cast of prevention itself, which may be substantial but, for simplic-
ity's sake, is being ignored). 
Chapter 23 makes it clear that a disease specific approach in these 
matters is necessary, even if only with the braad disease categories applied 
thel'e. \Vithin the fl'amework of an extended cause elimination Iife tabie, 
extended becanse it elinlÎnates diseases not just as a canse of death but as Cl 
cause of casts as weIl, it is shown that the effects of elimination differ by 
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disease. The disease categories can be distinguished in two classes: fatal and 
non-farnl diseases. Thc general conclusion is that there only a few cases of 
largely non-fatal diseases in which elimination of the disease will actually 
lowcr health care casts. 
In chapter 24 we look at the relation between health care costs and the 
largest avoidabie risk factor for population health status: tobacco smoking. 
The impact of smoking on health care casts is examined by estimating tluce 
life tables, ane for a mixed slllokers/llon-smokers' popnlation, one COllsist-
ing of s111okers, and onc of nOll-smokers. In addition we llse adynamie 
method to estimate the cffeers of smoking cessation on costs. 
Resnlts show that smokers are lllore expensive when alive, hut a 11011-
smokers' poptdation would be more expcllsive than the Cllrrent mixed 
population of smokers and non-smok ers. Nevertheless, given a short 
enongh follow-up period and a high enough discount rate, it would be eco-
nomically beneficial if smoking is abolished. 
Both these chapters use an interdisciplinary approach: methods from 
epidemioIogy, demography and economics are employed. The combined use 
of these methads is a source of much confusion, witlless the referee com-
ments we collected on these two papers. We will briefly review the main 
issues. 
Time and age 
In this part the demographic techniqne of the life table is used to allow for 
substitutiall of causes of death: elimination of a cause of death or a risk factor 
will, in the end, not resnlt in fewer deaths. All people die, but when a cause of 
death is eliminated 01' lowered they will do so from other causes, and at a 
higher age. The life table allows to calculate at what age. 
The life table is a well-established technique, with various extensions 
such as the cause elimination life table of chapter 23 and the multi-state life 
table we use in chapter 24 (Schoen, 1987). Two types of life table can be dis-
tinguished: the 'generation' life tabie, and the 'period' (or 'cnrrent') life tabie. 
The generation life table follows a single birth cohort using historical data, 
thus reproducing the actualmortality experience of that cohort. Interesting as 
this may be, for purposes of describing the mortality experience of the current 
population, this willnot do. 
The period life table therefore uses currently observed mortality prob-
abilities, which makes it better suited to describe currellt mortality, but at the 
same time makes its interpretation less clear-cut. The period !ife table has 
two, mutualJy exclusive interpl'etations, depending on how the age axis is 
looked upon. One interpretation is that the life table represents a single co-
hort, followed imo the future while it ages, the second that it stands for an 
entÎl'e popnlation at one point in time, the so called 'stational'Y population' 
interpretation (Shryock & Siege\, 1976). In the latter interpretation the age 
axis l'epl'esents jnst age, in the former bath age and time. Descl'ibing all entÎl'e 
Introduction 269 
population through time requires separate age and time axes, for exarnple a 
series of life tables, one for each point in time . 
.wInch of the methodological confusion lllentioned originates from the 
application of cliscounting, in particnlar in combillatioll with !ife table 
methods. Disconnting is au economie technique to help in the evaluation of 
future costs and benefits, lllonetary or otherwise. This evalnation is ha111-
pered by the pl'Opensity to enjoy money (or goods) now rather than later, 
and to pay later rather thannow (Drummond, Stoddart, & Tartance, 1990). 
This pl'Opensity, called 'time preference' by economists, makes it difficult to 
decide which of two different streams of future casts and benefits is the 
most attractive. 
Ta decide which of these different streams of future casts and benefits is 
preferred the streams are represented by their Present Discounted Values 
(PDV's): a weighted sum of the future casts and benefits, with an exponen-
tially lower weigIlt as the cast or benefit is further away in time (Branson, 
1979). The calculation requires assumptions to be made about how strong 
tbe time preference is (expressed in the value of the discount rate) and how 
long the follow up must be (the time horizon, see the appendLx far the equa-
tion llsecl). The procedure makes, assullling that time preference is adequately 
represented by snch an exponential function, the two future streams of costs 
andlor benefits that differ in timing comparable, and allows to choose 
which is preferred. 
More than one referee of the papers in chapters 23 and 24 criticized us 
for not using discounting in our life table estimates. We think they are mis-
taken, and fol' two l'eusons: 
1) The research questions are ahout estilllation: 'what would health care 
casts be if a disease or smoking would not exist'. Applying discounting 
to snch research questions confl1ses estimation and evalnation. 
2) The research questions are about populations. This implies that we use 
the stationary population interpretation of the life tables, with the age 
axis represellting only age and not time. Applying discOllllting would 
therefore amount to correcting for age preferellce (costs made at old 
age are less important), not time preference. 
The ouly exceptioll is the last research questioll of chapter 24, which looks 
at what would happen with pop,tlation health care casts aftel' an illterven-
tion would succeed to convince all current smokers to quito To answer this 
ql1estion adynamie popnlution model is nsed, with separate age and time 
dimensions, and not a life tabIc. To see whether the resnlting stream of fu-
ture health care costs is more attl'active than the one without the intel'ven-
tion, we then apply discounting, and concInde that, despite the eventually 
highcr heaIth care costs, the intervelltion is indeed economically attractive 
with reasonabJe va lues for discount rate and time horizon. 
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Appendix 
A decision maker is confronted with two investment projects that differ 
bath in timing of furore casts aud revenues as in a111ou11t5. The problcm for 
the dccision maker is which project, if all)', to choose. Tc be able to make 
this decision the two stl'cams are cOllverted to Present Discounted Values 
IPDV's) using: 
Where: 
r=tH p 
PDV= 2: I I 
,~O (l + /') 
t: time, with t=O the present. 
tH: time horizon of evaluation. 
Pt : umount of cost or bCllcfit at time t. 
r: discount rate. 
The decision maker maximizes profit when he picks the project with the 
highest PDV, and nevel' chooses a project with a negative PDV (because 
rhat project would make a 10ss). Nare that there arc two l1nknowns in the 
eql1ation: the time horizon tH and the discount rare r. \Vhile in a commer-
cial enter prise obvious valnes for these unknowns mar exist, like amortiza-
tion period and mal'ket rate of intel'est, this is Ie ss obvious fol' medica} in-
terventions (Dnulllllond, Stoddal't, & TOlTance, 1990). 
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Preventing fatal diseases 
increases health care costs: 
a cause elimination life table 
approach 
Abstract 
Objectives: Ta demonstrate that elimination of fatal diseases wil! in-
crease health care casts. 
Design: Mortality data from vital statistics are combined with health 
care spending in a cause elimination Iife tabie. Casts are al/ocated to 
specific diseases through the various health care registers. 
Setting and subjects: The population of the Netherlands, 1988. 
Main outcome measures: Health care casts of a synthetic Iife table co-
hort, expressed as Iife time expected casts. 
Results: The Iife time expected health care costs for 1988 in the Neth-
erlands were f 56,600 far men and f 80,900 for wamen. Eliminating 
fatal diseases, such as coronary heart disease, cancer or chronic ob-
structive lung disease increases health care casts. Major savings wil/ be 
achieved ani)' by eliminating non-fatal disease, stlch as musculaskeletal 
diseases and mental disorders. 
Conclusion: The aim of prevention is to spare human beings from 
avoidabie misery and death, not to save money on the health care s)'s-
tem. In low mortalit)' countries, eliminating fatal diseases by successful 
prevention increases health care spending because of the medical ex-
penses during added Iife )'ears. 
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Introduction 
In 10w mortality conntl'ies, health care costs - which are already snbstantial 
- are on the rise. Health promotion, based 011 the simple idea that by 
revellting illness, iIlness-related costs will be prevented, has been hailed as 
the solution by some.(1) However, it is doubtful whether eliminating fatal 
diseases wonld canse a decrease in chronic morbidity. Health care lleeds 
tel'minate at death.. Snrviving meallS ageillg, the stl'ongest determinant for 
diseases snch as osteoal'thritis, osteoporosis and related fractnrcs, cognitivc 
declinc or 10ss of vision or hearing. 
In demography, the effects of eliminating diseases are studied by cause 
elimination life tables.(2) In such life tables, a cause of death is eradieated, 
and the life expectancy recalculated. By linking disease-specifie health care 
costs to the life table population, the conseqne"nces of having eliminated a 
disease as a callse of death, as weil as of a source of casts, can be estimated. 
Methods 
In a previous study, all health care casts in the Netherlands in 1988 
(39,800 million Dutch guilders U), ± 11 400 million pounds sterling (E) at 
the exchange rate of 1988, for 14.8 million inhabitants) were allocated to 
age, sex, health care sector alld primary dia gnosis, based on comprehensive 
data onmorbidity, mortality and direct costs.(3-5) Same 25.2% of all casts 
were unable to be allocated to a primary diagnosis, either thl'Ough a lack of 
information Ol' becal1se of the nOll-personal nature of these casts 
(administration, genera I public health serviees, etc). 
The health care casts are linked to the Dutch period life table for men 
and wamen of 1986-1990.(6) The expected casts represent the tata I casts 
of the life table cohort during their lifetime. These casts are divided by the 
initial size of the life table cohort, i.e. "the population at bh,th", to yield the 
lifetime expected casts for an individual (see appendix). The interpretation 
of life time expected casts is analogous to the interpretation of life expec-
tancy. The imaginaty life table cohort is subjected to the unchanging casts 
of 1988 and the unchanging death rates of 1986-1990 untill extinction. 
The life expectancy is the sUin of all the years a life table person is expected 
to live, the life time expected costs are the Sl1111 of all the health care costs 
that person is expected to incur during these life years. Ta calculate the 
effect of e!'adieation, a specifie disease is eliminated bath as cause of death 
and as canse of costs: the cause elimination !ife table recalcnlates life expec-
tancy and lifetime expected casts as if the eliminated disease had never ex-
isted. A life table assmlles that persons lived on average for a half year in 
the year of death. In the year that an eliminated cause of death would have 
occurred, persons are now at risk of death from other canses during the 
enth'e year (instead of a half year), and remain fully at risk of other causes 
for the added life years. Only allocated casts are considered in the callse 
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elimÎnatian life tables. Becansc canse elimination life tables are interpreted 
as stational')' populations before or aftel' thc elimination of a diseasc,(7) the 
casts are not discounted. Cause-specific mortality data are available for 5 
year age gmups till the age of 84.(6) Af ter the age of 85, we assUlne the 
cause-of-death ratio (deaths from the specific cause divided by all deaths) 
and thc casts to remain constant with riSillg age. This assnmption underes-
timates the cast of added life years in the very aid. Specific causes of death 
are underregistered at older ages and health care casts increased steadil)' 
with age.(3-5, 8) 
Results 
Life expectancy in the Netherlands in 1986-1990 was 73.5 years for men 
and 80.0 years for wamen. The lifetime expected casts at birth for all 
health care totalled f 198,000 (E 56,600) for men and f 283,000 (E 
80,900) for wamen. Same f 155,000 (E 44,300; men) and f 219,000 (E 
62,600; wamen) were allocated to a primary dia gnosis (see tabie). 
The table shows the inverse relationship between fatality and casts: 
the highly lethal comnary heart diseases, causing nearly 19% of all deaths, 
cause only 2.7% of all health care casts. Mental disorders, including psy-
chiatrie discases, mental handicaps and dementia, are together responsible 
for only 0.6% of all deaths, but consume 26% of the allocated health care 
budget. Eliminating corona ry he art disease would substantially increase the 
burden on the health care budget, as th is would save few casts but add a 
considerable number of life years. lndeed, life expectancy would increase 
by about 1.9 years (2.5%), while casts would jump 6%. On the other 
hand, elimÎnatillg dementia would canse no notiecabie change in liEe expec-
tanc)', but would save 6% on the bealth care budget. 
Diseases whose elimination angments health care costs substantially 
arc coronary heart disease, cancer and chronie obstl'uctive lung diseases: 
the present targets of health promotion. The savings yielded by eliminating 
stroke and heart failllre-related costs outweigh the costs associated with. 
gains in life cxpectancy. Cancel' is more fatal among men than among 
women; conseqllcntly, the elinlinatioll of cancel' would add more Iife years, 
and therefore more costs, among men. 
EIiminating accidents and other unllatural callSCS of death adds life 
years and saves casts, in the light of bath the high burden of morbidity and 
mortalitl'. But the table shows that the largest gains are to be achieved 
through the elimination of mental disorders and mnsculoskeletal diseascs: 
limited sourees of lost life years, but major sources of casts. 
Discussion 
This paper shows that lengthening Iife gellerally will illcrease health care 
needs, particularly needs for long term nnrsing care, as most lifc years are 
Table 
All deaths trom 1985~1990 (S) and all allocated costs (in 1000 pounds) from 1988 (5) caused by various disease groups and the effects of 
elimination of these disease groups on life expectancy and lifetime expected costs. The numbers refer to the international classification of 
diseases, 9th revision.(14) The percentages in the life expectancy columns show the relative change as a consequence of elimination. 
all deaths (1986-90) all allocated casts life expectancy after Life time expected casts MEN (1000 f: 1988) elimination (f:) after elimination 
none 330717 (100%) 3755 (100%) 73.5 (100%) 44011 (100%) 
cardiovascular diseases (390-459) 131979 (39.9%) 480 (12.8%) 78.8 (7.1%) 46301 (5.2%) 
caronary heart disease (410-414) 69624 (21.1%) 153 (4.1%) 76.0 (3.4%) 46674 (6.0%) 
stroke (430-438) 24524 (7.4%) 126 (3.4%) 74.2 (0.9%) 43477 (-1.2%) 
heart !allure (428-429) 9571 (2.9%) 51 (1.4%) 73.8 (0.4%) 43762 (-0.6%) 
cancer (140-208) 101309 (30.6%) 233 (6.2%) 77.5 (5.3%) 47657 (8.3%) 
lung cancer (162) 36859 (11.1%) 49 (1.3%) 74.8 (1.8%) 45683 (3.8%) 
colorectal cancer (153-154) 9510 (2.9%) 26 (0.7%) 73.8 (0.4%) 44201 (0.4%) 
respiratory disease (460~519) 29257 (8.8%) 196 (5.2%) 74.3 (1.1%) 43257 (-1.7%) 
chronic obstructive lung dis. (490-496) 20154 (6.1%) 77 (2.0%) 74.1 (0.7%) 44150 (0.3%) 
unnatural causes of death (E800-E999) 15782 (4.8%) 205 (5.5%) 74.4 (1.2%) 42617 (-3.2%) 
traftic accidents (E800-E848) 5212 (1.6%) 58 (1.5%) 73.9 (0.5%) 43734 (-0.6%) 
mental disorders (290-316) 1406 (0.4%) 1025 (27.3%) 73.6 (0.06%) 33256 (-24.4%) 
dementia (290) 870 (0.3%) 84 (2.2%) 73.6 (0.02%) 42636 (-3.1%) 
musculoskeletal diseases (710-739) 1120 (0.3%) 300 (8.0%) 73.6 (0.04% 40812 (-7.3%) 
WOMEN 
none 298569 (100%) 4930 (100%) 80.0 (100%) 62292 (100%) 
cardiovascular diseases (390-459) 126988 (42.5%) 502 (10.2%) 85.0 (6.3%) 68964 (10.7%) 
coronary heart disease (410-414) 48279 (16.2%) 79 (1.6%) 81.5 (2.0%) 65994 (5.9%) 
stroke (430-438) 35609 (11.9%) 201 (4.1%) 81.0 (1.3%) 62263 (-0.05%) 
heart failure (428-429) 12163 (4.1%) 71 (1.4%) 80.3 (0.4%) 62176 (-0.2%) 
eancer (140-208) 76177 (25.5%) 282 (5.7%) 83.4 (4.2%) 66339 (6.5%) 
lung eancer (162) 5650 (1.9%) 10 (0.2%) 80.2 (0.3%) 62717 (0.7%) 
colereetal eancer (153-154) 10642 (3.6%) 32 (0.6%) 80.3 (0.5%) 62810 (0.8%) 
respiratory disease (460-519) 19152 (6.4%) 154 (3.1%) 80.5 (0.7%) 62101 (-0.3%) 
chronic obstructive lung dis. (490-496) 7928 (2.7%) 79 (1.6%) 80.2 (0.3%) 62340 (0.1%) 
unnatural eauses of death (E800-E999) 11409 (3.8%) 280 (5.7%) 80.5 (0.7%) 59183 (-5.0%) 
traffic accidents (E800-E848) 2168 (0.7%) 39 (0.8%) 80.1 (0.2%) 62045 (-0.4%) 
mental disorders (290-316) 2687 (0.9%) 1220 (24.8%) 80.0 (0.08%) 46853 (-24.8%) 
dementia (290) 2492 (0.8%) 301 (6.1%) 80.0 (0.07%) 57185 (-8.2%) 
musculoskeletal diseases (710-739) 3084 (1.0%) 486 (9.8%) 80.1 (0.1% 56165 (-9.8%) 
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added to old age. This is not a bad thing; prevention can hardi)' be blamed 
if it reaches its target, aud lowcrs mortality. Life sa ving thel'apy, sneh as 
antihiotic treatment of severe infectious Ol' oral rehydratioll in severe diar-
rhoea, has the same consequcnces. Indeed, wc firmly believe that primary 
prevclltion, such as an effectÎvc allti-tobacco polie}', is all excellent bu)'. 
But that does not impi)' that no bill has to be paid. Onr paper contra-
diets popldar belief that prevention might 'prevent' health care costs.(I) 
Acute medica I casts ma)' be averted, but the considerabie needs for long 
term nursillg care of frail elderly eau but increase. 
Eliminating causes in a life tabie demonstrates au unquestionable 
truth: we all have to die. If we eliminate a specific canse of death, we sim-
pI)' die later fro111 another. In the meantimc we grow older, become gcncr-
all)' more disabled and need more care.(9) In the Netherlands, cardiovas-
cular diseases and cancer were jointly responsible for nearly 700/0 of all 
deaths, yet accollnted for a me re 17% of all health care casts, whereas the 
largely non fatal diseases of the brain, joints and bon es, causing 11llder 2 0/0 
of all deaths, generated 35% of all casts (see tabie). If fatal diseases are 
eliminated, health care casts dnring the added Iife )'ears swamp the savings 
)'ielded b)' the eliminated disease, even if the intervention is radical and 
without extra casts. At any age, the imaginary pop nl at ion of the canse 
elimination life tabie spends Ie ss health care resources per person, yet total 
costs increase because more persons remaill alive, survivillg to older ages 
where chronic morbidit)' and demands for health care are highest (see fig-
ure). 
As the de bate has focnsed on health care costs,(I) we taak into ac-
count onl)' medica 1 costs. The non-medica 1 costs of added life )'ears, snch as 
pensions and non~medical care for the e1derly, would far outweigh any 
non-medica I casts of disease and death.(lO) 
In view of the fact that our cast data are comprehellsive, we were able 
to consider all health care spending, inclnding long term nursing care.(3-5) 
Previous studies have shown that in the US, paymellts for acute medical 
care are higher in the last )'ear befare death, irrespective of age.( 11) Our 
resnlts do not contradiet these findings, bnt demonstrate the high burden of 
chronic care for non-fatal diseases, which are not determined by death. 
Canse elimination life tables are simple mathematical modeIs, based 
on the assumption of the independellce of diseases. Only primary diagnoses 
are taken into accou11t, while co-morbidity is ignored. In real life, mally 
diseases are not independent, and death is aften the end of a complex pro-
cess. However, insights are garnered trom pal'simonious theoretica I ex-
periments predsel)' because the)' simplify a complicated realit)'. Taking all 
relevant disease interactions into account would incl'ease data lleeds and 
model complexit)' intolerably, but would not change the conclusions in a 
meaningful wa)'. Indeed, onl)' wlten a disease process can be postponed 
without postponing mortalit)' can mOl'bidit)' and health care needs be 
'compressed' b)' prevention.(12) 
From a humanitarian point of view, life is preferabie to death and 
health to iIIness.(13) The aim of health care is not to save mone)', but to 
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FIgure - Casts by age In a life table of men and women, subjected to death rates and to 
dlsease allacated casts from 1988. The area under the lines are the life time expected casts. The 
dashed lines show the effects of elimination of two major disease groups, one fatal (cardiovascular 
disease), and one non fatal (musculoskeletal affections). 
save hnmall beillgs from preventabie suffering and death . .wloreover, the 
medica I costs of added Iife years are trivia!. Life extension wOllld cost " f 
890 to f 1400 pel' life year added, which few wOllld considel' llnacceptable. 
But if prevention is used as an argument for constraining fnture health care 
expenditures, the medica I expellses in the added life yeal's are not insignifi. 
cant and cannot be ignored. There is 110 evidence that health care costs are 
increasing becanse citizens live l1nhealthier lives. In fact, quite the contrary 
wOllld appeal' to be the case. 
Wie have become increasillgly successfn) at postponÎtlg mortality lllltil 
advanced ages. Oid age, however, is associated not only with impending 
death but also with dementia, sodal isolation, osteoarthritis, hip fractnres, 
10ss of visioll and hearing. Even hnmble progress in disease prevention 
wOllld have a tangible impact. Any potental savings on health care costs 
wOllld be a nice icing on that cake. 
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Appendix 
Life time expected casts (LEC) are calculated by 
LEC = L (~' * Lx) 
x x 
",here ex is the cast of all causes in the age interval (x, x+l). N x is the 
nnmber of persons in the age interval (x, x+l) and Lx' the pel'son~years 
lived in the age interval (x, x+l), 
Eliminating a canse of death is based on the actllarial assumption that 
persons dying from the specific cause in the age interval x, x+ 1 were COll-
sidered to have been at a 0,5 year risk of dying Erom all other causes, Thc 
risk of dying at age x Erom aH other canses, adjusted fol' competillg canses, 
(qx"a) is therefore 
q ,,-u 
d ,,-u 
1 
1 --d 
x 2 x,a 
where d"a is the number of deaths in age interval (x, x+l) due to the cause 
a, cl",a is the number of deaths in age interval (x, x+l) due to all other 
causes than a and t is the number of survivors to age x (of the all causes 
life table cohort), The life table cohort is at risk for this adjusted force of 
mortality from other causes untill extinction,(2) 
The expected lifetimc casts at birth aftel' elimination of cause 
a (LEe,a) are given by 
LEe. =,,(C,<,-u*L,_) 
a L. N .\, a 
x x 
where Cx,.u l'cpresents the casts in the age interval (x, x+ 1) made for all 
other discases than a and L:;:.u gives the life years lived in the age interval 
(x, x+ 1) af ter elimillution o{~anse a. 
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The health care costs of 
smoking 
Abstract 
Background: Although smoking cessatian is desirabie fram a public 
health perspective, its cansequences witb respect ta bealtb care casts are 
still debated. Smokers bave more diseases tban nonsmokers, but nan-
smokers /ive langer and can incur more bealtb costs at advanced ages. 
We analyzed bealtb care casts far smokers and nonsmokers and esti-
mated tbe ecanamic cansequences of smoking cessatian. 
Methads: We used tbree life tables ta examine tbe effect of smoking on 
bealth care casts - ane far a mixed papulatian of smokers and nan-
smokers, ane far a papulatian of smok ers, and ane far a papulatian of 
nonsmokers. We alsa used a dynamic metbod ta estimate tbe effects of 
smoking cessatian on bealtb care casts over time. 
Results: Healtb care casts far smokers at a given age are as mucb as 40 
percent bigher tban th ase far nonsmokers, but in a papulatian in wbicb 
na ane smaked tbe casts wauld be 7 percent higher amang men and 4 
percent higher amang wamen tban the casts in the current mixed 
papulatian of smokers and nonsmokers. If all smokers quit, health care 
casts wauld be lawer at first, but af ter 15 years they wauld became 
higher than at present. In the long term, complete smoking cessatian 
wauld produce a net increase in health care casts, but it cauld still be 
seen as ecanamically favarable under reasanabie assumptians of dis-
count rate and evaluatian periad. 
Canclusialls: If peaple stapped smoking, there wauld be savings in 
health care casts, but ani)' in the short term. EventualI)', smoking cessa-
tion wauld lead ta increased health care casts. .' 
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Introduction 
Smoking is a major health hazard, and siuce nonsmokers are healthier than 
smokers, it seems onIy natural that not smoking would save money spent 
on health care. Yet in economie studies of health care it has been difficult 
to show who uses more dollars - smokers, who tend to suffer more from a 
large variety of diseases, 01' nonsmokers, who eau accumulate more health 
care costs beeause thcy live longel'. 
The Sm'geon General reported in 1992 that "the estimated average 
life-timc medical costs for a smoker exceed those for a nonsmoker by more 
than S6,000." I On the other hand, Lippiatt estimated that a I percent de-
cline in cigarette sales increascs eosts for mcdical care by $405 million 
among persous 25 to 79 years aId.' Manning et al. argue that although 
smokers inclU' higher medical eosts, th cse are balanced by tobacco taxes 
aud by smokers' shorter life spans (and hence their lower use of pensions 
and llllfSing homes).' Leu and Schaub showed that even wh en only health 
care expenditures are eonsidered, the longel' life expectancy of nonsmokers 
more than offsets their lower annual expenditures.4 
We have analyzed comprehensively the health care casts of smok-
ing. In doing sa we have distinguished between the assessment of differ-
enees betwcen smokers alld nonsmokers and the assessment of what would 
happen af ter interventions that changed smoking behavior. Would a non-
smoking population have lower health care eosts than one in whieh some 
people smoke? Are antismokillg interventions economically attractive? Wie 
sought to answer these qucstions and to determinc the consequcnces for 
health poliey. 
Methods 
Analysis of Smokers and Nonsmokers 
We examined the effect of smoking in the genera I population (a mixture of 
smokers and Bansmokers). \,/c studied the incidence, prevalence and tnor-
tality assaciated with five major categories of dis'ease - heart disease, stroke, 
IUllg ca neer, a heterogeneous gronp of other caneers, and chronie obstrue-
tive pulmonary discase (COPD). We used data on these diseases, in addi-
tion to mortality from all other canses, in an extension of the standat'd lifc 
tabIe, the multistate life tabie, that includes multiple health states, sueh as 
"alive, healthy" and "alive, with heart diseasc" 5,6 
Differences in the freqneney of the smoking-related diseases between 
smokers aud nOllslllokers are commonly expressed as rate ratios. Usillg 
these rate ratios, the prevalenee of smoking in the popnJation, and the age-
and sex-specific disease incidence of the slllokillg-related diseases in the 
mixed poplliation of smokers and nonsmokers, we can estimate the inci-
dence of the diseases separately among smokers and nonsmokers.6 
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Table 1 
Prevalence of smoklng* 
(In percent) 
Smokers 
Age (yr) Male Female 
0-14 0 0 
15-19 20 20 
20-34 39 37 
35-49 42 36 
50-64 39 27 
65+ 34 13 
* Data are averages for 1988-
1992 in the NetherJands. 12 
Assllllling that the relative 
survival of persons with these 
diseases is the same among both 
sl110kers and nonsmokers, two 
additional life· tables cau be 
caleulated - anc for smokers aud 
one for nonsmokers. The duee 
Iife tables diEfer with regard to 
Table 2 
Rate Ratios and Sensltlvlty Range 
Assoclated wlth Five categorles of 
Disease 
Rate Ratio 
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Category (Sensitivity range)* 
Heart 3 (2-4) 
Lung ca 10 (5.5-14.5) 
Stroke 2 (1.5-2.5) 
Other cat 2 (1.5-2.5) 
COPD' 25 (13-37) 
* Rate ralios refer to Ihe rate of Ihe 
disease in smokers as compared with 
nonsmokers. The lower and upper 
bounds of the sensitivity range were 
calculated as 1+0.5(RR-1) and 
1+1.5(RR-1), respectively, where RR 
denales Ihe rate ratio. 
tThis category includes neopJasms 
except for stomaeh, co!oreclal, lung, 
breasl, prostate, and skin cancers, and 
benign tumors. 
:t:COPD denales chronic obstructive 
pulmonary disease. 
the incidence of thc smoking-relatcd diseases and therefore in their 
associated prevalence, disease-specific 1110rtaJity, and overall mortality. 
Becanse of the difference in mortality, more people remain alive in the life 
table for ua us mokers than in the table for smokers, particularJy in the older 
age groups, and there are corresponding differences in lifc expectancies. 
In constructiug the life tables, we used epidemiological data on the 
incidence and pl'cvalence of the diseases7- iO, data on mortality from Statis-
tics Netherlands ll , data on smoking (TabIe 1)12, and rate ratias from an 
overview of the international Iiterature,13 We tested the sensitivitl' of the 
analysis by recalculatiug the life-tables with excess risks (rate ratio -1) that 
were 50 percent higher aud 50 percent lower (TabIe 2), 
The medical casts we used were based ou a study that allocated total 
health care casts in the NetherJands in 1988 (39,8 billion guilders, or $19,9 
billion against the present exchange ratel to categol'ies of age, sex, and dis-
case, 14 We used the Dutch populatiou of 1988 and the prevalence rates of 
the smoking-related discases from the Iife table for mixed smokers and non-
smokers to estimate thc cast per case of disease accofding to age aud sex. 
The remaining costs were assigned to "per capita costs fol' all other 
discases" (in categories according to age and sex) by dividing the casts bl' 
the number of people in the category in question. Using the pel' capita costs 
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for each disease and the "all other disease" costs we calculated the health 
care costs for the populations included in the tluee life tables. 
Assessment of the Effect of Complete Smoking Cessation 
The estimated health care cost derived from the life table of nonsmokers 
eall be seen as an es ti mate of the cast of health care if na one ever smoked. 
It does not provide an estimate of the health care costs if all smokers 
stopped smoking. In the latter case, the size of the elderly population would 
illitiully be the same as in the mixed population of smokers and nOllsmok-
ers. For it to become similar in size to the elderly popnlatioll amollg n011-
smokers, in which more clderly people are alive, wonld take several years, 
even if mortality declined rapidly. 
To describe the epidemiological changes and the changes in the popu-
lation over time, a dynamic model is needed. Fot' this pUl'pose, we llceded a 
series of linked life tables, one for each point in time, with the population 
at a given age (a) and time (t) depending on the population at age a-i and 
time t-l, and on illcidcllCe of clisease alld the associated mortality between 
t-i and t. We used the Prevent Plus computer program, which is designed 
to evaluate Îlltervcntions cOllcerning risk factor dynamically. 6,15 
This dynamic analysis produces a projection of future health care 
casts. Ta assess the economie attractiveness of all iutervention that would 
make smokers quit, these costs are compared with those expected when na 
intervention is made. One difficulty in such an evaluation is the fact that 
most people prefer to receive benefits as sa on as pos si bie, and to postpone 
payments. Economists call th is phenomenon "time preference" 16,17, and it 
is taken iuto account by discoUllting the future henefits and costs - that is, 
those further away in time are given Iower weights in the overall evalua-
tion. 
The degree of time preference is expressed in the discount rate. Typical 
va lues range Erom 0 to 10 percent, with 0 percent meaning th at there is no 
discounting and no time prefel'ellCe and 10 percent meaning that there is 
strong time prefel'ence. Since there is na generally agreed-upoll discount 
rate, we used varions rates (0, 3, 5 and "10 percent) in evaluating the intel'-
vention. 
A second difficulty in evaluating future costs and benefits is deciding 
how far into the future the analysis should go. There is no generally agreed-
upon duration of follow-up time in this type of analysis. For each projec-
tion of disconnted costs and bellefits, we therefore report the dl1ratioll of 
follow-up at which the benefits and costs expected in the fut ure exacdy 
balance each other (the break-even year) - the point at which carrying out 
the intervention is neither more nor less economically attractive than not 
doing sa. 
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Figure 1 . Estlmated Annual per Çapita Health Care Costs for Outch Men In 1988 and 
for the Male PopulatIon in a Life Tablej According to Age and Smoking Status. Per 
capita health care costs for women in the same age groups are very simIlar to those 
for men. 
Results 
Figllre 1 shows the auunal per capita health care casts for male smokers 
and nonsmokers 40 to 89 years aId, in 5-year age gronps (the casts for 
women in the same agc gronps arc very similar). Pcr capita costs risc 
sharply with age, increasing alm ast 10 times from persons 40 to 44 years 
of age to those 85 to 89 years of age. In each age gronp, smokers incnr 
higher casts than nonsmokers. The difference varies with the age group, bnt 
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among 65-to-74-year-olds the casts for smokers are as much as 40 percent 
higher among men and as mnch as 25 percent higher among women. 
However, the auuual cost pcr capita ignores the differcllces in longev-
it}' between smokers and nonsmokers. These differences are substantiaI: for 
smokers, the life expectallCies at birth are 69.7 for men and 75.6 for 
wamen; for nonsmokers the life expectancies are 77.0 and 81.6 (these life 
table estimates agree very weil with the empirical findings of Doll et al. "I. 
This meallS that man)' more nonsmakers than smokers live to aid age. At 
age 70, 78 percent of male nonslllokers arc stîll alive, as compal'cd with 
ani)' 57 percent of smokers (among wamen, the figm'cs are 86 percent and 
75 percent); at age 80, men's survival is 50 percent and 21 percent, respec-
rivel)' (among wamen, 67 percent and 43 percent). 
These differences in the numbers of elderly peop!e have a profound 
effect on the health care casts for the population, as Figure 1 shows. In the 
yonnger agc groups, in which mortality even among smokers is qllite low, a 
population of smokers has higher health care casts than a population of 
nonsmokers, in the groups of men 70 to 74 and over (and those of wamen 
75 to 79 and over), the lower per capita cast of the nonsmokers is out-
weighed by the greater number of peop!e remaining aHve. 
As Figure I shows, the nonsllloking population as a whole is more 
expensive than the smoking population. The area between the curves in 
which the smokers have higher health care casts than the nonsmokers is 
smaller than the area between the curves in which the nonsmokel's have 
higher health care casts than the smokers. This is shown in greater detail in 
Tab!e 3, where the total health care casts for the mixed, the smoking, and 
the nonsmoking poptdation are presented according to disease category. 
All the sll1oking-related diseases (with the nota bIe exception of stroke 
among men) are associated with higher costs in a population of slllokers, 
and lowel' costs in a population of nonsmokers. This l'elation is particularly 
strong for the diseases with the highest excess risk: lung cancel' and COPD. 
However, in the mixed population of smokers Bonsmokers, smoking-re-
lated diseases account for only 19 percent of total costs among men and 12 
percent of total casts among wamen, and the costs of all the other diseases 
have precisely the opposite relation. In a poptdation of smokers the casts 
associated with all the other diseases are Ie ss than th ase in the mixed 
population: 14 percent Ie ss for men and 18 percent Ie ss for wamen. Among 
nonsmokers, the casts of all the other discases are higher: 15 percent for 
men and 7 percent for women. 
The risk for the diseases not related to smoking is considered equal for 
smokers and nonsmokers, but the nonsmokillg popnlation lives langer and 
therefore illcurs more costs dlle to thase diseases, particularly in aid age, 
when the casts are highest. On balance, the total casts for male and female 
nonsmokers are 7 percent and 4 percent higher, respectively, than for a 
mixed population, whereas for smokers the total casts are 7 percent and 11 
percent lower. 
Table 3 also shows that changing the assumptions about the excess 
risk associated lVi th smoking-related diseases by as much as 50 percent in 
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Table 3 
Health Care Costs tor the Three Populations Studies with Llle Tables, 
According to Sex and Disease Category, wlth the Ratlos ot the Costs tor 
Smokers and Nonsmokers to Those tor the Mixed PopulatIon ContaJning 
Both. 
Sex and Smokers: 
Nonsmokers: Disease Population Mixed 
Category* Populatlo" Mixed PopulatIon 
...................... _-.................................................. -...... ' ................................ _._ .. ................................. 
Mixed Smokers 
Non-
smokers 
-.............. -...................................... 
miflionsaf$ cast ratio (sensitivity rangeJt 
MEN 
Heart 525 676 371 1.29 (1.18-1.35) 0.71 (0.84-0.61) 
Stroke 416 390 428 0.94 (0.91-0.97) 1.03 (1.06-0.98) 
Lung ca 114 211 33 1.85 (1.76-1.87) 0.29 (0.44-0.22) 
Other ca 226 254 203 1.12 (1.05-1.18) 0.90 (0.97-0.83) 
GOPD 165 275 23 1.67 (1.72-1.63) 0.14 (0.23-0.11) 
Other 6360 5463 7284 0.86 (0.89-0.84) 1.15 (1.09-1.18) 
Tolal 7806 7270 8342 0.93 (0.95-0.92) 1.07 (1.04-1.09) 
WaMEN 
Heart 386 538 330 1.39 (1.24-1.48) 0.86 (0.93-0.79) 
Stroke 510 571 502 1.12 (1.04-1.19) 0.98 (1.01-0.96) 
Lung ca 23 70 9 3.10 (2.61-3.32) 0.39 (0.55-0.31) 
Other ca 297 387 264 1.30 (1.16-1.42) 0.89 (0.95-0.84) 
GOPD 102 254 20 2.48 (2.45-2.45) 0.20 (0.31-0.15) 
Other 9358 7653 10013 0.82 (0.87-0.79) 1.07 (1.04-1.09) 
Total 10676 9473 11138 0.89 (0.92-0.87) 1.04 (1.03-1.05) 
* COPD denoles chronic obslructive pulmonary disease. 
tThe sensitivity range was calculated with Ihe lower and upper bounds of rate 
ratlos in Table 2. A lower rale ratio reduces Ihe difference between smokers and 
nonsmokers in the incidence, prevalence, and mortality from smoking-related 
disease. Therefore, nonsrnakers avert fewer cases of smaking-related disease 
(leading to lower savings) but simultaneausly gain less in Ufe expectancy 
(Ieading 10 lower added costs from ~atherW diseases). For most smoking-relaled 
diseases and ·other" diseases, lower rate ralios make Ihe difference in cosls 
smaller. 
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either direction does not change the conclusion, except in the case of 
stroke. The age-related increase in ineidence is steepest for stroke, and there 
is also an age-related increase for stroke in the cast pel' case; therefore the 
health care casts assoeiated with stroke are the 1110St sensitive to changes in 
life expectancy. 
Because of the casts of other diseases, the population of nonslllokers 
has higher health care casts, partly because these casts increase with age. 
To test the sensitivity of the analysis to th is age-related increase, we recal-
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Figure 2 - Percent changes in tatal health care costs for the male populatio" aftar 
smoking cessatlon, as determined in adynamie analysis, according the "umber of 
years slnce cassatIon, with na discounting and with three discount rates. 
The labels show Ihe ubreak-evenm years, when Ihe cost and benefJt of Ihe intervention 
balanee each ather. Shorter follow-up times make smoking cessation attractive 
economically, and longer follow-up makes it unaUraclive. With 10 percent discounting,.lhe 
break-even year is later than 50 years. 
culated the three life tables, keeping the health care casts assaeiated with 
"all ather disease" at the 65-ta-69-year-ald level far people over the age of 
65. The casts far the mixed papulatian and far the nanslllaking papulatian 
became virtually the same, and thase far the smoking papulatian were still 
the smallest, albeit by a smallmargin. 
Figure 2 shows what the economie consequences would be if all smok-
ers stopped smoking. Aftel' this abrupt change, the tatal health care casts 
for men (the "no discounting" curve) wauld illitally be lawer than they 
wauld have been (by up ta 2.5 percent), because the incidence of smaking-
related diseases amang the farmer smokers would decline to the level 
amollg llonsmokers. Prevalellce rates start to dedille, costs dedine, and the 
intervention shows a benefit. \Vith time, however, the benefit reverses itself 
to become a cast. The reason is that alang with ÏtlCidence and prevalence, 
smoking-related mortality declines, and the papulation starts to age. Grow-
ing lllunbers of people in the higher .ge groups mean higher casts for 
health care. By year 5, the benefit del'Îved from the presence of the new 
nonsmokers starts to shrink, and by year 15 these farmer smokers are pro-
ducing excess casts. Eventually a new steady state is reached in whieh casts 
are about 7 percent higher - the difference between the mixed and nan-
smoking populations. 
The health care casts of smoking 289 
Figure 2 shows the consequences of discollnting the projected costs 
and benefits by varions percentages. It is apparent that discounting, even at 
a rate as low as 3 percent, has a hl1ge impact, and this impact becomes 
greater as the costs become more distant in time. 
Having all smokers ql1it becomes economically attractive when the 
future benefits are largel' than the future costs 01') in terms of Figllre 2, 
when the area below the X axis is biggel' than the area above it. From the 
figme it is clear that this depends heavily on the duration of follow-up time 
considered and on the discount rate. With a shorter evaluation period and 
higher discount rates, stopping smoking looks economically more attrac-
tive. \\'ith a longel' evaluation period and lowel' discount rates, qnitting 
smoking loses its economie advantages. The break-even year, when the ini-
tial benefit is exacdy balanced by the eventual cost, occurs af ter 26 years of 
follow-up when there is no discounting, af ter 31 years with 3 percent dis-
cot111ting, and aftel' 37 yeal's with 5 percent discollnting. At 10 percent dis-
cOlluting, the break-even year occurs aftel' more than 50 years and may not 
occur at all. 
Discussion 
This study shows that although per capita health care costs for smokers are 
higher than those of nonsmokers, a nonsmokillg population wOllld have 
higher health care costs than the cmrent mixed population of smokers and 
nonsmokers. Yet given a short ènough period of follow-up and a high 
enongh discount rate, it would be economically attractive to eliminate 
smoking. 
Some eadier studies have had differing results, pardy because many 
have focused on costs attributable to smoking. From rate ratios and the 
prevalence of smoking in a population, the proportion of the total number 
of cases of a disease that can be attributed to smoking, - the population 
attributable risk - can be caleulated." Given the costs according to disease, 
one can calcnlate the casts attdbutable ta sllloking.20 For instance, in the 
life table population of mixed smokers and nonsmokers about 8 percent of 
total health care casts among men and almost 3 percent of tota! costs 
among women can be attribllted to smoking. Attriblltable costs, however, 
ean be interpreted as a potential savillg only when the diseases do not affect 
martality. In the case of most sllloking-related diseases) redllctions in 
smoking reduce mortality, creating new opportunities for 1110rbidity from 
other diseases in the years of life gained. 
Other studies of this subject estimate lifetime health care costs, taking 
the differences in life expectancy into account, and find that smokers have 
higher medica I costS. 3,21,22 In our stndy, lifetime costs for smokers can be 
caleulated as $72,700 alllong men and $94,700 among women, and life-
time costs alllong llonslllokers can be caleulated as $83,400 and $111,000, 
respectively. This amounts to lifetillle costs for nonslllokers that are higher 
by 15 percent amOllg men and 18 percent among women. 
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The studies cited abave appl)' disconnting to the lifetimc cast estimate. 
Because casts incllrred at cIder ages arc discounted morc, this approach 
rednees lifetÎ111c casts for nonsl11okers more than those for slllokers. For 
example, when one applies discOlUlting to onr lifc tables for smokers and 
l1onsmokers, smokers have higher health care casts WhCll thc discount rate 
is at least 4.5 percent in men or at least 5.5 percent in wamen. Wie disagree 
with this approach, however. Discounting should be used for purposes of 
evalnation and should not be applied in a descriptive context, sllch as the 
estimation of lifetime casts. 
DUf analysis is not very sensitive to snbstantially different values in 
the rate ratios. Neither is it very sensitive to the age-related increase in the 
cost of "all other diseases"; that is, an increase that is less steep in the 
United States than in the Netherlands will not lead to different conclnsions. 
Inclnding additional smoking-related diseases could change results only if 
they generate lllorhidity and costs without raising the excess risk of lllor-
tality. There may be some of these conditions, such as cataracts, but they 
are unlikely to change outcome. Fol' example, in our data all eye diseases, 
1110St of which are not related to smoking, account for about 1 percent of 
total health care costs. 
This study relied on rate ratios from epidemiologie studies to express 
the differences between s1110kers and nOllslllokers. To the extent that the 
ra te ratios do not describe these differences sufficiently, the results will be 
affected. Fot' example, the mnch lower cost for Inng cancel' among female 
smokers than among male smokers (Tabie 3) is hard to explain physiologi-
cally. But as long as the smokers have higher rates of lung cancer than the 
nonsmokers, snch shortcomings of the data will not affect the overall con-
clusions. 
The results of this study illustrate the ambiguities in any economie 
method of evaluation. Even a well-designed study of this type is marred by 
inevitable al'bitrariness concerning what costs to incIude, which discount 
rate to apply, and what duration of follow-np to use. There are differences 
of opinion - on the diSCOllllting of Iifetime costs, for example, and the 
evalnation of long-term effects.13,24 Recent effol'ts at standardizatioll \ViII 
remedy same of the arbitrariness2s-27, but fllndamental problems with the 
method stillremain. 
Finally, with respect to public health policy, how important are the 
casts of smoking? Society clearly has an interest in th is matter, now that 
several states are trying to reeanp Medicaid expenditures from tobacco 
firms and the tobacco companies have agl'eed to a settlement. Yet we be-
lieve that in formulating public health policy, whether or not smokers im-
pose a net financial bnrden ought to be of very Iimited importance. Public 
health policy is concerned with health. Smoking is a major health hazard, 
so the objective of a policy on smoking shonld be simple and c1ear: smok-
ing should be discouraged. 
Since we as a society are clearly willing to sp end money on added 
years of Iife and on healthier years, the method of choiee in evalnating 
medieal interventions is cost-effectiveness analysis, which yields costs per 
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year of life gained. Decision makers then implement the interventions that 
yield the highest return in health for the bndgct." We have 110 doubt that 
an cHcetivc antisl110king poliey fits the bill. 
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PART VI 
The evolution of senescence 
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Introduction to Part VI 
This paper presents a different outlook to the same problem of the . fmure developments of morbidity. The basic propositions of Fries are that life span is fixed, and that chronic degenerative diseases can 
be postponed til! aftel' the age of 'natural death' (Fries, 1980). Mortality 
can not decrease anymore, because the poptJ!ation of the USA (and that of 
the Netherlands) has almost reached the 'naturallimits', but degenerative 
disease eau. Others have pointed to the lllany contradictions in Fries' paper 
(Manton, 1982). Fries predicted the end of the mortality declitlC in aperiod 
when lllortality ratcs were declining sharply, even at au nnpl'ccedented 
tempo among the elderly and the oldest old. He stated that the population 
of USA had nearly reached their 'natural' life span, while at the same time 
he deelared that 80% of all causes of death were from chronic degenerative 
diseases, th us preventabie. 'Natura!' death was not to be caused by de-
gCllcl'utive disorders (but cellnlar senescence), while those dying at extreme 
cId age suffer characteristically from a wide range of degellerative diseases. 
Thc propositions of Fries should be tnrllcd inro questions: 
Is life span fixed, and if so, how and at what age? 
\Vhat is the relation betwecll chronie degenerative disease and 'natural' 
death? Why increase both exponentially by age? 
These questions arc hard to answer with human data. The long life expec-
tancies we cnjoy these days are uuprecedcllted in history, aud the extreme 
old are born in' aperiod wh en mortality was high and life expectancy, al-
thongh inercasing, was still very short. But sencseenee and senescent death 
is ubiquitous in all anima I species kept under sheltered conditions 
(Medawar, 1952). Since Darwin, we know that there has to be a good rea-
sou for snelt an nbiquitol1s charaeteristic. Indeed, as nOll-aging individuals 
seem to have a sedans reproductive advantage above aging individuals in 
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'the strnggle for Iife', there has to be a ver)' good reason indeed wh)' natura I 
selectioll has nevel' weeded out seneSCCllce (Kirkwood, 1985). 
In chapter 26, wc \ViII review themaillcvolutional.ytheodesofscll.es-
cence. Thc comm011 foundation of these theories is that natural selection 
has not been conccl'ucd with aId age, as we did rarely live long enough to 
get old. We wil! die an)'wa)', so survival is onl)' useful insofar our offspring 
bCllcfits. Nlaintcllance mcchanisms are tuned to he good cllongh to get 
through the norm al expectation of Iife 'in the wild', and to be able to raise 
health)' offspring, but not so good as to last forever (Kirkwood, 1996). 
The evolutionary theory of aging gives answcl'S to the central ql1CStiOll of 
(he fut ure evolution of ll1ol'bidity: 
Is life span fixed? Yes, but it is not fixed by 'hard' prograuuned limits, 
but by 'soft' probahilistic limits, a result of gelletic vadance and stochas-
tic damage (lvIanton & Tolle)', 1991). There is a large variation around 
an 'optimal' Iife span (Kirkwood, 1985). Senescent death is not the end 
result of a genetic program, but of neglect of energy consnming mainte-
nance systems. As a consequence, the numbers of genes and gene interac-
tions involved has to be tremendons, and 'genetic engineering' of the end 
of life seems an unlikel)' option (Kirkwood, 1996). 
Is senescent ll10rbidity independent of senescent mortality? This is an obR 
viously untenable assumptioll. The hU1l1an organism is a complex llllllti-
component systell1, each component havillg its own aging rate (Nlanton, 
1982). These rates are optimalised b)' the same life histol')', but which stil! 
allows large variatioll in these rates. Senescent death will be detennined 
by the fastest aging rate of a life sustaining component, senescent disabil-
it)' b)' all components which age faster but are disabling, not fatal. If an 
effective interventioll delays the failure of a life sustaining component, 
the aging rates of the disabling components ma)' or ma)' not be dela)'ed. 
If not, disabilit)' will I'eplace death. 
\V,'e conclude that the evolutionar)' theor)' as most 'pl'Oximal' biologica I 
explanation of senescence has to be the background of an)' future expecta-
tion of morbidity in Iow mortality coulltries. As long as this theory is 
standing, forecasts of hu man (disabilit)' adjusted) life expectanc)' which are 
inconsistent with the ll1aill predictiolls are to he rejected. 
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The expiry date of man 
• 
Abstract 
In industrialised cauntries, martalit)' and marbidit)' are daminated b)' 
age related chranic degenerative diseases. The health and health care 
needs of future papulatians will be heavil)' determined b)' these candi-
tions of aid age. Twa appasite scenarias of future marbidit)' exist: 
marbidit)' might decrease ('compress') , because life span is limited, and 
the incidence of disease is postponed. Or marbidit)' might increase 
('expand'), because death is dela)'ed more than disease incidence. 
Optimalit)' thear)' in evalutianar)' bialagy explains senescence as a 
by-praduct of an aptimised life histary. The thear)' clarifies haw senes-
cence is timed by the campeting needs far repraductian and survival, 
and why this leads ta a generalised deteriaratian of many functians at 
many levels. As death and disease are not independent, future marbid-
ity will depend fram duratian and severity of the pracess of senescence, 
partI)' determined by health care, palliating the disease severity but in-
creasing the disease duratian b)' pastpaning death. If marbidity might 
compress, health care needs will surely expand. 
I n this artide, we discuss expectations of future mOl'tality, morbidity aud health care casts in developed COlultries with high levels of heahh aud health care. The use of such expectatious indude estimating future de-
mands fOl' heahh care, identifying the types of services to be provided (e.g. 
hospita I care, nursing care, ot other types of institutional care) and deter-
mining the prevalence and range of disabilities that exist in a population, to 
mention a few. I Examples abound of the uses of forecasts of the size and 
health status of the population for health policy planning. Particularly the 
expected illcreases in chronic conditions of aId age sneh as dementia, hip frac-
tures, or heart failure are a matter of concern.'''' The projected growth of the 
elderly population, those aged 75 and older, caused bath by high binh rates 
in the past and incl'eased survival naw and in the future is the main determi-
299 
300 The evo/utioll of seneSCCllce 
nant of escalating needs for long term cul'c.3 Since nearly all fntnre residents 
of nursing homes and sufferers from disahling diseases of old age hetween 
now and 2060 have ah'eady heen hom, forecasts of the size of the health 
care needs of the elderly popldation rely heavily on estimates of future sur-
vival, and the health status of those surviving. Such long term forecasts of 
future morbidity and mortality to he based on an understanding of age re-
lated disorders. Why does ageing, or better senescing, happen?' 
The hallmark of SCllcscence is thc pl'ogre~sive increase in age specific 
death rates following puberty, observed in allmammals and many other spe-
cies kept Ullder conditions ideul for survival.6.S Underlyillg th is progressive 
il1crease is a gencralised deterioration in a braad spectrum of physiological 
and metabolical fllllctions. 9,10 These physiological decrcmcllts leave the 01'-
ganism incl'casingly vnlnerable to a variety of intrillsic and extl'Ïnsic factors 
that may cause disease, disahility and death. The evolutionary theory of age-
ing explains seneSCCllce as a process tailored by natural selectioll in evolution-
ary time. 
In this paper we will first explain the fundamentals of evolutiOtlaly the-
ory. Then we discuss consequences for future public health. 
A history of life and death 
Neo-DarwÎnian cvolutionary theory states that the hl1man geu01ne is the fe-
sult of the forces of natural selection thl'Ough evolutionary time-scales. 1l The 
evolutionary success of a species is determillcd by the Ilfitness" of its illdi-
viduals, the increase or decl'ease of numbers of desCClldants through sncces-
sive genemtions. 12,I3 
11 Genetic neglect 11 
Figul'c 1 shows thc mOl'tality history of Dntch men and women in the tWCllti-
eth century. While the life expectancy increased tremendously, the age de-
pendent mortality changes are remarkably similal' in all periods.' Child mor-
tality is highest immediately af ter conception, and drops to 10w levels at the 
end of childhood and the heginning of puherty. Even in the darkest of ages 
and the harshest of conditions, all our forefathers and -mothers succeeded to 
reach adulthood and have at least one child. Not a single one in our long line 
of ancestors died in infancy Ol' childhood. Genes commanding juvenile sur-
vival must be very good indeed. J4 
But aftel' the onset of puherty the cumulative pl'Ohahility of both suc-
cessfnl reproductioll and (violent) death is increasing. In llatm"ul conditions 
the mOl'tality hazard is high, and relatively constant over age. The probability 
thar a perSOll wonld be dead - from hunger, injury, infection or predation -
increases sharply by age, long hefore old age is reached. The power of natura I 
selection, weeding out detrimental mutatiolls, is consequclltly decreasillg. 
Genes protecting survival at older ages are not selected for, because ageing is 
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Figure 1 - Mortality rates by sex, age and 3 perlods In the 201h century. 
rare, aud iuconsequential to prodllction and survival of offspring.6 Evolution 
does not care about elderll" 
This is the central pillar of anl' evalutianarl' theary of ageing: with or 
without senescence, the length of life is limited.6,15,16 In natm-al conditions 
mOl'tality from hunger, illjury, illfection or predation is so high, th at few indi-
viduals survive into oid age. 
A body is a disposable good 
There is an additianal reasan why senescence exists. Millions of years of 
ruthless campetitian have aptimised the life histary of a species.I'.I' Faad 
(energl') is nearly always in short snppll" Given similar physialagies and envi-
ronmental cOllstraints, the organisll1 that makes the more of scarce resources, 
will have the stronger lilleage of sllccessful descendants. There are choices to 
be made between illvestillg resources in repl'oduction Ol' sUl'viva1.9,15,16 
Some species invest in much offspring early in life, but at the price of 
high martality and short lifespans. Others adapt acaring strategy: they live 
long, but reproduce late aud little. Homo Sapiens is the 11ltimate carel' among 
mammaIs. His very long life span is related ta his very long youth, which 
again is related to the large size of his brains.7•19,2o The larger the brain is, the 
langer edncatian and parental care is needed ta make use of its fuU potentia!. 7 
But af ter affspring is able ta fend far itself, the parent is disposable from the 
point of view of natura I selection, 
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The alterllative name of the optimality theOl'}' of SCllCSCCllCC, the 
"disposable soma" theory, refers to thc disposable goods from economy.9,16 
An optimal product takes into account the expected duration of use of that 
product. It is a waste of resources to invest in il1creased durability beyond 
that duration. Fot' animals that is thc natural life expectallcy in rhe wild.!' 
Organisms who succeed in diverting this cllcrgy to more successfnl reprodnc-
tion will outcompete the more wasteful. Fitness, i.e. successfn! offspring, not 
survivorship, determines evolutional'Y success. 
Optimality theary is consistent with other, l1on-evo!ntionary, theories of 
ageillg. Thc evolntion theory gives all 'ultimate' explallation, wh)' stodHlstic 
"weal" and tear 1l aneVol' soma tic damage snch as oxidative stress by free radi-
cals canse senescence.:!1-:!3 LastÎ.ng damage is not inevitable: living beings are 
dynamic systems, capable of maintellance aud l'cpair. Damage happeus be-
cause maintenance and l'epail' become illcreasingly less cffective at older ages, 
when the body is disposable. 
Theories of adaptation 
The previolls explanations of sel1escencc arc ca lIed non-adaptivc. Animals are 
not selected 'because' they senesce. Senescence is a by-product of lack of se-
lection pressm-e anel an optima! life history. Altel'native theories state that 
sencseeuee cau be adaptivc; they are based on an argument of crowding. 
"Grollps " arc selected for sencsccncc, because the older individuals are dis-
cardeel, and lcave room for the healthy young. First, there is a circularity in 
this argument: the reason why the aId are unhealthy and subfertile is because 
they senesce. If the drcularity is excluded by stating that the aId are as 
healthy and as fertile as the young, it is hard to see how these groups might 
be disadvantaged, campared to groups with unhealthy elderly. 
Baseel 011 theories of adaptatio11 the existcncc of "suicide gelles" eau be 
predicted, genes which actively programme the end of life. This is for the 
same reason llulikely: there would be strong seleetion pressm-e for mutatiolls 
deleting these genes. At least in the short term, these immortal (healthy and 
fertiIe) 'escape 111utants' wonld outcompete the ageing mortals in numbers of 
offspl'ing. Sneh escape mntants have never been obsel'ved in nature. 
Disability and death from evolutionary 
perspective 
Optimality theory states that the age dependent occurrence of degenerative 
diseases is timed by the life history of om' aneestors. Energy consuming main-
tenance systems at multiple levels, from subcellular DNA-repair to normal 
functioning of the brain, \Vill assure more or less the same life span.'·lO This 
implies that diseases caused by senescenee are timed by the same process. The 
elistÎ.nction between fatal and disabling conditions only makes sense in hu-
man societies: in natura! conditions, a disabled hun tel' has fcw chances for 
survival. If one of thc systems is set tOD "lcw", and fails consistently to~ 
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SOOI1, natllral selection \ViII tend to increase the level at which the system is 
set. If persolls prone to early cancel' have less offsprÏng or less opportunity to 
rear them successfuIly, their genes will disappear. But conversely, if one of the 
systems is set toa 11 high ti, and would fail always aftel' the others, natural se-
lection wiIl tune it down. The saved resources are, in terms of natural selec-
tion, better used to boost fitness. The optima I balance bet\veen spellding 
"enough rr and spenclillg "toa much" in survival is not very sharp.21 Selection 
pushes survival to all optimum, but the pressllre is \Veaker the more this op-
timum is approached. This aHows for cOllsiderable variance of senescence 
rates. Not all people age at the same rate, and not all systems of an individual 
deteriorate at the same rate. 
The future of death 
As mentioned in the introduction, estimates of the future size of the popula-
tion of elderly in the foreseeable fut ure are nearly entirely determined by their 
survival. FiglU'e 2 shows the stationary life table populations of women of 
two periods, 1950-54 (age standardised mortality 0.0104 y'l, life expectancy 
73 year), 1985-89 (age standardised mortality 0.0062 y", life expectancy 80 
year) and of a hypothetical period with a life expectancy of 85 year (age 
standardised mortality 0.0038 y'l). This hypothetkal life expectancy and 
mortality are reached when the mortality would decline at the same (age spe-
dfk) rate as between 1950-54 and 1985-89, which would correspond to the 
period 2020-24. The stationary life table population assumes that all birth 
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alld 111ol'tality l'ates remain constant at the level of a certaill period. In 1950-
54, when the Iife expectancy was 73 years, 6.6% of the Iife table population 
was over 75 year and 1.2% over 85 year aId. In 1985-89, at a life expectancy 
of 80 y, 10.5% was over 75 and 3.1% over 85. In 2020-24, at a projected 
life expectancy of 85 y, an estimated 14.0 % would be over 75 and 5.3 % 
over 85. In the Netherlands in 1994, the population of 75 and older com-
prised 5.5% of the popnlatiol1; this Emetioll is relatively low as a consequence 
of the large post-Wor/d War baby boom cohort. However, these 5.5% con-
s(1ll1ed 28.8 % of all health care casts." In 2020 the sUl'vivors of the baby 
boom COh01't8 \Viii start l'caching 75 y, their llltimate sizc being determined by 
the mortality decline in elderly populatiolls, as mortality among the young 
and adult is already very low. Ta be valid, any prediction of further declines 
in mortality rates should thcl'efore involve a theory abont senescence. 
Based 011 evolntionary theory, we eau make predictions about senescent 
death. Death is not 'programmed' by death gen es, but the result of a genera I 
neglect of the genetic material at older ages, bath by lack of historical selec-
tion pressure and by imperfect maintenance. Life span is not fixed by 'hard' 
programmed limits, but by 'soft' probabilistie limits, a result of genetie vad-
ance and stochastic accumulation of damage.25 Major breakthroughs in 
'genetic engineering' of SCllcscent mortality arc very unlikely, as the numbcl' 
of genes involving maintenance at multiple levels is large and the potential for 
syllcrgy immense. 26 Opportunities for slowülg the rate of SCllescence are to be 
sought in decrcasing the rate of accumulation of damage, which is idcntical to 
a familiar concept to pnblic health practioners and epidemiologists: dimin-
ishing exposure to risk factors. 
The question how mnch mortality reduction can be obtained by further 
risk factor reductions is not without answers. \X'ith the llotable exceptioll of 
smoking", simple risk factor models bui!ding on classieal epidemiologieal 
techniques show but modest extensions of life expectancy by risk factor re-
dnctioll) in the order of magnitude of one to a few years.18,19 :i\tIore complex 
multivariate ma deis, using longitudinal data of the Framingham Heart Study, 
arrived at similar results.30 Predictions of 'natural' life expectallcies of more 
than 95 years and life spans of over 130 y are based on few and hard to ver-
ify observations of extinct cohorts barn befare 1880 and many assumptions 
about the 'tai!' of the distribution of deaths at ages above 110.31 The pl'Ob-
abi!istie nature of the end of life, predieted by evolutionary theory, foresees a 
long tai! of scarce survivors reaching extreme aId age, but the population life 
expectancy is little sensitive to these smallllumbers. 
Another approach to the pl'Oblem of an uncertain future is to study the 
recent past, alld extrapolate the changes needed to reach a certain lue expee~ 
taney.n Figure 1 shows the evaintiall of mortality in the twcntieth century by 
age (since 1900), and figure 3 by cause of death (since 1950) in the Nether-
lands. 
Dudng the fh'st half of the century, mortality declined predominantly dudng 
chi!d- and adnlthood of both men and wamen, the changes in middle age 
being more modest. In the third quarter of the century, the difference 
Figure 3 
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between men and women is astollishing. wlcn experienced Îllcreasing cardio-
vasc111ar disease and cancel' mortality, caused by coronary heart disease ulld 
smoking induced respiratory cancers, while among women death rates de-
cl'cased from all causes. The most recent period shows agaÎl1 striking changes 
benveen men and women, but now in opposite directions. Among men, car-
diovascular mortality is going down rapidly, and cancel' mortality seems to 
have reached its peak, ul1d starts declining now. But umong \Vomen, the 
mortality decline is levelling oEf since 1980; from 1950 till 1980, age stan-
dardized mortality decreased by 1.5% per year, from 1980 till 1992 by 0.6% 
per yeal'. The decrease in cardiovascular 1110rtality slowed down.33 Cancel' 
ulld respirator)' disease mortality have been stagnating since long, and all 
other causes are illCl'easing, aS amollg men. To increase the actuallife expec-
tancy among women from 80 (80.3 year in 1994) till 85 year, all cardiovas-
cular mortality (the only declining cause of death since 1980) has to be eradi-
cated, 01' alternatively the present downward trend in mortality from all 
causes (an annual decline of 0.6%) has to persist for the next 85 years. 
Obviollsly, the recent mOl'tality experience of Dutch women does not 
necessarily mirror the experience of all women of the developed wodd. In-
deed, one study, reconstructing mortality and census counts of four ta-
ciaVethnie populations in the USA, showed that female inllnigrants of 
Asian/Pacific origin have reached a life expectancy of even more than 85 
years.34 But fU'st, migrant populations are a healthy selection of the popula-
tion of origin, even more so because USA immigration laws only allowed the 
highly educated and healthy. Second, moribund immigrants may retum to 
their colllltry of OrigUl to die, biasing death counts. Thu'd, exaggeration of 
age is prevalent in most humall societies; the majority of Asian ll1igrants are 
foreign-born, and their exact birth-year is not known. 35,36 Fonrth, the actllal 
period life table is the result of the low 1l10rtality hazard of modern time, ap-
plied to the selected survivors of past (higher) mortality. An earlier demo-
graphic transition37 and alowel' historical mortality might explain the stag-
nating increase of life expectaney, also observed iu other highly developed 
countries sllch as the Scandinavian countl'ies. 38 Higher (pel'iod) life expectan-
des are possible in societies moving more rapidly through the epidemiological 
transition, but only for a while. As the birth cohorts exposed to the high pre-
transitional mortality rates die out, the high mortality selection eady in life 
will disappeal'. 
The recent mortality experience of elderly in 27 developed countries 
showed a steady and unprecedented deeline between the 1960s and 1980s." 
However, this mortality decline was observed in cohorts of survivors exposed 
to 19,h centuries' high child Illortality and mostly before reaching life expee-
taneies of 80 and higher. The (relative) mortality decline, particularly among 
women, tapered oH with age, as expected when the end of life is programmed 
bya 'soft' probabilistic limit." 
The life expectaney of Dutch women of 85 in 2020-24 (figure 2) was 
reached by projeeting this historieally steep mortality decline between 1950-
54 and 1985-89 among women, and ignored largely the levelling oH in the 
most recent period. If we project the period 1985-1994, it will take nearly a 
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century before Dutch women reach 85 years. 50 for the foreseeable future 
(female) life expectancies above 85 seem l1nlikely in the Netherlands. In se-
lected populations, aud in popl1lations moving rapidly through the demo-
graphie transition, higher period life expectancies are possible at the end of 
the transition, but only for a while. While among hun ter gatherers grandpar-
ents are uscful to their genetic offspring because of the prolonged period of 
jnvenile depelldellce39• the mailltellance schednle of Homo sapiens does not 
foresee great~gral1dparents. 
Compressing disability, expanding health care needs? 
The lllortality trends trom the recent past among Dutch wamen are illsuffi-
dent to l'each a life expectancy of 85 year within a half century. However, 
even moderate increases in life expectancy will sharply increase numbers of 
elderl)', as we showed previol1sly. The next question is how disabled these 
future populations wil! be. 
The ql1estion if and how senescent disability among these elderly wil! 
change depends basieally on the equilibrium of three forces. The first force 
slows the rate of senescence, decreases incidence, and 'compresses' sellescence 
mltil old age. The second force decreases the mortality hazard, increases dis-
ease duration and expands senescence. Disability aud death at old age are 
timed by the same process, aud successfully postponing death from one cause 
wil! increase disability from other causes. And the of ten forgotten third force 
'compresses' morbidity, not b)' reducing the numbers but b)' reducing the se-
verity of disease: bl' successfully preventing, neating or palliating disability. 
There is consequendy a paradoxieal relation between disability and health 
care need. Actual disability is the disability not prevented and not palliated. 
One of Fries' prime examples of compression of disease, stroke, has been 
bougllt in part by health care, namel)' treatment of hypertension, whieh costs 
1.3 % of the total Dutch health care budget.14.40.41 HistoriealIl', it is reason-
abie to aSSmne that the epidemiologieal transition causes both decreasing 
mortality and decreasing disability as most of the transition is caused by pre-
velltion of infectious diseases.41,43 However, in the fonrth phase of the transi-
tion, the age of delayed degenerative diseasé"', health care is one of the prime 
forces of change. The effects of health care on disability are mixed: health 
care increases disability by delayillg (cardiovascular) death, decreases severity 
by palliating disease symptoms and prevents disability b)' treatÎllg risk factors 
such as diabetes mellitl1s, h)'pertensioll and cholesterol. 50 it is no surprise 
that disability free Iife expectauc)' is increasing and age adjusted disability 
trends in elderly are stil! decreasing in the fOl1rth phase of the transition. 45 
However, if life expectancy increases further, senescent diseases, timed by the 
same evolutionary farces as senescent death, are nncovered. Health care 
needs wil! increase to reduce the ensuing disability. If and how disability wil! 
compress, wil! depend mainl)' on the effectivit)' of that health care, but there 
is Iitde doubt that health care needs wil! increase. 
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27 
General discussion 
and conclusions 
Introduction 
In thc genera I illtrodnctioll of thls thesis wc presented its main theme, the 
future evolutioll of morbidity. \V/e argllcd that 'generic' lllorbidity was the 
resultallt of diverse developl11ents in "arions diseases; to gaill illSight, we 
had to start from these specific developments. The blll'den of morbidity of a 
disease is determined by the prevalenee and severity of its stages, 'stocks' 
cal1sed by 'flows' of incidence, rcmissioll or death. Captnring changes asks 
for d)'namie modeIs, modelling both stocks and flows, deseribing the main 
epidemiologieal eharaeteristies of a disease. In part II we described a nnm-
bel' of diseases and their developments ovcr time, nsing sneh dynamic epi~ 
demiological models. In part III we proposed a methodolog)' to deseribe a 
large number of diseases simultaneousi)'. In part IV we developed an indi-
cator of public health that allows to snmmarize the disease specific results 
in a gencl'Îc indicator capable of measuring compression and expansion. In 
part V we had a brief look at the relation between health care eosts, life 
extension and primar)' prevention. In part VI, finalI)', we refleeted on the 
ultimate, biologieal eauses of morbidit)' and mortalit)'. 
This leads to three questions. Thc main research question of this thesis 
is: H\X1ill there be compression Ol' expansion of morbidity?". The two main 
eharaeteristics of the methods used are a disease specifie, epidemiologieal 
approach, and a reliance on modelling to describe the complex il1teractiol1s 
betweel1 morbidity and mortality alld to integrate data from variOl1S 
sourees. We therefore formulated the two additional questions: "What ean 
a disease specific approach cOlltribl1te to the l1uderstallding of compl'eSSiOll 
and expansion at the level o(ovel'all population health status?", and: 
"How can epidemiology and 1110delling teehniques be integrated into public 
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health modeIs fit to answer questions of compression and expansion on thc 
discase specific level, aud on the level of overall popnlatioll health?" This 
discussiol1 starts at the last questioll, aud will end at the first. 
Models of disease 
The model paradox 
The main research question is Dnc about fllture developments, or predic-
tion. Accordillg to Papper prediction and explanatioll arc closel)' related 
because they consist of the same elements: initial conditions, a theoretical 
framework, and all ontcome. Ir depends on which two out of three we 
take, provisionally, for granted to detel'lnine what is done. When we look 
for initial cOllditions, given a11 Ol1tcome <tud a theoretical framcwork, all 
explanation is giVCll. USillg initial cauditions aud theoretical framework 
allows us to make predictions. And of course, given initial conditiolls and 
outeome we ean put the theoretical fralllewOl'k to the test (poppel', 1961). 
Theoretical frameworks are necessary for explanation and prediction. 
The theoretical frameworks we use are in large part embodied in the mod-
els described: as snch models are no different from theoretical frameworks, 
they are a detailed specification of a eausal theory (MeClelland, 1975). The 
necessary explicitness of models is an asset, that makes them, in principle, 
bet tel' transferable and testable. But the epistemologieal status of models is 
no different from any theoretica I framework, and therefore we call 
COllcentrate on the nseflliness of models in Pllblic health research. 
The ma in advantage of models is that they allow the desCl'iption of 
very complex relationships. Complexity ensnes, among others, from rela-
tions of many to many varia bles, from non-linear relations between vari-
ables, and from dynamic variables that display time-dependent behavior. 
Rather paradoxieally the capacity to handle eomplexity aften turns 
into the largest disadvantage of modelling. Many modeis, including some 
of our own earlier work, are toa complex, defy explanation, and th us do 
not eomply with basic lllethodologicairequirelllents of reproducibilit)' and 
intelligibilit)'. But despite the ha bit of over-eomplexity models tend at the 
same time to be toD simple to answer research questions of interest. \Ve wiII 
illustrate this dilemma with the pl'Oblem of modelling multiple diseases and 
risk factors simllltaneously, and derive from its discussion the genera I rule 
how to avoid the dilemma. This mie ma)' not be exaetly ncw, but the dis-
cnssion ma)' prove enlightcning nevertheless. 
Populatioll heterogelleity 
A basic methodologie al pl'Oblem of a multiple disease and risk factor model 
is how to deal with population heterogeneit)'. Independence assumptions, 
as presented in chapter 12, facilitate a multi-disease model but rule out 
man)' interesting research questions where hetel'ogeneity Ol' disease depend-
encies are involved. People run different risks 011 disease incidence, and 
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conseqllelltly on pl'evalence and mortality. As shown in chapters 13 and 14 
this l'esnlts in lllortality selection: the higher mortality risk lowcrs the 
prevalence of people at this higher risk. 
Mortality sclection defeats straightforward ways to describe risk fac-
tor exposure in the population with a continuons distribution, as wOl1ld be 
preferabIe for most risk factors. Because perSOllS at the extreme of the dis-
tl'ibl1tion are at the highest risk, they are selectively rellloved fro111 the 
poplliation, with the consequence that the COlltÏl1l10nS distriblltion is not a 
good descriptioll of the exposure au)' more. Wie are aware of jast one multi-
variate risk factor model with contiuuous distribntiol1s that is able to deal 
with mortality selection, but it does so at the price of a host of restrictive 
assumptions (Manton & StaHard, 1988). 
A pos si bIc solution to' the problclll, but onc not pursued in this thesis, 
is to use a micro-simnlation technique. \Vhell a popl1lation is described at 
the level of the individual, an)' nnmbel' and type of re1ations bctwccn risk 
factors, discases, and causes of death ca11, in principle, be described. Ho\\'-
ever, while micl'o-simulation cau solve the hetel'ogcllcity problem, there are 
also drawbacks to the technique. 
The solutioll chosen in chapter 13 is to use a categorical risk factor 
distribution: diabetics alld non-diabetics. Dividillg the popnlation into 
(more) homogelleous subpopulations allows to give each its own disease 
and morrality risks. But problems remain. It will be clear that with multiple 
risk factors (and in particular with several exposurc categories pel' risk fac-
tor) the numbel' of subdivisions grows exponentially. This becomes even 
more true when, likc in ,the Prevent model, time lags betweell changes in 
risk factor exposure alld health cHects are taken into account (Gunning-
Schepers, 1989; Gunning-Schepers, Barendregt, & van der Maas, 1989) 
Yet another soll1tion, and one that has been used in chapters 15 and 
18 (as in the Prevent model), is ra ignore population heterogeneity (and by 
implication mortality selection) altogether, and describe the effects of 
changes in risk factor exposure for a homogeneous population. This greatly 
simplifies the model, but whether it pl'Oduces valid l'esults depends on the 
research qnestion. 
As was explained in part III in a homogeneolls population only substi-
tlltÎOll of diseases and canses of death exists, while in a hetcl'ogeneons 
poptdation in addition to sl1bstitntion also competitioll exists. \,\lhen the 
research qnestion explicitly addl'esses a conseqnence of changing competi-
tion, as chapter 13 does for the diabetes prevalence af ter heart disease 11101'-
tality reduction, th en of comse the model shollld aHow for heterogeneity. 
\X'hen, on the other hand, the consequences of eliminating a risk factor are 
assessed, as is done in chapters 20 and 24 with smoking, competition pla)'s 
110 role: it exists only when the excess mOl'tality risk of onc smoking l'elated 
disease changes (in this case, disappears), while thc excess risk for others 
does 11ot. Sa, unless one assumes that Cl1rrellt slllokers wOllld have excess 
risks for same diseases even wh en they ,,,ould never have smoked, competi-
tion wilI not affect outcome. 
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A general ruIe for 1ll0deIling 
This leads to the general rule to avoid the dilemma of toa complex modeIs 
that are still too simpie: for ever)' research question the model used should 
be the simplest Dnc capable of answerillg it. A cltstom-made model made to 
fit the research question, instead of a general, all-plll'pose, public health 
model (the original aim of the TAM-project, see genera I introduction). Not 
cxactly a ncw rule indeed, becanse it goes straight back to Ockhams razor, 
and even funher down to Aristoteles (Enc)'cIopaedia Britannica, 1995). 
Thus, where possible, static life table models should be used instead of 
dyn,unic ones, ane-stage disease models instead of llluiti-stage Dlles, and a 
h01l10gCllCOUS risk factor model illstead of a heterogeneons ane. GiVCll this 
parsimonious approach, models are very nseflll, becallse the causal struc-
ture and quantified nature allow to explain observations and make predic-
tions (see the heart disease chapters), and allow to derive which wa)' the 
balance of two opposing tendendes will go (as for example in the preven-
tion alld casts chapters, 23 and 24), alld eau help to estimate all incidence 
in cases where data are very weak or unavailable (chapters 4, 5 and 13). 
A demographic epidemioIogy 
For same time now epidemiologists are debating the retnrn to pnblic health 
of epidemiology as a sdence. Many epidemiologists feel that their craft has 
drifted away toa far from its original goal of improving public health, and 
is increasingly occnpied with measuring as precisely as possible attribntes 
that bear little or na relevance for popuIation health status (Pearce, 1996). 
While few epidemiologists will dispute that the application of their results 
should be the ultimate goal, it is less cIear how this "return to public 
health" should be achieved. Same proposals are cIearly not appredated by 
everybody (Anonymous, 1997). 
Most of the research reported in this thesis is based on the application 
of epidemiology in the field of public health, and from the ontset it was 
c1ear that we might need to get onr hands diny (see chapter 2). We make 
assumptions, combine results from different studies and from different 
populations, and nse data from 11on-epidemiologieal, administrative reg is-
tri es. In all cases a model serves as au organizing principle: specifyillg 
causal reIatiolls between the variables enormously reduces the set of possi-
bie valnes that the variables can take on. 
The basic ingredient of all these models is age, the main determinant 
of health. Each prevalent case at same age llecessarily must have become 
incident at same earlier age. \Vhen people start survivillg previollsly fatal 
infarctions at some age they will necessarily be prevalent at later ages, 
howcver shortly. To model age and the "age dynamics" explicitly we em-
ploy methods from demographl', in particldar the (mnlti-state) life table 
aud extensions that include time. A concise description of ont" modellillg 
approach could be "embedding epidemiology in a demographic frame-
\Vork", 
General discussion and conclusions 317 
Thc dcmographic framework provides not just a model for age, but 
also the translation to outcomes on the level of overall population health 
status. By design life tables take care of substitution of causes of death: this 
averts overly optimistic estimates of the health gain of interventions that 
aHect mortality. And the life table produces indicators of overall popula-
tion health status: life expectancy and disability adjusted life expectancy 
(DALE), which allow to measure compression and expansion. 
The marriage of epidemiology and, largely demographic, modelling 
techniques forms a powerful tooi to translate epidemiologieal findings to 
outcomes on the level of population health. 
Disease specific approach 
Costs aud benefits 
The choiee to describe population health status and the changes therein on 
the level of specifie diseases and causes of death has two immediate conse-
quences: 
There is a large number of diseases and causes of death, so a description 
of public health on the disease specifie level wil! somehow have to deal 
with th is large number. For example, Murray and colleagues described 
for the Global Burden of Disease project the epidemiology of 107 dis-
eases and conditions (Murray & Lopez, 1996b). 
The disease speeific descriptions have to be integrated to one description 
of popldation health status. This thesis presented to that end a multi-dis-
ease model and a mapping from disease specifie to generie morbidity. 
The disease specifie approach therefore requires a substantial eHort, as 
compared to anc which directly measures morbidity on same generic level, 
like disability. Moreover, there wil! always some morbidity left unex-
plained: even one-hnndred diseases and conditions wil! leave some morbid-
ity not accounted for, and at least some morbidity is difficult or impossible 
to explain by specifie diseases, particnlarly among the elderly. 
Some research questiolls do not require a disease specific approach. 
For example, those who just want to measure morbidity and its changes 
over time, are bettel' oH measurillg generic lllorbidity ditectly, and avoid 
the disease specific overhead . 
.Nlany policy oriented questiolls, on the other hand, stress the need fol' 
a discase spccific approach. Ta determine the effect of poliey illterventions 
on population health status requit°es a link between exposure to risk fac-
tors, the occurrence of and survival with specific diseases, and same gellcric 
outcome measure like Disability Adjustcd Life Expectancy (DALE). 
This is a strong argument fol' a disease specific approach, but there is 
also at least one strong objection: bck of data. Data on risk factor and dis-
ease epidemiology are as a rule scarce, not consistent between studies, alld 
time series are in most cases sllnply not available (Baan, Bonneux, 
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Ruwaard, & Feskens, 1997; BOllnellx, van de j\,'lheell, Gunning-Schepers, 
& van der }"/laas, 1996; van de NIheen, BOllllCUX, & Gunning-Schepers, 
19951. ""'Iuch of the eEfort of the disease specifie chapters of part II was 
therefore devoted to the assimilation of available data to consistent sets of 
illcidence, pl'evalence, alld monality. 
In summar}', there are strollg argul11ents for a disease specific ap-
proach, but that "lso cat'l'ies a considerable eost. \X'hethel' these casts afC 
justified, depends all the benefits. 
The benefits are largei)' determined b)' the disease specifie diEferences. 
We have alread)' pointed out that the original proponents of bath the ex-
pansion and compressioll hypotheses had different diseases in 111ind: 
Kramer and Grllellberg primarily congellital mental disordel's, and Fries 
primaril)' cardiovascular diseases (Fries, 1980; Gruenberg, 1977; Kramer, 
1980). And indeed we also find differences between diseases. A braad dis-
tinctioJl ean be made between 'fatal' and 'disablillg' diseases. 
Fatal diseases 
Much of our eEfort has been directed towards the main causes of death: 
cardiovascular discase and cancel'. The two grollps of cardiovasculul' dis-
cases modelled, C01'ona1'y heal't disease inclllding heurt failllrc, alld stroke, 
showed complex interactions and paradoxieal results (see chapters 4-7). In 
coronary heal't disease, expansion of morbidit}, is distinct, driVCll by de-
creasing mortalit)' (see chapters 4,5 and 7). Expansion is likell' bath in 
numbers of disabled and in severity of disabilit)'. Acute corona rl' heart 
deaths are exchanged for severe morbidit)', caused b)' chronÎc congestive 
heart failme. Because 'outEIow' (deaths) decreased in all disease stages, the 
milder stages acred as risk factor for the more severe stages, callsing a cu-
mulation of cases in the severe heart failme stage (chapter 4). 
In stroke, compression is likeI)' to have occurred mltil 1987 (chapter 6 
and 7). The main diEference between stroke and coronaI')' heart disease is 
the lack of major progress in survival aftel' a fit'st event. Therefore, the 
tra de oEf of disease for death was less pronounced. Ma)'be another diEfer-
cnee with corona1'y heart disease was a more prollOl111ced illcidence decline 
of stroke, caused probabi)' b)' treatment of h)'pertension (Bonita, 1992; 
Bonita & Beaglehole, 1986; Higgins & Thom, 1993; Klag & Whelton, 
1993; McGove1'll, et al., 1992). 
Recently, compression of stroke seems to have come to a stop. Since 
1987 (and the massive introduction of tlll'ombol)'sis in the )'ears befare), 
the prevalenee of vascnlar disease is expallding rapidly, increasing the risk 
for cerebro-vascular disease (chapter 7, (Higgins & Thom, 1993; Howard, 
1993)). But for bath cardiovascular diseases same dela)' of disease ulltil 
higher ages could be obserl'ed: prevalence decreased at )'Ollnger ages, but 
increased among the oldest aid. 
Chronic vascular disease is all important risk factor fol' other sen es-
ccnt diseases. Chronic vascular disease is a direct risk for the vascular de-
mentia (Kase, 1991), but also for Alzheimers' disease (Bretelel', Claus, 
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Grobbee, & Hofman, 1994; Breteler, et al., 1994; Edelberg & Wei, 1996; 
Hofman, et al., 1997; Slooter, et al., 1997). A certain pathwal' is declining 
mortality selection of ullfavorable ApoE subtypes, increasing the risks for 
both atherosclerosis and Alzheimers disease, (obviously not cxclnding other 
pos si bie pathwal's such as endothelial damage by Jl-amyloid peptides) 
(Thomas, Thomas, McLendon, Sutton, & MuIlan, 1996). A similal' effect 
of declining mortality selection will be causing an incrcase of diabetes 
mellitus. Diabetes is a risk factor for heart disease, whieh implies that dia-
betes prevalence is being kept down by excess mortality from heart disease. 
As this excess mortality declines, the prevalence of diabetes will conse-
quentll' go up (chapter 14). The risk of hip fractures increases also, to some 
extent because of increased tendency of falling in cardiovascular impaired 
patients (Grisso, et al., 1991). Consequentll', this expansion of chronie vas-
cular diseases wiII weigh heavily in the morbidity balance. 
In eaneer, the overall picture is different. Fh'st, smoking re1ated ean-
cers follow the smoking epidemie with an exceedingll' long lag time 
(Gunning-Schepers, 1989; Gunning-Schepers, Barendregt, & van der Maas, 
1989). Only in the eighties, society has started to reap the benefits of the 
declining proportion of male smokers sinee the sixties. Because most 
smoking re1ated caneers are highly fatal, the ensuing eompression of mor-
bidity is modest (see chapter 19). In the (solid) cancers with bettel' progno-
sis, the history is dominated by increasing case detection, both increasing 
incidence and decreasing mortality (chapter 8) (Black & Welch, 1993; Doll 
& Peto, 1981; Feinstein, Sosin, & Wells, 1985). This means that morbidity, 
caused by dia gnosis and tl'eatment is increasing, but the severe terminal 
disease is decreasing (de Koning, van Oorstmal'ssen, van Ineveld, & van der 
Maas, 1990). This is another example of exchange. Earll' detection in can-
cel' exchanges death and terminal disease fol' increasing nnmbers of cancel' 
cases. Incidence increases, prevalenee increases, but the severe disability of 
terminal discase is diminishing. 
Disabling diseases 
Two important 'disabling' diseases were considered: hip fmctures and de-
mentia. The traditional epitheton 'non-fatal' is less appropriate, as both 
are associated with important excess mol'tality. 
There is more to hip fractnres than osteop0l'Osis (see chapter 9). A hip 
fractnre is asenescent disease, a COllllllon endpoint of multiple discases, as 
dementia is and heart failme. Risk for hip fractnres is dominated bl' age 
and co-morbiditl', more than bl' brittle bones. As such, hip fractnres are 
bound to resist prevention, particnlarly of interventiolls targeting a single 
factor of senescence, snch as postmenopausal bOlle 10ss among women. 
Indeed, we hl'pothesize that at least part of the hip fracture incidence in-
crease in developed conntries is caused by augmenting llumbers of frail sur-
vivors with multiple diseases. 
Dementia is the most health care demanding chronic neurodegenera-
tive disease in the Netherlands (Koopmanschap, et al., 1994; Polder, 
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Meerding, Koopmanschap, Bonneux, & Van del' Maas, 1997). We esti-
mated the stage l'elared excess l110rtality in the Rotterdam study, whieh 
turned out to be considerabIe in mild stages as weil (see chapter 10). This 
has important consequcllces for strategies aimed to slow progression of 
disease. If these progression is slowed, stage related death is postponed too, 
causing disability from dementia to decrease Ie ss than expected. There is 
little hope that the burden of morbidity will decrease substantiall)', as long 
as the prospeets for pl'cvcntion rcmaill extremely limited. 
Other main eauses of disability have not been covered in this thesis. 
Restricted in time aud resources, we had to limit oUl'selves to only a fcw 
examples. In the Global Burden of Discase project the major burden of dis-
ab Uit)' is determined b)' mental disabilit)', which is cansed b)' congenital 
handicap, nelll'odegenerative disease and chronic psychiatrie conclitions 
(Murra)' & Lopez, 1996a; Murra)' & Lopez, 1996b). Estimates of causes of 
health care costs support this finding for the Dutch circumstances 
(Koopmanschap, et al., 1994; Polder, Meerding, Koopmanschap, Bonnellx, 
& Van der Maas, 1997). The second major cause of disabilit)' are the mus-
culo-skeletal conditions, whieh are predominantI)' all types of joint disease, 
inclnding dorsopath)' (Koopmanschap, et al., 1994; Mmm)' & Lopez, 
1996a; Mnrra)' & Lopez, 1996b; Polder, Meerding, Koopmanschap, 
Bonnellx, & Van der Maas, 1997). 
Compression or expansion of morbidity? 
From disease specific to overall morbidity and mortality 
Becanse of the large holes in our coverage of total disabilit)' we can provide 
only partial answers ra the question of fntul'c expansion or compression. 
But the partial answers serve ver)' weil to iIIustrate that the issue is more 
complex than the simple qnestion sllggests. 
Fntllre disability in low mortality countries is governed by senescellt 
diseases and mental disability. Senescent diseases are characterized b)' the 
expollential increase of the occurrence of disease by age (Carnes, 
Olshansk)', & Grahn, 1996; Medawar, 1952), mental disabilit)' b)' various 
callses of mental disorders. The main mental disorders are caused by 
neurodegenerative diseases (and are fundatnentally senescent diseases), by 
congenital mental handieap or b)' chronic ps)'chiatric conditions. This the-
sis does not consider congenital mental handicap and chronic psychiatrie 
conditions, and is focused on senescent diseases. 
The future of senescence is detennined by changes in incidence, disease 
duration (mortality) and disease severit)'. Three types of epidemiologieal 
change may cause compression: 
The first, and by far the most easy to accomplish, is increasing mortality. 
As th is is contrar)' to the primar)' aim of public health, we do not pursne 
the possibility. 
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The second is to shorten disease dnration by delaying incidence without 
dela)'ing death. Fries took the example of stroke (see chapter 6; (Fries, 
1980)). Indeed, as long as the force of mortalit)' among patiellts does not 
decline, mortality fro111 other causes will cut short disease dnration at 
older ages. But compressioll of stroke stopped since 1987 (see chapter 7), 
and not onll' in the Netherlands (Howard, 1993; McGovern, et al., 
1992); other examp!es of dela)'ed illcidence are scarce. 
The third wa)' to achieve compressioll is by decreasing disease severit)'. 
Changes in disease sevedty have largely been ignored in the compression 
or expansion debate, but most health care is devoted to palliatillg sl'mp-
toms of disease: fighting pain, alleviating discomfort, rehabilitating the 
disabled. 
Thl'ee types of epidemiological change may canse expansioll: incl'easing 
incidellce, lengthening disease duration or intensifying disease severity. 
Increased incidence ma)' be caused bl' increased risk or stepped up case 
detection. Cancel' screening is an example of a health care illtervention 
which canses disease pl'evalence to rise because of increased case finding 
and increased survival. The disabilitl' balance ma)' nevertheless be posi-
tive as sevel'e terminal disease may be foregone. 
The second cause of expansion is delal'ing death hom degenerative dis-
easc by successfnl interventions that prevent patients to die. The saved 
patients wiII progress in the disease process, perhaps more slowi)' (see 
chapter 4). 
Thc same proccss may cause patients to accunlUlate in the more severe 
disease stages, th us intensifying average disease severity, the third canse 
of expansion. As health care is more and more successfnl to avert death . 
fro111 acute evcllts, the patients will ultimately fade away in terminal 
chronic disease. The most fundamental reason of senescellt disability is 
evolutionar)'. Natura! selection has not prepared homo sapiens for o!d 
age, as 'premature' death was llatura! (Kirkwood & Holliday, 1979; 
Medawar, 1952; Parker & Mal'nard-Smith, 1990). As we del a)' mortalitl' 
morc and more, we wiII meet more and more bugs in our genetic soft-
ware, which eitller have nevel' been selected for eradicatioIl, 01' which 
confer advantagc in juvenile survival and re product ion (Kirkwood & 
HoIIida)', 1979; Park er & Ma)'nard-Smith, 1990). 
In general there are more indications for fnture expansion than for C0111-
pression. Cardiovascular disease, as a large canse of morbidity and mo1'tal-
ity, shows an cxpansion by ave1'ting deaths from acute events, without 
stopping dise.se progression. The increase in life expectancl' that follows 
gives other senescent diseases the OPPol'tunity to emel'ge. \X1ith cancel' the 
drive for screening tends to cause expansion: while in some cases, like in 
breast cancel', the disability balance is most likel)' positive, in others, for 
example prostate cancer, it is al most sllrely negative (Adami, Baron, & 
Rothman, 1994). 
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Three major openings for the opposite trend of eompression exist. The 
most striking onc is still interventions to ftuther reduee smoking preva-
lences. Onr eakulations show that, despite the higher life expectancy of 
non-smokers, thc abolition of smoking wonld compress disability (chapter 
19). These results, based 011 life tabie calculations with relative risks, are in 
agreement with more empirieal studies (Rogel's, Nam, & Hummer, 1994,. 
In some countries, notably the USA, smoking pl'evalenees have been re-
duced much further than in the Netherlands, where the decline has sta lied, 
and may have reversed among the young (Ruwaard & Kramers, 1997). 
Thel'e is a pressing cause for au active poliey to redllce smoking, and in 
partienlal' to prevent the young from stal'tillg. 
The second opportunity for compression of morbidity is by reducing 
the disability consequences of chronic disease. Much of the effort in health 
care is devoted to this cause, and progl'ess has been made, for example in 
the rehabilitation of stroke patients and better medication for he art failure 
(SOLVD investigators, 1991). Further advances in this field can be ex-
pected. 
The third opporrunity to achieve compressi011 is more research atten-
tion for large disabling, in particular mental and mnsculo-skeletal condi-
tÏons. The relative neglect of these conditions has resulted in a large know-
ledge deficit, both epidemiologieal and etiologieal (van der J\'laas, et al., 
1996). A research effort to re duce this deficit is called fol'. 
The balance of expansion and compl'ession 
Changes in the overall population health status th us result from the balance 
of opposing tendencies towards compl'ession and expansion in the vadons 
canses of mOl'bidity and mOl'tality. wlol'eover, Clll'l'ently observed changes 
may have to be traced back to developments many years ago. For example, 
the decline in male smoking prevalences between about 1970 and 1985 wil! 
have an impact on morbidity for same time to come, given the long time 
lags involved (see chapter 24). 
Another complicating factor, and one we have not looked at, are co-
hort-l'elated changes in socio-economÎc composition . .wlanton et al report 
declines in age-standardized prevalence of disability and a number of dis-
eases, based on a longitudinal study (Manton, COl'der, & Stallard, 1997). 
They hypothesize that part of the change may be explained by the higher 
educatiollal and income status of the successive cohorts. IE a higher socio-
economic status is indeed a direct canse of bettel' health, the same hypothe-
sis may be held for the Netherlands (Stronks, 1997). 
Ml1l'ray and Lopez report from the cross-sectional Global Bl1l'den of 
Disease study that people in countl'Ïes which have progressed further in the 
epidemiologieal transition spend a smaller part of their life expectancy in 
disability than those still in the earlier stages (Murray & Lopez, 1997). 
They argue that this supports the compression of morbidity hypothesis. 
While we think the finding very plausible, we disagree with the conclusion 
(Barendregt, Nusselder, & Bonneux, 1997). The debate on compression 
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and expansion, perhaps l'ather parochially, so far concentrated on the low 
mortality countries in the last phase of the epidemiological transition. An 
expansion aftel' having reached th is last phase is entirely consistent with a 
compression dllrillg the transition throllgh the earl ier phases 
Ta the qllestion H\ViII l110rbidity expalld or compress?H is but one 
va lid answer: "It depends". \Xlith incl'cases in lifc expectancy going on there 
seelllS a general telldency of expansion, but there exist opportunities for 
active policies to achieve compl'cssion. \"hen these policies are pnrslled, on 
balance a compression of disability mal' wel! prevail. But of course such 
policies wonld have cOllscqnences for health care needs and casts. 
Disability, health care needs, and costs 
At first glance it might seem that expansion will coincide with greater 
health care needs and costs, while cOlllpression wOllld gellerate the oppow 
site. In partietdar Fries has repeatedly stated that delayed incidence will 
result in the double benefit of compressed morbidity and cast savings 
(Fries, et al., 1993; Fries, 1980). However, the relation between morbidity 
and disability on the one hand, and health care needs and casts on the 
othel' is not as simp Ie as that. 
A go ad counter example is provided by the results from the global 
Burden of Disease study. Comparing countries in the eady stages of the 
epidemiologieal transition (developing countries) with those in later stages 
(established market economies) reveals that during the transition a C0111-
pressioll of morbidity occurred, but also all enorlllOllS increase in health 
care expenditnres (Mmmy & Lopez, 1996b). We think this is na coinci-
dence: the ability of health care to compress disability expands the need for 
health care. Compression of disability may wel! go hand in hand with ex-
pansion of health care needs and casts. 
Cancer screening is an examp!e of a hcalth care illtervention which 
causes disease prevalence to rise. The disability balance mal' be positive as 
seve!'e terminal disease ma)' be foregone, but health care needs expand be-
canse of increased needs for (fnrther) diagnosis and treatment. Even one of 
the classic examples of Fries of compression of disease, declining stroke 
occurrence, has been bOllght at least in part by health care: tl'eatment of 
hypertension (Bonita & Beaglehole, 1986; Higgins & Thom, 1993; Klag & 
Whelton, 1993; McGovern, et al., 1992). For every stroke prevented, man)' 
had to take life long anti-hypertensive treatment. 
Of the three polic)' opportunities for compression onI)' successfn! ill-
terventions on melltal alld l11UScttlowskeletal disol'del's show the potentialof 
comhining compressioll of morbidit)' with lower health care costs, provided 
that these inte!'ventions would not be toa expensive (chapter 23). The sec-
ond policy opening, greater eHorts to reduce the disability consequences of 
chronic disease, wil! almost surely require additional health care money. 
Even a free, successfnl intel'Velltion to abolish smoking \Vill, while 
compl'essing lllorbidity (chapter 19), increase health care costs (chapter 24). 
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This resulr is not due ta same specific characreristic of smoking alld smok-
Îllg-related diseases, but has a more genera! explanatioll. Bath disability 
and casts l'ise steeply with age, drivcn by the age-related incl'case of senes-
cent discases. But sincc same discases can be treated more or less success-
fully they do genera te costs but no (or verl' little) disabilitl', while discases 
that generate disabilitl' and cannot be treated still generate costs for care. 
Therefore the age gradient of the cost curve is more steep than that of the 
disability curve. Interventions that extend Iife expectancl' will consequentIl' 
tend to add more costs than disabilitl" In the case of non-smoking the net 
gaill or 10ss of the intervention depends on the balance of the additions in 
the added life-years, and savings in eadier lifc. As the cast curve is steepel' it 
is entirell' possible that the costs on balance increase, while disability on 
balance decreases. 
On the whoie, and with the potential exception of the mental and 
musculo-skeletal disordel's, there seems to be Iittle scope for public health 
policies that both genera te desirabIe changes in population health status 
and save health care casts. The allocatian and containment of the health 
care budget is bonnd to remain a painflll and exasperating cxercise. This 
mal' be disappointing for some health researchers and policl' makers, but, 
as economists arc fond of saying, thcl'e is na such thing as a free lunch. 
Priorities for further research 
Given the size of the health care budget and the prominence people give to 
their health, it is surprising how Iittle is known about the occurrence of the 
large causes of morbiditl' in the Netherlands. There exist efforts in various 
diseases, but a systematic overvicw of incidence and pl'evalence of the main 
causes of morbidity is wanting. Conseqnentll' policl' makers have to decide 
on important policies in a ha ze of ignorance about repercussions for popn-
lation health status aud the health care bndget. A good example is the cur-
rent issue whcther to offer expensive but effective cholesterol lowering 
therapy, and if sa, to Wh0111. 
lt would be a major advance for public health research and policl' 
making in the Netherlands when in a sl'stematic effort the epidemiologl' of 
major diseases (Ol' disease categories) would be described bl' internally con-
sistent estimates of age-specific illcidence, prevalence and mortality. The 
Global Bm'den of Disease studl' mal' serve as an example (Murral' & 
Lopez, 1996b). A Bm'den of Discase project for the Netherlauds has started 
tentativell' bl' repeating the assessment of disabilitl' weiglHs for a large 
number of diseases. What is still lacking are consistent estimates of discase 
incidence and prevalence. Snch estimates should now have the highest pri-
oritl" To allow the assessment of temporal trends such an effort shonld 
preferabll' be made on a repeated basis. 
Three other research themes follow directIl' fro111 the work reported on 
in this thesis. The first is demographic epidemiologl'. Several examples in 
this thesis have shown that embedding epidemiologl' in a demographic 
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framework offers possibilities to appl}' epidemiologieal resnlts to research 
qllestions in public health. A systematie investigation of possibilities and 
l'cquil'ements of this interdisciplinary method is desil'able. 
The second theme is the relatioll ber-ween (changes in) populatioll 
health statns and health care costs. Combining the tooi of demographic 
epidemiology with costs of illness data allows to explme this relation, as 
two examples in this thesis have shown (see part V). Fllfther work in this 
direction shonld help to identify where health care money is spend less effi-
ciently, Ol' where gains in population health status could most economieally 
be achieved. 
The third theme is to further explore the epidemiologieal and popula-
tion health status consequences of the evolntionary basis of senescent dis-
ease. Most of the \Vork in the field of "biodemography" has so far been 
done by biologists and demographers. We are convinced that epidemiolo-
gists and pnblic health researchers can benefit from the \Vork they have 
done, but also can contribute to it. 
Public health is a research field that, by its very natnre, reqnires the 
input from various disciplines. Creating a truIy interdisciplinary approach 
to the guestions in the field is the challenge researchers face. 
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Summary 
Degenerative disease in an 
aging population 
Compression or expansion of disease? 
The main research question of th is thesis is how morbidity wHl evolve in all 
aging population. "Morbidity in a population" is the sum of diseases and 
the disability they cause. It incorporates all discomfort, brought about by 
disease: pain, physical disability hampering mobility, as weil as depression 
01' cognitive decline. "Populatioll aging" has two cal1ses: ane is that the 
pl'Oportion of e1dedy in the Dntch population will rise in the first half of 
the next century due to the large size of the post-war birth cohorts, the sec-
ond is that all increasing propol'tion of ally bil'th cohort reaches aId age. 
We mostly focns on the Iatter cause, while not completely ignoring the 
farmer. 
The main research question is closely related to the 'compressioll or 
expansion of lllorbidity' questioll, that has been debated for qllitc same 
time now. Kramer and Gruenberg started oH the debate by pOSitillg that 
1l10rbidity will expand, because niedieal technology successfully lowers 
mortality. As a cOllsequence, frail and diseasecl people survive longer, in-
creasing health care needs. Fries pilt forward the antithesis that morbidity 
would compress. He states that the Imman Iife span is fixed by biologieal 
limits, alld that in industrialized societies populations are near those fixed 
Iimits. Secoudll', he observes the preseuce of a cousiderable burden of pre-
venta bIe chrouie disease, caused bl' unhealthl' lifestyles. If the iucideuce of 
chronic disease cau be delal'ed, bl' health promotion aud other meaus of 
primary preventiou, but the Iifespan is fixed by 'natura I death', morbidity 
will be compressed at the end of Iife. A third positioll is held bl' Manton 
who argues that medieal intervelltious will slow the progression of degeu-
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erative disease, resulting in postponed death, and morc but less severe dis-
abilitl" 
This c01llpression versus expansion debate so far is mostly held in 
ter1l1S of generÎc morbidity, and only partlyon a quantitative level. A morc 
detailed and qnantitative approach might be helpfnl, and therefore we for-
mulate two additional questions. wlorbidity and mortality are phenomena 
detennined b)' incidence and dnration of diseases (albeit that among the 
oldest old specific conditions are hard to distinguish hom senescent decay). 
50 the first additional question is what a disease specific approach can con-
tribnte to the undel'standillg of cOlllpression and expansioll of morbidity, 
The secOild additiollal question origillates hom the observation that 
prevalellce of lllorbidity is thc resultant of incidellce, cure, and mortality, 
and that snclt dyllamÏc varia bles are best described using dynamic lllodel-
·Iing. The second additional qnestion, tberefme, is how epidemiologl' and 
quantitative model1ing techniques can be integl'ated into public health 
models fit to answer questions of compression and expansioll on the dis-
ease specific level, and on the level of overall poplliation health. 
These two additional qnestions largely detennine the outline of th is 
thesis. We first describe recent and possible future developments in the epi-
dcmiology of a number of important diseases, nsing quantitative modeJing 
techniqnes (Part lI). Next we propose a methodology to combine the dis-
ease specific modeIs in a comprehensive model of pnblic health (Part III), 
and examine the possibilities to derive an indicator of poplliation health 
status that allows to define and describe compression and expansion of 
morbidit)' (Part IV). In addition we look at the impact of prevention (a po-
tential wa)' to re ach compression) on health care costs (Part V), reflect on 
the causes of senescent morbiditl' and mortality (Part VI), and draw con-
clusions (Part VII). 
An epidemiological point of view 
This thesis is based on epidemiology, the science of discase occurrellce, and 
focuses in partÏcl1lar on degencl'ative diseases, Dcgcllerative diseases arc 
caused by 'age' and 'damagc'. Damage is partly caused by the environment, 
and particnlarly b)' unhealthl' life st)'les. Not all damage is preventabie, but 
some is. 
Primal'Y prevention is then the avoidance of damage (such as not 
smoking), secondary prevention is early detection of a disease with the aim 
of intCl'Velling early in thc natural history of the disease. Effcctive trcatment 
may avert death and prevent or delay complications, l'chabiJitatioll may 
prevent permanent disabilitl" Changes in morbidity are the snm of all the 
effects of all interventions in all diseases, in addition to explained and un-
explained autonomous trends. Therefore it is difficult to sal' what will hap-
pen on the generallevel, unless the disease specific level is described first. 
Part II focuses on the disease specific level. Chapters 4 to 7 show 
changes in cardiovasculal' mOl'bidity. Because effectivity of treatment of 
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acute myocardial infaretions has improved dntmatieally, the increasillg 
numbel's of survivors boost 11l11nbers of patients with heart disease, at risk 
for ftl1'ther cardiovascnlar disease, predollinantly heart failure (chapters 4 
& 5). In stroke, control of hypertension is in all likelillOod one of the main 
reasons of the incidenee decline, but therapentic progress in the manage-
ment of the cerebrovascnlar accident itself remains limited (chapter 6). The 
eonsequenee is that heart disease is expanding, and stroke mOl'bidity was 
compressing. "\Vas" eompressing, beeanse the expansion of heart disease 
patients incl'eases vasenlar risk. and therefore tends to expand stroke mor-
bidity again. In the same disease gronp, detel'lnined by the same type of 
degellerative praeess (atherosclerose), lllorbidity trends, which are heavily 
detennined by health care interventions, are opposite. Chapter 8 shows 
opposite trends in the same disease: in colorectal cancer, incidenee is in-
creasing but mortality is declining. These changes are probably detennined 
by eadier diagnosis. \Vhile numbers of new and oid cancel' patients arc 
'expanding' , the prevalellce of terminal disease is decreasing and the sever-
it)' of disease is probably 'deelining'. 
In chapter 9, we show the effect of an isolated monofactorial risk fac-
tor intervention on a typical senescent disease such as hip fractures. As hip 
fractures are caused by many interacting age related factors, tal'geting of a 
single determinant snch as bone mineral density is bonnd to be little effi-
eient, even more so if the illtel'Vention (slowing of the fast postmenopansal 
bone loss) has to precede the presumed effect for many decades: hip frac-
tures occur predominalltly af ter age 80. 
Multiple diseases 
Ta describe changes in popnlation health, more is needed than a single dis-
ease and a single risk factor. Part IIIdescribes how multiple diseases and 
risk factors can be considered together in a single model. At the he art of 
this part is "competing risks" theory. Causes of diseases and canses of 
death can be considered as competing hazards, dependent or independent. 
If they are considered independent, observed crnde risks composed by sev-
eral disease specific components can be split up in the vadous specific dis-
ease hazards. Af ter eIil11illation of one callse of death, another cause of 
death will 'substitnte' the eliminated cause of death, why we cal! this COI11-
petition lUlder conditions of independence also 'sllbstitution of lllortality'. 
A hall mark of 'substitution of eaUses of death' is that the Illortality of other 
causes of death is increasing, because the age distriblltion of the population 
is changing, but that at any age the death rates remain constant. 
However, risks are not distributed illdependently over the populatiollj 
sOllle have a higher disease risk than others. This heterogeneous disease risk 
canses 'mortality selectioll': those with the higher risks die at youngel' ages, 
aud the survivors at older ages are a selectioll of the 'strong'. Af ter elimilla-
tion of a canse of death, mortality seleetion will ease, and the frail Slll'vÎvors 
wiII conseqllelltly make the popltlation on average less healthy. Now 11101'-
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tality of other causes will go up, uot ouly because of the changing age dis-
tribution, but also becanse of the increasing risk for disease in the frailer 
survivors. Af ter age standardization, the death rates still increase. Because 
of the c0111petition between the dependent risks, we call this 'competition of 
mortality) . 
An example is in chapter 14, that shows the changes in prevalence of 
diabetes as a consequence of lawel' cal'diovascnlar mortality. Diabetes is all 
important risk for cardiovascnlar death, alld lawel' cardiovascnlar mortal-
ity will increase the prevalcllce. However, as shown in the same chapter, 
age standardized prevaleuce of diabetes does iucrease, but only weakly so. 
Wie therefore conclude that, nnless the depClldcllt risk and its consequcllces 
are the subject of the research question, in most cases litde is lost by muk-
ing the simplifying independcllce assumptioll. 
A comprehensive measure of population health 
status. 
Iu parts II and III we have shown how chaugiug morbidity cau be described 
by chauging prevalences of diseases, calculated by siugle and multi-disease 
1110dels. But uow the problem adses how these chaugiug prevaleuces cau be 
summed aud c0111biued with mortality to au iudicator of chauges in overall 
populatiou health status. Populatiou health status is determiued by mor-
bidity aud 1110rtality from various diseases, aud therefore au indicator 
shonld provide a cammon denominator for these variolIs mUllifestations of 
ill health. 
In the introdnction of part IV, we present "time" as snch a common 
denominator. Mortality causes loss of years of life, and similarly years lived 
with disease cau be considered lost. The sevedry of the disease can be in-
corporated by the proportion of a yeal' lived with disease that is considered 
lost: nearly all fol' vel'y severe disease, only a litde for mild disease. 
Varions methods to construct comprehensive measures of population 
health status, all based on time as a C0111111011 denominator, are discnssed. 
The most used measure is 'healthy life expectancy (HLE)', which combines 
prevalence of ill health and mortality in a life tabie. The HLE is then the 
number of years a life table cohort lives 'without disease'. Nlost implelllen-
tations of the HLE do not account for disease sevedry, but fol' the thresh-
old value used to discriminate health from disease. Typically the years lived 
with disease are considered completely lost (have value 0), which implies 
that illterve11tions that are life saving but do not cure have strictly na value, 
which is contrary to soeietal preference. Anothel' problem of many HLE 
implementations is the cOlllbination of cross-sectional disease prevalences 
and mOl'talit}': th is cOlllbinatio11 of "stock" and "flow" varia bles causcs 
biased results in case of swift changes in flows. 
There is Ilcvertheless a sound reason wh}' HLE is the most llsed meas-
ure, despite its disadvantages. Ir is by far the most simple method, requiriug 
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the least data. \Vhen 'change' is not an issue, as in a simple descriptioll of 
health status, the HLE is an excellent method. However, as the subject of 
this thesis is 'change', the HLE is insllHicient. 
Disability adjusted Iife years (DALYs) avoid most of the problems of 
HLE. The aim of DALYs is te evaluate policy decisions. Therefore DALYs 
are on a disease specific basis, use weights for disease sevel'ity and arc abIe 
to gauge the effects of change by converting prevalences to incidence and 
duration. But thel' also use real populations, making DALYs dependent on 
the age distribution of the population at hand. Moreover, DALYs include 
discomtting of futllrc bCllefits and costs, and all age-weighting schedule that 
va lues years Iived by economie productive adults more than years Iived by 
the ver)' young or the ver)' old. This makes the DAL Y a complex indicator, 
which may, as chapter 18 shows, yield unexpected results. 
It is possible to combine varions attractive elements of HLE and 
DALYs: Iife tabie, disease specific approach, and disabilitl' weights. The 
result is a "disability adjusted Iife expectanc)' (DALE)". The DALE can be 
interpreted as the sum of healthy Iife years and diseased life )'ears (weighted 
for disease severity) a membel' of the synthetic Iife table cohort is expected 
to live. This implies that the difference between the life expectancl' (LE) 
and the DALE is a cross-sectional measure of the burden of morbidity in a 
population at a certain period. If that period (LE - DALE) increases, mor-
bidity is expanding, if that period decreases, morbidity is compressing. 
While not without problems (chapter 20) its properties make the DALE a 
powerful indicator of poplilation health status. 
Prevention and health care costs 
An important rcason for the interest in compression and expansioJ1 of mor-
biditl' is the relation with health care costs. Part V presents estimates of the 
eHects of preventivc measures on health care costs using pllblic health 
models. In the health cconOlnics Hteratllre, we al'gue in the introdllction, 
estimation is aften confused with evalnation, and age with time. Estimatioll 
is simply concerned with measllrÎng the amollnts of money involved with 
health care intel'ventiollS. Evaluation, on the other hand, is concerned with 
dcciding which of these illtervcntions is economically most attractive. 
EconomÎc cvaluatioll is complicated by the existence of 'time prcfer-
encc': we prefer to pay tomorrow instead of today, aud to receive today 
instcad of tomorrow. \Vhen thc cHects of interventions are spread out over 
time, time prefcrcncc makes the afternative interventions as such incompa-
mble. The standard solution to make comparison possible is to cabilate 
the present value of these streams of future costs and benefits b)' appll'ing 
discounting: amoullts of money gct a lower weight in the present value as 
they are flIrther away in time. 
In chapter 23 population health care costs are estimated in the absence 
of selected diseases as cause of death and cause of casts. Eliminatian of a 
disease will 011 the one hand save casts, but on the other generatc costs be-
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canse of added life years. lt tnrns ont that the elimination in only a few 
non-fatal cases wiII cause net savings: in most cases the disease specific 
saving is ontweighed by the casts of added life years. 
We did nOl appll' disconnting, for two reasans. The first is that we are 
only estimating, and not evalnating an intervention. The second is that in 
the analysis the life table is interpreted as a stationary popnlation at one 
point in time. This means that there is no time dimension in the model, 
ani)' age. 
In chapter 24 the distinction between time and age becomes even more 
deal'. \Y/e show th at smokers are more expensive than non-smokers at all 
ages. that in the absence of smoking health care casts will llevertheless be 
higher, but that stopping with smoking is desirabIe from a purely economie 
point of view, given a suitable rate of time preference and length of evalna-
tion periad. Stopping \vith smoking increases health care budgets in the 
long run, becanse the costs of added life years are higher than the savings 
from pl'cvented diseascs. But initially costs become lowcr, making thc in-
tervention economically more attractivc with higher discount rates and 
shone!' evaluation pcriods. 
Senescence from a perspective of theoretical 
biology 
As degenerative diseases eau be expected to cause mnch of future morbid-
ity, a theorl' of degenerative disease is helpfnl in predicting fntnre morbid-
itl'. Wh)' does the risk for degenerative disease increase at middle age (even 
a,s soon as af ter sexual maturation)? \Y/hy is aging nearIy synonymons with 
scnesccuce? In Part VI we discnss the fllndamental nature of senescence. 
At the heart of evoIntionary theory explaining scnescenec is the obsel'-
vation that old age is rarel)' reached in natural conditiolls, due to preda-
tion, starvation, and the like. Recent insights from evolntionary theory 
state that investing in old age is not very usefnl: there is a tradc off between 
illvestillg energy in offspring versus investing in body maintenance. The 
evolntionary optimal point wil! be one where bod)' maintenance falls shon 
to prevent sencscence, becanse an organism investing in offspring will be 
the more snccessfn!. The disposable soma theory postnlates that body 
maintenance is geared to attain a natnrallife expectancy, reached nonnally 
in the wild, but not more. 
This theor)' permits predictions about the nature of senescence. First, 
senescence is predominantly a cOllsequence of neglect. There is na fixed life 
span in the sense of a geneticauy progranuned end. The natural end of life 
is probabilistic, caused by stochastic damage and deficient maintenance of 
a life sustaining system, leading to failure and death. If failme in a life sus-
taining component can be delayed, senescence rates in other componcnts 
wil! go on. If these components cause disability instead of death, disability 
wil! replace death. The future of morbidity from degenerative diseases wil! 
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be detenllined by th is equilibrium between delay of failure inlife susraining 
systems and delay of failme in systems responsible for disabling, non-fatal 
diseases. 
Conclusion 
\Y/e draw cOllcll1siollS by discussing our three research questions: first the 
llse of modeling, then the usefulness of a disease specific approach. Next 
the main research question is discussed, alld finally we propose priorities 
for further research. 
The use of public health models 
Modelers are easily tempted to try to imitate a complex reality as c10sely as 
possible, and to expand their models ever funher. But complex models are 
a mixed blessing: as data needs, assumptions, and uncel'tainties 1l1ultiply, 
the intelligibility of models dec1ines, the results can not be validated, let 
alone be reproduced independently. And, ultimately, even the most com-
plex model is simplistic, compared to reality. 
Modern epistemology stresses the centra I role of theory in the ac-
quirement of knowiedge: even an observation cannot be made without a 
theory. A computer model is nothing but a quantified theory, therefore the 
rules applicabie to them are those of any other theory. A basic rule, known 
as Ockham's razor, states that all elements which arenot strictly needed for 
an explanation have to be e1iminated. The best model is the simplest model 
capable of answering the research qnestion. 
Given th is rule, models are useful in public health research for two 
reasons. Thc first is that they allow to reconstruct a consistent set of age 
and time specific incidence, prevalence and 1110rtality for a disease, based 
on the available figures. The second use is to calculate changes in morbid-
ity. Dynamically detenllined by flows, changing prevalence of morbidity 
over time and age is hard to predict without formal modeling. 
Why a disease specific approach? 
The usefulness of a disease specific approach is weil ilIustrated by the ex-
amples in the original articles arguing for eithel' expansion Ol' compression 
of morbidity. Kramer, defendillg expansion, takes Down's sYlldrome, de-
mentia, and ot her types of chronic mental handicap as examples. Fries 
looks at cerebrovascular disease and the health consequences of smoking. 
Both are right. 
In this thesis we show how onc cardiovasclllar disease (coronary heart 
disease) has expanded, while the other (stroke) compressed. In colorectal 
canccl', numbers of patiellts are expallding, but severity of diseasc becOlnes 
less. A single scenario applicable to all diseases seems very unlikely, as inci-
dence and progllosis of conditions are dependellt on many processes. 
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Policy makers want to change the evolution of morhidity in a desirahle 
direction. Therefore they need causal models, linking risk factors and dis-
eases with mortality and morhidity. We present snch models and show how 
morhidity compresses if risk factors for a disease decline, and how morhid-
ity expands if the prognosis improves. But we could do so only hy taking 
disease specific characteristics into account. 
Compression or expansion? 
How wiII mOl'bidity evolvc? The right allSWCl' is: it depends. Compression 
of ll1ol'hidity is cal1sed by illcreasing mortality, decl'casing incidence <tud 
decl'casing sevel'Îty. Expansion of mOl'bidity is caused by the opposite. 111-
creasing mortality is by far the most effective way of decreasing morbidity, 
illustl'ating that compl'cssion of morbidity cunHor be all aim in itself. 
\"'(,Ie find more indications for expandillg than for compressing 11101'-
bidity. Decreasillg mortality of cardiovascular diseases and illcreasing case 
detection of cancers are powerful generators of morhidity. Any delay of 
mortality williead to increased disahility of non-fatal senescent conditions, 
if they are independent of the delayed cause of death. 
However, there are also processes compressing morhidity. Stopping 
with smoking is the most striking opportunity. And while life saving inter-
ventions in health care generally lead to expansion of morhidity, he al th 
care illtervcntions ma}' also canse compression. The Burdell of Disease 
project showed that the epidemiological transition coincides with compres~ 
sion of disability, in particular of infectious diseases alld materllal causes of 
disahility. And finally, it is no Law of Nature that no progress can he made 
in the therapy and prevention of disahling degenerative diseases: research 
directed at preventahle determinants of chronic psychiatric dise.se and 
joint disease should have the highest priority. 
How morbidity will change is uncel'tain, and will depend to some ex~ 
tent on policy choices in puhlic health and health research. If relatively 
more resources are spent at prevention alld treatment of disability to im-
prove the quality of life, and less to life extension, morhidity might com-
pl'ess. 
Compression of morbidity is of ten thought to cause compression of 
health care costs. The relation is not so simpie, however: while stopping 
with smoking compresses morhidity (chapter 19), it expands health care 
casts (chapter 24). There exists a poorly uuderstood paradox hetween 
needs and costs. The existiug morhidity is the result of not prevented dis-
ease and prevented death. If health care cau successfully treat, it compresses 
morhidity, hut it also uses resomces. This leads to the paradox that mor-
hidity compresses, while health care costs expand. Indeed, one of Fries' 
prime examples, stroke, is all installce of that paradox. At least part of the 
decline in stroke is caused by hypertension control, which prevents stroke 
disahility, hut consumes considerable resources. There is little douht that 
needs alld demallds for health care will go on increasing, even as morbidity 
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compresses. The ollly exception might he the preventioll or cure of dis-
abl1ng but non-fatal conditions that currendl' require a lot of care. 
Priorities for further research 
Our priorities for further research cOllsist of one general reconllnendation 
and three specifie research fields. The genera 1 recommendation is that 
Dutch public health policl' needs a national "Burden of Disease" project. 
Consistent age specific estimates of illcidence, prevalence alld lllortality of 
major diseases are badll' needed. Together with the project describing 
"Casts of Diseases in the Netherlands", policy makers would posses illfor-
mation abont all thl'ee dimensions needed to determine efficiency: mol'tal-
ity, morbidity alld costs. Ta allow assessment of tempora! trends, such na-
tional studies should be repeated on a regular basis. 
The first research field of interest to be explored is demographic epi-
demiologl" Om thesis shows several examples how the embedding of epi-
demiology in a demographic framewol'k allows to explore the consequences 
of epidemiological change fol' population health. The secO!ld field is the 
relation between changes in population health status and health cal'e costs. 
In part Vare two examples, that show the consequences of a changing epi-
demiologl' fol' health costs. Furthel' work in th is direction should allow to 
identify where mone)' is spent less efficiendl' and where gains in population 
health status could be achieved economiealll'. The thil'd field relates the 
consequences of the evolutionar)' basis of senescence to demographic epi-
del11iolagy. "Biodemography", which studies human mOl'tality using con-
cepts of theoretica I biolog)', has been founded bl' demographel's and biolo-
gists. Theil' illSights certaillly can enlightell epidellliolagists, but jllst as 
likel)' the research field of biodemographl' would profit from epidemiolog)', 
pal'ticulady the epidellliology of senescent diseases. 
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Samenvatting 
Degeneratieve ziekte 
in een verouderende bevolking 
"Compressie of expansie van ziekte?" 
De kernvraag van dit proefschrift is de vraag hoe ziekte verandert in een 
verouderende bevolking. Ziekte in de bevolking is de optelsom van alle 
vormen vall ongemak, die hun oorzaak vinden in een aandoening. Dit geldt 
zowel voor fysieke beperkingen die bewegingsvrijheid of activiteiten van 
het dagelijks levell hinderen als voor pijn, depressie of verstandelijke 
achteruitgang. 
De vraag over 'verandering in ziekte in de bevolking' komt overeen 
met de door Kramer, Gruenberg en Fries ingeleide discussie over 'expansie 
of compressie van morbiditeit'. Kramer en Gruenberg verdedigden de 
expansiegedachte. De kern van hun stelling was dat de levensverwachting 
toenam dool' de toenemende successen van de medische technologie, cn dat 
daardoor meer mensen chronische aandoeningen langer overleefden. Als 
antwoord op deze eerder pessimistische visie formuleerde Fries zijn 
befaamde omgekeerde stelling. Fries betoogde dat de levensverwachting in 
ontwikkelde landen niet veel meel' kon toenemen. Daarentegen bleef er in 
die geïndustrialiseerde wereld een groot potentieel aan voorkoombare 
degeneratieve aandoeningen. Als de incidentie van degeneratieve ziekte kon 
uitgesteld worden, maal' de sterfte niet, dan volgde daaruit natuurlijker-
wijze 'compressie' van ziekte aan het einde van het leven. Fries veronder-
stelde dus, in tegenstelling tot Kramer en Gruenberg, dat de incidentie van 
degeneratieve ziekten kon afnemen,' maar de sterfte niet. NIanton zal later 
opmerken dat de voorstanders van zowel de expansie- als de compressie-
theorie ziekte en sterfte als onafhankelijke processen behandelen. In de 
expansietheorie worden de mensen ziek zoals vroeger, maal' sterven ze op 
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hogere leeftijd, in de compl'cssietheorie blijven Inensen langer gezond, maar 
leven ze toch niet langer. 
Ter beantwoording van de vraag van expansie of compressie stellen ons 
daarom twee bijkomende vragen. 
De eerste vraag is wat de bijdrage is van een ziektespecifieke aanpak 
tot het vraagstuk van de toekomstige morbiditeit. Ziekte en sterfte in de 
bevolking wordt uiteindelijk bepaald door de incidentie, duur en letaliteit 
van specifieke aandoeningen (al kunnen op hogere leeftijd de bijdragen van 
specifieke aandoeningen en aftakeling slecht gescheiden worden). 
De tweede vraag is hoe wiskundige modellen en epidemiologische 
gegevens kunnen geïntegreerd worden om uitspraken te kunnen doen over 
expansie of compressie van ziekten. 
Een epidemiologische invalshoek 
Door zich te baseren op aantallen en aard van de aandoening, baseert dit 
proefschrift zich op de epidemiologie: de leer van het voorkomen der 
aandoeningen. Voor een pure beschrijving van de staat van de volks-
gezondheid zon een beschrijving van de gezondheidstoestand van de 
betreffende bevolking voldoende zijn. lVIaar als we deze veranderingen 
willen begrijpen, en indien mogelijk beïnvloeden, hebben we een verklarend 
model nodig dat een verband legt tussen oorzaak en gevolg. Een medisch-
epidemiologisch model is dan het meest voor de hand liggend. 
In een hoog ontwikkelde gemeenschap na de demografische transitie, 
gekenmerkt door een lage sterfte en een hoge levensverwachting, zijn de 
belangrijkste oorzaken van morbiditeit psychische stoornissen en dege-
neratieve aandoeningen. Dit proefschrift spitst zich toe op de degeneratieve 
aandoeningen. Degeneratieve aandoeningen worden veroorzaakt door 
(leef)tijd en schade. We worden geboren met een bepaald genetisch 
gezondheidspotentieel en worden gedurende ons leven aangetast door 
beschadiging. Deze schade is deels onvermijdelijk, deels veroorzaakt dool' 
vermijdbare ongezonde omstandigheden. 
Pl'irnaire preventie bestaat vooral uit het voorkomen of verminderen 
van de milieuschade (bvb. het voorkómen van roken), secundaire preventie 
uit het vroegtijdig opsporen en behandelen van degeneratieve aandoeningen 
(bijv. kankerscreening). Behandeling kan de gevolgen van een aandoening 
voorkómen of uitstellen (bijvoorbeeld thrombolyse na een hartinfarct). 
Revalidatie kan invaliditeit voorkomen of verminderen (zoals na een 
beroerte) en palliatieve behandeling kan de nog overblijvende levens-
kwaliteit bewaren. "Verandering in morbiditeit" is de som van de effecten 
van al deze interventies. 
In deel Ir van dit proefschrift staan meerdere voorbeelden die het nut 
van een epidemiologische, ziektespecifieke invalshoek illustreren. Hoofd-
stukken 4 tot 7 bespreken veranderingen in cardiovasculaire morbiditeit. Er 
zijn steeds meel' patiënten met een chronische hartziekte, omdat behande-
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ling en prognose van een acute hartziekte zo sterk verbeterd is. De 
patiënten overleven, maar zijn daarom niet 'genezen' van hun chronische 
aandoening. Daarentegen was el' tot 1987 een sterke afname van patiënten 
met een beroerte, mede door behandeling van hoge bloeddruk. Bij ver-
schillende types van hart- en vaatziekten, gedeeltelijk gedetermineerd dool' 
het hetzelfde degeneratieve proces, atherosclerose, constateren we een 
tegengestelde evolutie: 'expansie' van chronische hartziekte en 'compressie' 
van beroerte. Sinds 1987 lijkt de expansie van hartziekte uiteindelijk 
aanleiding te geven rot een afbreken van de compressie in beroerte. 
Hoofdstuk 8, over dikke-dal'lukanker, toont hoe de toenemende 
incidentie en de afnemende sterfte alleen maar goed verklaard kunnen 
worden door toenemende vroeg diagnose. Daardoor verandert wel het 
karakter van de morbiditeit van dikke darmkanker: er komen steeds meel' 
nieuwe en oude patiënten met kanker, maal' minder terminaal zieken. Bij 
dezelfde aandoening is er dus een expansie van aantallen, maal' een com-
pressie van ernst. Hoofdstuk 9 toont het belang van 'leeftijd' voor 
heupfracturen. Waar het probleem van heupfracturen nogal eens herleid 
wordt tot osteoporose, blijkt veroudering als oorzaak van vallen een veel 
belangrijker determinant. Opsporen en/of preventief behandelen van osteo-
porose lijkt hierdoor weinig zoden aan de dijk te zetten. 
Het nut van volksgezondheidsmodellen 
"Volksgezondheidslllodel" betekent in dit proefschrift een model dat een 
wel bepaald gezondheidsprobleem beschrijft in termen van vóórkomen van 
ziekte en sterfte in de algemene bevolking. Omdat dit complex is, is het 
formuleren van een volksgezondheidsmodel een evenwichtsoefening tussen 
eenvoud en complexiteit, tussen wetenschappelijk herleiden en inhoudelijke 
relevantie. In dit proefschrift dienen modellen een dubbel doel: ze brengen 
gegevens uit verschillende bronnen met elkaar in verband in een consistent 
geheel, en maken dynamische veranderingen van morbiditeit over tijd en 
leeftijd zichtbaar 
'Metasynthese' 
Veranderingen in de epidemiologie van degeneratieve aandoeningen 
worden aangedreven door veranderingen in 'stromen'. Nieuwe patiënten 
stromen binnen dool' een incidentie, en oude patiënten stromen buiten door 
sterfte of (zelden relevant in degeneratieve aandoeningen) door genezing. 
Wie veranderingen in de epidemiologie wil volgen heeft bijgevolg gegevens 
nodig over de 'stromen' van incidentie en sterfte. Terwijl sterfte aan 
belangrijke aandoeningen deels kan afgeleid worden uit het register van de 
doodsoorzaken, zijn gegevens over veranderingen in incidenties bijzonder 
lastig te vinden. Het Nederlandse Ziekenhuisregister registreert echter 
sinds de jaren '70 diagnosen bij ontslag. Voor sommige aandoeningen, 
zoals acute hartil1farct~n of opnames voor kanker, is dit een vrij getrouwe 
342 DisctlssiOl1 Gl1d summary 
weergave vall de totale aantallen klinische 'gebeurtenissen', zeker op niet te 
oude leeftijd. Indien we een 'model' van de ziekte hebben dat de ziekte-
geschiedenis kwantitatief beschrijft door incidenties, recidieven en sterfte, 
knullen wc een incidentie 'tCl'Ugl'CkCllCll' op basis van deze gebeurtenissen. 
Uit de combinatie van incidentie en sterfte kan dan weer de prevalentie 
berekend worden. De tijdStl'OmCll uit het ziekenhuisregisters gekoppeld aan 
de tijdstromen uit het sterftcl'cgister leveren dan veranderingen in 
prevalenties op. Voorbeelden van deze tCl'ugreken-modellen kunt u even-
eens vinden in deel II (met name de hoofdstukken 4, 5, 6 en 8). Een andere 
benadering van hetzelfde probleem staat in boofdstuk 13, waar een 
incidentie van diabetes berekend wordt op basis van schattingen van 
prevalentie cn sterfte. Dit combineren van gegevens uit allerhande bronnen 
om met behulp van een rekenmodel de ziektegeschiedenis te reconstrueren 
wordt in analogie met 'meta-analyse' ook wel 'meta-sYllthese' genoemd. 
Veranderingen over tijd en leeftijd. 
Morbiditeit is een voorraad, afhankelijk van een in- en uitstroom. Zoals de 
waterstand van een meer afhankelijk is van het water dat er is ingestroomd 
en nog niet is uitgestroomd, zo is de huidige morbiditeit afhankelijk van 
voorbije stromen van incidentie, genezing en sterfte. Voor degeneratieve 
aandoeningen in een menselijke bevolking betekent dit ook dat de 
morbiditeit het gevolg is van incidentie, opgetreden op jongere leeftijd en 
sterfte, nog op te treden op latere leeftijd. De dynamische veranderingen 
over tijd en leeftijd, en de gevolgen daarvan voor een reële bevolking, zijn 
bijzonder moeilijk te schatten zonder een formeel model, zeker als we 
meerde!'e oorzaken van ziekte en sterfte tegelijkertijd beschouwen. Vooral 
de exponentiële toename van incidentie en sterfte van degeneratieve 
aandoeningen met de leeftijd spelen het menselijk verbeeldingsve!'mogen 
parten. Voor de niet-ingewijde blijft het verbazing wekken dat wanneer alle 
oorzaken van sterfte aan hart- en vaatziekten zouden voorkómen worden, 
samen de helft van alle doodsoorzaken, de levensverwachting toch maal' 
met een vijftal jaren zal toenemen. 
Méér ziekten 
Om veranderingen in volksgezondheid te beschrijven is méér dan één ziekte 
en méér dan één deternlÏnant nodig. Hoe meerdere ziekten, meerdere 
risicofactoren en ziekten die tegelijkertijd een risicofactor Vaal' andere 
ziekte vormen kunnen gemodelleerd worden staat formeel beschreven in 
de_d IIL De harde kern van deze methodensectie bestaat uit de formele 
beschrijving van ziekte en sterfte als concurrerende J'isico's. Oorzaken van 
ziekte en sterfte kunnen als onafhankelijk van elkaar beschouwd worden; 
via eenvoudige wiskundige technieken kunnen risico's dan uitgesplitst 
worden in hun samenstellende specifieke hazards. Bij uitschakelen van de 
ene doodsoorzaak, zal een andere ze dan 'vervangen' (waarom we dit ook 
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'vervangende sterfte' noemen). Anderzijds is het risico op ziekte en sterfte 
niet homogeen verdeeld over een bevolking: de een heeft een hoger risico 
dan de ander, Dit geeft aanleiding tot sterfte-selectie: mensen met een 
hoger risico zullen eerder overlijden. Bij uitschakelen van een doods-
oorzaak, zal sterfte-selectie afnemen, en zal de overlevende bevolking een 
hoger risico hebben op afhankelijke doodsoorzaken. Daardoor zal sterfte 
aall andere oorzaken toenemen (ook na leeftijdsstandaardisatie). \Xlegens 
afhankclijkheid en de competitie tussen risico's noemen wc dit 'concurre-
rende sterfte'. 
Het expliciet modelleren van afhankelijkheden is ongetwijfeld realisti-
schel" maal' er dient een hoge prijs voor betaald te worden. De gegevens-
behoefte en de modelcomplexiteit neemt toe met het exponent van het 
aantal risico factor toestanden dat men wil beschouwen. Op basis van 
Ockham's scheermes (hou verklarende modellen zo eenvoudig als mogelijk) 
is het modelleren van afhankelijkheden bijgevolg enkel aan de orde indien 
dit relevant is. Een voorbeeld is in hoofdstuk 14, dat veranderingen in 
sterfte aan hart- en vaataandoeningen gebruikt om veranderingen in 
prevalentie vall Diabetes NIellitus te verklaren; hart- en vaataandoeningen 
zijn een belangrijke doodsoorzaak bij Diabetes. 
Van prevalenties naar een integrale 
volksgezondheidsmaat 
In delen II en III hebben we aangetoond hoe we de veranderende morbi-
diteit van specifieke aandoeningen kunnen beschrijven met behulp vall 
prevalenties, verkregen door ziektemodellen, en hoe we meerdere aandoe-
ningen en determinanten kunnen combineren in een algemeen volks-
gezondheidsmodel. Het optellen van prevalenties van aandoeningen is 
echter het befaamde probleem van het optellen van de appelen en de peren; 
eczeem is niet direct vergelijkbaar met longkanker. Bovendien toonden we 
in hoofdstukken 4, 5 en 7 aan hoe de morbiditeit kan toenemen door de 
dalende sterfte. Het zou de grote successen van de cardiologie geeü'recht 
doen indien we die toenemende morbiditeit als louter negatief voor de 
volksgezondheid beschrijven. Het doel van een geïntegreerde maat is dus 
het combineren van ziekte (morbiditeit) en sterfte in één maat, zodat 
zinvolle vergelijkingen tussen aandoeningen mogelijk worden. \Y/e moeten 
een gemeenschappelijke noemer identificeren voor zowel de ernst vatl 
aandoeningen als voor sterfte, zodat prevalenties van verschillende aan-
doeningen en verloren levensjaren door sterfte kunnen opgeteld worden. 
In de inleiding van ~y: (hoofdstuk 15) presenteren we 'tijd' als een 
gemeenschappelijke noemer. Wie overlijdt verliest levensjaren door te ster-
ven, maar wie ziek is ook: de zieke is beperkt in zijn gewone activiteiten. 
Wie zich niet erg ziek voelt, beschouwt dit waarschijnlijk niet als een groot 
verlies. ~IIaar wie niet in staat is om wat dan ook uit te voeren, en zich 
bovendien ellendig voelt, zal weinig 'waarde' hechten aan de tijd dat hij 
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ziek is. De levensverwachting kan dan verminderd worden met de tijd 
doorgebracht met ziekte, gewogen voor de gemiddelde ernst van die ziekte. 
Het resultaat is 'disability ad;usted Iife expeclancy (DALEr of voor 
morbiditeit gecorrigeerde levensverwachting, de som van de levensjaren 
doorgebracht in goede gezondheid en doorgebracht met ziekte, gewogen 
VQor de gemiddelde ernst van die ziekte. Het verschil met de ongecorri-
geerde levensverwachting is dan een maat voor de gemiddelde duur en de 
gemiddelde ernst van ziekte in de gemeenschap. De vraag over expansie of 
inkrimping van ziekte kan bijgevolg beantwoord worden door de verande-
ring in verloren levensvenvachting door ziekte te meten: de DALE minus de 
LE llife expeclanc)', de ongecorrigeerde levensverwachting). Neemt deze 
roe, dan neemt morbiditeit În de gemeenschap toe, neemt deze af dan neemt 
morbiditeit af. 
Methoden en problemen 
In deel IV worden de verschillende methoden en problemen beschreven van 
geïntegreerde gezondheidsmaten, zoals de gezonde levensverwachting of de 
Disability Ad;usted Life Years (DALY; niet te verwarren met DALE). De 
gezonde levensverwachting combineert prevalenties van 'ziekte' met sterfte 
in ecn sterftetafel. De prevalenties zijn niet gewogen voor de ernst van de 
aandoening, wat betekent dat er een drempelwaarde moet gekozen worden 
tussen 'gezond' en 'ziek', Daardoor komt gezonde levensverwachting in 
families, afhankelijk van de onvermijdelijk arbitraire keuze van een 
drempelwaarde. Bovendien is het gestandaardiseerd opmeten van dergelijke 
drempels in verschillende bevolkingen en over verschillende tijdstippen 
nagenoeg onmogelijk, wat de vergelijkbaarheid ernstig in gedrang brengt. 
Omdat de jaren doorgebracht met ziekte geen waarde hebben, wordt el' 
evenmin waarde toegekend aan levensverlengillg bij zieken, ook al is hun 
levenskwaliteit niet noodzakelijk heel laag. 
Tijd en leeftijd zijn de essentiële dimensies van iedere geïntegreerde 
maat, en zoals steeds bij de determinanten tijd, leeftijd en geboortecohorte 
dienen er keuzen gemaakt te worden tussen perspectieven. Indien men de 
huidige prevalenties combineert met de huidige sterfte, zoals bij het 
berekenen van een gezonde levensverwachting volgens de Sullivan methode, 
vergelijkt men een 'voorraad') opgebouwd door instroom uit het verleden, 
met sterfte, een uitstroom uit het heden (hoofdstuk 16). Indien er grote 
veranderingen hebben plaats gehad in deze stromen in het recente verleden, 
kan dit tot foutieve schattingen leiden. 
Door zijn relatieve eenvoud levert de gezonde levensverwachting een 
bruikbare beschrijving van de huidige staat van de volksgezondheid, maar 
de gezonde levensverwachting is niet geschikt om veranderingen in die staat 
betrouwbaar weer te geven. Omdat de methode niet dynamisch is, is een 
historische beschrijving van trends over de tijd onbetrouwbaar, en omdat el' 
geen ziektespecifiek causaal model aan ten grondslag ligt zijn effecten van 
een veranderend gezondheidsbeleid niet voorspelbaar. 
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De DAL Y is ontwikkeld dool' lvIurray en Lopez om de effectiviteit van 
bundels interventies weer te geven. De DAL Y voorkomt de methodologi~ 
sche problemen van de gezonde levensverwachting door ziektespecifieke 
incidentie~duur modellen te gebruiken, en te wegen voor de ernst van de 
aandoening. De DALY gebruikt vergelijkbare methoden met de DALE, 
maar door zijn ander doel zijn el' ook grote verscbillen. De DAL Y is 
afhankelijk van de leeftijdsstructuur van de bevolking waarop de maat 
wordt toegepast, en om redenen van vergelijkbaarheid wordt een ideële 
standaard-sterftetafel gebruikt. De DAL Y incorporeert zowel een leef tijds-
voorkeur als een tijdsvoorkeur: gewonnen levensjaren op kinderleeftijd of 
op oude leeftijd worden minder zwaar gewogen, en levensjaren gewonnen 
in de toekomst wegen minder zwaar naarmate die toekomst verder 
verwijderd is (discontering). Er bestaan hier solide economische redenen 
voor, al blijkt de combinatie van expliciete leeftijdsgewichten in een 
sterftetafel (die eveneens weegt voor leeftijd dool' meer verloren levensjaren 
toe te kennen naarmate de patiënt jonger overlijdt) tot andere resultaten te 
komen dan verwacht (hoofdstuk 18). 
Tot slot is er het steeds weerkerend probleem van afhankelijkheden. 
Co~morbiditeit is een vorm van afhankelijkheid, waar de ernst van de 
gezondheidstoestand afhangt van meel' dan één aandoening. Zoals voor~ 
dien beschreven betekent rekening houden met afhankelijkheden dat com-
plexiteit en gegevens behoef te toeneemt met het exponent van het aantal 
ziektetoestanden dat men wil beschrijven. Hoofdstuk 20 toont dat het 
expliciet modelleren van co-morbiditeit weinig effect heeft op de DALE; 
rekening houden met co-morbiditeit is dus enkel noodzakelijk indien co-
morbiditeit het onderwerp van studie uitmaakt. 
Volksgezondheidsmodellen en kosten van de 
gezondheidszorg 
&~ bestaat uit economische analyses ingebed in volksgezondheids-
modellen. Nu dient ook economische theorie geYntegreerd te worden in de 
epidemiologische en demografische technieken. Economische evaluaties 
beschrijven keuzen in het gebruik van schaarse middelen. Indien kosten en 
baten van verschillende investeringen optreden op verschillende momenten 
in de toekomst moeten we rekening houden met tijdsvoorkeur. Ceteris 
paribus verkiezen we volgend jaar te betalen in plaats van vandaag, en 
morgen te genieten van een betere gezondheid in plaats van volgend jaar. 
Indien het doel echter is kosten te schatten, zoals in hoofdstnk 23 dat 
de kosten van levensverlenging schat, speelt tijdsvoorkeur geen rol. Kosten 
zijn sterk leef tijdsafhankelijk, zo aanzienlijk dat bij het elimineren van 
fatale aandoeningen, zoals hart- en vaatziekten en kanker, de gezond-
heidszorgkosten paradoxaal toenemen. De kosten van de geëlimineerde 
aandoening vallen weg, maar de bevolking veroudert dool' de afgenomen 
sterfte. 
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Schatten en evalueren komen beiden aan bod in hoofdstuk 24 over de 
kosten van roken. Rokers kosten meer aan gezondheidszorg dan niet-rokers 
zolang ze leven, maar niet-rokers kosten meer omdat ze langer leven. \Vie 
verwacht dat niet roken de kosten voor de gezondheidszorg zal verlagen, 
zal dus bedrogen uitkomen, máál' enkel op lange termijn. Het duurt bijna 
twee decennia vooraleer de kosten van levensverlenging opwegen tegen de 
besparingen door minder ziekte. Omdat de besparingen vóórlopen op de 
kosten, is niet-roken economisch voordelig bij ecn redelijke tijdsvoorkeur. 
Het kost meer, maar we waarderen die late kosten minder clan die eerdere 
besparingen. 
Leeftijd vanuit een fundamenteel biologisch 
perspectief 
Toekomstverwachtingen over verouderingsgebonden aandoeningen moeten 
uiteindelijk gebaseerd zijn op een theorie over veroudering. Deel 6 be-
spreekt de meest fundamentele theorie over de oorzaak van veroudering, de 
evolutieleer. Veroudering is een kenmerk van alle hogere diersoorten, er 
moet een reden voor zijn. De kel'nreden is dat de levensloop in natuurlijke 
omstandigheden beperkt is door hongersnood, ongevallen, infectieziekten, 
of andere jagers (inclusief onze soortgenoten). De prehistorische mens 
bereikte zelden een hoge leeftijd. Daardoor stond het genoom, verantwoor-
delijk voor het fenotype op hogere leeftijd, niet onder selectiedruk en 
konden fouten in de genetische software, die hun effect slechts hebben op 
hoge(re) leeftijd, zich ongestraft opstapelen. 
Naast deze acculllulatie van mutaties, schadelijk op hoge leeftijd, had 
het geringe evolutionaire belang van een hoge ouderdom nog een tweede 
effect. Energie is schaars. Investeren in hoge leeftijd is verloren vanuit een 
evolutionair standpunt, als die hoge leeftijd niet omgezet wordt in meer 
leefbaar nageslacht. Daarom worden energievragende onderhoudsproces-
sen verwaarloosd, als die energie beter kan aangewend worden voor de 
voortplanting. 
Uit deze theorie volgen een aantal voorspellingen over de aard van het 
verouderingsproces. Het einde van het leven is niet bepaald door een 'hard' 
genetisch progmmma, maar doOl' een 'zacht' probabilistisch einde, waar 
stochastische schade en gebrekkig onderhond uiteindelijk leidt tot falen van 
een systeem, noodzakelijk om te overleven. Gezien velerlei systemen op 
velerlei niveaus noodzakelijk zijn, zijn het aantal betrokken genen en gen-
interacties astronomisch hoog, en lijkcn genetische ingrepen nict echt een 
optie. Dool' de aard van het evolutionaire optimaliseringsproccs is er een 
grote vari<1tie in de snelheid V<1n verouderen, zowel in bevolkingen als in 
systemen binnen één individu. Als hct falen van één levensnoodzakelijke 
componcnt kan uitgesteld worden, zal veroudcring blijven optrcden in de 
andere componenten. De toekomst van de morbiditeit wordt dus bepaald 
door het evenwicht tussen uitstel van falen in systemen verantwoordelijk 
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voor degeneratieve, niet fatale aandoeningen en uitstel van falen van 
levensnoodzakelijke componenten, leidend tot de dood. 
Besluit 
In het begin van dit proefschrift hebben we ons de vraag gesteld hoe 
morbiditeit zou evolueren in de toekomst. WTe kozen voor een ziekte-
specifieke aanpak omdat dit ons inzicht kon bieden in de onderliggende 
redenen van verandering. Om een dergelijke ziektespecifieke aanpak 
mogelijk te maken gebruikten we rekentechnieken om gegevens uit aller-
hande bronnen te synthetiseren in ziektemodellen, pasten we die model1en 
toe om veranderingen over tijd en leeftijd te berekenen en ontwierpen we 
een methode om die veranderingen in morbiditeit en mortaliteit te 
aggregeren in een unieke maat voor de staat vall de volksgezondheid, de 
Disability Adjusted Ufe Expectancy (DALE). We zullen eerst het gebrnik 
van rekenmodeJlen bespreken, en vervolgens het nut van eell 
ziektespecifieke aanpak. Dan komen de belangrijkste resultaten aan de 
orde. Tot slot zullen we ons afvragen welke de prioriteiten zijn voor 
toekomstig onderzoek. 
Het nut van volksgezondheidsmodellen 
Zonder de PC en de moderne software zou dit pl'Oefschrift waarschijnlijk 
niet mogelijk geweest zijn, maar de enorme uitbreiding vall mogelijkheden 
is ook een giftig geschenk. De verleiding is groot om een complexe realiteit 
steeds getrouwer te trachten weer te geven, en modellen steeds verder uit te 
breiden. De honger naar gegevens blijkt gauw niet te stillen. Naarmate de 
veronderstellingen en de onzekerheden zich vermenigvuldigen, wordt het 
model minder doorgrondelijk, minder valideer baar en minder reproduceer-
baar door onafhankelijke onderzoekers. En uiteindelijk blijkt ook het meest 
complexe model te simplistisch in vergelijking met de realiteit. Het 
eenvoudige basisprincipe van verklarende modellen werd het meest radicaal 
geformuleerd door de 13 de eeuwse monnik William van Ockham: 
verwijder alle elementen uit de verklaring die niet strikt noodzakelijk zijn. 
De tegenstelling met het naïeve geloof in de kracht van theoretische 
modellen wordt geleverd dool' het naïeye geloof in het geobserveerde 
gegeven. In de moderne wetenschapsfilosofie is het echter een vaststaand 
feit dat er zelfs geen observatie gemaakt kan worden zonder theoretische 
context. Computermodellen leveren een dergelijke theoretische gekwantifi-
ceerde context. De kwaliteit van een model wordt geleverd door de 
mogelijkheid zijn voorspellingen te verwerpen, wat de filosofische grond-
reden is om modellen doorzichtig te houden. 
Volksgezondheidsmodellen zijn dus rekenmodellen die voorspellingen 
leveren over ziekte en sterfte in een bevolking op basis van een ge-
kwantificeerde theorie. Dit proefschrift identificeerde een dubbel doel. Een 
eerste doel is het opbouwen van een consistente set gegevens over de des-
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criptieve epidemiologie van ecn aandoening. Het rekenmodel dwingt tot 
consistentie, dool' incidentie, prevalentie en sterfte met elkaar te verbinden. 
Een tweede doel is het in beeld brengen en berekenen van lastig te doorzien 
dynamieken. Vooral verschuivingen over tijd en leeftijd van tijds- en leef-
tijdsafhankelijke parameters zijn niet gemakkelijk intuïtief te bevatten. 
Waarom een ziektespecifieke aanpak? 
Het nut van de ziektespecifieke aanpak wordt goed geïllustreerd door de 
artikelen te bekijken die de basis vormden van de discussie over expansie en 
inkrimping van ziekte. Kramer, die de thesis van expansie van ziekte verde-
digde, legde de nadruk op Down, dementie en andere vormen van ver-
standelijke handicap. Fries nam beroertes als voorbeeld, die sterk zijn 
gedaald. Beiden hadden op basis van het door hun gekozen voorbeeld 
'gelijk'. In dit proefschrift toonden we hoe de ene hart- en vaataandoening 
toenam (hartziekte), terwijl de andere afnam (beroerte). In dikke-darm-
kanker neemt het aantal patiënten toe, maar het aantal terminaal zieken 
neemt af. Een uniek scenario is onwaarschijnlijk omdat incidentie, beloop 
en ernst van aandoeningen afhankelijk zijn van velerlei beïnvloedbare 
processen. 
Een beleidsmaker wil enerzijds een idee hebben over de verwachte 
evolutie, anderzijds wil hij die evolutie waar mogelijk beïnvloeden naar een 
gewenste richting. Dit kan niet zonder een idee te hebben van de causale 
verbanden, die bepaald worden door leeftijd, geslacht, risicofactor en uit-
eindelijk aandoening. Zowel sterfte als morbiditeit wordt uiteindelijk ver-
oorzaakt door ziekte of aftakeling, en kunnen dus niet onafhankelijk van 
elkander behandeld worden, zoals dit bij Fries of Kramer het geval is. 
In dit proefschrift staan meerdere specifieke voorbeelden hoe mor-
biditeit 'expandeert' door verbeterende prognose verbetert en dalellde 
sterfte, en hoe morbiditeit 'comprimeert' als risicofactoren voor die aan-
doening afneemt. 
Compressie of expansie? 
Hoe zal morbiditeit nu evolueren? Het juiste antwoord is, dat dat er van af 
hangt. De grootste bronnen van morbiditeit in Nederland zijn aangeboren 
zwakzinnigheid, chronische psychiatrische aandoeningen en veroudering. 
De Iladruk lag ill dit proefschrift op verouderingsgebonden aandoeningen. 
We identificeerden meerdere epidemiologische processen die kunnen leiden 
tot expansie of tot compressie. Compressie van morbiditeit wordt ver-
oorzaakt door toenemende sterfte, afnemende incidentie, of afnemende 
ziekte-ernst. Het feit dat toenemende sterfte de gemakkelijkste manier is om 
ziekte te comprimeren toont dat compressie van ziekte geen doel op zich is. 
Toenemende morbiditeit wordt veroorzaakt door toenemende incidentie 
(ook door toegenomen diagnostische activiteit), afgenomen sterfte en 
toenemende ernst (dit laatste staat meestal in verband met uitgestelde 
sterfte). 
Samenvatting 349 
Over het algemeen zijn er meer aanduidingen voor expansie dan voor 
compressie. De dalende sterfte aan hart- en vaataandoeningen en de toe-
nemende vroegdiagnose bij kanker is een krachtige motor voor expansie 
van chronisch zieken. Ieder uitstel van sterfte zal steeds aanleiding geven 
tot toename vall die verouderingsgebonden aandoeningen die onafhankelijk 
zijn van de dalende sterfte-oorzaken. Er zijn echter ook mogelijkheden tot 
compressie. Stoppen met wken biedt de gwotste kansen. 
Terwijl de gezondheidszorg deels aanleiding geeft tot expansie, dool' 
verbetering van de prognose, is gezondheidszorg ook verantwoordelijk voor 
compressie, door genezing (vooral van invaliderende infectieziekten) of het 
verminderen van de ernst van de aandoening . .wlurray en Lopez tonen in 
het Burdcn of Discase project dat de epidemiologische transitie gepaard 
gaat met compressie van morbiditeit, vooral van infectieziekten en moeder-
lijke oorzaken. Het aandeel vall de gezondheidszorg hierin is niet gering. 
En tot slot is het niet een natuurwet dat er geen voorkoombare determinan-
ten van niet-fatale aandoeningen zijn. Onderzoek naar voorkoombare 
determinanten van chronische psychische aandoeningen en ziekten van het 
bewegingsstelsel hoort de hoogste prioriteit te genieten op de onderzoeks-
agenda. 
Morbiditeit en kosten van de gezondheidszorg 
Het debat over compressie en expansie van ziekte had mede de kosten van 
de gezondheidszorg als achtergwnd. El' bestaat een tot nog toe slecht 
herkende paradox tussen zOl'gbehoefte en gezondheidszorgkosten. De 
bestaande morbiditeit is het resultaat van voorkomen sterfte en niet 
voorkomen ziekte. Het is deels de taak van de gezondheidszorg morbiditeit 
(en mortaliteit) te comprimeren. \Vaar dit mogelijk is, ontstaat vraag naar 
gezondheidszorg, wat leidt tot de paradox dat compressie van ziekte 
gekocht wordt met expansie van gezondheidszorg. Het type voorbeeld van 
compressie, beroerte, is gedeeltelijk verworven door medicamenteuze 
behandeling van hoge bloeddruk. Een ander voorbeeld van deze paradox 
uit ons proefschrift is stoppen met roken. Terwijl stoppen met roken de 
morbiditeit doet afnemen, doet het de kosten van de gezondheidszorg 
toenemen. Sommige aandoeningen kunnen behandeld worden. Deze geven 
dan geen aanleiding meer tot morbiditeit, maal' wel nog tot behandel-
kosten. 
Hoe morbiditeit in de toekomst zal evolueren, is onzeker, en zal deels 
van keuzen in de gezondheidszorg en het gezondheidszorgondel'zoek af-
hangen. Naarmate meer middelen zullen besteed worden aan het verbe-
teren van de levenskwaliteit (adding lifc to years) en minder aan levens-
verlenging (adding ycars to life) zal de morbiditeit afnemen. Maar dat de 
behoefte aan en de vraag naar gezondheidszorg daarbij zal toenemen, staat 
buiten kijf: er is geen lineair verband tussen morbiditeit en kosten van 
gezondheidszorg. 
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Hoe nu verder? 
Gegeven de hoeveelheid middelen besteed aan gezondheidszorg en het 
belang dat de mensen hechten aan gezondheid, is het merkwaardig dat de 
kennis over het vóórkomen van de grote oorzaken van ziekte zo beperkt en 
zo versnipperd is. Terwijl verklarende epidemiologie grote snccessen heeft 
geboekt (cn daar terecht trots op is), was er weinig aandacht voor goede 
beschrijvende studies. Het Nederlandse volksgezondheidsbeleid heeft daar-
door behoefte aan een nationaal "Bnrdcl1 of Disease" project. De eerste 
Nederlandse stndie die gewichten voor de ernst van de belangrijke ziekten 
bepaalt is gepubliceerd, nu zijn er nog consistente schattingen nodig van 
incidentie, prevalentie cn sterfte van deze ziekten. El' is grote behoefte aan 
een dergelijke nationale studie, die met ecn zeker ritme zou moeten 
herhaald worden, samen met de studie over HKosten van Ziekten in 
Nederland". Voor het eerst zal dan gelijktijdig informatie bestaan over de 
drie voor volksgezondheid relevante assen: sterfte, morbiditeit en kosten. 
Terwijl el' in onderzoek de trend bestaat om steeds verder te specia-
liseren, en steeds meer deelgebieden af te splitsen, is er evenzeer behoefte 
aan onderzoek dat de grote lijnen weer opneemt en de verschillende 
vakgebieden weer integreert. Dit onderzoek toonde het belang van het 
leggen van verbanden tussen epidemiologie, economie en demografie, en 
uiteindelijk ook met theoretische biologie. Het inbedden van epidemiologie 
in demografische technieken leverde krachtige modellen om vraagstukken 
over de volksgezondheid te beantwoorden. Het combineren van de 
demografische epidemiologie met de gegevens over kosten van ziekten legde 
verbanden tussen de staat van de Nederlandse volksgezondheid en gezond-
heidszorgkosten, en zon in de toekomst richtingen moeten kunnen 
aanwijzen waal' maximale gezondheidswinst het meest economisch kan 
bereikt worden. Fundamentele biologische theorie over de natuU1'lijke ge-
schiedenis van veroudering maakte voorspellingen mogelijk over de aard 
van ziekte en sterfte (en dus epidemiologie) op hoge leeftijd. 
Volksgezondheid bestrijkt vele vakgebieden. De grootste wetenschap-
pelijke uitdaging voor de nabije toekomst ligt in de verdere integratie van 
epidemiologie, demografie, economie en biologie. 
Dankwoord 
Gezamenlijk 
Als wij allen die ons hebben bijgestaan in de lange geschiedenis van dit 
project en onze eigen lange wetenschappelijke voorgeschiedenis met naam 
en toenaam zonden moeten vermelden, dan zou de omvang van dit 
dankwoord beginnen concurreren met de omvang vall dit proefschrift. Wie 
willen ons daarom bij voorbaat verontschuldigen bij al diegenen die we hier 
ten ollrechte niet vermelden. Wie zullen eerst onze gezamclijke dank 
betuigen, met daarna van ieder van ons tweeën ecn meer persoonlijke noot. 
Het lijkt 111aal' eerlijk om te beginnen met diegenen die aall de wieg 
van dit proefschrift hebben gestaan. De wieg heette TAM, maar de ambities 
die in die wieg lagen waren ver van tam. TAM stond voor "Technology 
Assessment J\llethods", en had als hoog gegrepen doel 'referentie-waarden', 
een soort waardehepalende peilstokken, te ontwikkelen voor ecn grote 
reeks medische interventies met behulp van een "volksgezondheidsmodel", 
dat NIMPH gekerstend werd: Netherlands Integrated Model of Public 
Health. Dit was niet mogelijk geweest zonder de lange termijn visie en de 
financiële steun van het toenmalige ministerie van Welzijn, Volksgezond-
heid en Cultuur en het huidige Ministerie voor Volksgezondheid, Welzijn 
en Sport, met name vooral Jannes Mulder en Josee Hulshof, die TAM en 
zijn bedenkers steeds gesteund hebben. 
Bij TAM hoorden vroeger een heleboel namen, die al dan niet van 
dichtbij ons reilen en zeilen volgden. Bij diegenen die ons een vliegende start 
gaven horen zeker Gerrit van Oortmarssen, Ben van Hout, GOllke Bonse1 
en .i\tIark Koopmanschap speciaal te worden vermeld. Gerrit was de strenge 
wiskundige, die ons wild geraas enigszins wanhopig binnen formele grenzen 
trachtte te houden, en zonder Ben hadden we nooit dat belachelijk inge-
wikkelde maal' toch ook belangrijke boek van Manton en Stallard gelezen 
en begrepen. Gonke's encyclopedische medische kennis en lvIark's econo-
mische inzichten bleken steeds beschikbaar. Terwijl de vorigen ons 
verlieten, is één gebleven, altijd GLIMmend van bekwame behulpzaamheid, 
de aardigste biostatisticus van het westelijk halfrond (en omstreken), 
Caspal' Loomall. Welwillende peters aan de TAM wieg waren ook nog Dik 
Habbema, Johan Mackenbach, Frans Rutten, en Louise Gunning-Schepers; 
over Lonise lees je verder nog meer. 
Na deze TAMmers van het eerste uur zijn anderen gekomen en weer 
gegaan. Leona van Roijen versterkte de economische poot, en Jacqueline 
van den Bosch kwam helpen om de almaar groeiende berg, hoe zullen we 
het zeggen, beknopt gedocumenteerde computercode in bedwang te 
houden, maar leverde daarnaast ook onschatbare wiskundige en modelleer 
expertise. 
Ook drie medici op stage kruisten ons pad: Louis Niessen, Babs 
Reichgelt en Elke Witthaus, ieder zijn of haar sporen nalatend in dit 
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proefschrift. Hieronder wijdt Luc nog enige warme 'dokters onder elkaar' 
woorden aan deze ontmoetingen. 
Als jonge gezondheidswetenschappers en deels aan onze zorg 
toevertrouwde AIO's hadden Perla van de Mheen en Caroline Baan 
ongetwijfeld, en terecht, op wat meer vastigheid gehoopt. Perla en 
Carolillc, ben je soms in wanhoop over ons (geweest), het moge een magere 
troost zijn dat we veel van jullie hebben geleerd. En jullie wraak is zoet: 
PerIa passeerde ons moeiteloos op het promotietl'aject, en wij hebben nog 
haast moeten maken 0111 te voorkomen dat Caroline hetzelfde zou doen. 
Tot slot mankeert hier nog iemand in deze lange TAM-lijst. We 
hadden gaarne samen opgetreden, met ons drietjes op dezelfde dag, maar 
uiteindelijk ging het dan toch niet door. Wie het onderwerp van dit 
proefschrift leuk vindt, mag zeker de toekomstige promotie van \Vilma 
Nnsselder, demografe en zeer verwante ziel, niet missen. 
\\lij konden onze eigenzinnige muziekjes maken omdat we zo goed 
ingebed zijn in een soliede, harmonieus instituut, het instituut Maat-
schappelijke Gezondheidszorg. Hier hoort een eresaluut voor de vele 
aardige en goede onderzoekers die mee dit instituut maken. Een dubbel 
saluut is er voor het secretariaat, de financiële administratie en de computer 
ondersteuniug, alles onder leidiug van Koos Lubbe. Het is een vaststaand 
feit dat het secretariaat steeds behulpzaam is, op alle vragen een antwoord 
weet, en zich steeds uit de naad wil werken voor weer een veel te laat 
binnengekomen opdracht. En tot ons onnoemelijke genoegen worden alle 
administratieve en financiële bekommernissen ver van ons gehouden, en 
werken onze computers. 
Speciale dank gaat uit naar Anna Bosselaar, die bereid was in 
vliegende haast dit proefschrift op te maken, naar Karin Mulder, die 
tekende voor het omslag, en naar Karen Gribling, die hier en daar ons 
kreupele Engels heeft trachten te behandelen. 
En tenslotte, dit hele onderzoek was natuurlijk totaal uitgesloten 
zonder de man die diep inzicht paart aan een brede kijk: Paul van der 
Nlaas. De samenwerking tussen Paui en ons zal voor iedere buitenstaander 
altijd wel een onbegrijpelijk en vooral chaotisch gebeuren blijven. Vergelijk 
het met die puzzels, waar bizar kronkelcnde stalen staafjes in elkaar moeten 
gepast worden. Dat lukt zelden, en als het lukt krijg je die dingen niet meel' 
uit elkander. Zo pasten de wel erg rare kronkels van onze drie stellen 
hersenen perfect in elkaar, en werd dat geheel veel meer dan de som del' 
delen. Beste Paul, het spijt ons dat je op de voorkaft van dit boek als auteur 
moet ontbreken, maar we zijn wel allemachtig trots je als promotor te 
kunnen opvoeren. 
Jan 
Velen hebben mij de afgelopen jaren gevraagd hoe ik, als historicus, nu in 
vredesnaam ben beland in het volksgezondheidsonderzoek. In de loop van 
de tijd is daar een standaard antwoord op ontstaan: ~probeer maar eens een 
onderzoeksbaan te vinden als historicus, dan begrijp jc het wel'. Ondanks 
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deze handicap denk ik toch met veel plezier terug aan de opleiding 'maat-
schappijgeschiedenis': het mnlti-disciplillaire karakter en de sterke 
methodologische vorming bewijzen nog altijd hun nut. De opleiding werd 
gedragen door een groep enthousiaste docenten, waarvan ik de meesten 
onrecht aandoe door er hiel' slechts twee te noemen: Antoon vall den 
Braembussche (nog zo'n Belg op mijn pad) en Peter Klein. 
Met de volgende fase in mijn opleiding is de naam verbonden van Joel 
lvlokyl', van het depal'tment of economics van Northwestern University. Op 
basis van een scriptie waarin zijn werk weliswaar instemmend werd aan-
gehaald maar op sommige punten ook stevig bekritiseerd, bezorgde hij mij 
een 'fellowship'. Daardoor kon ik kennis maken met de hogedrukpan sfeer 
van ecn Amerikaanse Graduate School, ecn ervaring met ecn hoog 'Pietje 
Bell in Amerika' gehalte, maar ook een uitstekende inwijding in de 'dismal 
science'. 
Het getuigde van enige moed dat iMGZ en in het bijzonder Louise 
vervolgens met mij in zee durfden te gaan: op dat moment was ik, om 
mezelf te citeren, tenslotte niet meer dan een gesjeesde biologiestudcllt, 
gemankeerd historicus en werkloos econoom. Beste Lonise, het was in de 
samenwerking met jou dat ik er achter kwam wat een interessant onder-
zoeksterrein volksgezondheid is. Dat dit proefschrift er nu ligt, is dus zeker 
voor een deel aan jou toe te schrijven. 
Ten slotte wil ik dank zeggen aan mijn familie, al was het maar voor 
de getoonde kiesheid om niet bij iedere gelegenheid te informeren wanneer 
het proefschrift nu eindelijk eens klaar ging zijn. Mijn dank geldt in het 
bijzonder mijn ouders, die door alle eigenzinnige wendingen heen mij steeds 
zijn blijven steunen in het volste vertrouwen dat ik uiteindelijk wel op mijn 
pootjes terecht zou komen. Het is dan ook aan jullie dat ik mijn deel van 
dit proefschrift opdraag. 
Luc 
Als 'medicus' hou ik de beste herinneringen over aan mijn medische 
'stagiairs', en co-auteurs in de ware zin van het woord: Louis Niessen, Babs 
Reichgelt en Elke Witthaus. We zijn arts en generatie-genoot, en dat levert 
toch die extra herkenbaarheid op die de vonk nog sneller doet over-
springen. Verder denk ik dankbaar tel'llg aan de talrijke en soms verhitte 
. discussies met Karin Nleeter en Huib Pols, en via Louis Niessen met Peter 
Koudstaa!. Als goede clinici hielden ze ons tegen de harde grond van echte, 
niet gesimuleerde, mensen en het moeilijke klinische werk. Vooral Karin, 
die onze eerste stapjes bijna moederlijk begeleidde, wil ik graag een 
schriftelijke natte kus op de wang drukken. 
Als ik verder tel'llgblik dan TAM en iMGZ, komen weel' zovele 
gezichten boven, dat ik vele namen onrecht aan moet doen. \Vijlen 
Geoffrey Rose van de London School of Hygiene and Tropical Medicine, 
epidemioloog, arts en goeroe, leerde me dat epidemiologie een menselijke 
wetenschap is. De centrale vraag die hij stelde was of mensen er uiteindelijk 
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beter van werden. Alleen al het idee dat hij goedkeurend zon hebben 
geknikt bij lezing van dit proefschrift doet mij veel plezier. 
Ik ben en blijf uiteindelijk een product van de afdeling 
Volksgezondheid van het Antwerpse Instituut voor Tropische Genees-
kunde. Professor Van Baelen (hier geen Harrie) en Professor .NIercenier 
(laat staan Pierre) leerden me eigenzinnig en kritisch denken, ook en vooral 
over geneeskunde en volksgezondheid. En soms mis ik Pangu, Kangombe, 
de familie edel, cn al die anderen waarmee ik heb mogen werken in 
Kasongo. De vele praktische problemen en Kongolees-Zairese frustraties 
vervagen door het patina Vall de tijd, wat overblijft zijn de mooiste jaren 
van mijn beroepsbestaan. En tot slot zou het wel heel onrechtvaardig zijn 
Peter Piot te vergeten, die me aan mijn eerste 'echte' wetenschappelijke 
artikel hielp. 
Waar het Instituut voor Tropische Geneeskunde zowel letterlijk als 
figuurlijk te klein bleek, is te schaarse middelen een terecht excuus. Afwe-
zige ondersteuning dool' het beleid van wetenschappelijk onderzoek leidt 
tot afwezige ondersteuning van het beleid door wetenschappelijke onder-
zoekers. De recente Belgische geschiedenis leert dat dat toch niet straffeloos 
gaat. Als ik uiteindelijk de kans kreeg om uit te groeien tot wetenschapper, 
heb ik die van de Nederlandse samenleving gekregen. Van deze dankbare 
Belg hoor je zelden domme grappen over de gierige Hollander. 
En tot slot ik ben niet, nergens, zonder mijn thuis, mijn veilige wanne 
nest. Er is het gezin waar ik groot werd, deel van een grote Limburgse 
familie, met zijn bijna Afrikaanse gevoelen voor afkomst en geschiedenis. Ik 
weet dat jullie trots bent op mij, ik ben even trots op jullie. Ik draag mijn 
deeltje van dit proefschrift op aan mam en papa, mijn voorouders, die 
trotser dan trots zouden geweest zijn op dit kleine schakeltje in hun ketting. 
En el' is mijn kleine thuis, mijn altijd roerige gezin, waar het goed is 
om weer tot rust te komen, afstand te nemen van het razen van de tijd, en 
samen met Rita te leven met onze viel' schakeltjes die we voegden aan de 
menselijke ketting. Eeuwig student, eeuwig zoekend 11aar de zin van het 
bestaan, heb ik die tegelijkertijd al lang gevonden in je armen en in onze 
vicr fantastische kinderen waar deze kecr ik trotser dan trots op ben. 
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Ziekten in Antwerpen en als wetenschappelijk onderzoeker aan het depar-
tement Microbiologie van het Instituut voor Tropische Geneeskunde. In 
1988 behaalde hij de titel van Master of Science in Epidemiology aan de 
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Stellingen 
Stellingen behorende bi; het proefschrift 
DegcllCl'ative disease in an aging popnlation. ~lodels aad cOl1jectm"es 
van Jan Barendregt en Luc Bonneux. 
1. De functie van het disconteren van toekomstig geld of goederen is om de keuze 
tussen twee of meer wegens tijdsvoorkeur onvergelijkbare alternatieven moge-
lijk maken. Disconteren dient dan ook tot deze toepassing beperkt te blijven. 
2. Beperking van de groei van de uitgaven voor de gezondheidszorg tot een percen-
tage lager dan de groei van de Nederlandse economie betekent een relatieve 
bezuiniging. Dat is strijdig met de status van gezondheidszorg als luxe goed. 
3. Incidentie-prevalentie-sterfte modellen zouden tot de standaarduitrusting van de 
epidemioloog moeten behoren. 
4. Algemene uitspraken over de te verwachten compressie dan wel expansie van de 
totale morbiditeit krijgen slechts betekenis wanneer ze de grote verschillen in 
veranderingen van de morbiditeit van belangrijke ziekten expliciet in de ver-
wacluing betrekken. 
5. Op populatieniveau wordt mortaliteitselectie een minder belangrijk fenomeen 
naarmate de overlevingscnrve rechthoekiger is. 
6. Het onderscheid tussen 'vervangende' (substitutie) en 'concurrerende' (competi-
tie) ziekte en sterfte is niet louter academisch, maar cruciaal voor goed begrip 
van sommige epidemiologische trends. 
7. Van de 'gezonde levensverwachting' zijn zoveel verschillende varianten, dat een 
schatting zonder nadere toelichting in feite geen informatie verschaft. 
8. DALYs zijn net QALYs, maar dan anders. 
9. De stelling van sigarettenfabrikanten dat hun reclame-inspanningen uitslui-
tend zijn gericht op bestaande rokers van andere merken is ongeloofwaardig 
en bovendien in tegenspraak met de constatering dat een groot deel expliciet 
is gericht op veelal nog niet verslaafde jongeren. 
10. It ain't necessaril)' so. (I. Gershwin) 
11. Een opleiding tot historicus vormt in principe geen beletsel voor een loopbaan 
als onderzoeker op het terrein van de volksgezondheid. 
12. 'Sterven in schoonheid' is het vermoedelijke lot van de perfectionist in een 
'publish or perish' omgeving. 
13. Het begrip 'autoalann' is bijzonder goed getroffen, gegeven de grote neiging 
van deze installaties om zonder enig merkbare aanleiding af te gaan. 
Rotterdam, 14 ;anuari 1998 
Jan Barendregt 

Stellingen 
Stellingen behorende bij het proefschrift 
Degellerative disease in au aging popnlation. Models ul1d conjectures 
van Jan Barendregt en Luc Bonneux. 
1. De morbiditeit in een moderne samenleving is de paradoxale optelsom van niet 
voorkomen ziekte en wel voorkomen sterfte. (dit proefschrift) 
2. De dalende sterfte aan coronaire hartziekte wordt 'bekocht' met toenemende 
aantallen patiënten met hartfalen en beroerte. (dit proefschrift) 
3. Preventie van heupfracturen door interventies die het snelle postmenopausale 
botverlies bij vrouwen moeten tegengaan is gedoemd tot lage doelmatigheid, 
omdat heupfractmen gemiddeld pas decennia later optreden. (dit proefschrift 
4. Verouderingsgebonden morbiditeit en mortaliteit zijn fenomenen van hetzelfde 
proces. De klassieke 'expansie' of 'compressie' theorieën, die beiden als onaf~ 
hankelijk van elkander behandelen, zijn daardoor onhoudbaar. (dit proefschrift) 
5. Half de jaren 80 toonden eenvoudige modellen aan dat een AIDS epidemie in de 
geïndustrialiseerde wereld buiten groepen met hoge aantallen seksuele (of 
spniteul'uilende) partners onwaarschijnlijk was. Het verwaarlozen van deze 
kennis heeft wereldwijd geleid tot verspilling van middelen en overbodige angst-
nemosen. (Bonneux & Houweling, Ned Tijdschr Geneeskd 1989;133:1922) 
6. Non sunt mu/tip/icanda entia praeter necessitatem (William of Ockham, 1285-
1347/49; vrij vertaald: vermijd alle overbodige complexiteit). Eenvoudige mo-
dellen doen ons de realiteit begrijpen, ingewikkelde modellen geven de realiteit 
weer zoals de onderzoeker vindt dat ze moet zijn. 
7. Een eenvoudig demografisch model op basis van gegevens van Rwanda toont 
dat interventies die de kindersterfte verlagen weinig invloed op de bevol-
kingsexplosie hebben. Er is bijgevolg geen contradictie tussen volksgezondheid 
en dumzame ontwikkeling. (Bonneux, Lancet 1994;344:1689) 
8. Egoïstische genen geven onvermijdelijk aanleiding tot altruïstische samenlevin-
gen, omdat samenwerking een evolutionair superieure strategie is (uit Axelrod: 
The evo/ution of cooperation en Matt Rid/ey: The origins of virtue). 
9. De wetgeving op de vrijheid van pers is gebaseerd op het recht op vrije 
meningsuiting en het bestraffen van aangetoond misbruik. De wetgeving op de 
bescherming van de persoonlijke levenssfeer ('privacy') zou zich moeten baseren 
op het recht van vrije illformatiegarillg en het bestraffen van aangetoond 
misbruik. 
10. Het afschermen van wetenschappelijke gegevens voor onafhankelijke onder-
zoekers leidt tot overbodig dupliceren van onderzoek en is een invitatie tot 
fraude. Na een redelijke termijn dient het intellectuele eigendom van de indivi-
duele onderzoeker te vervallen en moeten gegevens publiek bezit worden. 
11. Om vooruitgang te boeken in onze kennis over behandeling en eventuele 
preventie van chronische psychiatrische aandoeningen is deskundig (klinisch) 
epidemiologisch onderzoek een noodzakelijke vereiste. 
12. De juiste vraag is niet 'of' een interventie kosten-effectief is, maal' 'bij wie'. De 
effectiviteit van een interventie wordt immers bepaald dool' de prognose van 
de patiënt. Wie de doelmatigheid van de gezondheidszorg wil verbeteren, zal 
dns indicatiestellingen moeten kuunen sturen. 
13. De grote belangstelling voor voedingsonderzoek in Nederland staat in schril 
contrast met de geringe belangstelling voor de kwaliteit van het voedsel ge-
serveerd in een uuiversiteitsl'estanrant. 
Rotterdam, 14 januari 1998 
Luc Bonneux 
